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Abstract  
Of the environmental factors which influence body weight, nutrients have the most 
impact. Saturated fatty acids (SFAs) are a macronutrient, which induce obesity, 
characterised by metabolic dysfunction and altered feeding behaviour. Currently, 
there are no effective pharmaceutical treatments for obesity. Nutraceutical 
intervention, including consumption of polyunsaturated fatty acids (PUFAs), 
represents a promising alternative. PUFAs oppose the effects of SFAs, attenuating 
weight gain by enhancing satiety. However, in studies using human and rodent 
models findings are difficult to interpret, due to variation in protocols. The primary 
aim of this project was to create a rational model of chronic PUFA consumption.  
Obesity is underpinned by alterations in hypothalamic neuronal plasticity including 
impairment of neurogenesis. These changes occur in response to nutrients or by 
regulation of appetite-related hormones. In contrast, dietary restriction stimulates 
neurogenesis, and evidence has suggested that PUFAs enhance hypothalamic 
neurogenesis. The secondary aim of this project was to pilot methods for stimulating 
and observing neurogenesis in hypothalamus of rat. These two lines of enquiry were 
pursued to begin addressing the complex research question of whether PUFAs exert 
beneficial effects on body weight by stimulating hypothalamic neurogenesis. 
Wistar rats fed commercially formulated diets equally enriched with high 
concentrations of SFAs and PUFAs, from lard and fish oil, respectively, for two 
months showed no difference in energy intake or body weight. Both diets induced 
leptin and insulin resistance, but PUFAs reduced triglyceride concentrations. Hence, 
PUFAs improved lipid metabolism independently of induced obese phenotype. The 
meal pattern signatures associated with each diet were also similar; however, PUFA-
fed animals demonstrated enhanced diurnal satiety. Closer examination of the diet 
compositions revealed the overlap of results was likely due to the presence of SFAs 
in the PUFA diet. This led to reformulation, using fatty acids of greater purity. The 
chosen sources were coconut oil (SFAs), and a commercial preparation of omega-3 
PUFAs. A shorter-term, preliminary investigation involving three weeks’ dietary 
exposure was conducted. Energy intake was again similar between SFA- and omega-
3-fed animals but weight gain was attenuated and adiposity reduced by omega-3 
feeding. However, the enhanced satiety previously observed was not borne out. A 
rise in concentration of brain-derived neurotrophic factor, known to be associated 
with beneficial effects of PUFA intake, in the final study week suggests that studies 
of longer duration may be required to fully assess the effects of dietary PUFAs.  
Concurrent pilot work showed that hypothalamic cell proliferation could be 
stimulated in response to simple enrichment (play tube) introduced to the cage. 
However, a full study failed to repeat these findings, supporting the notion that 
neurogenesis is subject to many influences, including age, species, strain and stress, 
the degrees of influence of which would have to be determined in a series of 
systematically controlled studies. Failure to stimulate cell proliferation in PUFA-fed 
rats suggested further that change in dietary fatty acid composition is not a powerful 
enough intervention to stimulate neurogenesis, when used alone in Wistar rats. 
In conclusion, application of appropriate controls for dietary energy content and 
composition show that benefits to body weight metabolism of long-term 
consumption of diets highly enriched with PUFAs, and, in particular, omega-3 fatty 
acids can be successfully modelled in rat. However, further work is required to 
determine the precise timeline of their emergence and underlying mechanisms. 
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General Introduction 
1.1 Energy Homeostasis  
1.1.1 Regulation of Appetite & Body Weight 
Energy homeostasis, which is essential for survival, is maintained by a balance 
between energy intake and energy expenditure. This concept is known as the energy 
balance equation (see Figure 1.1; Harvey & Withers, 2008).  
1.1.2 Energy Balance Equation 
Energy is readily available from the foods we consume; this particular source is 
known as ‘Energy In’. Although food items contain a number of nutrient sources, 
energy is provided primarily by sources of protein, carbohydrate, and fat (Schoeller, 
2009).  
 
Figure 1.1. Example of a normal energy balance. Energy homeostasis is maintained by a 
balance between energy intake and energy expenditure. Source: Lowrie, 2008. Human 
Biology. Heinemann Publishing. 
 
 
1.1.3 Controlling Energy Intake 
‘Energy In’ is exclusively regulated by the amount of energy consumed. This occurs 
mainly through decreasing portion size and/or regulating the quantity of high fat and 
refined sugar items as well as ‘calorie counting’. Energy in is also influenced by the 
opposing sensations of hunger and satiety (Schoeller, 2009). Hunger is a 
physiological state controlled by internal factors involving the nervous and endocrine 
systems; some of which are described in more detail in the following sections of this 
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thesis. Physiological factors that may lead to decreased energy intake include 
increased circulating concentrations of peptides, proteins and hormones, as well as 
increased temperature, stress, sensory mechanisms and conditioned responses 
whereby one trains oneself to eat less. However, the peptides, proteins and hormones 
that lead to increased food intake have not been completely characterised. 
Furthermore, there are also sensory mechanisms linked to smell and palatability of a 
food item that may influence food intake (Kalra & Kalra, 1990). Regulation to 
control ‘Energy In’ is complex and involves the interaction of many signals. 
1.1.4 Controlling Energy Expenditure 
In comparison, energy expenditure is represented by ‘Energy Out’ and has three 
constituents: 1) an individual’s basal metabolic rate (BMR), 2) the energy used for 
physical activity, and 3) the thermic effect of food (Prentice & Jebb, 2004). The 
majority of an individual’s daily energy expenditure (approximately 70%) is spent 
on the basal metabolic rate. BMR represents the energy used to carry out basic 
metabolic processes, within the body, such as breathing, regulating body temperature 
and maintaining a heartbeat (Zakeri et al., 2008). The amount of energy required for 
these processes varies depending on factors such as age, growth, body composition 
(Fulton et al., 2009), stress, surrounding temperature and fasting. Physical activity 
amounts to approximately 25% of the body’s energy output, which varies dependent 
on type and duration of the activity. This is also affected by factors such as gender, 
age and weight of the person. Finally, the thermic effect of food refers to the energy 
necessary for the digestion of food consumed as food items need to be broken down 
into more usable structures within the body for later use as an energy source 
(Simopoulos, 1987; Rolland-Cachera et al., 1997; Hill et al., 2003). This energy 
balance equation remains neutral in instances where the energy consumed is equal to 
the energy expended through exercise and metabolism (Harvey & Withers, 2008). 
The control mechanisms which regulate energy consumption are described in the 
following sections.  
1.1.5 Forms of Energy Balance 
Although energy intake and expenditure are often variable from day to day, they tend 
to remain equal over long periods of time in order to maintain a stable body weight. 
However, sometimes the mechanisms described above are altered due to external 
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factors and an imbalance may occur. This imbalance will either result in excess body 
fat accumulation, if there is a surplus of energy, or in wasting and cachexia, if there 
is an energy deficit. Both conditions are accompanied by changes in morphology and 
regulation of energy homeostasis, and very importantly constitute health threatening 
conditions. In the following sections, examples of both negative and positive energy 
balances are discussed; however, it is situations of positive energy balance which are 
the emphasis of this review.  
1.1.5.1 Negative Energy Balance 
Individuals suffering from an insufficient intake of energy and/or a lack of specific 
nutrients are thought to be malnourished. This is an example of a negative energy 
balance (see Figure 1.2). Negative energy balance is dependent on a number of 
factors including age, sex, height, weight and waist measurements (Parvanta et al., 
1994).   
 
Figure 1.2. Example of a negative energy balance. When energy expenditure is greater 
than energy intake then a negative energy balance occurs. Source: Lowrie, 2008. Human 
Biology. Heinemann Publishing. 
 
Examples of negative energy balance include anorexia, which is 
characterised by a significant weight loss as a result of excess energy restriction 
(Huse & Lucas, 1999), bulimic tendencies (Yanovski, 1999), and cachexia where an 
individual experiences weight loss, muscle wastage and loss of appetite (Lainscak et 
al., 2007). However, negative energy balance can also occur in normal situations 
such as lactation. Many mammals use the energy reserves stored during pregnancy in 
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early lactation to support milk production but most mothers then go through a 
negative energy situation whereby energy consumption does not meet the demands 
of the milk production which often results in weight loss (Barbosa et al., 1997; 
McGuire et al., 2004).       
1.1.5.2 Positive Energy Balance 
Positive energy balance occurs when more energy is consumed than expended (see 
Figure 1.3). Increased consumption and subsequent weight gain can be adaptive in 
the short term, for example, in hibernation (Forbes, 2000) where excess fat stores 
allow the animal to survive throughout the winter, but is maladaptive in the longer 
term, as shown clearly by the metabolic dysregulation and co-morbidities associated 
with weight gain and ultimately obesity (Storlien et al., 1991; Cruciani-Guglielmacci 
et al., 2005; Schelbert, 2009).   
 
Figure 1.3. Example of a positive energy balance. When energy intake is greater than 
energy expenditure then a positive energy balance occurs. Source: Lowrie, 2008. Human 
Biology. Heinemann Publishing. 
 
1.1.6 Regulation of Appetite: Homeostatic vs. Hedonistic Control 
Energy consumption is controlled by both metabolic and non-metabolic influences. 
In humans, the non-metabolic, or non-homeostatic, influences include those of the 
environment, cognition, emotion and reward systems. The latter three components 
are involved in the hedonic control of appetite. These factors are co-ordinated by the 
limbic system which incorporates the ventral striatum, prefrontal cortex and 
amygdala regions of the brain, whereas, the homeostatic influences originate from 
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the hypothalamus (see Figure 1.4). The hedonistic control mechanisms can override 
the homeostatic influence (Berthoud, 2006; 2011).   
 
Figure 1.4. Diagram of the medial view of a sagittal section of the brain. The 
hypothalamus is positioned centrally in the brain and is involved in the regulation of energy 
homeostasis. Source: Fix, 2008. Atlas of the Human Brain and Spinal Chord. Jones and 
Bartlett Publishers. 
 
 
1.1.6.1 Homeostatic Control of Appetite 
The central nervous system (CNS) integrates inputs from all over the body to 
coordinate how the body acts. Within the CNS, the brain plays a specific role in 
monitoring the body’s nutritional state through a complex system of neurons, which 
communicate via widespread circuitry (forebrain – hypothalamus – brainstem), as 
well as with peripheral organs (fat, liver, gut), through the substances they secrete 
(hormones, metabolites, neuropeptides) (see Figure 1.5). Furthermore, the 
hypothalamus, which is located adjacently to the third ventricle (3V), consists of 
neuronal populations, some of which are critically involved in the regulation of food 
intake (Schwartz et al., 2000). When food is eaten, it is broken down by the digestive 
system into nutrients, such as glucose (Levin et al., 2006) and fatty acids (FAs) 
(Migrenne et al., 2011) that circulate in the bloodstream and directly activate specific 
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neuronal populations in the hypothalamus. Also, these neuronal populations can be 
indirectly activated by changing levels of peripheral adiposity and appetite-
regulating hormones, such as the adipokine, leptin (Chen et al., 2008). This supports 
a primary role for the brain in the regulation of energy metabolism (Pella et al., 
2011; Södersten et al., 2011), alongside growing knowledge of important peripheral 
drivers, such as lean body mass (Blundell et al., 2012).  
1.1.6.2 Hedonic Control of Feeding 
The process of eating is thought to initially start as a cognitive decision from the 
cortex despite the presence of energy stores. Therefore, even when satiated, the 
limbic (including the hippocampus) and cortex systems can override the 
hypothalamus to make an individual eat and often occurs in response to an external 
non-homeostatic factor such as the presence of readily available, palatable, energy 
high foods (see Figure 1.5; de Castro & Plunkett, 2002). The palatability of a food 
item is one of the major causes behind the process of energy intake. Palatable foods 
are thought to stimulate the brain’s hedonistic reward pathways to override the 
homeostatic signals within the hypothalamus that would normally curb appetite 
(Bessesen, 2011). Despite the difficulties encountered by researchers when trying to 
establish the neurological and psychological control mechanisms behind the feeling 
of pleasure, when specifically applied to food intake, the emotion is often associated 
with the consumption of refined sugar and fatty food items (Kelley et al., 2002). The 
nutrient sensory mechanisms behind this are discussed in the following sections. 
This process is thought to involve connective circuitry between the nucleus 
accumbens and the lateral hypothalamic area (LHA) (Mogenson et al., 1980; Usuda 
et al., 1998; Otake & Nakamura, 2000; Zahm, 2000). Several studies have shown 
that the activation of opioid receptors in regions of the nucleus accumbens stimulates 
high-fat feeding (Zhang & Kelley, 1997, 2000; Zhang et al., 1998; Will et al., 2003) 
whereas the blocking of glutamate receptors in the LHA via injections of agonists 
into the nucleus accumbens prevented food intake (Maldonado-Irizarry et al., 1995). 
From a hedonic point of view, opioids are implicated in the consumption of highly 
palatable, energy dense foods, and craving for these foods is often considered as a 
form of opioid-influenced addiction (Nogueiras et al., 2012).  
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Figure 1.5. Schematic diagram showing the major factors determining neural control 
of appetite and regulation of energy balance. The brain monitors the internal milieu 
through a number of hormonal and neural nutrient sensing mechanisms and is under constant 
influence of the environment and lifestyle through the senses and mainly the cognitive and 
emotional brain. The two streams of information are integrated to generate adaptive 
behavioural (food intake) and autonomic/endocrine responses determining nutrient 
partitioning, energy expenditure and overall energy balance. All the peripheral and central 
signalling steps are subject to individual predisposition either through genetic, epigenetic or 
non-genetic early life imprinting mechanisms. Source: Berthoud, 2011. Curr Opin Neurobiol 
21(6):888-96. 
 
1.1.7 Hypothalamic Neuronal Populations and Functions  
Dietary nutrients can profoundly affect the brain’s organisation and function, which 
can have extensive effects on physiology, metabolism and behaviour. Many 
advances have been made in defining the nature of CNS control over appetite and 
feeding behaviour. This research began with lesion studies in experimental animals, 
which identified “satiety” and “appetite” regions of the hypothalamus, and now 
includes defining the appetitive function of individual neuronal proteins, through 
their absence, in transgenic mice (for review see Coll et al., 2007).  
The suggested existence of “genes-to-behaviour” inter-relationships is 
evident from a combination of research findings in humans and rodent models. For 
instance, known gene defects contribute to the metabolic disturbance of obesity in 
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both species (Harvey & Withers, 2008), both of which also show similar 
disturbances in meal patterns (Castonguay et al., 1982; Berg et al., 2009). An 
emerging area of particular interest suggests that dietary fatty acids, depending on 
their degree of saturation, exert differential effects on energy homeostasis in humans 
and rodent models (including meal patterns) (Cha & Jones, 1998; Lawton et al., 
2000). These effects appear to be underpinned by the degree of neuronal activation 
and proliferation in the brain (neurogenesis) (Wang et al., 1999; Mattson et al., 
2003; Kokoeva et al., 2005). 
1.1.8 Feeding Nuclei of the Hypothalamus 
The specific hypothalamic nuclei which are associated with regulation of energy 
balance include the arcuate (ARC), ventromedial (VMH also known as the satiety 
centre), dorsomedial (DMH), paraventricular (PVN) nuclei and lateral hypothalamic 
area (LHA also known as the appetite centre) all of which surround the third 
ventricular cavity (3V) (see Figure 1.6). Specific neurons located in these nuclei 
produce chemical messengers, which stimulate or inhibit feeding behaviour. Due to 
the presence of a week blood–brain barrier (BBB) in the median eminence (ME), 
communication between the periphery and the brain is possible (Coll et al., 2007).  
Some of the hypothalamic peptides produced by these nuclei are described in the 
following sections.  
 
Figure 1.6. Cross-sectional view of hypothalamic nuclei and key neuropeptides 
involved in feeding. Abbreviations: AGRP= Agouti-related peptide; ARC=arcuate 
nucleus; CART= cocaine and amphetamine-regulated transcript; DMH=dorsomedial 
hypothalamic nucleus; LH/LHA= lateral hypothalamic nucleus; ME= median eminence; 
NPY= Neuropeptide Y; PFA= perifornical area; POMC= pro-opiomelanocortin; 
PVN=paraventricular nucleus; VMH=ventromedial hypothalamic nucleus; 3V=third 
ventricle. Source: Schwartz et al., 2000. Nature 404(6778): 661-71. 
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1.1.9 Appetite-Related Signals in the Hypothalamus and CNS 
Several hypothalamic peptides are essential to the control of homeostatic influenced 
energy balance (Elmquist, 2001). There is an extensive regulatory system to control 
energy homeostasis. Neurons present in the lateral and mediobasal hypothalamus 
control the autonomic, behavioural and endocrine systems responsible for energy 
intake and expenditure. There are many metabolic pathways in the hypothalamus: 
the PVN provides a link to the autonomic outflow through the medulla and spinal 
cord, as well as the endocrine axis. Other groups of neurons in the LHA connect the 
autonomic systems in the brainstem and neurons within the ARC are able to detect 
the presence of circulating factors and in doing so can then regulate the metabolic 
state of an individual (Berthoud, 2006). Neurons present in the hypothalamus 
produce mediators that have orexigenic or anorexigenic purpose, which are secreted 
within the hypothalamus, but are also projected to other regions of the brain, also 
involved in the control of feeding, such as the brainstem. Numerous peptides which 
stimulate or inhibit food intake have been discovered within the hypothalamus 
(Meister, 2007), some of which are described in the following sections.  
1.1.9.1 Arcuate Nucleus 
The ARC, situated around the base of the 3V, lies immediately above the median 
eminence (Figure 1.6). The ARC is a collection of neuronal cell bodies and is 
subdivided into several functional categories. For example, neuropeptide Y (NPY) 
and agouti-related peptide (AgrP), both potent stimulators of food intake, are 
colocalised in a population of neurons in the ARC (Broberger et al., 1997; Kalra et 
al., 1999; Kamiji & Inui, 2007), while pro-opiomelanocortin (POMC; the precursor 
of alpha-melanocyte- stimulating hormone (α-MSH)) and cocaine- and 
amphetamine-regulated transcript (CART), which induce an anorexic response, are 
colocalised in an adjacent subset of ARC neurons (Elias et al., 2001; Berthoud, 
2006; Meister, 2007). These two populations interact with each other (see Figure 
1.5). The ARC also has extensive connections with the PVN, DMH, VMH and LHA. 
The endocannabinoid neurotransmitters, which are synthesised in the ARC, are also 
known to regulate appetite (Matias & Di Marzo, 2007; Di Marzo et al., 2009; 
Richard et al., 2009). Homeostatic regulation is mediated in the ARC, PVN and 
through the nucleus of the solitary tract in the brainstem, and the hedonic regulation 
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is mediated in part through effects in the nucleus accumbens, hypothalamus and 
brainstem (Volkow et al., 2011). Studies have shown that administration of 
endocannabinoid antagonists reduces energy intake and adiposity, and increases 
leptin sensitivity in rodent models (Ravinet Trillou et al., 2004; Di Marzo et al., 
2009). 
1.1.9.2 Paraventricular Nucleus  
The PVN lies at the top of 3V and is an integrating centre, on which converge many 
neural pathways that influence energy homeostasis, and is abundantly supplied by 
axons projecting from the ARC, including NPY/AgrP and POMC/CART neurons 
and from the orexin neurons of the LHA (see Figure 1.6). The PVN is rich in 
terminals containing numerous appetite-modifying neurotransmitters, including 
NPY, α-MSH, serotonin (5-HT), galanin, noradrenaline and the opioid peptides, and 
the PVN is particularly sensitive to these neurotransmitters’ effects on feeding and 
energy expenditures (Williams et al., 2001). Noradrenaline is secreted into the 
hypothalamus from the brainstem via specific fibres that are known as noradrenergic 
fibres. Lesions to these fibres results in over eating and obesity, whereas the 
administration of noradrenaline into the PVN of the hypothalamus reduces eating by 
affecting satiety (Schwartz et al., 2000). Serotonin is expressed by neurons in the 
raphe nuclei of the brainstem which has many projections in the CNS (Descarries et 
al., 1982; Sinton & Fallon, 1988; Hajós et al., 1995). Studies have shown that 
injections of drugs which increase serotonin into the hypothalamus inhibit feeding 
and promote weight loss (Leibowitz & Alexander, 1998); in contrast, ablation of 
serotonergic neurons induces over eating known as hyperphagia (Nonogaki et al., 
1998). Not all cells within the raphe nucleus are serotonergic (Vertes & Crane, 
1997), and other neurotransmitters may also mediate effects on food intake 
(Wirtshafter, 2001). Studies have shown that the catecholimines (dopamine, 
adrenaline and noradrenaline) have a varied effect on food intake. Injections of 
adrenaline into the raphe nucleus decreased energy intake and shortened meals in 
energy restricted rats, but increased feeding and meal number in free feeding 
animals, suggesting that adrenergic receptors in this particular nucleus are 
components of appetite-related neural circuits which control feeding initiation (dos 
Santos et al., 2009).  
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1.1.9.3 Ventromedial Hypothalamic Nucleus  
The VMH, one of the largest nuclei of the hypothalamus, has long been considered a 
‘‘satiety centre’’. Stimulation of the VMH inhibits feeding, whereas lesions to this 
region cause overeating and weight gain (Kalra et al., 1999). Recent studies have 
shown high abundance of leptin receptors (long form: Ob-Rb) in neurons of the 
VMH, and evidence indicates that this region may be an important target for 
circulating leptin (Williams et al., 2001). Studies have shown that glutamatergic 
neurons, which secrete the excitatory amino acid glutamate, are abundant in the 
VMH, possibly implicating this amino acid in the communication of metabolic 
pathways (Collin et al., 2003). An injection of glutamate directly into the 
hypothalamus causes an increase in feeding in satiated rats (Stanley et al., 1993); this 
is due to the excitatory role of glutamate on orexigenic neurons (Elias et al., 2001). 
Dopaminergic activity in the VMH is involved in the control of meal number and 
inter-meal interval (IMI) (Meguid et al., 1996; Fetissov et al., 2002). The VMH has 
direct connections with the PVN, the LHA and the DMH. 
1.1.9.4 Dorsomedial Hypothalamic Nucleus  
The DMH, located immediately dorsal to the VMH, has direct connections with 
other hypothalamic nuclei such as the PVN, the LHA and the brainstem. The VMH 
and the LHA have no direct connections but connect indirectly through the DMH 
and the PVN. The PVN and the DMH may cooperate functionally as a unit, which is 
involved in initiating and maintaining food intake. The DMH contains numerous 
insulin receptors as well as leptin receptors (Ob-Rb). Some ARC NPY/AgrP neurons 
also terminate in the DMH (Williams et al., 2001). 
1.1.9.5 Lateral Hypothalamic Area 
The LHA comprises a large, varying population of neurons including populations 
that express orexins and melanin-concentrating hormone (MCH), both peptides that 
stimulate food intake (Qu et al., 1996; de Lecea et al., 1998; Sakurai et al., 1998). 
The LHA was viewed classically as the feeding centre. Stimulation of this nucleus 
increases food intake, while its destruction attenuates feeding and causes weight loss 
(Williams et al., 2001). Dopaminergic activity in the LHA is involved in the control 
of meal size (Meguid et al., 1996; Fetissov et al., 2002). This nucleus also contains 
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large numbers of glucose-receptive neurons that respond to circulating glucose levels 
and are discussed further in later sections of this review.  
1.1.10 Peripheral Appetite Signals   
In addition to the hypothalamic peptides already discussed, there are numerous 
peripheral tissues which produce hormones and peptides that act on the brain, the 
ARC in particular, to control both short- and long-term feeding and energy 
expenditure.  
1.1.11 Adiposity  
There are several specific hormones that aid in the regulation of adiposity within the 
body. The main examples are described below.  
1.1.11.1 Insulin 
The discovery of insulin led to the first indication that hormonal signals may be 
implicated in the regulation of body weight by CNS control mechanisms. Insulin is a 
peptide hormone secreted from the β-cells of the pancreas and accesses the brain 
through the blood acting on neurons in the ARC to reduce energy intake (Werther et 
al., 1987). Furthermore, insulin receptors allow the transport of this hormone across 
the blood-brain barrier (BBB) of the brain and intracerebroventricular (i.c.v.) 
infusion of insulin results in suppression of food intake in a concentration dependent 
manner (Baskin et al., 1999). Insulin is critically involved in the regulation of fat 
metabolism within the body as it causes liver, muscle, and fat tissues to absorb 
glucose from the blood whereby it is then stored as glycogen or triglycerides (Najjar, 
2001). Insulin is present in the body in concentrations sufficient to remove glucose 
from the blood. When glucose concentrations drop, for example, just prior to a meal 
being taken, the body utilises stored sugar via the process of glycogenolysis which 
hydrolyses glycogen stored in the liver and muscle into glucose which can then be 
used as an energy source. If the control of circulating insulin concentration fails then 
the hormone becomes less effective at maintaining glucose homeostasis, which can 
result in the development of diabetes and this can have profound adverse effects on 
other physiological functions. Neurons are dependent on glucose as their energy 
source and a lack of this source can result in reduced function of the CNS (Ashcroft 
& Rorsman, 2012).  
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1.1.11.2 Leptin 
Leptin is a hormone secreted from white adipose tissue (WAT) which circulates in 
direct proportion to the total amount of fat in the body (Zhang et al., 1994) and 
therefore, is known as an adipokine. It functions as part of a negative feedback 
mechanism to control energy intake, and hence, impacts on both adiposity and body 
weight regulation by crossing the BBB, acting on anorexigenic neurons in the ARC, 
and therefore inhibiting appetite (Berthoud, 2006). Leptin has an important role in 
the development of neurons within the hypothalamus (Bouret et al., 2004; Pinto et 
al., 2004). Studies have shown that the absence of receptors for leptin, for example 
in the db/db mouse, or the Zucker rat (fa/fa) results in uncontrolled feeding and 
obesity (Panchal & Brown, 2011). These leptin receptors are expressed in neurons of 
the ARC known to regulate energy balance (Håkansson et al., 1998, 2000; Meister 
2000). Elevated concentrations of leptin inhibit orexigenic neurons but stimulate 
anorexigenic neurons in the ARC nucleus to result in decreased food intake and 
increased energy expenditure. Leptin decreases food intake by opposing the effects 
of NPY and promoting the production of the appetite suppressant α-MSH (Pinto et 
al., 2004). Currently, leptin and insulin are the only known adiposity regulators.   
1.1.11.3 Adiponectin  
Adiponectin is also an adipokine hormone secreted from white adipose tissue, 
however, unlike leptin it is inversely correlated with body fat accumulation (Scherer 
et al., 1995; Fasshauer et al., 2002; Viengchareun et al., 2002). Circulating 
concentrations of adiponectin act on three receptors; AdipoR1, AdipoR2 and T-
cadherin, to exert important functions in the control of glucose and lipid metabolism 
(Arita et al., 1999; Yamauchi et al., 2003; Kadowaki & Yamamuchi, 2005). 
Administration of recombinant adiponectin to rodents resulted in increased glucose 
uptake and fat oxidation in muscle, reduced hepatic glucose production, and 
improved whole-body insulin sensitivity (Kadowaki & Yamamuchi, 2005; 
Kadowaki et al., 2006). In animal models of obesity and diabetes, treatment with 
adiponectin reduces blood glucose levels by hampering hepatic glucose production 
and increasing muscle glucose uptake. In addition, adiponectin increases free fatty 
acid oxidation in liver and muscle, which reduces the concentrations of free fatty 
acids in circulating plasma (Berg et al., 2001; Yamauchi et al., 2002; Karbowska & 
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Kochan, 2006; Yoon et al., 2006). Studies have shown that i.c.v. administration of 
adiponectin into the hypothalamus provides an anorexigenic stimulus by activating 
the same signal transduction pathways as leptin and insulin (Coope et al., 2008). In 
the hypothalamus, insulin acts in concert with leptin to provide the most robust 
adipostatic stimulus, informing the central nervous system about the peripheral 
energy stores and coordinating a complex neuron circuitry that maintains body 
energy homeostasis (Schwartz et al., 2000). Adiponectin has a similar role inhibiting 
the orexigenic neurons of the hypothalamus.  
1.1.11.4 Ghrelin 
Ghrelin is a hunger stimulating hormone produced by cells which line the stomach 
and is responsible for stimulating energy intake (Kojima et al., 1999). 
Concentrations of circulating ghrelin increase before a meal, acting as signal of 
nutrient status in the gut, and decrease after a meal indicating energy sufficiency. 
The presence of ghrelin stimulates the production of growth hormone and ghrelin 
will bind to the growth hormone receptor present in the ARC nucleus of the 
hypothalamus and vagal-afferent endings in the gastrointestinal tract (Kojima et al., 
1999; Hewson & Dickson, 2000; Page et al., 2007; Castañeda et al., 2010). Ghrelin 
also activates cells in the ARC that include the orexigenic neuropeptide Y (NPY) 
neurons (Page et al., 2007). There is also strong evidence that ghrelin has a 
peripheral appetite modulatory effect on satiety by affecting the mechanosensitivity 
of gastric vagal afferents, making them less sensitive to distension resulting in over 
eating (Kojima et al., 1999; Hewson & Dickson, 2000; Castañeda et al., 2010). In 
rodents, the expression of ghrelin is increased by energy restriction and weight loss, 
and i.c.v. infusion stimulates energy intake and body weight gain (Hewson & 
Dickson, 2000).   
1.1.12 Satiety 
Insulin and leptin are both involved in the longer-term regulation of energy intake, 
whereas short-term regulation is dependent on signals from the gastrointestinal tract 
which are generated in response to nutrient intake (McMinn et al., 2000).  
 
 
CHAPTER 1 
16 
 
1.1.12.1 CCK  
One of these hormones is cholecystokinin (CCK) which is released from the 
duodenum following the ingestion of fat and other dietary components, it aids in 
digestion and enhances satiety locally by acting on CCK-A receptors and centrally in 
the hypothalamus through CCK-B receptors (see Figure 1.7; Wilding, 2002; 
Dockray, 2004; Woods, 2004).  
1.1.12.2 Peptide YY 
Peptide YY (PYY) is another short-term regulating hormone secreted from cells that 
line the ileum and colon in response to the amount of energy consumed. PYY 
belongs to the same polypeptide family, as NPY and inhibits feeding by binding to 
NPY receptors in the ARC and therefore preventing action of the NPY 
neurotransmitter (see Figure 1.7; Batterham et al., 2002).  
 
Figure 1.7. Appetite controllers. The body produces hormones that act through the brain to 
regulate short- and long-term appetite and metabolism. The diagram shows the sources of 
several of the hormones know to influence these control mechanisms. Abbreviations: CCK 
= cholecystokinin; Ghr = ghrelin, PYY = Peptide YY. Source: Marx, 2003. Science 
299(5608): 846-9.  
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1.1.13 Nutrient Sensing  
Neurons sensitive to both glucose and fatty acids (FAs) are present in the 
hypothalamus and brainstem and play a key role in the CNS control of energy 
homeostasis.  
1.1.13.1 Glucose 
Several mechanisms have evolved for detecting and regulating concentrations of 
plasma glucose and these are dictated by the presence of sensors located in a number 
of regions in the body, particularly the brain (Pénicaud et al., 2000). Glucose is the 
primary energy source for the brain and is absorbed into the blood stream and 
crosses the BBB. The presence of neurons and glia sensitive to variations in glucose 
concentrations is well demonstrated in the brain, and in particular, in the 
hypothalamus (Levin, 2002; Pénicaud et al., 2002). Glucose accesses the 
hypothalamus via the CSF in the 3V. Cell types which sense the presence of glucose 
contain specific transporters and channels which detect the presence of the refined 
sugar. There are two types of glucose-sensing cells: those that increase their activity 
when glucose increases (responsive) and those that decrease their activity under the 
same conditions (sensitive) (Levin, 2002). These cells are also involved in the 
control of food intake, energy expenditure and lipid metabolism (Pénicaud et al., 
2000). Short-term food intake is increased in response to low concentrations of 
circulating glucose (Mayer, 1955).  
Glucose sensors are also present in different cell types throughout the body. 
The most commonly studied of these is the pancreatic β-cell where glucose sensors 
link plasma glucose variations to insulin secretion. These specific cell types express 
glucose transporter 2 (Glut2) and glucokinase. Glut2 facilitates a rapid glucose 
uptake irrespective of the extra-cellular concentration, whereas glucokinase controls 
glycolysis (Thorens, 2001). The cells within the brain which contain glucose sensors 
behave in a similar way (Jetton et al., 1994; Leloup et al., 1994) as confirmed by the 
presence of Glut2 (Jetton et al., 1994; Roncero et al., 2000; Thorens, 2001) and 
glucokinase in regions of the hypothalamus known to contain glucose sensitive 
neurons and glia (see Figure 1.8).  
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Figure 1.8. Proposed glial-neuronal loop at work in central sensing of hypoglycaemia 
via GLUT2. This scheme illustrates the pivotal role of GLUT2 in glial cells in first-hand 
detection of hypoglycaemia. How these specific glial cells then connect to neurons within 
the brainstem (NTS and dorsal motor nucleus of the vagus) to relay information is unknown 
but may involve the lactate shuttle as well as signalling via ATP-regulated K+ channels (not 
illustrated). The drop in glycaemia may also be directly sensed by neurons and pancreatic α 
and β cells but not through GLUT2 (the transporter/detectors involved are so far unknown). 
Ultimately, autonomic nervous signals and the drop in intra islet insulin levels promote 
glucagon secretion. Source: Klip & Hawkins, 2005. J Clin Invest 115(12): 3403–3405. 
 
Glucose sensors are present in a number of brain regions. Specifically, 
responsive neurons are found in regions known for their involvement in the control 
of feeding, such as the VMH, ARC and PVN of the hypothalamus, the substantia 
nigra of the midbrain, the nucleus of the solitary tract, as well as the motor nucleus 
of the vagus in the brainstem (Dunn-Meynell et al., 2002). Studies have shown that 
injecting an antisense against the glucose transporter, into the ARC of rats, results in 
a reduction in body weight (Levin, 2000). The most impressive effect of this 
treatment, however, is the complete inhibition of insulin secretion induced by an 
increase in blood glucose concentrations following an injection into the carotid 
artery (Leloup et al., 1998). Other factors, such as fatty acids, hormones including 
insulin and leptin, and neurotransmitters, including NPY and orexin, also affect 
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glucose-responsive neurons (Yang et al., 1999; Schuit et al., 2001; Williams et al., 
2001).  
The hormones insulin and leptin and their respective hypothalamic receptors 
are responsible for the control of energy homeostasis by regulating food intake and 
energy expenditure. Studies have shown that insulin and leptin hyperpolarize rat 
hypothalamic glucose-responsive neurons by opening ATP sensitive potassium 
channels (KATP) (Spanswick et al., 2000a, 2000b). Therefore, glucose sensing 
neurons are part of a system which control energy homeostasis in an individual. 
However, studies have shown that these neurons are less abundant and function 
differently in models of metabolic disturbance such as obesity and type 2 diabetes 
(Rowe et al., 1996; Spanswick et al., 2000b; Levin, 2000; Song et al., 2001; Levin, 
2002).   
Research has revealed changes in the brain of a rat model of obesity, induced 
by consumption of a highly palatable diet (Pickavance et al., 2001). Interestingly, 
this diet incorporates only moderately elevated levels of macronutrients (fat and 
refined sugar), and therefore, is thought to exert its hyperphagic effects through the 
stimulation of hedonistic mechanisms, via “pleasure centres” within the brain, 
although this has yet to be proven. This model shows alterations in the size and 
character of specific populations of neurons in the hypothalamus and brainstem, 
which normally sense falling levels of glucose (glucose-sensitive) in the blood (Al-
Qahtani et al., 2008; Williams et al., 2008). This has particularly important clinical 
implications; that obese people, with type 2 diabetes may be particularly vulnerable 
when treated with insulin or drugs designed to reduce glucose levels, as they may not 
be able to sense the induced hypoglycaemia, and therefore, trigger the counter-
regulatory response. These, and many other, findings support a primary role for the 
brain in causing systemic dysfunction. The following section describes the role of 
fatty acid sensing in energy homeostasis.   
1.1.13.2 Fatty Acids 
Previously, it was thought that FAs were unable to cross the BBB; however, it has 
since been proven that lipids present in the brain are sourced from the plasma as well 
as by local synthesis (Rapoport et al., 2001). This is likely due to the week integrity 
of the BBB in the region of the ARC/ME, although, some such as polyunsaturated 
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FAs (PUFAs) are able to cross the BBB regardless due to specific transporters 
(Edmond, 2001; Watkins et al., 2001). FAs have been shown to activate neurons in 
the LHA (Oomura et al., 1975) and modify firing rate of neurons in the ARC (Wang 
et al., 2006). Studies have shown that i.c.v. infusion of the monosaturated FA 
(MUFA), oleic acid, decreases food intake, but replacing this FA with octanoic acid, 
a saturated fatty acid (SFA), had no effect, implicating the chain length and degree of 
saturation of the FA in this role (Obici et al., 2002). The same effects on food intake 
can be seen when inhibiting hypothalamic FA oxidation, as inhibition results in an 
increase in acyl-CoA, an enzyme involved in the metabolism of FAs, which, in 
excess, will act as a satiety signal (Lam et al., 2005). Studies showed that rats 
receiving a systemic or i.c.v. infusion of triglycerides (TGs) for two days increased 
plasma TG concentrations, which induced a decrease in sympathetic nervous 
activity. This decrease was responsible for the glucose-induced insulin secretion 
which characterises the pre-diabetic state (Magnan et al., 1999) and hepatic insulin 
resistance (Clement et al., 2002). The use of rodent models has also demonstrated 
that FA β-oxidation in the brain is required for their effects on insulin secretion and 
action (Cruciani-Guglielmacci et al., 2004; Dowell et al., 2005).  
The hypothalamus can detect and respond to changes in circulating FA 
concentrations through the involvement of lipid-sensing neurons. These neurons use 
FA as a signalling molecule to regulate their membrane and action potential. 
Therefore, FA can modify ion channel activity and consequently induce changes in 
the secretion of neurotransmitters (Oishi et al., 1990; Honen et al., 2003). Studies 
have shown that there are oleic acid-sensitive neurons in the ARC which are excited 
by a closure of chloride channels, and inhibited by activation of KATP (Wang et al., 
2006). However, oleic acid-sensitive neurons are insensitive to glucose 
concentrations. Therefore, it is suggested that among the neuronal population of the 
ARC some are sensitive to FAs and some to glucose. Yet, glucose concentrations 
seem to be involved in the function of FA-sensitive neurons (Pénicaud et al., 2002). 
In vitro studies have shown that ARC neurons grown with steady-state glucose 
concentrations are mainly excited, whereas neurons maintained with low glucose 
concentrations are inhibited, following the administration of oleic acid. These 
findings suggest that the interaction between glucose and FAs regulates oleic acid-
sensing in ARC neurons and that FA-sensitive neurons are activated or inhibited 
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dependent on the hypo-, normal, or hyperglycaemic state of an individual (Migrenne 
et al., 2007). As FAs are known to decrease food intake in the short term, it can be 
expected that they act through the stimulation of anorexigenic (POMC/CART) and 
inhibition of orexigenic (NPY/AgrP) neuropeptide expression. Studies have shown 
that i.c.v. infusion of oleic acid inhibits glucose production and food intake by 
decreasing hypothalamic expression of NPY (Obici et al., 2002).  
1.1.14 Other CNS Centres and Systems  
As mentioned previously, in the description of hedonic control of feeding, there are 
other CNS centres and systems involved in the control of feeding (see Figure 1.9). A 
brief overview of these additional regions is included below.   
1.1.14.1 Hippocampus  
The hippocampus is not only central to memory, it is also involved in the regulation 
of feeding through its processing of mnemonic techniques; including remembering 
whether one ate, where food is located, identifying hunger and remembering how to 
relieve this state (Volkow et al., 2011). The death of neurons within the 
hippocampus is linked with reduced cognition and memory as well as Alzheimers 
disease. Studies, using rodents, have shown that lesions of the hippocampus prevent 
the animal’s ability to determine between the states of hunger and satiety (Davidson 
et al., 2009), and in female animals resulted in hyperphagia (Forloni et al., 1986). 
Human imaging studies have shown activation of the hippocampus in states of 
hunger (Haase et al., 2009). The hippocampus expresses cannabinoid receptor type 1 
(CB1) receptors, ghrelin and insulin all factors involved in the control of feeding 
regulation suggesting that the hippocampus may be involved in the regulation of 
energy intake via other homeostatic processes (McNay, 2007; Massa et al., 2010).  
1.1.14.2 Reward Pathways 
Reward pathways, such as those regulated by opioids and dopamine are heavily 
involved in the control of energy homeostasis. As mentioned previously, dopamine 
is a neurotransmitter which regulates reward-like behaviours through its projections 
from the ventral tegmental area into the nucleus accumbens, dorsal striatum, 
hippocampus and amygdala and LHA (Wise, 2006). Human studies have shown that 
the ingestion of palatable, energy dense foods results in an increase in dopamine 
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within the dorsal striatum in proportion to self-reported pleasure gained from eating 
the item (Small et al., 2003). However, this can develop into a predictor of reward 
upon habituation to a food item and dopamine is then released upon anticipation 
(smell of food) rather than consumption (Epstein et al., 2009; Schultz, 2010), 
resulting in the development of a conditioned response. The extensive glutamatergic 
afferents from dopamine neurons to regions involved in homeostatic (hypothalamus) 
and reward (nucleus accumbens) control regulate activity in response to varying food 
cues (Meguid et al., 2000; Epstein et al., 2007; Geisler & Wise, 2008). Mice with a 
dopamine deficiency die of starvation because of a lack of motivation to eat 
(Szczypka et al., 2001), but restoration of this process prevents this. The hedonic 
properties of food also depend on endocannabinoid neurotransmission. Studies have 
shown that Tetrahydrocannabinol, the psychoactive constituent of the cannabis plant, 
acts via CB1 receptors in the hypothalamic nuclei to directly increase appetite. 
Hypothalamic neurons produce endocannabinoids that work to tightly regulate 
hunger (Berridge, 2009). The amount of endocannabinoids produced is inversely 
correlated with the concentration of leptin in the blood. Studies have shown that 
mice without leptin become obese but express high levels of hypothalamic 
endocannabinoids as a compensatory mechanism (Matias & Di Marzo, 2004).  
 
Figure 1.9. Sagittal section through the rat brain depicting reward pathways (red and 
green lines). Behavioural and anatomical observations suggest that nucleus accumbens to 
hypothalamus to hippocampal projections are involved in the reward-driven food intake by 
modulating hypothalamic feeding circuits, thought to be crucial for homeostatic control of 
energy balance. Indirect projections though the ventral pallidum and projections from the 
amygdala and relevant cortical areas may also be important. Abbreviations: 5-HT, serotonin; 
ACh, acetylcholine; ADH, antidiuretic hormone; AMG, amygdala; Arc, arcuate hypothalamic 
nucleus; Cb, cerebellum; CPu, caudate putamen (striatum); DA, dopamine; GABA, gamma-
aminobutyric acid; Glu, glutamate; HIP, hippocampus; HYP, hypothalamus; LC, locus 
coeruleus; NAc, nucleus accumbens; NA, noradrenaline; PFC, pre-frontal cortex; PVN, 
paraventricular hypothalamic nucleus; TH, thalamus; VTA, ventral tegmental area. Source: Ash 
& Djouma, 2011. J Addict Res Ther 4:003. 
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Many of the feeding related control mechanisms described above display 
elements of circadian rhythm. This clock-like control mechanism is controlled by 
several of the hypothalamic nuclei mentioned previously, as well as the 
suprachiasmatic nucleus (SCN).  
1.1.15 Circadian Rhythms    
Many of the biological functions which are essential for an individuals’ needs 
demonstrate a rhythmic pattern which tracks the 24-hour clock. These daily 
variations are called circadian rhythms and allow for the preparation of 
environmental changes such as the diurnal (light) and nocturnal (dark) phases and 
associated food availability. Hence, the timing of many metabolic, behavioural and 
physiological processes is controlled by this circadian clock in association with any 
environmental changes. In mammals, this circadian system is comprised of several 
endogenous clocks. The main clock is located in the suprachiasmatic nucleus (SCN) 
of the hypothalamus (Welsh et al., 1995). Neurons present in this nucleus receive 
direct input from the retina in order to synchronise with changes in light, i.e. from 
diurnal to nocturnal phase (Meijer & Schwartz, 2003). When the presence of light 
activates the receptors of the retina, nerve impulses are conducted via the retino-
hypothalamic tract directly to the SCN (Hattar et al., 2002) which allows for the 
rhythmic control of metabolism via neuronal connections and circulating factors, 
within a 24-hour time period (Figure 1.10). Circadian clocks function because of 
specific genes known as clock genes. Clock genes are expressed in almost all tissues 
and their products interact at the transcriptional level to generate circadian 
oscillations (Ko & Takahashi, 2006).       
1.1.16 Circadian Control of Metabolism   
There are several hypothalamic nuclei which receive direct neuronal input from the 
SCN. These include the PVN (Dibner et al., 2010), which projects to peripheral 
tissues, such as the liver (Shibata, 2004), pancreas (Buijs et al., 2001) and adipose 
tissue (Kreier et al., 2002) via autonomic pathways. Furthermore, the VMH, LHA 
and ARC contain glucose-sensing neurons which receive nutritional information 
from glucose and hormones, including leptin and insulin in the plasma, and neuronal 
messages from the brainstem, including the nucleus of the solitary tract (NTS). 
These circulating factors are all known to influence energy homeostasis, and 
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concentrations follow a 24-hour pattern (Kalsbeek et al., 2001; Yamamoto et al., 
1987). Additionally nonesterified fatty acids in the liver also follow this pattern, 
thereby demonstrating that the SCN regulates the different clock genes in central and 
peripheral tissues.  
 
Figure 1.10. Organization of the circadian timing system. The master clock, located in 
the suprachiasmatic nucleus (SCN) of the hypothalamus, adjusts the timing of many 
secondary clocks/oscillators in the brain and peripheral organs, in part via nervous pathways 
(dotted red lines). Light perceived by the retina is the most potent synchronizer of the SCN 
clock (dashed yellow line); while meal time can synchronize peripheral clocks (blue arrows). 
Source: Delezie & Challet, 2011. Ann N Y Acad Sci 1243: 30-46. 
 
In rats, ablation of the SCN removes the circadian pattern of food intake 
(Nagai et al. 1978). While the master clock in the SCN is mainly synchronized by 
light, clock gene oscillations in peripheral tissues can be shifted by feeding time 
(Stokkan et al., 2001; Feillet et al., 2006). However, in conditions of extreme energy 
restriction, the synchronization of the SCN to light can be modified (Challet, 2010); 
this is potentially due to feedback from peripheral hormone signals confirmed by the 
presence of insulin, leptin and ghrelin receptors in the SCN (Håkansson et al., 1998; 
Zigman et al., 2006). This reinforces the role of the circadian system in the daily 
variation seen in parameters of metabolism (Delezie & Challet, 2011).  
Studies have shown that in the ob/ob mouse alterations in peripheral clocks 
occur before the onset of obesity and hyperinsulinaemia, suggesting that the clock 
can play a role in obesity in addition to the leptin deficiency. Within the SCN of 
these mice, the molecular clockwork is unchanged (Ando et al., 2011). Short-term 
high-fat feeding reduces circadian variations of leptin concentrations in rats (Cha et 
al., 2000) and humans (Havel et al., 1999) which could contribute to the 
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development of obesity. In mice, high-fat feeding attenuates the daily pattern of food 
intake, with a higher consumption during the day and a decrease during the active 
period, long before any significant weight gain is observed (Delezie & Challet, 
2011). Furthermore, changes in concentration and temporal pattern of glucose, 
insulin, leptin, and nonesterified fatty acid expression were also observed (Kohsaka 
et al. 2007). Diets high in fat seem to have a direct effect on the SCN as shown by 
studies where mice fed high-fat diets had disrupted synchronization to light 
(Mendoza et al., 2008).  
In clock gene, knockout mice, the development of hyperphagia is associated 
with an increased food intake during the diurnal/light phase, and attenuated energy 
expenditure at night, thus contributing to body weight gain in excess. Furthermore, 
these mice displayed hypertriglyceridemia, hyperglycemia, increased insulin 
sensitivity and altered gluconeogenesis (Rudic et al., 2004). In addition, there were 
also changes in the expression of hypothalamic neuropeptides, like CART and 
orexin, which play a role in central circuits controlling feeding and pleasure (Turek 
et al., 2005). Therefore, in summary, impairment of clock gene oscillations and 
metabolic pathways may explain the altered coordination of metabolic functions and 
clock-controlled output signalling, contributing to obesity and associated disorders. 
1.1.17 Definition of Obesity 
Obesity is a chronic metabolic disease resulting from an imbalance between energy 
intake and energy expenditure. The defining feature of obesity is an elevated body 
weight, due to an abnormal level of adiposity (Schwartz & Brunzell, 1997; Seidell & 
Flegal, 1997). White adipose tissue is the major site for storage of excess energy in 
the body. It is composed of adipocytes, extracellular matrix, vascular and neural 
tissues, preadipocytes, fibroblasts, stem cells, and immune cells such as macrophages 
and T lymphocytes. Adipose tissue secretes numerous peptides collectively known 
as adipokines such as leptin and adiponectin (described previously), and 
inflammatory cytokines such as Interleukin 6 (IL-6), Interleukin 1 (IL-1) and Tumor 
necrosis factor-alpha (TNF-α). Thus, adipose tissue is a dynamic endocrine organ 
with major roles in energy balance, glucose homeostasis and immune function. 
Excessive triglyceride (TG) accumulation within adipocytes, as a result of a positive 
energy balance (Figure 1.3), leads to adipocyte hypertrophy and a dysregulation of 
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adipokine secretory patterns. This has been primarily attributed to an imbalance in 
inflammatory adipokines. Thus, obesity is associated with a chronic low-grade 
inflammation in the adipose tissue (for a review see Kalupahana et al., 2011). Major 
cell types that play key roles in the inflammatory response during the onset of 
obesity can be seen in Figure 1.11. Obesity is considered a disorder of low-grade 
chronic inflammation, both peripherally, in the adipose tissue, and centrally, in the 
hypothalamus, as an increase in circulating TGs activates hypothalamic 
inflammatory signalling pathways, resulting in increased food intake and nutrient 
storage (Lumeng & Saltiel, 2011).  
 
Figure 1.11. Obesity-associated immune cell infiltration of adipose tissue. Lean 
individuals exhibit higher ratios of M2:M1 macrophage, Th1:Th2 T cell, and regulatory 
effector T cell. Excessive TG accumulation leads to adipose tissue remodelling, relative 
hypoxia, and endoplasmic reticulum (ER) stress, which trigger production of chemokines 
and changes in the above cell ratios, culminating in increased production of proinflammatory 
adipokines and reduced production of anti-inflammatory adipokines. Abbreviations: Ang II, 
Angiotensin II; IFN-γ, Interferon-gamma; IL-1, Interleukin 1; IL-6, Interleukin 6; IL-10, 
Interleukin 10; MCP-1, monocyte chemotactic protein-1; MIP-1α, Macrophage 
Inflammatory Proteins; MMP, Matrix metalloproteinases; PAI-1, Plasminogen activator 
inhibitor-1; RANTES, regulated and normal T cell expressed and secreted; TNF-α, Tumor 
necrosis factor-alpha. Source: Kalupahana et al. 2011. Adv Nutr 2:304-316. 
 
Obesity is caused by the interaction of multiple genetic and environmental 
factors (Vandenbroeck et al., 2007) and at present there is a lack of evidence for 
effective preventative measures (Brown et al., 2007). Research clearly indicates that 
human biology gives many individuals an underlying tendency to accumulate energy 
and conserve it because of factors such as genetic risk (Farooqi & O’Rahilly, 2007), 
the influence of early life experiences (Simopoulos, 1987; Schwartz & Brunzell, 
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1997; Seidell & Flegal, 1997; Barker, 2007; Singhal & Lanigan, 2007) and the 
sensitivity of the appetite control system (Bloom, 2007; Rolls, 2007; Wardle, 2007). 
However, these factors alone are unable to fully account for the recent rapid increase 
in the prevalence of obesity in the population, and this is likely to be the result of 
many biological, social and environmental factors including changes in food 
production and lifestyle patterns such as lack of exercise. These changes have 
resulted in an ‘obesogenic environment’ which has detrimental effects for the human 
population.  
The clinical assessment of body fat is approximated using a formula that 
combines an individual’s weight and height. This is known as the body-mass index 
(BMI), which is the weight of a person in kilograms divided by the square of their 
height in meters. Because of differences in body composition among the human 
population, the measure of BMI may not always accurately correspond to the same 
degree of fatness, but it is currently the most commonly used method for calculating 
it. An individual with a BMI between 20 and 24.9 is classified as ‘normal’, between 
25.0 and 29.9 is classified as overweight, and a person with a BMI above 30.0 is 
classified as obese. In extreme cases where BMI is over 40, a person is classified as 
morbidly obese (Kopelman, 2000). 
1.1.18 Risk Factors for Obesity 
Obesity develops because of an imbalance in energy intake and expenditure, as a 
result of behaviours (feeding and time spent active) and physiology (resting 
metabolism and expenditure when active), both of which are affected by genetic and 
environmental factors. The dramatic increase in the numbers of obese people in 
current society reflects changes in environmental factors such as increased food 
intake and reduced physical activity. However, in all populations some individuals 
will remain lean. These differences are likely as a consequence of genetic factors as 
is supported by the high heritability of body composition (Speakman, 2004). 
1.1.18.1 Environmental Factors  
The prevalence of overweight and obese individuals has increased dramatically in 
the last few decades. It is easy to identify some of the factors influencing this 
problem. One of these factors is an increase in the number of hours spent watching 
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the television (Armstrong et al., 1998; Crawford et al., 1999; Hernandez et al., 1999; 
Dennison et al., 2002; Janz et al., 2002; Lowry et al., 2002) and the negative impact 
this has on the hours spent conducting physical activity (Janz et al., 2002; 
Eisenmann et al., 2002). Many other changes in physical activity patterns have also 
changed, for example most people will now use the car to drive to a large 
supermarket rather than walk to their local shops (Eisenmann et al., 2002). At the 
same time as changes in level of physical activity have occurred, dietary habits have 
also altered. These alterations include the increased consumption of meals away 
from the home (Binkley et al., 2000) and greater consumption in total energy intake 
through snacks, sugary drinks, and fatty and fast food items (Nielsen et al., 2000; 
Nielsen & Popkin, 2003). Insights in neurobiology show how powerfully the wide 
variety and appeal of modern foods, with their increased palatability and capacity to 
heighten sensory stimulation, drive us to reward ourselves with the consumption of 
more food (Chipperfield et al., 2007; Jackson & Harris, 2007; Maio et al., 2007; 
Rolls, 2007; Vandenbroeck et al., 2007; Wardle, 2007). Therefore, combinations of 
reduced physical activity and increased energy consumption are likely responsible 
for the rise in obesity.  
1.1.18.2 Genetic Factors   
Despite the increase in the number of overweight and obese individuals, not 
everyone fits this category. This effect can be traced to individual differences in 
behaviour and physiology. These behavioural differences have a large genetic 
component to them. Therefore, despite individuals being exposed to similar 
environmental factors some people will develop obesity because their genetic 
makeup is such that they are more likely to adopt behaviours, or physiologies (such 
as low BMR), that predispose them to a positive energy balance (Speakman, 2004).   
1.1.18.3 Monogenic Forms of Obesity 
Studies have shown that obesity can, though rarely, develop as a result of one single 
gene mutation (Loos & Bouchard, 2003). For example, a small number of children 
have been found to have a leptin mutation. The phenotype of these individuals is 
very similar to the ob/ob mice which are obese, hyperphagic and hyperinsulinaemic 
(Montague et al., 1997). Some of these children were treated with recombinant leptin 
for a year and showed a reduction in weight and food intake as well as a normalising 
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of circulating hormones (Farooqi et al., 1999). Another example of a single gene 
mutation resulting in obesity is obvious in individuals with POMC deficiency 
syndrome characterised by early-onset obesity, hyperphagia, hypocortisolaemia and 
red hair with pale skin due to a reduction in melanocortin receptors (Farooqi et al., 
2006). The rodent homologue is the agouti (Ay) mouse which is obese with yellow 
fur, the mice exhibit mild hyperphagia and hyperglycemia (Manne et al., 1995). 
There are other rodent models of monogenic forms of obesity including the db/db 
mouse, Zucker and ZDF rats.  
1.1.18.4 Polygenic Forms of Obesity  
Individual cases of obesity caused by a single-gene mutation are rare; however, 
interactions between the polygenic variants in a range of genes are more common. 
Any of a group of alleles at distinct gene loci that collectively control a phenotype is 
termed a ‘polygenic’ variant. A polygenic effect can only be identified by showing 
that such an allele occurs in greater numbers in an obese individual than their lean 
counterpart. Potentially, many such polygenic variants play a role in body weight 
regulation. If an individual harbours many polygenic variants that increase body 
weight, obesity can ensue. Any single variant will have a higher frequency in obese 
than in normal weight and lean individuals. A polygenic basis of obesity implies that 
the specific set of polygenic variants relevant for obesity in one individual is unlikely 
to be the same in another obese subject (Hinney & Hebebrand, 2008). When 
researching the nature of polygenic obesity, many studies have selected candidate 
genes on the basis of their involvement in pathways of energy balance or adipose 
tissue biology. Both transgenic knockout mice and human studies have identified the 
leptin gene as a candidate, as increases in expression of this gene show positive 
associations with body weight, weight loss and BMI. Association studies between 
obese phenotypes and other key proteins (POMC, AgrP and NPY) are limited and 
require replication (Hinney et al., 2010). Genome-wide scans have identified 
evidence that the chromosome 2p22 is linked with both leptin and adiponectin 
influence on obesity (O’Rahilly et al., 2003). The modelling of polygenic obesity in 
rodents is discussed in Chapter 2 Section 2.1.2.2. Subtle differences between obese 
phenotypes and additional effects of the environment make characterising the genetic 
basis of obesity quite difficult (Figure 1.12).  
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Figure 1.12. The major causal linkages among genetics, environmental effects, 
physiology, behaviour, and energy balance. Multiple causal routes exist by which both 
environmental and genetic effects may exert their influence. The diagram clarifies that 
behaviour is not an alternative mechanism to genetics; they are different levels of the same 
phenomenon. Source: Speakman, 2004. J Nutr 134(8): 2090-2105. 
 
1.1.19 Significance of Obesity 
1.1.19.1 Obesity as a Medical Problem 
Obesity is a major worldwide health issue which dramatically increases the risk of 
developing several disorders, including impaired glucose tolerance, insulin 
resistance, type 2 diabetes, cardiovascular diseases, dyslipidaemia, arthritis, gallstone 
formation (Mokdad et al., 2001; Lobstein et al., 2007), attendant disorders including 
cancers, such as breast, colon, uterus, pancreas, and kidney cancer (Calle et al., 
2003; Kaidar-Person et al., 2011) and cognitive impairment and neurodegenerative 
disease e.g. Alzheimer's disease (Doherty, 2011).   
1.1.19.2 Type 2 Diabetes  
In instances of diabetes during obesity, fasting insulin concentrations are elevated, 
resulting in an increased insulin response to a glucose load. The enlarged presence 
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and distribution of adipose depots influences glucose metabolism, increasing 
apoptosis and thus, the release of free fatty acids from abdominal adipocytes, 
resulting in a greater uptake of insulin by the liver and finally, in increased 
gluconeogenesis and dyslipidaemia. These changes then lead to the development of 
hyperinsulinaemia and decreased skeletal insulin sensitivity. The inability of β-cells 
to adapt, long term, to this situation, and produce more insulin, leads to the 
development of type 2 diabetes. Studies have shown that even a relatively small 
weight gain of 5 kg increases the risk of diabetes by 50%, while losing the same 
amount of weight reduces the risk by the same (Kokkoris & Pi-Sunyer, 2003).  
1.1.19.3 Neurodegenerative Conditions 
Furthermore, obesity also increases the risk of neurodegenerative conditions such as 
dementia, Alzheimer’s, and Parkinson’s disease, which threaten quality of life and 
shorten life span. These diseases are characterised by the loss of structure, function, 
and death of neurons and are often associated with ageing. Leptin resistance or 
insensitivity often develops in individuals suffering from obesity, and in addition, the 
leptin signalling system is less active in the elderly (Doherty, 2011). These findings, 
and those that demonstrate that leptin has beneficial effects on both the survival and 
neurophysiology of the neurons that are lost in Alzheimer’s disease, reveal that this 
particular hormone may be a link between neurodegeneration and obesity or ageing 
(Doherty, 2011). Furthermore, obesity is associated with an increased consumption 
of diets high in fats and refined sugars; these dietary components are also associated 
with cognitive impairment within the hippocampus (Stranahan et al., 2008); a region 
known for its control of memories and learning. Studies have shown that increased 
consumption of diets high in these two items results in hyperphagia and obesity by 
interfering with hippocampal dependent memory inhibition that is critical in the 
ability of animals to refrain from responding to environmental cues associated with 
food, and ultimately from consuming energy intake in excess of that driven solely by 
essential need (Kanoski & Davidson, 2011).  
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1.1.20 Socioeconomic Significance of Obesity 
1.1.20.1 Burden on the NHS 
Dealing with the long-term consequences of obesity costs an estimated £5.1 billion 
each year (Scarborough et al., 2011), placing a huge strain on the NHS. Furthermore, 
the NHS has had to invest substantial sums of money in specialised facilities and 
technologies for handling morbidly obese patients, including lifting equipment, 
reinforced surgical tables and bariatric ambulances (Scarborough et al., 2011). 
Levels of obesity in the UK are increasing, with over a quarter of the adult 
population now classed as obese (HSCIC, 2012). It is estimated that these figures 
could reach 60% for men, 50% for women and 25% for children by 2050 
(McPherson et al., 2007). As a consequence, the proportion of associated disease, 
such as type 2 diabetes and metabolic syndrome will also increase substantially 
(Kopelman, 2007; McPherson et al., 2007). Expert opinion has suggested that, in the 
absence of additional interventions, the prevalence of obesity will continue to rise 
with no expectation of any reversal (Chipperfield et al., 2007). Therefore, the 
developments of both pharmaceutical and natural interventions which protect against 
this dysfunction are important to human health (Dourish et al., 2008; Buckley & 
Howe, 2009) as well as the economy.  
1.1.20.2 Economic Impact 
In addition to the well-documented health impacts, obesity also leads to a loss of 
individuals in the work force (Johnson et al., 2008). Obese workers tend to have 
higher rates of absenteeism and take more sick leave therefore increasing costs for 
the employer and reducing productivity (Neovius et al., 2009). Furthermore, 
specialist equipment, such as wider chairs, must be purchased to accommodate obese 
workers (Bakewell, 2007). Studies have shown that employees with a BMI of 40+ 
(morbidly obese) regularly have many more accidents such as falls at work, resulting 
in claims, than employees with a BMI of 18-25 (Ostbye et al., 2007). Due to the ever 
increasing rates of obesity, airlines currently face higher fuel costs and pressures to 
increase seating width (Dannenberg et al., 2004).  
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1.1.20.3 Growing Prevalence in the Developing World 
Until the last few decades, incidences of obesity were rare (Haslam, 2007). In 1997, 
the world health organisation (WHO) officially recognised obesity as a global 
epidemic. In 2005 WHO estimated that over 400 million adults, approximately 10% 
of the total population at that time, were obese, with greater prevalence among 
females (Caballero, 2007). Obesity rates in Australia, Canada and the USA are 
currently increasing at greater rates than the overall worldwide rate (Howard et al., 
2008). Previously, obesity was considered as a problem for developed countries 
only, but now incidences are increasing worldwide (Tsigos et al., 2008). Currently, 
sub-Saharan Africa is the only remaining region where obesity is still uncommon 
(Haslam & James, 2005).  
1.1.21 Treatment of Obesity 
Currently, there are limited options for treating obesity, and regimes including 
dieting and increased physical exercise (see Figure 1.2), as a combination with 
behavioural modifications are commonly recommended. A combined intervention 
consisting of a reduced-energy diet, increased physical activity and behavioural 
modification is the most effective therapy for weight loss and maintaining that loss. 
Weight loss occurs by generating a negative energy balance, which is achieved by 
consuming less energy (energy in), than that expended (energy out) (Figure 1.2; 
Blackburn & Walker, 2005; Tate, 2007). As a last resort there are also 
pharmaceutical and surgical interventions (Rucker et al., 2007). Surgical 
interventions such as the insertion of a gastric band or gastric bypass may assist with 
weight loss, and/or the surgical reduction of stomach volume and bowel length may 
lead to effects of increased satiation and reduced ability to absorb nutrients from 
food consumed (Mathus-Vliegen & Tytgat, 2005; Imaz et al., 2008). However, side 
effects include deficiencies in vitamins, iron, calcium and electrolytes (Korner et al., 
2006).  
1.1.21.1 Pharmaceutical Intervention 
Anti-obesity pharmaceuticals may also be taken to decrease appetite and/or inhibit 
the absorption of fat into the body but these are intended to be taken in conjunction 
with a suitable diet and physical activity regime. Over the years there have been 
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around 120 different types of anti-obesity medications; however, currently there is 
only one licensed medicine available, known as Orlistat. It works by preventing the 
digestion of fat, so it is not absorbed into the body, and is passed out in faeces. This 
medicine helps to prevent weight gain but must be combined with diet and exercise 
regimes to aid in weight loss and even then, weight loss may be slow (Rucker et al., 
2007). Doctors will only prescribe this drug when a significant attempt at weight loss 
through diet and exercise has been demonstrated and the patients BMI is 30 plus or, 
if the patients BMI is 27 plus and they have an associated condition of obesity such 
as diabetes or heart problems. There are a number of side effects associated with this 
drug, they include oily discharge and oily stools, urgent and frequent passing of 
stools, flatulence, stomach cramps, headaches and respiratory tract infections 
(Rucker et al., 2007). In July 2012, two other medications were also approved for 
use by prescription only; these include lorcaserin and a combination pill of 
phentermine and topiramate (Bays, 2011a, b). Lorcaserin is a selective 5-HT2C 
receptor agonist and activation of these receptors in the hypothalamus activates 
POMC production and therefore promotes weight loss through satiety (Thomsen et 
al., 2008). In comparison, phentermine is an appetite suppressant and achieves this 
through stimulation of the amphetamine and phenethylamine classes. Topiramate is 
an anticonvulsant that has weight loss side effects due to its ability to reduce appetite 
(Hellmich, 2012).  
There are numerous side effects associated with taking these anti-obesity drugs and 
many have been removed from the market due to serious issues such as depression, 
suicide, cardiovascular problems and birth defects (Rucker et al., 2007).  
1.1.21.2 Relative Success 
Currently, there is no simple cure for obesity. The management of numerous external 
factors have to be considered when evaluating obesity as a whole. Necessary 
adjustments are required to dietary habits, physical activity and behavioural traits. 
Furthermore, drug treatment is currently available, but retrospectively it has mostly 
been a disappointing proponent in the initiative against obesity due to detrimental 
side effects. Anti-obesity drugs are able to assist in short-term weight loss but are 
unsatisfactory when considering maintaining a lower weight. Surgical interventions 
are available but even they have negative side effects. 
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1.1.21.3 Potential for Nutraceuticals 
As the prevalence of obesity is continuing to rise (Chipperfield et al., 2007) and 
current pharmaceutical treatments are lacking, the development of natural 
interventions which protect against this dysfunction are important to human health 
(Dourish et al., 2008; Buckley & Howe, 2009).  
1.1.21.4 Nutraceuticals 
Nutraceuticals are food items that provide health and medical benefits (Wildman, 
2001) and these products are expected to prevent chronic illnesses, improve health 
and increase life expectancy (Kalra, 2003). In the case of obesity, the preference for 
research of nutraceuticals over pharmaceuticals is clear due to a lack of available 
drugs to treat the condition.  
1.1.21.5 Examples of Nutraceuticals 
There are several examples of food items that have medicinal properties; these 
include the antioxidants which prevent oxidation of molecules into free radicals 
which can cause cell damage, tumour formation and cancer (Rajamani et al., 2011). 
Examples of beneficial antioxidants include resveratrol from red grape products, 
flavonoids inside citrus fruits, tea, red wine, and dark chocolate, and anthocyanins 
found in berries (Aggarwal, 2010). Dietary fibre has also been shown to reduce 
hypercholesterolemia (Weingartner et al., 2008), and broccoli, which contains 
sulforaphane, is thought to have anti-cancer properties as the sulforaphane enhances 
the expression of tumour suppressor proteins (Hayes et al., 2008). Furthermore, the 
isoflavonoids found in soybean are thought to improve arterial and cardiac health 
(Aggarwal, 2010). One of the most versatile and well recognised of the nutraceutical 
families are the omega-3 polyunsaturated fatty acids (PUFAs) found in fish oil. 
1.1.21.6 Omega-3s as Nutraceuticals  
The omega-3 PUFAs are precursors for the eicosanoids (DeCaterina & Basta, 2001), 
which are signalling molecules that act as vasodilators and bronchodilators in 
conditions such as asthma and heart disease (Funk, 2001; Judé et al., 2006). These 
FAs may also prevent the activity of the enzyme tyrosine kinase (Carpentier et al., 
2006), which is involved in the cell-growth signalling mechanism and this reduces 
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cardiac hypertrophy and the rapid cell proliferation involved in cancer formation 
(Wildman, 2001). PUFAs also appear to inhibit the synthesis of fatty acid synthase, 
which is the principal enzyme involved in fatty acid synthesis (Buckley & Howe, 
2009). This leads to decreased quantities of body fat reducing the likelihood of 
obesity and therefore, indirectly reducing the development of associated conditions 
such as hyperinsulinaemia, hypertension and hyperlipidemia (Wildman, 2001).  
Alpha-linoleic acid (omega-6 PUFA) from flax and omega-3 fatty acids 
present in fish oil are already well established as reducing the risk of cardiovascular 
disease (Shibamoto et al., 2008; Weingartner et al., 2008). However, they are also 
known to prevent cognitive decline, dementia (Cunnane et al., 2009), macular 
degeneration (Poudyal et al., 2011), breast, prostate, and colorectal cancer (Rose & 
Connolly, 1999), inflammatory disorders, arthritis and inflammatory bowel 
conditions (Sijben, 2009). They are also involved in promoting brain cognition and 
development as well as visual acuity (Poudyal et al., 2011). Dietary omega-3 PUFAs 
are also important for neonatal health and development (Horrocks & Yeo, 1999; 
Innis, 2000; Voigt et al., 2000) in addition to the generation of a healthy immune 
system (Sijben, 2009). The structure and function of the omega-3 PUFAs is 
discussed in later sections of this review.  
1.1.21.7 Health Benefits Associated with omega-3 Fatty Acids 
Studies have shown that dietary modifications, including an increase in the relative 
abundance of omega-3 PUFAs in the diet, can protect against metabolic disturbances 
(Yashodhara et al., 2009). The cardioprotective effects of omega-3 fatty acids, 
especially Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA), have 
been well defined by cell culture, animal and human studies (Anderson, 2009; Duda 
et al., 2009; Lee et al., 2009; Saremi et al., 2009; Yashodhara et al., 2009). The main 
source of EPA and DHA in the human diet is from fish (Lee et al., 2009), which 
acquire these PUFAs by consuming algae rich in linoleic acid which is then 
converted into the longer and more unsaturated forms (Wildman, 2001). There is 
considerable evidence, through studies involving rodents, that supplementing a diet 
high in fat with omega-3 PUFAs can attenuate weight gain and reduce body fat, 
particularly the epididymal depot, as well as reducing circulating plasma TGs 
(Cunnane et al., 1986; Belzung et al., 1993; Hainault et al., 1993; Baillie et al., 
1999; Ruzickova et al., 2004). The impact of consuming omega-3 PUFAs on body 
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composition has yet to be fully determined in the human population but research has 
shown that increasing consumption of omega-3 PUFAs by approximately 3 g per 
day can also reduce body weight and body fat in the overweight and obese (Kabir et 
al., 2007).  
1.1.21.8 Mechanisms behind Health Benefits  
Increasing the dietary intake of omega-3 PUFAs may assist with body weight and 
body fat reduction by several mechanisms. These include altered gene expression 
(activate AMP-activated protein kinase), resulting in increased fat oxidation in 
adipose, liver, cardiac, intestinal and skeletal muscle tissue and reduced fat 
deposition in adipose tissue (Buckley & Howe, 2010; Kalupahana et al., 2011). 
Omega-3 PUFAs also increase satiety therefore preventing hunger, although most 
studies, including those in rodents, have not observed reduced food intake (Cunnane 
et al., 1986; Hainault et al., 1993; Hill et al., 1993). Results from some studies have 
indicated that omega-3 PUFAs may promote an increase in lean body mass, 
therefore increasing metabolic rate and decreasing body fat (Buckley & Howe, 
2009). Discrepancies in the results of many studies which administer PUFAs to 
rodents make it difficult to draw valid conclusions on their exact beneficial roles. 
More systematic studies need conducting in order to overcome this problem. This 
concept is discussed in more detail in Chapter 2.    
PUFAs are natural ligands at the key transcription factors, the retinoic acid 
receptors (RARs), retinoid X receptors (RXRs) and the peroxisome proliferator-
activated receptors (PPARs), and in this way directly regulate gene transcription 
related to a range of functions, including energy metabolism and cognition. By this 
mechanism, they act at the level of the adipocyte to attenuate the accumulation of 
adipose tissue by inhibiting expression of lipogenic genes and stimulating 
transcription of those involved in lipid oxidation (see Figure 1.13; Bordoni et al., 
2006). Omega-3 PUFAs modulate adipokine secretion from adipose tissue. They 
increase plasma adiponectin levels in obese humans and rodents (Flachs et al., 
2006), which could be a potential mechanism by which they improve insulin 
sensitivity. They also induce leptin secretion and reduce the expression of several 
inflammatory cytokines from the adipose tissue, including TNFα and IL-6 
(Kadowaki et al., 2006). Production of inflammatory cytokines is dependent on 
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activation of the NF-kB and JNK pathways. Omega-3 PUFAs bind to G protein-
coupled receptor (GPR) 40 or 120, and inhibit NF-kB and JNK, attenuating this 
response (Kalupahana et al., 2011).  
 
Figure 1.13. The PPARα pathway. Through activation of PPAR, omega-3 (n-3) PUFAs 
are able to regulate metabolism and other cell and tissue responses, including adipocyte 
differentiation and inflammation. Abbreviations: ACO= acyl CoA oxidase; ApoA= 
apolipoprotein A; COX= cyclooxygenase; CYP4A= cytochrome P450 4A; FABP= fatty acid 
binding protein; L= ligand; NFkB= nuclear factor kappa B; PPAR= peroxisome proliferator-
activated receptors; RXR= retinoic acid receptor. Source: Calder, 2012. J Nutr 142(3): 592-
599.  
 
1.1.21.9 Advantages over Other Therapies 
As the current treatments to tackle obesity are lacking, the discovery that omega-3 
PUFAs have such positive effects makes for an interesting avenue of research. As 
many individuals are reluctant to take pharmaceuticals, and compliance issues are a 
problem with the use of energy-restrictive diets and physical activity, the simple 
suggestion to introduce omega-3 PUFAs to an individual’s diet may meet with 
greater compliance. The effects of nutrients on body weight are discussed in more 
detail in the following sections. 
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1.2 Importance of Diet Composition in Body Weight Regulation 
1.2.1 Macronutrient Effects on Body Weight 
The major groups of nutrients have been classified according to the amounts in 
which they are required, their chemical nature and functions in the body. There are 
two types of nutrients, macronutrients and micronutrients. Macronutrients are 
defined as the components within a diet that provide sources of energy to the 
individual, of which there are three groups: protein, fat and carbohydrate. In 
comparison, micronutrients are the nutrients required in small quantities, to control a 
range of physiological functions but which the individual cannot produce 
themselves. These include minerals and vitamins which, although essential, do not 
have an energy component to them (Barasi, 2007).   
1.2.2 Carbohydrates 
A carbohydrate is an organic compound comprised of carbon, hydrogen and oxygen 
molecules. Carbohydrates are saccharides, easily divisible into four groups: 
monosaccharides, disaccharides, oligosaccharides, and polysaccharides. These 
groups vary in degree of complexity. The monosaccharides and disaccharides form 
simple carbohydrates (refined sugars) (Flitsch & Ulijn, 2003), whereas the 
oligosaccharides and polysaccharides are more complex (Barasi, 2007). 
Monosaccharides are the simplest type of carbohydrate; examples include glucose, 
fructose, lactose and ribose. Monosaccharides are the precursors for the 
disaccharides, such as sucrose, and polysaccharides such as starch. Polysaccharides 
function as energy stores (e.g. starch and glycogen) and as structural component of 
cells (e.g. cellulose and chitin). Oligosaccharides contain a small number of simple 
sugars and often remain undigested until they reach the colon where they undergo 
fermentation serving as a food source for intestinal microflora (Barasi, 2007).   
Saccharides and their associated derivatives include many important 
biological molecules such as the monosaccharide ribose, which is a component of 
RNA, and deoxyribose, a component of DNA (Flitsch & Ulijn, 2003). Some 
carbohydrates resist digestion and comprise the non-starch polysaccharides which 
are part of the dietary fibre which aids in the function of the gastrointestinal tract 
(Barasi, 2007). In terms of food consumption, complex carbohydrates such as 
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cereals, bread, and pasta contain starch, whereas the simple carbohydrates, found in 
sweets and jams, contain refined sugars.  
1.2.2.1 Carbohydrate Metabolism  
The most utilised of the carbohydrates is the monosaccharide glucose, which can be 
successfully metabolised by all organisms. Simple carbohydrates, such as refined 
sugars, can be broken down in cells. More complex carbohydrates, such as the 
disaccharide sucrose, are broken down in the small intestine by enzymes specific to 
the sugar which split the chain releasing simple sugars. In the instance of sucrose, 
this is broken down by sucrase. If sucrase is not secreted, then intolerance will 
develop which can lead to malabsorption and diarrhoea. Another carbohydrate 
example is the polysaccharide starch, which is metabolised by the enzyme amylase, 
present in saliva of the mouth. This enzyme breaks the starch into amylose which is 
then further digested in the duodenum into maltose and glucose (Barasi, 2007).  
There are other carbohydrates, such as cellulose, that humans cannot digest 
as they do not produce the enzymes necessary for the process. Carbohydrates are an 
instant fuel source because they are easier to metabolise than fats and protein. For all 
mammals, glucose is the most important carbohydrate, and the brain is fuelled 
primarily by this sugar. The concentration of circulating plasma glucose is involved 
in the control of insulin concentrations (Barasi, 2007).   
1.2.2.2 Glucose Regulation  
When carbohydrates are metabolised, glucose is transported from the small intestine 
across the apical membrane and into the bloodstream by a twostep process. Firstly, 
glucose transporter proteins, present in cell membranes, facilitate the movement of 
glucose down its concentration gradient from the lumen of the small intestine into 
the apical cells. Secondly, glucose moves from the apical cells into the bloodstream 
via facilitated diffusion (Barasi, 2007). This process allows for the maintenance of 
steady concentrations of glucose in the body, but this can also be helped by choosing 
foods with certain glycaemic index. The glycaemic index provides an indication of 
how blood glucose concentrations change after the consumption of different 
carbohydrates. Essentially, glycaemic index is a measure of how quickly food 
glucose is absorbed. Lower glycaemic index foods are preferable in situations where 
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an extended period of glucose release is necessary, for example to regulate diabetic 
control, or for athletes in training for sporting events (Barasi, 2007).    
1.2.2.3 Dietary Treatment of Type 2 Diabetes 
As mentioned previously, type 2 diabetes is a disease increasing in prevalence due to 
the rise in the number of obese individuals. This disease results from a dysfunction 
in carbohydrate metabolism as characterised by hyperglycemia (McGeoch et al., 
2011). The importance of glycaemic control in the prevention of chronic 
complications associated with diabetes was demonstrated by the UK Prospective 
Diabetes Study (Stratton et al., 2000). The consumption of carbohydrates is one of 
the main factors affecting glycaemic control and both the quantity, and quality (as 
indicated by the glycaemic index), of the ingested carbohydrate has an effect on 
diabetic control (Jenkins et al., 1981). The regular consumption of foods with a high 
glycaemic index has been linked with the development of several conditions such as 
diabetes, obesity and cardiovascular disease, whereas low glycaemic index foods are 
recommended as preventative measures and even treatments (McGeoch et al., 2011). 
These diets, low in glycaemic index, tend to have a higher amount of fibre which 
aids in the absorption of dietary cholesterol, contributing to a greater release of 
satiety signals and reducing the likelihood of feeling hungry, thus helping to 
maintain body weight control. In patients with type 2 diabetes, this results in a lower 
insulin discharge which helps to maintain a normalised, steady, blood glucose 
concentration (Jenkins et al., 2002 Willett et al., 2002; Colombani, 2004).  
Additional macronutrients which effect body weight regulation are described in the 
following sections.  
1.2.3 Fatty Acids 
The consumption and composition of dietary fatty acids has been the subject of 
extensive research because of the involvement of fats in the development of diseases 
such as obesity, diabetes and cardiovascular disease. Fats are essential in the diet to 
provide a source of energy, structural components within the body and as a 
constituent of metabolic pathways. Most dietary fats take the form of triglycerides 
(TGs), which contain three fatty acids (FAs) attached to a glycerol backbone. These 
fatty acids are the main components of dietary lipids. Their basic structure comprises 
a carbon backbone, with a carboxyl (-COOH) group at one end and a methyl group (-
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CH3) at the other end. The FAs differ from one another in their chain length and 
number of double bonds (degree of saturation). These variations determine how they 
are metabolised and therefore, their effects on health. Specific FAs are important for 
cell membrane structure and function. There are several general categories of these 
fatty acids; these include the saturated fatty acids (SFAs), monounsaturated fatty 
acids (MUFAs) and polyunsaturated fatty acids (PUFAs) (Moussavi et al., 2008).  
A FA nomenclature system exists as follows: number of carbon atoms, 
number of double bonds, followed by location of first double bond (carbon atom 
counting from the methyl group end); e.g. 18:1 (n-9) (oleic acid) is an 18-carbon 
chain with one double bond located at the 9th carbon from the CH3 end; n is 
sometimes written as omega (ω); e.g. n-3 = ω-3. Additional examples can be seen in 
Table 1.1.  
1.2.4 Saturated Fatty Acids 
The SFAs contain no double bonds along the chain length and have the maximum 
number of hydrogen atoms on each carbon molecule, and because of this, they tend 
to be solid at room temperature. Milk fat, containing SFAs synthesised by bacteria in 
the bovine rumen, is the main dietary source of short-medium chain SFAs (4-10 
carbons), and these are present in butter products. The majority of dietary SFAs are 
medium chain (14-18 carbons) and come from palm oil, coconut oil, animal fats and 
hydrogenated fats. Longer chain SFAs (24 carbons) are synthesised within brain 
tissue membranes (Barasi, 2007). An example of a SFA can be seen in Figure 1.14 
(also see Table 1.1). 
 
 
Figure 1.14. Chemical structure of the SFA, stearic acid. Stearic acid has 18 carbon 
molecules and is present in many animal fats. However, it is also present in high 
concentrations in cocoa and shea butter. Abbreviations: C= carbon; H= hydrogen; O= 
oxygen. Source: www.chemspider.com 
 
SFAs are one of the main culprits behind the current obesity epidemic. One 
of the likely reasons behind this is their role in passive overconsumption.  
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1.2.5 Role of Passive Overconsumption in Obesity 
When eating, food items provide sensory signals to the body through taste, texture, 
smell, sight, and sound. These signals then prompt a postingestive response within 
the body (Stubbs et al., 2001; Brunstrom, 2007). Because of this, an individual 
learns to expect certain satiety responses based on the sensory signals of the foods 
consumed. However, in today’s food climate, the sensory signals are often 
disconnected from their original nutritional consequence. For example, when an 
individual consumes food items such as cake, which is high in fat content, they often 
have difficulty identifying these foods as actually being high in fat (Drewnowski, 
1988; Drewnowski & Schwartz, 1990; Lawton et al., 2000; Stubbs et al., 2001). This 
is because the item lacks the sensory properties associated with fat, such as thick but 
creamy texture, and therefore, one is unable to recognise the real nutrient content of 
the item due to inappropriate sensory signalling (Drewnowski, 1995). This 
disconnection between sensory and metabolic messages results in an inadequate 
adjustment of energy intake when consuming food items which are high in fat and 
energy dense (Blundell & MacDiarmid, 1997; Mazlan et al., 2006; Westerterp, 
2006). The consumption of these types of food then stimulates passive 
overconsumption, which ultimately leads to weight gain (Viskaal-van Dongen et al., 
2009). Studies have shown that following episodes of overconsumption, in many 
instances, individuals do not adjust their energy intake to return to an energy balance 
situation (Levitsky et al., 2005; Jebb et al., 2006; Viskaal-van Dongen et al., 2009). 
These results support an inability to detect a high energy intake, which may result 
from sensory signals that are not in accordance with the actual nutrient content of the 
food (Viskaal-van Dongen et al., 2009).  
Furthermore, the passive overconsumption effect of eating a diet high in fat is 
likely linked to the actual high energy density of high-fat foods (Blundell & 
MacDiarmid, 1997). Dietary fat provides double the amount of energy per gram of 
food intake than either protein or carbohydrates (Poppitt & Prentice, 1996); 
therefore, a meal consisting of high-fat food is usually smaller in weight than a high 
carbohydrate meal leading the individual to eat again sooner (Castellanos & Rolls, 
1997). This may also be compounded by the fact that diets high in fat exert a weaker 
effect on satiety than protein and carbohydrate (Blundell et al., 1993; Blundell & 
MacDiarmid, 1997; Fernández-Quintela et al., 2007). The process of passive 
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overconsumption is thought to play a major role in the development of obesity; 
however, not all FA types influence consumption in this way, in fact, some have 
opposing effects.  
1.2.6 Monounsaturated Fatty Acids 
In comparison to SFAs, MUFAs contain one double bond. An example of this is 
oleic acid (see Figure 1.15 and Table 1.1), derived primarily from rapeseed and olive 
oil. Fish oil may also provide a small amount of MUFAs (Barasi, 2007).  
 
Figure 1.15. Chemical structure of the MUFA, oleic acid. Oleic acid has 18 carbon 
molecules and one double bond. It is present in olive and rapeseed oil, as well as some 
animal fats. Abbreviations: C= carbon; H= hydrogen; O= oxygen. Source: 
www.chemspider.com 
 
1.2.7 Polyunsaturated Fatty Acids 
Finally, PUFAs have the lowest melting point of all the FAs because of the multiple 
double bonds in their structure, and they form a liquid at room temperature. The 
majority of PUFAs contain 18-22 carbon molecules and up to six double bonds; 
these belong to the omega-6 and omega-3 families (see Figure 1.16, 1.17 and Table 
1.1). The families are dictated by the position of the first carbon-carbon double bond. 
PUFAs regulate the fluidity and other properties of cell membranes, with particular 
roles in the brain, CNS and retina. They are also precursors of the eicosanoids, which 
are involved in the regulation of metabolic processes. Eicosanoids from the omega-3 
and omega-6 families vary in their potency and function, and an altered balance can 
affect functions such as inflammation. The body is unable to synthesise the omega-3 
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FAs; DHA and EPA, and therefore, they must be supplied from dietary sources 
(Barasi, 2007).  
 
Figure 1.16. Chemical structure of the omega-6 PUFA, linoleic acid. Linoleic acid has 18 
carbon molecules and two double bonds. It is present in vegetable oils such as sunflower oil. 
Abbreviations: C= carbon; H= hydrogen; O= oxygen. Source: www.chemspider.com 
 
 
  
  
Figure 1.17. Chemical structures of the omega-3 PUFAs, docosahexaenoic acid (DHA) 
and eicosapentaenoic acid (EPA). DHA has 22 carbon molecules and six double bonds, 
whereas EPA has 20 carbon molecules and 5 double bonds. Both DHA and EPA are present 
in fish oil. The body cannot generate these PUFAs, and therefore, they must be consumed in 
the diet. Abbreviations: C= carbon; H= hydrogen; O= oxygen. Source: 
www.chemspider.com 
DHA 
EPA 
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Expansion of the nomenclature system for the example FAs included above can be 
found in Table 1.1.  
 
Table 1.1. Nomenclature for example FAs. The common name, nomenclature and 
chemical name for all FA examples included here.  
 
Common Name Nomenclature Systematic Name 
Stearic acid 18:0 Octadecanoic acid 
Oleic acid 18:1 (n-9) (9Z)-9-Octadecenoic acid 
Linoleic acid 18:2 (n-6) (9Z,12Z)-9,12-Octadecadienoic acid 
Docosahexaenoic acid 22:6 (n-3) (4Z,7Z,10Z,13Z,16Z,19Z)-4,7,10,13,16,19-
Docosahexaenoic acid 
Eicosapentaenoic acid 20:5 (n-3) (5Z,8Z,11Z,14Z,17Z)-5,8,11,14,17-
Icosapentaenoic acid 
 
1.2.8 Properties and Metabolism of Fatty Acids 
Saturated and unsaturated fats vary in their energy content and melting point. As 
unsaturated fats (MUFAs and PUFAs) contain fewer carbon-hydrogen bonds than 
SFAs with the same number of carbon atoms, they will yield slightly less energy 
during metabolism than SFAs with the same number of carbon atoms (see Figures 
1.14-1.17). SFAs can coordinate themselves into a closely packed arrangement, so 
they can freeze easily and are typically solid at room temperature (see Figure 1.18). 
For example, animal fats, such as lard, are high in SFA content and are solid in form. 
In comparison, MUFAs and PUFAs, which often come from olive and fish oils, are 
highly unsaturated and form an oily liquid at room temperature (Moussavi, 2008). 
  
Figure 1.18. Diagrammatic representation of fatty acid types. Fatty acids contain a 
glycerol head with a fatty acid tail. The unsaturated (MUFA and PUFA) examples contain 
carbon-carbon double bonds which appear as kinks in the FA tail. In comparison, the SFA 
has a straight tail which allows them to be closely packed together. Source: Adapted from 
www.sciencedirect.com. 
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The variability in fatty acid structure, such as chain length, degree of unsaturation, 
and position of the double bonds affects the rate at which the fatty acid is oxidised 
(DeLany et al., 2000; Moussavi, 2008). Carbon labelling techniques have shown that 
PUFAs oxidise more rapidly than SFAs (Mead et al., 1956; Cenedella & Allen, 
1969). Measurement of FA oxidation in rats with a range of fatty acids has shown 
that oxidation of SFAs decreases with increasing carbon chain length. However, for 
unsaturated fatty acids, the medium chains FAs (8–14 carbons) are oxidized the most 
rapidly (Leyton et al., 1987). More recent human studies have shown that oxidation 
of oleic acid (MUFA) is greater than that of linoleic acid (omega-6 PUFA), which is 
greater than that of stearic acid (SFA). Therefore, short- and medium-chain 
unsaturated fatty acids (oleic and linoleic acid) are oxidised more rapidly than the 
long chain SFAs (palmitic and stearic acid) (DeLany et al., 2000). Human feeding 
studies, in which the ratios of PUFA to SFAs in the diet are altered, suggest that 
PUFAs are more greatly oxidised than the SFAs in general (Jones & Schoelloer, 
1988). These results confirm the findings of others that the PUFAs, linoleic acid 
(omega-6) and linolenic acid (omega-3), are highly oxidised in comparison to SFAs 
(DeLany et al. 2000). The observed differences in rates of oxidation may also relate 
to differences in weight gain observed when different types of FA are consumed. As 
PUFAs are more highly oxidised than the SFAs, this may lead to less storage of the 
PUFAs, in adipose depots, in comparison to the SFAs, hence these animals gain less 
weight (Mercer & Trayhurn, 1984; Cunnane et al., 1986; Jones, 1989; DeLany et al., 
2000).   
1.2.9 Differential Effects on Body Weight and Adiposity  
It is well established that those who eat a diet high in fat are more likely to become 
obese than those eating a diet low in fat (Blundell & King, 1996; Blundell & 
MacDiarmid, 1997). This is evident in both humans and rodents, as shown in studies 
where the intake of a high-fat diet (HFD) can cause severe obesity, even in the 
absence of increased energy intake (Oscai et al., 1984). The effects of HFDs on body 
weight depend not only on the amount consumed, but also on their energy content 
and how they are metabolised. As triglycerides, which are not immediately used for 
fuel, are stored in adipose tissue (Barasi, 2007), a diet high in fat will encourage 
weight gain, but how much adipose tissue accrues, and where it is deposited, will 
depend on whether the fats are SFAs or PUFAs (Fernández-Quintela et al., 2007).  
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The results of some short-term studies indicate that PUFAs exert a relatively stronger 
control over appetite than SFAs and this is likely to be due to mechanisms involving 
the control of the gut satiety hormone CCK and the varying oxidative capacity of 
ingested fats (Lawton et al., 2000; Moussavi et al., 2008). When the receptors in the 
gut lining detect the presence of fat in the intestine, CCK is secreted by I-cells in the 
mucosal epithelium of the small intestine, slowing down the pace of digestion by 
inhibiting gastric emptying and gastric acid secretion (Dockray, 2004; Cummings & 
Overduin, 2007). This, along with raised enzymatic secretions from the pancreas, 
and increased hepatic bile into the intestine, allows for the complete digestion of fats 
by catalytic reactions. Additionally salts present in the bile cause emulsification of 
the fats, therefore, aiding in digestion and absorption (Capasso & Izzo, 2008). As the 
levels of fat drop, the concentration of CCK also reduces. Circulating concentrations 
of CCK increase when fed a diet high in PUFAs in comparison to one high in SFAs 
which may explain their differential effects on satiety (Beardshall et al. 1989; 
Relling & Reynolds, 2007). As CCK is also a neuropeptide, it works as a satiety 
factor by acting on the corresponding receptors in the CNS (see Figure 1.7; Morton 
et al., 2006; Dockray, 2009). The mechanism behind the suppression of hunger is 
thought to be due to the decrease in gastric emptying (Shillabeer & Davison, 1987), 
and the satiety effects of CCK are reduced in obese rats (Fink et al., 1998).  
1.2.10 Protective Effects of PUFAs on Body Weight 
Feeding rats diets high in the omega-3 PUFAs, EPA and DHA, found in fish oils has 
been shown to improve protection against body fat gain (Belzung et al., 1993; 
Hainault et al., 1993; Hill et al., 1993; Baillie et al., 1999). This is important, as the 
incidences of glucose intolerance, which precedes obesity-induced type 2 diabetes in 
humans, is affected by both the amount and distribution of body fat (Kissebah et al., 
1982).  
Studies using rodent models have shown that PUFAs attenuate the 
accumulation of adipose tissue resulting from consumption of SFAs (Buckley & 
Howe, 2009). They do this by inhibiting expression of lipogenic genes and 
stimulating transcription of those involved in lipid oxidation (Fernández-Quintella, 
2007). Additionally, when SFAs are incorporated into the membranes of cells they 
have the capacity to reduce metabolic rate and reduce β3 adrenoceptor binding 
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(Matsuo & Suzuki, 1997). This has implications for energy balance, as the β3 
adrenoceptor is present in adipose tissue and aids in the enhancement of lipolysis 
(Ferrer-Lorente et al., 2005). Conversely, the addition of PUFAs to the diet increases 
membrane fluidity (Fernández-Quintella, 2007) and β3 adrenoceptor affinity 
(Nicolas et al., 1991). In addition to their roles as energy and cell-structural 
elements, it is now clear that fatty acids act as potent gene regulators on enzymes of 
endogenous lipid synthesis and adipocyte proliferation (Clarke et al. 1997; Storlien 
et al., 2000). 
Therefore, to summarise, SFAs, found mostly in animal fats (e.g. in meat) 
and dairy products, tend to be less satiating, and increase body weight by increasing 
adiposity. In contrast, PUFAs may enhance satiety and promote weight loss. These 
include the essential fatty acids, which must be supplied in the diet; i.e. the omega-3 
PUFAs (e.g. in fish oils) and omega-6 PUFAs (e.g. in seed oils). However, due to 
discrepancies in the results of some studies, additional work is required to create a 
rational rat model of chronic PUFA consumption (see Chapter 2 for more detail). 
The use of isocaloric diets will remove the confounding effects of varying energy 
contents, allowing for the direct comparison of different macronutrients. However, 
macronutrients should ideally be tested in isolation as many of the dietary studies 
involving the consumption of an HFD  have also included sucrose, which is known 
to promote insulin resistance (Kokoeva et al., 2005; Chang et al., 2008; Hwang et 
al., 2008; Hofmann & Tschöp, 2009; Kim et al., 2009; Park et al., 2010; Rivera et 
al., 2011; Boitard et al., 2012; Lee et al., 2012; McNay et al., 2012; Thaler et al., 
2012; Yoo et al., 2012).  
Currently, of the environmental factors which impact on body weight, 
nutrients are the most influential. Within normal limits, hypothalamic and related 
neuronal populations correct perturbations in energy metabolism, to return the body 
to its nutritional set-point, either through direct response to nutrients, or indirectly 
via peripheral appetite signals. Excessive intake of certain macronutrients, such as 
simple carbohydrates and SFAs, can lead to obesity and attendant metabolic 
dysfunction, also reflected in alterations in structural plasticity, and intriguingly, 
neurogenesis, in some of these brain regions. Some of these alterations are discussed 
in more detail in the following sections of this review.   
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1.3 Role of Neuroplasticity in Body Weight Regulation 
Neuroplasticity refers to changes in neural pathways which are due to changes in 
behaviour, environmental influences, neural processes and occasionally bodily injury 
(see Figure 1.19; Pascual-Leone et al., 2011). Neuroplastic changes in the 
hypothalamus, including altered neurochemical phenotype, neuronal activation, 
synaptic connections, and dendritic growth and pruning, can be stimulated by dietary 
factors, not only during critical periods of development, but also in adulthood (Wang 
et al., 1999; LaBelle et al., 2009; Bouret, 2010; Horvath et al., 2010; Ravussin et al., 
2011; Lee et al., 2012; McNay et al., 2012). This is also true of neurogenesis (Chang 
et al., 2008; Kokoeva et al., 2005; McNay et al., 2012), the process by which 
neurons are born, proliferate, differentiate and integrate into established circuitry 
(Eriksson et al., 1998; Balu & Lucki, 2009). The technical aspects of measuring 
neurogenesis are described in Chapter 2.   
 
 
Figure 1.19. Schematic representation of the concept of plasticity. Brain plasticity allows 
for rapid adaptation to environmental changes that occur quicker than genetic or epigenetic 
response times. Source: Pascual-Leone et al., 2011. Brain Topogr 24(3-4): 302-315. 
 
1.3.1 Neuroplastic Changes in Response to Diet 
In the hypothalamus, cells which line the 3V have stem cell capabilities in the adult 
and can proliferate into neurons which migrate to nearby nuclei (Kokoeva et al., 
2007) and are engaged in responding homeostatically to peripheral satiety signals, 
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such as leptin (Zivlan et al., 2009). Expression and release of such signals is 
determined, not only by volume of food intake, but also diet composition, as 
demonstrated by the consumption of diets high in SFAs and PUFAs which have 
roughly opposing effects on energy metabolism. For instance, SFAs alter appetite to 
drive overeating, which is expressed as disturbed feeding behaviour (meal patterns) 
(Lawton et al., 2000; Wang et al., 2002), and consequently, to induce weight gain. 
They do this by overriding the effects of satiety hormones (Lawton et al., 2000) and 
reducing the expression of appetite-stimulating neuropeptides within hypothalamic 
nuclei (Wang et al., 2002). In addition, high-SFA intake impairs the growth of new 
neurons (neurogenesis) in the adult brain. This occurs even before the onset of 
obesity (Park et al., 2010; Kanoski & Davidson, 2011). In contrast, PUFAs attenuate 
weight gain, but what mediates this attenuation centrally is unclear. As dietary 
restriction is known to induce both hypothalamic neurogenesis (Lee et al., 2002) and 
weight loss in rodent models (Wang et al., 2002), it is possible that PUFAs control 
body weight by mimicking effects of dietary restriction.   
1.3.2 Development of Obesity  
Developmental exposure of animals or humans to a range of nutritional and 
metabolic insults, such as maternal obesity, diabetes, malnutrition, and early 
postnatal over-nutrition can result in predisposition to obesity in later life (Levin, 
2000; Plagemann, 2006; Gillman et al., 2008). Both maternal obesity and gestational 
diabetes increase the risk of obesity and type 2 diabetes in the offspring (Levin & 
Govek, 1998; Taylor & Poston, 2007). Furthermore, malnutrition in the mother also 
increases the likelihood of the offspring developing obesity in later life (Field et al., 
2005; McMillen et al., 2005).  
1.3.3 Critical Periods 
The developmental programming of brain feeding pathways in utero represents a 
potential underlying cause for obesity development (Horvath & Bruning, 2006; 
Bouret, 2009). Sensitive periods of brain development, during which the brain is 
sensitive to environmental exposures, occur due to the processes of cell proliferation, 
migration, differentiation, axon growth and apoptosis (Bouret, 2010). The first 
important phase for hypothalamic development is formation, with neurogenesis 
occurring in the prolific ependymal lining of the 3V, during mid-gestation in rodents. 
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Migration and differentiation occur during late embryonic development (Markakis, 
2002). The interruption of any of these stages can result in structural and functional 
abnormalities of the hypothalamus (Davis et al., 2004). The second phase of 
hypothalamic development is during the early weeks of postnatal life, when neurons 
send out axonal projections to their specific target sites. Studies have shown that 
ARC projections are immature at birth but develop at week two of postnatal life 
(Grove et al. 2003; Bouret et al., 2004). Different regions of the hypothalamus 
develop at different times, and the projections from the DMH and VMH develop 
before those in the ARC. Hypothalamic development in rodents can take days, 
whereas in humans, it can take weeks or months. Also, rodents undergo more 
postnatal development than humans, who undergo more prenatal maturation of 
hypothalamic structures (Bouret et al., 2004).  
Hormones have been shown to play an important role in hypothalamic 
development (Simerly, 2002). Leptin deficiency in mice results in abnormal 
development (stunted growth), and reduced number, of axonal projections from the 
ARC to other regions of the hypothalamus. During early postnatal life, leptin acts as 
a trophic signal, influencing developmental stages in pathways that will aid leptin 
signalling in mature mice (Bouret et al., 2004). However, leptin can still affect the 
brain in adults, resulting in the rearrangement of excitatory and inhibitory inputs on 
ARC neurons, suggesting that this particular brain circuit remains relatively plastic 
throughout adult life (Pinto et al., 2004). Other hormones such as insulin have also 
been shown to have a role in the developing hypothalamus, as demonstrated by 
injection of postnatal insulin, resulting in morphological changes in the VMH 
(Plagemann et al., 1999). Furthermore, mature hypothalamic neurons are also 
sensitive to external influences. For example, an injection of ciliary neurotrophic 
factor (CNTF) in adult obese mice induces increased neurogenesis in the 
hypothalamus (Kokoeva et al., 2005). These results support the ideas that 
hypothalamic plasticity remains sensitive to neurotrophic cues during adult life. 
However, the extent and type of response may differ between adults and neonates 
(Bouret, 2010). 
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1.3.4 Influence of Maternal Nutrition on Obesity  
As mentioned previously, the hypothalamus is exposed to two major environments; 
the first in utero, and the second postnatally. These time periods represent important 
phases during which the alteration of metabolic and hormonal signals may result in 
abnormal hypothalamic development (Bouret, 2010). Studies have shown that with 
animal models of maternal obesity, prenatal nutrition influences the development of 
hypothalamic appetite-regulating networks. HFD feeding during pregnancy and 
lactation results in neonates with hyperphagia and obesity, associated with 
dysregulation of hypothalamic gene expression (Kirk et al., 2009; Morris & Chen, 
2009), and abnormal central leptin sensitivity in the ARC. This reduces the number 
and length of neural projections from the ARC to the PVN (Kirk et al., 2009). These 
studies imply that the correct function of leptin during neonatal life is crucial for the 
maintenance of energy homeostasis and hypothalamic function (Bouret, 2010).  
These types of changes in neuroplasticity can be influenced by both genetics 
and the environment (dietary influence). Studies have shown that by exposing late 
fetal and neonatal rats to increased HFD via feeding of the mother, the neonatal rat 
displays several of the physiological and behavioural changes linked to obesity, 
including elevated concentrations of leptin, increased body weight gain and food 
intake, modest preference for fat-containing food types, as well as the onset of 
hypothalamic leptin resistance. In contrast, in the hippocampus, both the fetal and 
neonatal rodent treated with leptin show similar increases in neurogenesis and 
survival of newborn neurons (Walker et al., 2008). Alterations of neurochemical 
phenotype which relate to obesity also occur in the adult, as discussed below. 
1.3.5 Adult Obesity 
Dietary macronutrients differentially affect both brain structure and activity at the 
cellular level. Particularly striking results have been observed in rodent models, 
when comparing the effects of diets enriched with different types of FAs. Work by 
Levin and colleagues has shown that these plastic changes also appear to underpin 
susceptibility and resistance to obesity. For example, they showed that rats with diet-
induced obesity (DIO) from consumption of an HFD (31% of energy as fat), had 
long primary dendrites on VMH neurons which were 19% shorter than those in their 
diet-resistant (DR) counterparts (La Belle et al., 2009). The work of Storlien and 
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colleagues compared mice fed HFDs containing 58% of energy as fat from different 
sources (SFAs, omega-3 PUFAs, or omega-6 PUFAs). They showed that c-Fos 
immunoreactivity (where c-Fos is an early gene marker of neuronal activation) was 
increased in the LHA (appetite centre) and decreased in the VMH (satiety centre), 
following one week of SFA consumption (Wang et al., 1999). In contrast, both 
omega-3 and omega-6 PUFA-fed mice showed unchanged activation in the LHA, 
but an increase in the VMH. At seven weeks, following substantial fat accumulation, 
the SFA-fed mice demonstrated an increase in PVN activity; however, following a 
switch to the omega-3 PUFA diet for four weeks, this activation was reversed by 
approximately 50%, and activation in the ARC was increased by 400%. These 
results demonstrated that dietary SFAs influence hypothalamic neuronal activity by 
increasing levels of activation in the lateral regions, but by decreasing levels in the 
ventromedial regions, as obesogenic effects develop. In contrast, omega-3 PUFA 
diets reverse this effect. The mechanisms behind these relationships were 
unexplained; however, it was suggested that the direct effects of FAs on ARC leptin 
receptor activation and downstream signalling may be involved (Wang et al., 1999). 
Indeed, the cellular machinery (transporters, receptors and metabolic pathways) 
required for direct sensing of nutrients, including FAs and glucose, are known to 
exist in the neurons of the discrete hypothalamic regions involved in feeding 
regulation (Levin, 2002; Lam et al., 2005; Levin et al., 2006). 
1.3.6 Neurogenesis in the Adult Brain  
More recently, research attention has been turning to the role of neurogenesis in the 
regulation of body weight, and the differential effects of dietary macronutrients on 
this process are only beginning to emerge.  
Neurogenesis is the process by which neurons are born, proliferate, 
differentiate, migrate and then integrate into already established brain circuitry. 
These stages are regulated by a diverse range of factors present in the neurogenic 
niche, including intrinsic (e.g. transcription factors) and extrinsic molecular signals 
(trophic factors), as well as neurotransmitters (dopamine and amino acids; Pathania 
et al., 2010).  
Previously thought to occur only in the embryo, neurogenesis has now been 
demonstrated in the adult brain (Eriksson et al., 1998; Balu & Lucki, 2009) and can 
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be influenced by a range of factors, including age, sex, stress, environmental 
enrichment and animal species and strain (Balu & Lucki, 2009; Bonfanti & Peretto, 
2011; Clark et al., 2011; Ming & Song, 2011; Simpson & Kelly, 2011; Kageyama et 
al., 2012).  
1.3.7 Hippocampal Neurogenesis 
The most prolific neurogenic niches have been identified as the subventricular zone 
(SVZ) of the lateral ventricle and the subgranular zone (SGZ) of the dentate gyrus 
(DG), within the hippocampus (see Figure 1.20; Balu & Lucki, 2009). The 
hippocampus is crucially involved in the regulation of cognition and mood. A 
prevailing assumption in the field of adult neurogenesis is that the continuous 
generation of new neurons within the hippocampus offers, in addition to synaptic 
plasticity, a cellular flexibility to this system (Couillard-Despres et al., 2011), and 
that this supplementary population is especially important  for memory and learning. 
Indeed, newly generated neurons are particularly excitable and can therefore be more 
sensitive to incoming input (Schmidt-Hieber et al., 2004; Couillard-Despres et al., 
2006). Many studies support the concept that young neurons contribute to and 
facilitate the learning of hippocampal-dependent tasks (e.g. Gould et al., 1999; Deng 
et al., 2009; Tronel et al., 2010; Couillard-Despres et al., 2011). This assistance 
could be mediated, for example, through the lower threshold required for the 
induction of long-term potentiation in newly generated neurons (Ge et al., 2007). 
Studies have shown that newly generated neurons are integrated very rapidly into the 
hippocampal network, and that they can trigger action potentials upon stimuli that 
are much weaker than those required to stimulate mature granule cells (Schmidt-
Hieber et al., 2004; Couillard-Despres et al., 2006, 2011). Hence, the presence of 
numerous immature neurons in the hippocampal network might provide a higher 
sensitivity to incoming inputs, thereby facilitating information processing (Couillard-
Despres et al., 2011).  
It is also well established that several growth factors are involved in the 
mechanisms regulating adult hippocampal neurogenesis (Lee & Son, 2009). The 
involvement of growth factors in the mechanism underlying the effect of anti-
depressant drugs on hippocampal neurogenesis and anti-depressive disorders has 
been much investigated. Adult hippocampal neurogenesis is positively affected by 
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chronic anti-depressant treatment (Malberg et al., 2000), and neurotrophic factors, 
such as brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), and 
neurotrophin-3 are known to be implicated in adult neurogenesis and neuroplasticity. 
Among these, BDNF has been intensively studied and shown to be involved in 
learning and memory, and synaptic plasticity (Poo, 2001). Spatial learning and 
memory is defective in a BDNF-deficient animal model (Mu et al., 1999), and 
overexpression of BDNF causes both anxiogenic and antidepressant behaviour 
(Govindarajan et al., 2009). Because of the traditional association between 
neurogenesis and the hippocampus, this brain region has been the main focus of 
studies investigating links between neurogenesis and diet. These studies have 
included alterations in feeding regimes, calorie restriction and dietary nutrients 
(Mattson et al., 2003; Stangl & Thuret, 2009; Park et al., 2011), which are reviewed 
below (Section 1.3.9). The assumption that the hippocampus may be involved in 
such a relationship is not unreasonable, as hippocampal function is required for 
normal feeding behaviour (Davidson et al., 2007). However, whereas there is 
substantial evidence to suggest the functional significance of hippocampal 
neurogenesis in cognition, this is less so with respect to energy metabolism. 
Relationships between hippocampal neurogenesis and diet have been documented as 
phenomena, without significant insight into underlying mechanisms. It is true that 
obesity is becoming increasingly linked with depressed mood, impaired cognition 
and neurodegenerative diseases, including Alzheimer’s, which are  underpinned by 
neuroplastic changes (Bruce-Keller et al., 2009; Barnes & Yaffe, 2011; Farooqui et 
al., 2012). Indeed, the link between obesity and brain neuropathology has been 
substantiated by showing that weight reduction improves cognition (Siervo et al., 
2011). Thus, it has been proposed that adult hippocampal neurogenesis may link 
energy metabolism and cognition in order to regulate body weight (Park & Lee, 
2011), functioning as an “interface” between the two (Vaynman & Gomez-Pinilla, 
2006). However, direct evidence is lacking.  
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Figure 1.20. Neurogenesis in the adult mammalian brain. A sagittal section of rodent brain showing the sites of neurogenesis in the dentate gyrus (DG) of 
the hippocampus, and the olfactory bulb. Cells proliferate in the subgranular  zone (SGZ) of the DG, from which they migrate and differentiate into mature 
neurons. Source: Kempermann et al., 2004. Trends Neurosci 27(8): 447-452. The hypothalamus is currently emerging as a neurogenic site, with cell-types A-
C found in the wall of the third ventricle (Migaud et al., 2010).
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1.3.8 Role of Neurogenesis in Body Weight Regulation 
1.3.8.1 Hypothalamic Neurogenesis 
Recently, the hypothalamus has also been shown to satisfy the criteria for a 
neurogenic niche in mammals (Magavi et al., 2000; Pencea et al., 2001; Migaud et 
al., 2010; Yuan & Arias-Carrión, 2011). It has the capability of generating new 
neurons and expresses phenotypic markers of cell proliferation and neuronal fate, 
including the endogenous cell-cycle proteins, Ki-67 and proliferating cell nuclear 
antigen (PCNA), and uptake of the thymidine analogue, bromodeoxyuridine (BrdU). 
Newly formed cells within the 3V region migrate to appropriate areas of the 
parenchyma, including the LHA (Xu et al., 2005), where they then express a range 
of specific markers related to feeding metabolism (Markakis et al., 2004; Kokoeva et 
al., 2007). More recent studies have also shown that newborn neurons are present in 
the mediobasal hypothalamus (Li et al., 2012), as well as the tanycytes of the median 
eminence (Lee et al., 2012). Hypothalamic neurogenesis is impaired by diet-induced 
and genetic forms of obesity, but can be restored by calorie restriction (McNay et al., 
2012). Until very recently, its function was thought to be simply to replace dead 
neurons (Markakis, 2002). As it is only recently that researchers have begun to 
identify the appetite-related factors which may mediate the relationship between diet 
composition, obesity and neurogenesis (in both hippocampal and hypothalamic 
sites), it is only now that the true extent of this functional role is finally emerging 
(Lindqvist et al., 2006; Chang et al., 2008; Park et al., 2010; Rivera et al., 2011; 
Boitard et al., 2012; Lee et al., 2012; Li et al., 2012).   
1.3.8.2 Energy Restriction 
Energy restriction, in the form of fasting, has been shown to increase hippocampal 
neurogenesis in rats and mice. Lee et al. (2000a, 2002b) showed that there were no 
differences in neurogenesis between energy-restricted and control animals at day one 
of fasting, but there were after three and four weeks of fasting. Studies from the 
same group suggested that energy restriction does not affect proliferation of neural 
stem cells, but does increase the survival of newly generated neural cells; and that 
improved learning and memory function shown in rats fed an energy restricted diet 
may be as a result of increased neurogenesis within the hippocampus (Mattson et al., 
2003).  
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Previously, it was assumed that all positive benefits associated with energy 
restriction occur as a result of a reduction in cumulative energy intake (Weindruch & 
Sohal, 1997). However, a more recent study showed that a fasting energy restriction 
paradigm induces weight loss in Sprague-Dawley rats but not in C57BL/6 mice. 
Measurement of energy intake showed that on days the mice had access to food they 
ate twice as much as their controls. However, the fasting mice did display anti-
ageing changes equal to those maintained on a reduced energy diet, including 
reduced plasma insulin and glucose concentrations. Furthermore, fasting was more 
effective than daily restricted energy intake at protecting hippocampal neurons 
against injury (Anson et al., 2003). As a result of the current obesity epidemic, and 
the difficulties in getting people to reduce their food intake, research into the 
development of pharmaceuticals, nutraceuticals and/or dietary restriction mimetics 
are crucial.  
1.3.9 Effects of Dietary Macronutrients on Neurogenesis 
As mentioned previously, one of the theories behind the sudden development of the 
obesity epidemic is the overconsumption of foods, specifically those with a high 
SFA and/or refined carbohydrate content. These macronutrients have been shown to 
cause changes in neuroplasticity, as described above, hence it is also possible that 
they influence neurogenesis.  
1.3.9.1 Simple Carbohydrates 
The increase in the overconsumption of sugary foods and drinks is of major concern 
when addressing issues surrounding the increased prevalence of obesity. When 
considering high-sugar drinks, high-fructose corn syrup (HFCS) has been identified 
as an ingredient which may be detrimental (Purcell et al., 2012; Stanhope, 2012). 
Well-known soft drink brands can contain from 48-65% HFCS (Ventura et al., 2011; 
Sievenpiper et al., 2012). Studies involving rodent models have elucidated a link 
between body weight gain and consumption of simple sugars in liquid format.  
Rats consuming liquid sucrose or fructose (23% w/v) for four weeks showed 
no changes in body weight compared to controls consuming water, despite increased 
gonadal fat depots (van der Borght et al., 2011). However, terminal serum 
concentrations of triglycerides, leptin, ghrelin and pro-inflammatory cytokines 
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(molecules which promote inflammation) were elevated in both groups, and newly 
mature neurons in the dentate gyrus were reduced by 50%, while numbers of 
apoptotic cells were increased. The authors suggested that elevated cytokines were 
responsible for the failure of neurons to survive, through both apoptosis and 
impairment of the BBB by triglycerides, which are known to compromise its 
integrity (Banks, 2008). Consequently, leptin is then prevented from crossing the 
BBB, depriving the hippocampus of its known neuroprotective effects (Kokoeva et 
al., 2005; Garza et al., 2008; Belsham et al., 2009; Migaud et al., 2010; Pierce & Xu, 
2010; McNay et al., 2012).  
Interestingly, far lower concentrations of fructose (10%) have been 
associated with markers of metabolic syndrome, such as increased concentrations of 
circulating triglycerides, impaired glucose metabolism and increased abdominal 
adiposity, and in some cases, these changes have been observed in the absence of 
actual weight gain (Bocarsly et al., 2010; Sheludiakova et al., 2012). In contrast, 
additional studies have shown that six weeks of liquid carbohydrate diet containing 
10% sucrose (w/v) had no effect on cell proliferation in the dorsal vagal complex (an 
additional region of the brain that has shown prolific activity), on body weight, or on 
circulating concentrations of BDNF (Zeeni et al., 2009). BDNF is a growth factor 
which is involved in the control of body weight through central mechanisms, 
including neurogenesis (Mattson et al., 2003; Vaynman & Gomez-Pinilla, 2006; 
Cordeira & Rios, 2011; Noble et al., 2011). Although the relationship between 
circulating concentrations of BDNF and body mass is unclear, reduced central 
expression is associated with obesity (Noble et al., 2011). These studies  show that 
appetite-related and inflammatory signals appear to mediate the impaired 
hippocampal neurogenesis resulting from chronic intake of refined sugars (at least in 
liquid form) at concentrations lower than those consumed by humans, and that these 
effects are independent of obesity. 
1.3.9.2 Saturated Fatty Acids (SFAs) 
A study has also shown that feeding mice an HFD for two months, where 58% of 
energy was provided by SFAs, suppressed hypothalamic neurogenesis (see Figure 
1.21; McNay et al., 2012). This change was seen in the ARC and was linked to early 
apoptosis of newly proliferating cells. This decrease was partially reversed by calorie 
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restriction. The same research group determined that centrally infused CNTF 
stimulated proliferation within the hypothalamus of these obese mice and caused 
sustained weight loss. Many of the newly proliferating cells demonstrated functional 
phenotypes relevant to energy balance, such as leptin sensitivity, but the mechanisms 
that allow HFD to inhibit neurogenesis remained unclear (see Figure 1.22; Kokoeva 
et al., 2005). However, the roles of circulating insulin and glucose have been linked 
with neurogenesis, as rodent models of diabetes show impaired hippocampal 
neurogenesis (Stranahan et al., 2008; Guo et al., 2010).    
 
 
Figure 1.21. DIO inhibits adult hypothalamic neurogenesis. Sixteen-week-old mice were 
i.c.v. infused with BrdU for 7 days and brain tissue harvested 4 weeks later (A–C). The 
number of newborn (BrdU-labelled) cells was significantly reduced in the hypothalamus of 
DIO mice compared with that in lean controls. Scale bar: 100 µm. Data are mean ± SEM. n 
= 5 chow; n = 6 DIO. Abbreviations: BrdU= bromodeoxyuridine; DIO= diet-induced 
obesity. Source: McNay et al., 2012. J Clin Invest 122(1): 142-52.  
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Figure 1.22. CNTF reduces body weight long term and induces cell proliferation in the 
hypothalamus. A: Mice were i.c.v infused for 7 days with BrdU (12 mg/day) in artificial 
cerebrospinal fluid alone or together with CNTF (0.75 mg/day). Body weight (BW) is shown 
as percentage difference from initial body weight (all data are mean ± SEM; n=5/group). B: 
BrdU-labelled cells in coronal sections of the hypothalamus at the level of the arcuate 
nucleus. Abbreviations: 3V= third ventricle; Arc= arcuate nucleus; BW= body weight; 
CNTF= ciliary neurotrophic factor; icv= intracerebroventricular; Me= median eminence.  
Source: Kokoeva et al., 2005. Science 310(5748): 679-83. 
 
In contrast to these studies, Lee et al. (2012) demonstrated that young adult 
mice fed an HFD, providing a similar amount of energy from SFAs (60%), display 
active neurogenesis in the median eminence (see Figure 1.23a). Mice were fed up to 
2.5 months of age (between postnatal days 5 and 75), after the diet had previously 
been supplied to their mothers. When this proliferation of cells was prevented, using 
irradiation (Figure 1.23c), weight gain was attenuated (Figure 1.23b) and energy 
expenditure and activity was increased (Figure 1.23d & e), suggesting a direct role 
for neurogenesis in body weight regulation. Interestingly, the rate of neurogenesis 
had increased significantly by postnatal day 75, indicating that HFD activation 
persists into adulthood, and suggests that it may modulate hypothalamic neural 
circuitry in later life.  
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Figure 1.23. Young adult mice fed an HFD display active neurogenesis in the median 
eminence. P19 mice received BrdU (P10–P18), and hypothalamic sections were examined 
for BrdU immunostaining. (a) Hypothalamic proliferative zone (HPZ): enriched BrdU+ cell 
population (green) along the median eminence (MEm) ependymal layer of 3V floor. 
Sections counterstained with DAPI (blue), a nuclear marker. Scale bar: 50 µm. (b) 
Attenuated weight gain in HFD-fed irradiated mice compared with sham controls (n = 9). (c) 
MEm neurogenesis reduced in irradiated versus sham-irradiated mice (n = 4). (d) Higher 
energy expenditure observed in irradiated mice (n = 11). (e) Higher total activity observed in 
irradiated mice (n = 11). Mean ±SEM; *P < 0.05, **P < 0.01; ***P < 0.01. Abbreviations: 
3V= third ventricle; ArcN= arcuate nucleus; BrdU= bromodeoxyuridine; HFD= high-fat 
diet; HPZ= hypothalamic proliferative zone; MEm= median eminence; Rad= irradiated 
Source: adapted from Lee et al., 2012. Nat Neurosci 15(5): 700-2. 
 
This idea is further supported by the work of Chang et al. (2008) who had 
observed that offspring of rat dams fed a high-fat diet (50% of energy from SFAs) 
displayed increased proliferation of neural stem cells (NSCs) and neural progenitor 
cells (NPCs) in the hypothalamus which prevailed at least until termination at 
postnatal day 70. In addition, enhanced differentiation and migration toward 
hypothalamic regions where these neurons ultimately expressed orexigenic peptides 
was also seen. This was linked with an increase in circulating lipids (triglycerides 
and free fatty acids) in the dams and offspring. Although a precise mechanism had 
not been determined, it was proposed that the purpose of this neurogenesis was to 
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prepare the juveniles for the increased food intake and high-fat diet preference they 
would probably show after weaning (Chang et al., 2008). 
In contrast, another study demonstrated that the number of adult 
hypothalamic NSCs in the VMH of three-month old mice was reduced and the 
process impaired following the chronic consumption of an HFD (58% energy from 
SFAs). Following an additional month of feeding this inhibition was even more 
severe. This was linked to the proinflammatory pathway involving IқB kinase β 
(IKKβ) and the downstream nuclear factor –қB (NF-қB) which mediates HFD-
induced hypothalamic inflammation. Activation of the IKKβ and NF-қB pathways 
impairs the regulation of cell survival, growth, apoptosis and differentiation 
contributing to the neurodegenerative mechanism of obesity and related diabetes (Li 
et al., 2012). This study differs from that of Lee et al. (2012), as short-term HFD 
feeding was reported to promote hypothalamic neurogenesis in juveniles, whereas 
long-term (4-month) HFD feeding described by Li et al. (2012) remarkably depleted 
hypothalamic NSCs and impaired neuronal differentiation. Li et al. suggest that 
whereas neurogenic upregulation by short-term HFD feeding may represent a 
compensatory reaction, long-term HFD feeding is detrimental for the cell fate of 
adult hypothalamic NSCs. They suggest that the neurodegenerative actions of 
chronic HFD feeding are attributed to IKKβ and NF-қB pathway overactivation, 
concluding that these NSCs are vulnerable to hypothalamic inflammation induced by 
chronic HFD feeding (Li et al., 2012).  
In contrast, another study has found no effect of HFD feeding on cell 
proliferation or neurogenesis in the hypothalamus or the hippocampus of rats fed a 
diet containing 60% of energy from SFAs for three months (Rivera et al., 2011). 
Despite the rats developing obesity, there were no differences in neurogenesis, when 
compared to a low-fat-fed control group, in the SGZ, SVZ or hypothalamus, 
consistent with similar concentrations of metabolism markers (plasma adiponectin, 
insulin and leptin concentrations) between the groups. The lack of effects may have 
been due to dietary composition, as sucrose and lard were present in both the high-
fat diet and low fat control diets. This may have led to some metabolic dysfunction 
in the control group such that metabolic markers failed to differ.  
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1.3.9.3 Interaction with the Endocannabinoid System in Neurogenesis 
Rivera’s research was also attempting to find a link between cell proliferation and 
the endocannabinoid system in their model of diet-induced obesity. As mentioned 
previously, the endocannabinoids (intracellular signalling lipid-related molecules), 
play a regulatory role in controlling energy homeostasis through the activation of 
specific receptors in the hypothalamus and hippocampus which stimulate feeding 
(Piomelli, 2003; Pagotto et al., 2006; Gamage et al., 2012). In vitro work and and the 
use of cannabinoid receptor knockout mice, has shown that endocannabinoids 
regulate neurogenesis in both the developing and adult nervous systems (Jin et al. 
2004; Aguado et al., 2005; Galve-Roperh et al., 2007; Oudin et al., 2011). However, 
how the two phenomena were linked was unknown. Blocking the endocannabinoid 
receptors with antagonists such as rimonabant, the banned anorectic antiobesity drug 
reduces appetite, and therefore food intake, resulting in weight loss, increased energy 
expenditure and improvements in metabolic parameters (Matias & Di Marzo, 2004; 
Pavon et al., 2008; Scheen & Paquot, 2009). The rats from both dietary groups were 
treated with the cannabinoid receptor type 1 (CB-1) receptor agonist, AM251, which 
reduced food intake, caused weight loss and improved metabolism, as expected. 
However, accompanying reductions in circulating cholesterol, triglyceride and 
glucose levels were more pronounced in the HFD group and intriguingly, neurogenic 
change was stimulated only in this group. These changes were region-specific, with 
increases in neurogenesis observed in the SGZ, but reductions in the SVZ and 
contrasting with the findings of McNay et al. (2012), the hypothalamus. However, it 
is difficult to compare between studies utilising different species (mice vs. rats), diets 
and methods of inducing weight loss. The authors suggested that the 
endocannabinoid system is sensitised by HFD feeding, enabling the CB1 signalling 
system to adapt, in order to limit obesity-induced functional impairment in the brain. 
In addition, this adaptation is mediated by appetite-related signals. Overall, they 
concluded that cannabinoid modulation of cell proliferation in adult neurogenic 
regions is obesity-dependent (Rivera et al., 2011).  
In summary, it is difficult to make comparisons between all of these studies 
as they utilise different species, diets and methods for inducing weight loss; 
however, under most experimental paradigms using adult rodents, consumption of 
diets high in SFAs inhibits neurogenesis, a change that may be more nutrient- than 
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obesity-dependent. This alteration in neurogenesis within the hypothalamus and 
hippocampus may be mediated by changes in numerous metabolic signals. These 
may include triglycerides, glucose, and the trophic factors CNTF and BDNF. The 
full extent of at least some of their effects may depend on interaction with the 
endocannabinoid systems. Neuroinflammation, which, as described above, can also 
precede obesity, or develop independently of increased adiposity, during high-SFA 
consumption, is another phenomenon known to impair neurogenesis (Cota & 
Marsicano, 2011; Thaler et al., 2012). Whether it, in turn, is mediated by these same 
factors in this context remains to be tested. So far, chronic high-SFA consumption 
has been associated primarily with inhibition of neurogenesis, but the probable 
complexity of this relationship requires the careful design of studies comparing time 
course, fatty acid composition and concentration, model species, strain, age and 
neurogenic site.  
1.3.9.4 Polyunsaturated Fatty Acids (PUFAs) 
In comparison to SFAs, PUFAs have been shown to improve VMH dysfunction in 
rodent models of metabolic syndrome (Pella et al., 2011) through the normalising of 
appetite by restoration of neuropeptide concentrations (Das, 2008) and reducing 
hedonistic effects through the alteration of the dopaminergic and endocannabinoid 
systems (Golub et al., 2011). These alterations result in a reduction of appetite, 
enhancing satiety and reducing weight gain. Nonetheless, findings are generally 
inconsistent and in the human literature, only the addition of PUFAs as a supplement 
in the short-term has been examined (Lawton et al., 2000; Buckley & Howe, 2010). 
In general, the metabolic effects of long-term consumption of PUFAs incorporated 
into foodstuffs on the CNS needs to be clarified by utilising rodent models, 
specifically rat, under controlled conditions employing isoenergetic, purified and 
low-fat control diets (see Chapter 2). 
As mentioned previously, the neuroprotection provided by omega-3 PUFAs 
is linked with membrane fluidity, neurotransmission, enzyme modulation and gene 
expression (Mazza et al., 2007). The benefits of dietary consumption of omega-3 
PUFAs have been demonstrated in both humans and rodent studies in the form of 
improved cognition in healthy individuals and those with neurodegenerative 
conditions such as Alzheimer’s (Wu et al., 2004; Dyall, 2010; Su, 2010). It has been 
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proposed that these improvements occur through the stimulation of neurogenesis 
(Dauncey, 2009; Venna et al., 2009; Matsuoka, 2011).  
The omega-3 fatty acid, eicosapentaenoic acid (EPA), was the first to be 
associated with up-regulation of neurogenesis (Beltz et al., 2007). This was shown in 
the lobster which has innately elevated levels of neurogenesis, making it easier to see 
neurogenic changes following an intervention. Increased cell proliferation was seen 
within the brain of lobsters consuming a diet enriched with PUFAs from brine 
shrimp or the microalgae Spirulina, which is often consumed by humans as a 
nutritional supplement (Beltz et al., 2007). This increase manifested as an overall 
rise in baseline levels of neurogenesis, leading the author to conclude that the 
nervous system benefits from this nutritional addition. However, as no metabolic 
parameters were measured it is not known whether the improvement was directly 
stimulated by PUFAs or mediators of energy metabolism. 
The patented LMN diet, rich in polyphenols and PUFAs, has been shown to 
enhance neurogenesis in the SGZ and SVZ in mice, but also to prevent cognitive 
decline seen with ageing and Alzheimer’s disease (Valente et al., 2009; Fernández-
Fernández et al., 2012). Unfortunately, no metabolic factors were measured in either 
of these studies and therefore, it is impossible to make a connection between the 
PUFA consumption, metabolic factors and any potential influence they may have 
had on the enhancement of neurogenesis. Additional studies have explored the 
mechanisms behind the protective role of omega-3 FAs in learning and memory with 
ageing (Dyall et al., 2010). Supplementation with EPA and DHA reversed some of 
the decrease observed in hippocampal neurogenesis in elderly rats and prevented the 
reduction in hippocampal nuclear receptors (RARs/RXRs) involved in cell 
proliferation (Goncalves et al., 2009). Since the effects of the PUFA-enriched diet on 
energy metabolism were not investigated, no direct relationship was suggested for 
the mediation in neurogenesis. Instead the authors suggest that BDNF was the most 
likely candidate for controlling the observed changes, as its expression is known to 
be enhanced by omega-3 PUFA consumption and the nuclear receptor agonists, 
tamibarotene (Am80) and imipramine (Katsuki et al., 2009; Venna et al., 2009).   
A study has established the link between adult neurogenesis and the 
consumption of the omega-3 PUFA, DHA, by showing that it stimulates 
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hippocampal neurogenesis in the dentate gyrus of adult rats (Kawakita et al., 2006). 
DHA is one of the main structural lipids in the mammalian brain, and plays a crucial 
role in the development and function of brain neurons (Barasi, 2007). The authors 
validated this finding through an in vitro study. By using primary culture of neural 
stem cells from 15-day-old rat embryos, and culturing these cells under different 
conditions with or without DHA, the study demonstrated that DHA is an essential 
molecule for cell differentiation by promoting cell cycle exit and preventing cell 
death (Kawakita et al., 2006). One study suggests that DHA enhances neuronal 
differentiation of NSCs, in part, by controlling the expression level of basic helix-
loop-helix (bHLH) transcription factors and promoting cell cycle exit (Katakura et 
al., 2009).  
Furthermore, PUFAs have also been shown to activate the fat-sensing G-
protein-coupled receptors (GPRs) present in tissues involved in the control of 
inflammation and energy metabolism (Oh & Lagakos, 2011; Talukdar et al., 2011). 
These include the receptors GPR40 and GPR120, which have been investigated for 
their role in PUFA-mediated reversal of SFA-induced hypothalamic inflammation 
associated with obesity (Cintra et al., 2012). The GPR40 receptor is involved in the 
upregulation of hippocampal neurogenesis required for improved memory function, 
and DHA has been shown to directly activate this receptor thereby suggesting 
another potential mechanism by which it may stimulate neurogenesis (Ma et al., 
2008; 2010; Yamashima, 2008). 
In summary, evidence continues to surface that the chronic consumption of 
PUFA-enriched diets stimulates adult neurogenesis in brain regions associated with 
cognition and this may involve the GPRs. However, further work is required to 
determine fully the role of PUFA-induced changes in energy metabolism on 
neurogenesis itself, and within the hypothalamus, as the evidence for its role so far 
comes from non-dietary studies. There is evidence that omega-3 PUFAs exert their 
effects on cognition by affecting molecular events implicated in both synaptic 
plasticity and energy metabolism. BDNF is one proposed mediator between these 
two processes (Gomez-Pinilla, 2011), as PUFAs are known to enhance synthesis, 
secretion and intracellular signalling of this molecule, and therefore, may restore 
neurogenesis by this means (Wu et al., 2004; Balanzá-Martínez et al., 2011). As of 
yet, it has not been examined whether PUFAs exert their effects on body weight 
CHAPTER 1 
69 
 
homeostasis through changes in hypothalamic neurogenesis and whether these 
changes are mediated by BDNF. The slow turnover of hypothalamic neurons 
(Kokoeva et al., 2007) alongside the technical limitations of labelling methods 
involving BrdU (Taupin et al., 2007; Cifuentes et al., 2011), as discussed further in 
Chapter 2, may explain why this relationship has not been explored further. If a 
relationship could be established, it would provide a neurobiological basis for the 
positive health benefits of dietary PUFAs, further supporting their role as a 
nutraceutical.     
1.3.9.5 Implications of Altered Neurogenesis 
Determining how PUFAs regulate neurogenesis under conditions of altered energy 
metabolism, such as obesity, is key to fully appreciating their benefit as a 
nutraceutical. The potential for change in hippocampal neurogenesis has been 
suggested as a target for development of treatments for neurodegenerative disorders 
(Lindvall et al., 2012), including those associated with changes in energy 
metabolism, such as diabetes (Balu & Lucki, 2009). The management of dietary 
intake is now viewed as an effective strategy to counteract neuronal disorders 
(Gomez-Pinilla & Gomez, 2011) and with further research, it may emerge that it also 
modulates hypothalamic neurogenesis to attenuate the development of obesity. This 
may encourage greater patient compliance than a pharmaceutical strategy. This is 
important to consider, as currently no dietary, pharmacological or lifestyle 
intervention has had any success in combating obesity (Lemieux & Lapointe 2008; 
Rössner et al., 2008). In summary, more research is required to fully quantify the 
relationships between individual macronutrients and neurogenesis. Once a more 
methodical approach to dietary intervention is adopted, and more information is 
acquired about the neurogenic capacity of the hypothalamus, particularly in the rat, 
scientists can start to consider possible mechanisms of action and translation to 
functional relevance in humans.  
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1.4 Summary 
The literature review presented here has demonstrated the importance of regulating 
body weight for lifelong health and well-being as well as survival in general. A key 
factor involved in this regulation is the macronutrients we consume, some of which 
have been shown to have negative effects (SFAs and refined carbohydrates), and 
some, positive effects (PUFAs). We have seen that diets high in SFAs drive animals 
to overeat, overriding the effects of satiety hormones, and impairing neurogenesis, 
even before the onset of frank obesity. In contrast, separate lines of evidence show 
that dietary intake of PUFAs attenuates weight gain and stimulate neurogenesis. This 
raises the question of whether the control PUFAs exert over body weight is mediated 
by neurogenesis, as it appears to be with respect to SFAs.  
1.4.1 Hypothesis 
Beneficial effects of PUFA intake on energy metabolism are mediated, at least 
in part, by stimulation of hypothalamic neurogenesis. 
The literature review above clearly shows how this complex hypothesis could not 
be tested fully in a three-year project. Indeed, an appropriate animal model, 
satisfactorily integrating valid phenotypes of PUFA feeding and hypothalamic 
neurogenesis would have to be established first. Most of the research conducted 
in this field has involved the use of mouse models, but as neurogenesis is known 
to be influenced by animal species and strain, there is a need to conduct further 
studies that investigate hypothalamic neurogenesis in rat. The technical aspects 
of this requirement are expanded upon in Chapter 2. Thus, even before an 
integrated model could be achieved successfully, two parallel aims would have to 
be satisfied: 
1.4.2 Aims 
1. to create a rational rat model of chronic PUFA consumption 
2. to pilot methods for stimulating and observing neurogenesis in the 
hypothalamus of rat 
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General Methods 
2.1 Animals and Treatment 
2.1.1 Animal Experimentation 
Laboratory animal experimentation in the United Kingdom is strictly governed by 
Home Office regulations, which have been devised to ensure that animals are treated 
humanely. Therefore, throughout the studies presented here, codes of conduct and 
treatments outlined in the Animal Scientific Procedures Act (1986) were adhered to. 
The Act sets out to provide clear definitions of a ‘protected animal’ and regulated 
scientific and experimental procedures which may be applied to said animal. It also 
serves to outline the conditions under which these protected animals are to be killed, 
and the humane methods by which this is to be carried out. It also states that before 
work can commence both a personal and project licence must be approved by the 
Home Office. Experimental procedures detailed under these licences have been 
tailored to the specific requirements of the studies described within this thesis.   
One of the current aims of the Home Office is to encourage researchers to 
follow the 3Rs principle of replacement, reduction and refinement (Russel & Burch, 
1959). This means that before a project licence is approved, applicants must have 
done the following, while still enabling their scientific hypotheses to be addressed: 
(1) tried to find alternative means, not involving the use of animals 
(replacement);  
(2) ensured through appropriate experimental design and use of statistics, that 
the minimum number of animals would be used (reduction); and 
(3) justified their choice of animal, as being of the lowest sentience, which 
could still enable project aims to be addressed, and explaining how their suffering 
would be minimised while doing so (refinement). 
The following sections explain how the studies presented in this thesis were 
designed and implemented with these principles in mind. 
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2.1.2 Use of Rodent Models in Studies of Body Weight and Feeding Regulation 
Rodents respond to dietary interventions in ways that usefully model humans. These 
interventions range from caloric restriction to induction of obesity and in many cases, 
result in similar sequelae to those observed in humans (e.g. Buettner et al., 2007; 
Panchal & Brown, 2011). In general, their small, manageable size enables studies, 
such as these, where reproducibility is desired, and replication is necessary to obtain 
statistical significance. With a relatively short lifespan, they allow for relatively rapid 
collection of data along multiple parameters of feeding and body weight metabolism. 
Advantages are that these can be examined at whole-body, integrated levels in vivo, 
and then at tissue and cellular levels ex vivo. In vivo measures can include energy 
intake in response to a variety of diet compositions and feeding schedules, resulting 
body weight, composition, adiposity and fat distribution, and behavioural indices, 
such as timing and volume of meals consumed. Concurrent intermittent body fluid 
sampling allows for monitoring of progression of dietary effects, through 
measurement of key endocrine and metabolic factors (e.g. West & York, 1998; 
Dobrian et al., 2000; Keenan et al., 2005; Buettner et al., 2007).  
Rodents also allow for the convenient study of mammalian body-brain 
relationships and interactions, the complexity of which cannot be replicated in less 
sentient species or non-animal alternatives. This is particularly true when behavioural 
expression of these interactions is of interest, for example in the form of food 
selection and meal patterns (Farley et al., 2003). Given that one of the main 
objectives of the work presented in this thesis was to examine associations between 
brain and body in the context of feeding, specifically, changes in hypothalamic cell 
proliferation in response to dietary fatty acids (Chapter 1, Section 1.4), animals 
which could model the sophisticated physiology of other mammals which have 
shown these relationships (Buettner et al., 2007; Panchal & Brown, 2011), were 
essential to the work. Sub-mammalian species differ too fundamentally from humans 
in their systems physiology and brain structure to have more than limited relevance 
in this context. The alternative of human testing would have been unethical, as post-
mortem tissue was required to examine changes in the brain at the level of resolution 
of individual cells.  
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These considerations also clearly show that in vitro work is not suitable in 
this research area because it cannot answer questions regarding phenotypic 
identification, number and regional distribution of cells in intact brain regions. It is 
self-evident that neither does it allow for development of a whole-animal dietary 
phenotype.  
2.1.2.1 Selection of Species  
Rodents are the vertebrate group of lowest neurophysiological sensitivity which have 
also provided the best-characterised models of peripheral and central regulation of 
appetite (e.g. Schwartz et al., 2000). Some mouse strains, such as the C57BL/6 can 
be more sensitive to dietary intervention, and weight gain, in particular, than 
commonly used outbred rats, such as the Wistar and Sprague-Dawley (Rossmeisl et 
al., 2003). However, as models for examination of, and intervention in, already well-
characterised feeding behaviours, they are less apt than rats (Anson et al., 2003). 
Studies described here involved investigation of feeding behaviour expressed as meal 
patterns (see Section 2.4, below, and Chapters 3 & 5).  Whereas there is no published 
evidence that mice have been used for this purpose previously, rats are commonly 
studied in such paradigms; for example, the behavioural satiety sequence (BSS; 
Halford & Blundell, 1996; Halford et al., 1997; Cooper et al., 2010) and studies of 
circadian rhythmicity of feeding (Kohsaka et al., 2007; Hariri & Thibault, 2011). 
This provides an appropriate context into which results generated in this project can 
be placed.  
2.1.2.2 Selection of Strain 
In investigating effects of dietary enrichment with PUFAs, it was important to 
incorporate the correct control diets into experimental design, as discussed in more 
detail below (Section 2.3.3). These included diets equally enriched in SFAs, and 
based on extensive literature, were predicted to induce obesity. Outbred rat strains, 
including Wistar and Sprague-Dawley, when fed such diets, become progressively 
more obese than their standard chow-fed littermates and develop insulin resistance 
and hyperleptinaemia (e.g. Storlein et al., 1986; Chang et al., 1990; Kraegan et al., 
1991; Buettner et al., 2006; Chen et al., 2010; Hariri et al., 2010), similar to obese 
humans (Kopelman, 2000; Woods et al., 2003; Hariri & Thibault, 2010). They do not 
develop overt diabetes, and therefore, do not display β-cell failure or hyperglycaemia 
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(Levin et al., 1997; Rossmeisl et al., 2003; Collins et al., 2004; Chatzigeorgiou et al., 
2009; Peyot et al., 2010). This is typical of the prolonged period of impaired glucose 
tolerance observed in insulin-resistant obese humans, which can prevail for many 
years, preceding eventual development of frank diabetes (Ferrannini et al., 2004). In 
this way, outbred rat strains with diet-induced obesity (DIO) are more appropriate 
models of human obesity and its associated metabolic dysfunction than monogenic 
strains, such as the Zucker or Zucker Fatty Diabetic (ZDF) rat. The current consensus 
is that most human forms of obesity are diet-induced and occur against a polygenic 
background; that is, they are multi-factorial, resulting from the interaction between 
several susceptibility genes and environmental influences, such as sedentary lifestyle 
(Speakman, 2004). Outbred rats in a given colony or sample population will show 
variable responses to diets of a given composition.  No two randomly selected 
populations will gain weight to exactly the same extent or within exactly the same 
time period (Sclafani et al., 1976; Levin et al., 1983; Levin & Sullivan, 1987; Chang 
et al., 1990; Levin et al., 1997; Reuter, 2007; Schariff & Ziv, 2009), as discussed in 
Chapter 1, Section 1.1.18.4.  In contrast, the monogenic forms of obesity are due to 
single-gene defects, such as those resulting in the failure to produce a functional 
form of leptin or its receptor (Montague et al., 1997).  
In the studies detailed here, the Wistar rat was the outbred strain of choice 
because it had been shown in-house to reliably develop DIO when exposed to a 
highly-palatable diet (Pickavance et al., 1999; 2000; Harrold et al., 2000a; Fatani et 
al., 2007; Al-Qahtani et al., 2008; Moore et al., 2008). This would enable direct 
comparison of project data to previous in-house data for the purposes of monitoring 
body weight and metabolic change. Males were selected over females to avoid the 
potential influence of hormonal cycling on the parameters of interest and to enable 
comparison with the majority of the literature in the field (use of males being the 
convention). Rats were supplied by Charles River U.K. Ltd. (Margate, U.K.) at 
sexual maturity (about 6 weeks of age; 225-250 g), to restrict parameters to those of 
an adult model. 
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2.1.3 Experimental Design 
Upon arrival, animals were stratified by body weight and randomly assigned to 
dietary (Part A; Chapters 3-5) or enrichment (Part B; Chapter 6) treatment groups, in 
factorial designs, in preparation for studies with the following generic schedule (Fig. 
2.1). 
Figure 2.1. Study timeline. After assignment to treatment groups, rats acclimatised to the 
new environment of the Biomedical Services Unit, University of Liverpool, for 1-2 weeks. 
Baseline measures, including body weight and 24-hour food intake were then collected, 
along with an initial blood sample, prior to any intervention. Interventions included exposure 
to diets of differing fat content (Chapters 3-5 & 7) or simple environmental enrichment in the 
form of a play tube (Chapter 6). Phenotyping involved continued periodic collection of 
morphometric, biochemical and behavioural (meal pattern) data (Chapters 3 & 5) until 
termination. Terminal outcomes were measures capable of being taken just prior to death by 
perfuse-fixation (including final body weight, food intake, blood samples, and later measures 
from harvested tissues). A more detailed summary of workflow and outcome measures can 
be seen in Figure 2.2. 
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PART A: Dietary & Metabolic Methods (Chapters 3-5) 
 
PART B: Neurogenic Methods (Chapters 6 & 7) 
 
ANIMALS
Male Wistar rats
Isoenergetic high-PUFA-and-SFA diets
(40% kcal from fat)
Low-fat control group (10%)
METABOLISM
Plasma concentrations of 
appetite-related factors: 
ELISA
MORPHOMETRY
Weekly body weight
Bioimpedance analysis
FURTHER 
MORPHOMETRY
Termination
Dissection & weighing of fat 
pads, muscle and liver
ADIPOKINE GENE 
EXPRESSION
in WAT: PCR
DATA ANALYSIS
Summary measures:
Mean ± SEM
% change from baseline
Statsitical analysis:
1-way ANOVA
Student's t-test
BEHAVIOUR
24-h food intake
Sample MP analysis
ANIMALS
Male Wistar rats
ENVIRONMENTAL 
ENRICHMENT 
Play tube in cage
CELL 
PROLIFERATION 
BrdU administration 
STRESS & TROPHIC 
CIRCULATING 
FACTORS
Plasma CORT and BDNF 
ELISA
NEUROGENEIC 
MARKERS
Termination
Immunohistochemistry
IMAGE ANALYSIS
Microscopy
Image capture
Stereological analysis
Statistical analysis
Figure.2.2. Workflow and outcome measures. Some or all of the outcome data shown here were collected at the end of each of the studies outlined in Chapters 3-7 depending on 
its purpose. Work in Chapters 3 and 6 were concurrent (see Figure 2.21). Abbreviations: ANOVA=analysis of variance; BDNF= brain-derived neurotrophic factor; BrdU= 5-
bromo-2-deoxyuridine; CORT= corticosterone; ELISA= enzyme-linked immunosorbent assay; MP = meal pattern; PCR= polymerase chain reaction; PUFA= polyunsaturated fatty 
acid; SEM= standard error of mean; SFA= saturated fatty acid; WAT= white adipose tissue. 
CHAPTER 2 
 
78 
 
2.1.4 Sample Size Determination 
2.1.4.1 Power Analysis 
Power analysis, which is defined as the probability of finding a real biological 
difference if it exists, is often used to determine the number of animals required in a 
treatment group. However, there are often occasions when it becomes difficult to use 
a power analysis because there is no information on inherent variability, such as 
standard deviation, and because it is difficult to specify the expected size of effect 
from variables (Grafen & Hails, 2002). An alternative method for appropriate sample 
size determination was proposed by Mead (1988). The method is considered 
appropriate for comparative experiments which can be evaluated using analysis of 
variance (Grafen and Hails, 2002; Kutner et al., 2004), such as exploratory 
experiments and complex biological experiments with several factors and treatments 
(such as those described in this thesis). Inherent study complexity (involving several 
dependent variables, such as diet-type) warranted the use of Mead’s resource 
equation over the more commonly used power analysis to determine how many 
animals should be assigned to each group (n).  
2.1.4.2 Mead’s Resource Equation 
Dietary effects can be influenced by many factors (e.g. strain, age), and masked by 
many sources of variation (e.g. palatability and texture). In the design of animal 
experiments, Mead’s resource equation is used to first design pilot studies which 
identify these sources, and then to determine the correct numbers of animals needed 
to give sufficient statistical power for full-scale studies. This then gives confidence in 
the findings, such that repetition of studies, and hence, use of additional animals is 
unnecessary (Festing et al., 2004).   
Mead’s resource equation is as follows:  
E = N - T – B 
In an example taken from this project,  
E = error degrees of freedom (df) (between 10 and 20)  
N = total df = total number of experimental units (animals) - 1  
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T = treatments df = number of treatment (diet) combinations – 1  
B = blocks df = number of blocks (cage runs*) – 1  
*The parameter of meal pattern was measured by automated cages (Section 2.4, 
below). Availability of only 4 cages required rats to be monitored in groups of 4, 
with group members counterbalanced across each cage position and set of 
automated sensors. A “monitoring session”, therefore, constituted a source of 
variation that had to be blocked. 
Selecting 8 animals/group,  
E = (8 rats/group x 2 treatment groups -1) – (2-1) – (4-1) = 15 – 1 – 3 = 11  
Mead’s resource equation states that E should fall between10 and 20; i.e.10 < E < 20. 
Therefore, for this example, 10 < 11 < 20. When selecting 7 animals/group,  
E = (7 rats/group x 2 treatment groups -1) – (2-1) – (4-1) = 13 – 1 – 3 = 9,  
where 9 < 10.  
Therefore, an attempt to address the 3Rs by reducing animal numbers to 
seven per group would fail to satisfy E, but eight animals per group would be an 
optimal minimum sample size to reveal a biological effect, if one exists.  
2.1.5 Assignment to Treatment Groups & Counterbalancing 
Rats were assigned to treatment groups so as to address issues of logistics and 
potential bias, thereby minimising sources of variation. Stratification involved 
grouping the animals into categories predefined by body weights ranging from 
lowest to highest. They were then assigned to treatment groups to ensure that group 
mean starting weights were not significantly different. 
Counterbalancing  position of  rats’ cages across  cage racks, according to 
their assigned treatment group, controlled for variation arising from exposure to the 
scent of a neighbour’s diet or degree of exposure to overhead room lights, for 
example. The cage array also corresponded to the order in which animals were to be 
terminated (Figure 2.3). This controlled for ultradian variation in concentrations of 
circulating factors in terminal blood samples.   
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Batch A (TD1) Batch B (TD2) 
ID Diet ID Diet ID Diet ID Diet ID Diet ID Diet 
114 PUFA 117 Control 120 SFA 123 PUFA 126 Control 129 SFA 
115 SFA 118 PUFA 121 Control 124 SFA 127 PUFA 130 Control 
116 Control 119 SFA 122 PUFA 125 Control 128 SFA 131 PUFA 
 
Figure 2.3. Example of a cage array. This illustrates the configuration employed in studies 
of dietary intervention (Chapters 3-5), but the same principles were applied in studies of 
environmental enrichment intervention (Chapter 6). For logistical reasons, animals were (1) 
split into two equivalent batches for which sampling and termination were separated by x 
days, and (2) Terminated across two days. Diets were enriched in PUFAs or SFAs. Control 
animals received a standard, low-fat diet. Abbreviations: ID = rat identification number; 
PUFA = polyunsaturated fatty acid; SFA = saturated fatty acid; TD = termination day.  
 
A counterbalanced design was also applied to the use of the automated cages 
used for meal pattern data acquisition. The availability of only four cages limited the 
number of rats which could be monitored at any one time, such that several ‘runs’, in 
a configuration similar to that shown below (Fig. 2.4), would be required to analyse 
all animals.  
Batch A       
Day 1 
    Cage 1       Cage 2        Cage 3 Cage 4 
Diet 1 Diet 2 Diet 3  Diet 1 
Day 2 
Diet 2 Diet 3 Diet 1 Diet 2 
Day 3 
Diet 3 Diet 1 Diet 2 Diet 3 
 
Batch B 
Day 1 
Diet 3 Diet 1 Diet 2 Diet 3 
Day 2 
Diet 1 Diet 2 Diet 3 Diet 1 
Day 3 
Diet 2 Diet 3 Diet 1 Diet 2 
 
Figure 2.4. Example of counterbalanced configuration used for meal pattern data 
acquisition. Diet group members were counterbalanced across each cage position and set of 
automated sensors. In effect, meal patterns were ‘sampled’ at predetermined intervals, just as 
other data sets collected over the time course. Rats were removed from home cages and 
placed in automated cages for 24- to 72-h periods. In a 72-h run, days 1-3 were consecutive.  
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2.1.6 Housing and Maintenance  
Rats were singly housed, which allowed for individual food and water intake 
measures. The ability to collect individual data is essential for accurate measurement 
of feeding parameters, but can impoverish the cage environment. Therefore, the risk 
of social isolation, was controlled by the use of high-topped cage lids, enabling 
visual and olfactory contact with neighbours, and the physical environmental was 
enriched with a PVC ‘play’ tube in the case of all rats dietary studies (Chapters 3-5 
& 7) and experimental rats in enrichment studies (Chapter 6).   
Rats were housed on shavings in solid-bottomed cages cleaned out once 
weekly at the same time.  They were maintained at 22 ± 2°C on a 12-hour light-dark 
cycle (lights on at 08.00) and had free access to tap water throughout each study. 
They had ad libitum access to standard laboratory chow (3.4 kcal/g; CRM, Special 
Diet Services, Horley, UK) for a seven-day minimum acclimatisation period prior to 
the start of studies. In enrichment studies (Chapter 6), this continued throughout. In 
dietary studies (Chapters 3-5, 7), rats then received specialised formulated diets 
(Research Diets Inc™, NJ, USA; see Section 2.3). Post-acclimatisation, food and 
water intake were measured daily and body weight weekly to monitor metabolic 
change in response to experimental diets (Chapters 3-5, 7) or as a general health 
check in response to intake of cell proliferation tracer (Chapter 6). Although 
recorded, water intake data did not show any differences between treatment groups 
and are not presented here. Rats were weighed using an animal weighing density 
determination check system which compensates for their movements (Precisa, 
Precision BJ2100D, Milton Keynes, Bucks., U.K.).  
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PART A: Dietary and Metabolic Methods 
2.2 Blood Sampling for Measurement of Circulating Hormones and Lipids    
Before blood sampling, rats underwent an overnight fast to reduce variability in 
plasma concentrations of hormones and metabolites. This took the form of providing 
about 50% of the rats’ average overnight intake at the end of the day. 
Blood was obtained for diagnostic assay by extraction from the tail. This was 
performed on a weekly or fortnightly basis during periods of diet exposure (Chapters 
3-5), or on termination (Chapter 6). Rats were first lightly anaesthetised with gaseous 
isoflurane (2% for 5 minutes) and the extreme tip of the rat’s tail was removed, 
avoiding the terminal vertebrae. Known as tail-tip amputation, this allowed for 
repeated sampling from the same rats in studies following the progression of 
metabolic changes. It enabled quantities of blood (approx. 250 µl), yielding plasma 
in sufficient volume for assay, to be quickly and painlessly removed from the rat. A 
scab would form at the tail-tip overnight and was simply snipped off for the next 
sampling a few weeks later and blood collected directly. At the time of collection, 
whole-blood glucose concentrations were measured using a hand-held blood glucose 
monitoring system and glucose-oxidase strips (Ascensia Breeze 2, Bayer HealthCare, 
Leverkusen, Germany). 
Blood was collected in lithium-heparin microfuge tubes and centrifuged at 
6000 revolutions per minute (rpm) for ten minutes (min) (Sorvall Legend Micro 17, 
Thermo Scientific, Waltham, USA). Plasma was then separated and stored at -20°C 
for later measurement of hormones and lipids by enzyme-linked immunosorbent 
assay (ELISA) or diagnostic assay (see below for descriptions of these assays: See 
Section 2.6).  
2.2.1 Anaesthesia  
The small body size of the rat makes intravenous (i.v.) injection difficult, and drugs 
are usually administered by intraperitoneal (i.p.) routes. If these routes are used it is 
not possible to administer a drug gradually to effect, and the anaesthetic must be 
given as a single calculated dose. Because of the wide variation in drug response 
between different strains of rat, between male and female animals, and between 
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individuals, it is best to use a drug, or drug combination, providing a wide margin of 
safety.  
The anaesthetic combination of choice for rats detailed here is medetomidine 
(Domitor™) and ketamine (0.6 ml/kg and 0.4 ml/kg, respectively). Medetomidine is 
a potent non-narcotic α2-adrenoreceptor agonist which produces sedation and 
analgesia. Ketamine is classified as an NMDA receptor antagonist, and has opioid-
like effects. Medetomidine is often used in combination with opioids, in this instance 
ketamine, to induce complete relaxation in the rat, and is given intraperitoneally (i.p.) 
to produce general anaesthesia. The combination provides a good degree of muscle 
relaxation, with the effects lasting approximately 20-40 minutes (Flecknell, 1996). 
This combination was used for the purposes of perfuse-fixation in all studies 
described here. Administration of pre-anaesthesia by inhalation of isoflurane was 
also used to reduce the effects of stress, which could have affected circulating 
concentrations of corticosterone, one of the outcomes of interest, and levels of 
neurogenesis (Chapter 6, Section 6.3).  
The number of anaesthetic exposures was minimised by performing 
bioimpedance (described in Section 2.5.2) and blood sampling, both short 
procedures, under the same anaesthesia.  
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2.3 Dietary Studies   
As discussed in Chapter 1, dietary studies, both human and rodent model, are largely 
in need of greater systematisation and application of appropriate controls. The 
following sections describe how this was addressed in this project. 
2.3.1 Choice of Commercial Diets  
It was determined that the primary requirement of the chosen supplier would be the 
ability to modify fatty acid (FA) content of the rodent diets in such a way that (1) the 
specific fatty acids desired could be incorporated into a pelleted chow (so as to be 
compatible with wire mesh feeding hoppers); (2) any two high-fat diets (HFDs) 
would be equivalent in energy content  (isoenergetic); and that, (3) along with any 
standard, low-fat control diet (LFD), would have, as far as possible, identical nutrient 
compositions, apart from the constituent (fatty acid) of interest. It was discovered 
that Research Diets, Inc.™, (NJ, USA; hereafter, ‘Research Diets’; Figure 2.5), as 
opposed to other potential suppliers,  such as Purina® and Teklad™, were able to 
meet these criteria. Their diets are referred to as OpenSource® (hereafter, 
‘OpenSource’), which simply means that they have ‘open’ formulas (i.e. that are 
published and available to the scientific community) and that each nutrient is 
supplied by a separate, purified ingredient.   
 
Figure 2.5. Examples of solid pellet diet products manufactured by Research Diets. 
Diets are provided as nutritionally complete to prevent nutritional imbalance. Different 
dietary compositions incorporate different food dyes for identification purposes. Fatty acid 
content above 60% requires that the diet be provided in paste form. Source: 
www.researchdiets.com.  
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Because the purified ingredients used in these diets are refined materials, as 
opposed to the less refined ingredients found in standard chow provided by other 
suppliers, the company can define the nutritional requirements of animals by 
selectively removing one nutrient at a time from the diet. This allows for endless 
modifications and researcher specifications. Previously, high-fat diets have been 
made by adding high levels of fat to grain-based chow diets. Critically, this dilutes 
other essential nutrients such as vitamins and minerals (Cybulsky et al., 1999). Many 
diet manufacturers claim to offer the same “open source” formulas as Research 
Diets. However, although their formulas are open, as defined above, they often vary 
in their sources of ingredients, or vitamin and mineral mixes. Currently, the only way 
to ensure the consistency of diets across studies is to purchase from Research Diets 
(Gajda et al., 2007). 
2.3.2 Modification of Diet Composition 
The main issues associated with dietary studies are the correct selection of 
macronutrients (type and concentration) and their appropriate controls. Numerous 
modifications can be made to OpenSource diets to satisfy these requirements, 
ranging from alterations in macronutrient energy source (e.g. carbohydrate vs. fatty 
acids) to removal of micronutrients (vitamins and minerals) in order to model dietary 
deficiencies and define requirements (Gajda et al., 2007). The studies in this project 
involved not only modification of fatty acid content, but also fatty acid type, in a 
base, or standard control, diet; for example, replacing a baseline concentration of 
polyunsaturated fatty acids (PUFAs) sourced from soybean oil, with one of saturated 
fatty acids (SFAs) sourced from coconut oil, sufficient to quadruple the energy 
contributed by fat (Chapter 5). One of the parameters commonly adjusted by 
Research Diets during formulation is the elevation of sucrose concentration to allow 
researchers to study the development of insulin resistance, the implications of which 
are discussed in Chapter 3 (Section 3.4.4). All dietary modifications described here 
were made to the original Research Diets ‘low-fat control’ D12450B (Table 2.1).  
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Table 2.1.  Nutritional breakdown of low-fat control diet (D12450B; Research Diets, 
Inc.)  
Product  D12450B 
 gm% kcal% 
Protein 19.2 20.0 
Carbohydrate 67.3 70.0 
Fat 4.3 10.0 
Total  100.0 
Kcal/gm 3.85  
 
Ingredient   
Casein, 80 mesh 200 800 
L-Cystine  3 12 
Corn Starch 315 1260 
Malodextrin 10 35 140 
Sucrose 350 1400 
Cellulose, BW200 50 0 
Soybean oil 25 225 
Lard 20 180 
Mineral Mix S10026 10 0 
DiCalcium Phosphate 13 0 
Calcium Carbonate 5.5 0 
Potassium Citrate, 1 H2O 16.5 0 
Vitamin Mix 10 40 
Choline Bitartrate 2 0 
FD & C Yellow Die No.5 0.05 0 
TOTAL 1055.05 4057 
 
Complete nutrient breakdown is provided in gm% and kcal% format. Macronutrients with 
the potential for modification are highlighted: Protein = green; Carbohydrate = blue; Fat = 
orange/yellow. For the studies described here, it is the fat source which was altered. Source: 
www.researchdiets.com.  
 
2.3.3 Control Diets 
Rodent diets typically fall into two categories, the standard chows (maintenance 
diets) and the purified OpenSource diets. The endless capacity for dietary 
modification clearly supports the concept that OpenSource diets are superior, not 
only as experimental diets, but also as their controls. Standard chow diets are 
commonly used as the control diet as they are inexpensive, yet provide suitable 
nutrition. However, it is important to consider that these chow diets contain plant 
material with varying nutritional content (Thigpen et al., 1999), therefore, making it 
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impossible for each batch to be the same (Wang et al., 2005). This makes their use in 
dietary studies, where nutritional intake requires strict control, difficult. Additionally, 
most chow formulas are closed to the public and modifications are unreliable, as 
each plant ingredient contains numerous nutrients (Brown et al., 2001).  
Research Diets formulate the experimental and matching control diets to meet 
the specific study needs, including the animal model, desired phenotype and dietary 
requirements. It is important that when modifications are made, the remainder of the 
diet remains identical to the unmodified control. This allows for comparisons across 
the experimental groups, as only one diet component changes. This principle is 
simple to understand when it comes to removing or adding components that do not 
have caloric content, such as vitamins and minerals. However, when macronutrient 
(protein, carbohydrate, or fat) content is modified, it becomes more difficult, and it 
is, therefore, necessary to look at the ratio of a nutrient per calorie of diet, as animals 
tend to eat for calories, not for weight. This is seen when rodents that are used to 
consuming a diet low in fat begin eating less food by weight (grams) when they are 
switched to a high-fat diet (HFD). This further explains why diets of varying caloric 
(energy) density should be formulated to have similar nutrient-to-calorie ratios, 
ensuring that, per calorie of intake, animals consuming diets of varying caloric 
density will still receive the same amount of nutrients (Ricci & Ulman, 2008).  
2.3.4 Isoenergetic Diets 
There are two types of control diets, one which controls for normal growth and the 
other which controls for energy content (isoenergetic). Isoenergetic diets which are 
identical in all but the FA type are nutritionally complete and take the form of solid 
pellets, thereby controlling for variability in total energy intake and texture. 
Commonly, when comparing a modified diet high in a particular FA (e.g. a PUFA), 
results are compared to another HFD of identical energy content but different FA 
type (e.g. a SFA). These diets then act as controls for one another. A third group, or 
second control, is the included, wherein animals are fed standard (low-fat) chow. 
This groups acts as a control for obesity induction, demonstrating normal weight gain 
and food intake. A common mistake made by many researchers is the use of a 
standard chow diets as a low-fat control in dietary studies. As mentioned above, 
standard laboratory chows contain plant material with varying nutritional content and 
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therefore, diet formulations will vary from batch to batch, introducing additional 
factors, which may confound results (Ricci & Ulman, 2008). Ideally, a control diet 
should match the experimental diet not only in energy content (i.e. be isoenergetic), 
but all other ingredients as well, except for the modified compound of interest. 
2.3.5 Varying Fatty Acid Composition 
When formulating Research Diets the LFD control, the protein requirement is 
commonly met by the milk protein, casein, carbohydrates are supplied by corn starch 
and sucrose, soybean oil provides the fat, and cellulose supplies the fibre (Table 2.1). 
Formulation of the diets required for this project involved modification of some of 
these standard ingredients to meet experimental aims, as described in Chapters 3-5. 
Thus, varying fatty acid composition would enable exposure of animals to differing 
fatty acid types and elevated concentrations. However, in order to keep overall 
energy content constant, concentrations of other macronutrient constituents also had 
to be altered. Importantly, vitamin and mineral mixes specific to rodents were always 
added at concentrations to ensure nutritional adequacy.  
Thus, in project studies (Chapters 3-5, 7), isoenergetic HFDs, equally 
enriched in SFAs or PUFAs, were compared for effects on a range of phenotypic and 
metabolic parameters, including novel aspects of feeding behaviour (meal patterns). 
Diets were formulated to provide 40% of energy from fat. Consultation of the 
literature indicated that this was the highest concentration which could be produced 
in pellet form, and which also would be likely to stimulate both metabolic and 
neurogenic change. Pelleting was important for preventing loss of diet through the 
hopper, a disadvantage of soft, very high-fat diets (e.g. providing 60% of energy 
from fat), which can crumble (Fatani et al., 2007). This ensured energy intake 
measures remained accurate. The outcomes of HFD consumption were compared to 
those of a low-fat control diet (providing 10% of energy from fat) with an otherwise 
equivalent nutrient composition. All were variations of the base diet composition 
shown in Table 2.1. Development of the individual diets used in this project is 
outlined in Chapter 3 and 5. Full nutritional breakdowns and respective fatty acid 
profiles can be found in the Appendix I-IV.  
 
CHAPTER 2 
 
89 
 
2.4 Meal Pattern Analysis 
2.4.1 Why Measure Meal Patterns? 
The measurement of periodic food intake over a set unit of time, such as 24- hour 
intervals, is defined by the researcher and not the experimental animal. From this 
type of data collection, the amount of food consumed during the time period is 
calculated by difference from a previous measurement. Most commonly, a known 
amount of diet is given to the animal, and after a defined time elapses (set number of 
hours, days), the food is re-weighed and the amount consumed is calculated. Feeding 
episodes, bouts, and meals cannot be distinguished by this periodic manual collection 
of data. These types of methods are time consuming and cannot be carried out 
continually. People collecting the periodic data can also affect the animals’ 
behaviour. The act of moving the animal and its food to weigh it can interrupt a 
meal, affecting food intake. Therefore, the more manual measures taken in a day, the 
less likely the data is to be a true representation of the animal’s natural feeding 
behaviour. In comparison, episodic food intake is the automatic recording of the 
animal’s individual eating episodes. Each eating episode is recorded as a unique 
record including the start time, duration, and amount consumed. From this 
information, meal records can be constructed. Specialised cage systems have been 
developed to automate this process, saving labour and limiting disruptive human 
contact with feeding animals, as well as allowing undisturbed and continuous food 
and water weighing across nocturnal and diurnal time periods (Ulman et al., 2008). 
Much can, and has, been learnt about total periodic food and water intake using 
systems based on this principle. This includes information on the nocturnal and 
diurnal control of appetite, as well as characterisation of circadian rhythmicity of 
feeding (Hairiri & Thibault, 2011).   
2.4.2 Feeding and Meal Pattern Parameters 
Obesity has many correlates, including disrupted (abnormal) meal patterns (MPs), 
which have been modelled in rodents. These not only include changes in intake 
(volume), but also meal duration, frequency, distribution across the day and night 
(temporal sequence), and inter-meal intervals (Farley et al., 2003; Farshchi et al., 
2005). Thus, obesity is a disorder expressed on several levels, ranging from genetic 
to behavioural (Vandenbroeck et al., 2007). The advantage of studying MPs in this 
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kind of detail gives us a greater understanding of how appetite is regulated by signals 
from the brain and body tissues, which switch on or off at different times in relation 
to when meals are taken (Leidy & Campbell, 2010). In addition, the nutrient 
composition of food, and its overall energy density, control meal size and feelings of 
fullness (satiety), determine when the next meal will be consumed. Automated cage 
systems aid in generating extensive data for each animal on simultaneous progression 
of several subtle and otherwise difficult-to-measure, aspects of feeding and drinking, 
such as meal volume and periodicity (Ulman et al., 2008). It also allows for the 
monitoring of day-to-day rodent health when administering substances.  
The most significant advantage of these types of studies is both practical and 
ethical: Each individual animal generates a large amount of data, enabling smaller, 
more manageable and quickly processed experiments, and hence a higher turnover of 
research outputs; reducing the number of animals to answer research questions also 
importantly works toward fulfilling the 3Rs. 
Acquiring data on MPs with automated cages helped to fully characterise the 
dietary model described within this project. The measurement of MPs was an integral 
part of these studies as it provided important behavioural information on the effects 
of eating a diet high in fat, especially as MP signatures for diets high in PUFA 
content had yet to be determined in a rat model.  
2.4.3 The LabMaster™ System 
Crude measures of feeding and drinking behaviour were taken by manual weighing 
of food hoppers and water bottles at the same time of day every 24 hours throughout 
the duration of study.  Detailed analysis of feeding (meal) and drinking patterns was 
carried out periodically by transferring rats to automated cages largely equivalent to 
the home cages used for daily intake measures. These were connected to data 
acquisition software (LabMaster™, TSE Systems, Hamburg, Germany; hereafter 
referred to as ‘LabMaster’), allowing for the collection of a series of weights as raw 
data measurements, which were then analysed using various parameters to calculate 
aspects of feeding, including day/night volume, periodicity and satiety. (As water 
intake did not alter in response to any dietary interventions, data are not presented in 
this thesis.) 
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The LabMaster system (see Figure 2.6) was chosen for MP analysis because 
it is specially designed to monitor metabolism and behaviour of small laboratory 
rodents. This particular system was chosen over other possible alternatives, such as 
BioDAQ® (Research Diets Inc.™, NJ, USA) and the Oxymax Lab Animal 
Monitoring System (Columbus Instruments, OH, USA) because it is the only cage 
and software system which performs its own initial basic meal pattern calculations 
for parameters such as feeding rate. Furthermore, LabMaster is modular and can be 
expanded in future to include more cages and attachments for measuring additional 
locomotor activity parameters and ultimately, full metabolism (e.g. body weight, 
calorimetry, activity monitoring etc.). 
 
Figure 2.6. LabMaster™ cage system. Each cage is equipped with a suspended food 
hopper and water bottle attached to sensors from which changes in weight are transduced to 
raw data collected across time and which can then be analysed according to various feeding 
parameters. Source: www.tse-systems.com.  
 
Solid-bottomed cages were used in these studies to provide an environment 
for monitoring unbiased, stress-free animal behaviour. Drinking and feeding 
behaviour was measured by high-precision weighing sensors fixed to the tops of the 
cage lids (Fig. 2.6) and connected by cables to a computer which transduced 
mechanical weight change information into raw numerical data. This was then 
exported in text and CSV file formats to Microsoft Excel files, with which both are 
compatible, and analysed by statistical programs. The LabMaster system itself was 
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capable of carrying out limited meal pattern analysis, which aided monitoring of 
experimental progress while studies were underway (Fig. 2.7). 
Rats were monitored in these cages intermittently for 24-72 hours, depending 
on the study in question, and were given ad libitum access to diet and water.  
 
Figure. 2.7. Example of graphical data presentation by LabMaster™ software.  The 
graph displays information on feeding rate, showing individual meals (green bars) over a 
three-day period (x-axis units in hours). The y-axis shows feeding rate in grams consumed 
per minute. Nocturnal phases are highlighted in grey.  
 
2.4.4 Defining Meal Patterns 
2.4.4.1 Defining a Meal 
The LabMaster system allowed uninterrupted, undisturbed recording of individual 
meals for each animal. Commonly, a meal is defined as a single episode of 
uninterrupted feeding, with a specific start time, feeding duration, and quantity 
consumed. During the studies described here, the weight of the food hopper was 
recorded at 10-minute intervals, as recommended by TSE Systems as a feasible 
resolution for the collection of feeding data; i.e. providing sufficient detail while 
avoiding generating unmanageable quantities of data. A meal was defined as a 
change in hopper weight of ≥0.1 g, separated from other meals by >10 minutes. No 
spillage was noted during these studies. As the food hopper was suspended above the 
cage floor, this prevented fouling of the food with urine or faeces, potentially adding 
to its mass artificially.  
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2.4.4.2 Meal Pattern Parameters  
Raw data were analysed using previously published methods, considered suitable 
here, as they had been applied to data also generated by an outbred rat strain, with 
DIO induced by diets also formulated by Research Diets (Farley et al., 2003; Table 
2.2).  
Table 2.2. Definitions of meal pattern parameters.  
Parameter Description 
Cumulative Energy Intake (kJ) Sum of food intake volume (expressed as energy 
content) across all meals in a defined time frame, 
such as or nocturnal or diurnal phase. 
Number of Meals  Count of those meals which make up the 
cumulative energy intake. 
Meal Duration (min) Interval in minutes from the start to the end of a 
meal. 
Rate of Feeding (g/min) Volume of food intake consumed, expressed as 
grams per minute of meal duration. 
Inter-Meal Interval (min) Time interval from the end of one meal to the 
beginning of the next meal.  
Satiety Ratio (min/kJ) Ratio of inter-meal interval-to-meal size, 
expressed as energy content. 
 
Raw data collected by the LabMaster system was summarised according to these measures. 
Satiety ratio represented the duration of postprandial non-eating time per unit food intake. 
Source: Farley et al., 2003. Obes Res 11(7): 845- 851. 
 
2.4.4.3 Syntax Development 
In order to allow for systematic handling of the large quantities of raw data produced 
by the LabMaster system, and to aid in the calculation of meal pattern parameters, 
syntax script for Microsoft Excel 2007 was developed in-house (Table 2.3). 
Assistance in the development of this script was provided by Dr. A. Jones, leader of 
the Post-Genomic Bioinformatics Group, Institute of Integrative Biology, University 
of Liverpool.   
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Table 2.3. Syntax script.   
Function Script 
Food =IF((D13-D12) >0.1, D13-D12, 0) 
Is Meal End =IF( AND(L12<>0, L13=0), “Meal End”, “”) 
Is IMI End =IF( AND(L12=0,L13<>0), “End IMI”,””) 
Temp IMI Length =IF(M12=”Meal End”,0,O11+10) 
Real IMI Length =IF(N12=”End IMI”, O12,””) 
Temp Meal Length =IF(N11=”End IMI”,0,Q10+10) 
Real Meal Length =IF(M12=”Meal End”,Q12,””) 
 
This enabled processing of extensive raw data generated by the LabMaster  
system, aiding in the calculation of meal pattern parameters defined in Table 2.2.    
 
2.4.4.4 Analysing Circadian Rhythmicity 
Biological function and behaviour, including eating, exhibit 24-hour patterns that are 
driven by an endogenous circadian clock mechanism (Duguay & Cermakian, 2009). 
Metabolism, associated with feeding, also follows a circadian pattern (Queiroz, 1974; 
Hillman, 1976; Ramsey et al., 2007; Laposky et al., 2008; Maury et al., 2010). 
Altered circadian behaviour and sleep patterns are associated with increased hunger, 
decreased lipid and glucose metabolism and changes in satiety that often result in 
obesity and diabetes (Knutson & Van Cauter, 2008). 
The parameters of feeding rhythm and pattern include the size and frequency 
of meals, as well as the time of eating during the day or night. Recently, consumption 
of a diet high in fat has been shown to alter the expected pattern of circadian 
rhythmicity in relation to energy intake in mice (Kohsaka et al., 2007) and rats 
(Hariri & Thibault, 2011) and as this pattern had yet to be explored in relation to 
PUFA intake, it was included as part of meal pattern analysis in this project.  
2.4.4.5 Data Binning 
In order to graphically represent the circadian pattern of feeding in this project, the 
raw feeding data generated by LabMaster software was ‘binned’. Data binning is a 
pre-processing technique which replaces outliers with a mean value, reducing the 
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overall effect of the results into a summary measure format. This involved two 
processes: Firstly, meals were averaged over the 24- or 72-hour time frame, and 
secondly, the data were compressed into 30-minute intervals or ‘bins’, as described 
previously (Cattone et al., 2007; Hariri & Thibault, 2011). Once the data had been 
‘binned’, they were then plotted to demonstrate the distribution of meals over time, 
something which the summary measures of meal pattern analysis (Table 2.2) do not 
show. The technique was modelled on that used by Hariri & Thibault (2011), as 
shown in Figure 2.8. 
 
Figure 2.8. Plot of circadian energy intake. This graph displays energy consumed (as kcal, 
expressed as mean ± SEM) by rats during exposure to a high-fat, lard-based diet. Meals are 
indicated by vertical solid bars and diurnal and nocturnal phases by horizontal open and solid 
bars to the left and right, respectively, under the x-axis. Source: Hariri & Thibault, 2011. 
Chronobiol Int 28(3): 216-228.    
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2.5 Termination and Surrogate Measures of Body Composition 
Before termination, rats underwent an overnight fast to reduce variability in plasma 
concentrations of hormones and metabolites. The quantity of food given during this 
fast was approximately half of their nocturnal intake. The next day, under deep 
anaesthesia, rats underwent thoracotomy. A 1-2-ml blood sample was collected from 
the right atrium before transcardial perfusion with 50 ml of 10 mM PBS at room 
temperature, followed by 100 ml of fixative (4% paraformaldehyde, with 0.2% picric 
acid) at 4°C. During perfusion, the descending aorta was clamped to prevent fixation 
of abdominal organs, as only the brain required fixing for immunohistochemical 
purposes. After dissection, fixed brains were processed for histology, detailed in 
Section 2.10. White adipose tissue (WAT) depots (epididymal, perirenal and 
inguinal), interscapular brown adipose tissue (BAT), muscle (gastrocnemius and 
soleus), liver and spleen were also dissected free  by blunt dissection, weighed, snap-
frozen in liquid nitrogen, and stored at -80°C for later analysis. Specific anatomical 
sites of the WAT and BAT analysed can be seen in Figure 2.9. WAT and BAT were 
weighed as indices of adiposity and WAT further processed for molecular analysis, 
as described in Section 2.8. Muscle and spleen were processed for histological 
analysis, as detailed in Section 2.10.  
 
 
Figure. 2.9. The adipose organs of a rodent. The organ has been dissected with the aid of a 
surgical microscope and each depot has been placed on the diagram mimicking its 
anatomical position. The organ is made up of two subcutaneous and several visceral depots. 
Abbreviations: A= deep cervical; B= anterior subcutaneous (interscapular, subscapular, 
superficial cervical); C= visceral mediastinic; D= visceral mesenteric; E= visceral 
retroperitoneal (including epidiymal); F= visceral perirenal, G= posterior subcutaneous 
(dorso-lumbar, inguinal and gluteal).  Source: Cinti et al., 2005. Prostaglandins Leukot 
Essent Fatty Acids 73(1): 9-15.  
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Assessment of body composition is an important indicator of nutritional 
status, and growth and development of individuals, as well as populations. 
Throughout these studies, fat mass was expressed as a percentage relative to body 
weight. A surrogate body composition measure of fat-to-lean tissue was calculated as 
the ratio of the sum of dissected WAT depot to muscle masses (Pickavance et al. 
2001; 2005); i.e.   
Body Composition Index = Σ WAT depot masses (g)  
Σ muscle masses (g) 
 
Animals predisposed to gaining weight are more ‘food efficient’, than their 
lean counterparts, meaning that rather than expending energy, they store it more 
readily as adipose tissue. Food efficiency was calculated as the ratio of cumulative 
body weight gain to 24-hour energy intake, over the course of diet exposure; i.e.   
Food Efficiency = ∆ Body Weight (g)  
        Σ Energy Intake (MJ) 
 
2.5.1 Ectopic Fat Deposition 
Increased liver and BAT weights were taken as a possible indication of infiltration by 
white adipocytes. The former could also indicate metabolism of PUFAs, as discussed 
in Chapter 3, Section 3.4.1. Individuals who consume high-fat diets display variable 
responses in the way in which they store the fat within the body. Excess intra-
abdominal (visceral) fat may be a marker of the inability of subcutaneous adipose 
tissue to act as an ‘energy sink’ for excess energy as a result of excess intake. The 
inability of subcutaneous fat to store excess energy may cause fat to accumulate at 
alternative locations such as the liver, skeletal muscle and heart. This process is 
known as ectopic fat deposition. Although liver fat has been frequently linked to 
excess intra-abdominal fat, several studies have shown that liver fat and intra-
abdominal fat each contribute independently to the metabolic complications of 
abdominal obesity (Nguyen-Duy et al., 2003). In order to monitor ectopic fat 
deposition, weights of liver and BAT were also recorded.  
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2.5.2 Bioimpedance Analysis 
By the time work described in Chapter 5 was in the planning stages, facilities for 
assessment of whole-body composition had become available. It was measured by 
total-body electrical conductivity (TOBEC), using an Em-Scan/TOBEC® scanner 
designed for small animals (model SA-3000; Royem Scientific, Luton, UK). TOBEC 
is a non-invasive, non-destructive, rapid method for the in vivo estimation of lean 
body mass (LBM), total body fat (TBF), percent body fat relative to body weight 
(TBF%) and fat-free mass (FFM). Assessment of these measures was conducted 
using previously described equations (Morbach & Brans, 1992; Table 2.4).  
Table 2.4. Bioimpedance equations.  
Body composition measures Formulae 
Lean body mass (LBM) = 0.5E + (0.3 x total body weight) 
Total body fat (TBF) = total body weight – lean body mass 
Total body fat % (TBF%) = (total body fat x 100)/ total body weight 
Fat-free mass (FFM) = 16.28 + 0.4E 
 
These formulae were applied to the raw data collected in the study described in Chapter 5 
only. E value was generated by the machine when scanning animals (see text). Source: 
Morbach & Brans, 1992. J Pediatr Gastroenterol Nutr 14(3): 283-92.  
 
This method involved measuring the TOBEC of rodents as they were passed 
through an electromagnetic field (Van Loan et al., 1987), generating an E value, 
which was then substituted into the equations detailed in Table 2.4. The technique 
has been calibrated previously in-house for the measurement of body composition in 
male Wistar rats across a wide range of body weights (Cassidy et al., unpublished 
observations).  
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2.6 Acquisition of Metabolic Data 
2.6.1 Plasma Concentrations of Hormones and Lipids 
Concentrations of appetite-related factors were measured to investigate any potential 
for their change over time, as a result of consuming diets high in fat. In order to do 
this, enzyme-linked immunosorbent and enzymatic assays were used. To characterise 
the models piloted in this project, a selection of ‘classic’ circulating factors relevant 
to appetite mediation (Chapters 3-5) and neurogenesis (Chapters 6 & 7) were 
assayed. Their significance in these contexts is outlined in the General Introduction 
(Chapter 1) and their relevance to high-fat consumption, in particular, is detailed 
further in individual experimental chapters.  
2.6.2 Enzyme-Linked Immunosorbent Assay 
Enzyme-linked immunosorbent assays (ELISAs) are analytical biochemical assays 
that employ a solid-phase enzyme immunoassay (EIA) to detect a substance in a 
liquid sample – in this instance, blood plasma. ELISAs employ a sensitive method, 
capable of detecting low concentrations of an antigen of interest, and because of this 
sensitivity, allow for the assay of small volumes, which is useful when samples are 
precious. The method requires an antigen, or target protein, which can be 
immobilized on the solid-phase and then bound to a detection agent, which is 
normally a specific antibody linked to an enzyme. Multiple wash steps ensure that 
only specific binding of the antibody takes place and a quantifiable signal is 
generated, most commonly detected as a colour change in the reaction mixture 
(Lequin, 2005).    
2.6.3 Types of ELISA 
There are several types of ELISA, including indirect, competitive and sandwich. 
Indirect ELISAs use non-specific antigen immobilisation methods so that small 
concentrations of antigen in plasma samples have to compete with other plasma 
proteins when binding to the well surface. The sandwich ELISA corrects this 
problem by employing a capture antibody specific for the test antigen. Competitive 
ELISAs are time consuming and require incubation with large sample volumes prior 
to the running of the assay. Since specific antigens were of interest and blood 
samples were precious in the studies presented here, sandwich ELISAs were used.   
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2.6.4 Principle of the Sandwich ELISA 
In simple terms, a sandwich ELISA works on the principles illustrated in Figure 
2.10, below.  
 
Figure 2.10. Example of a generic sandwich ELISA. The target protein first attaches to the 
plate coated with capture antibody. The detection antibody then attaches to the target protein, 
and the TMB substrate causes a reaction which results in a colour change that can be 
monitored using a plate reader. Abbreviations: HRP = horseradish peroxidase; TMB = 
3,3’,5,5’-tetramethylbenzidine. Source: www.sigmaaldrich.com.     
 
For the ELISAs described here, the plate was coated with capture antibody 
and blocking agent, and the blood plasma was added to the wells, allowing the 
antigen of interest to bind to the capture antibody. Detection antibody was then 
added to the wells, where it bound to the antigen. Enzyme-linked secondary antibody 
was added, which, in turn, bound to the detection antibody, and the plate was washed 
so that any unbound reaction mixture was removed. Finally, a substrate was added 
which converted the enzyme present into a quantifiable colour change. The 
absorbency of the reaction mixture was then measured in the individual plate wells 
using a plate reader (Labsystems Multiskan Ascent, Thermo Fischer Scientific, 
Surrey, UK). This allowed for determination of the quantity of the antigen present in 
the blood samples, as the optical density (OD) of the individual samples was 
compared to those generated by known sample concentrations in a standard curve. 
All ELISAs were carried out according to the manufacturers’ protocol.   
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2.6.5 ELISA Validation 
Method validation, to check that the combined procedures of sample preparation and 
analysis yielded acceptably accurate, precise and reproducible results for a given 
antigen, had been tested by the manufacturers and documented in the product user’s 
guide. A second validation was carried out in-house. This involved the assaying of 
standards and control samples of known concentration provided with the kit, as well 
as spare in-house samples, repeatedly over several days for all of the ELISAs used. 
This enabled the standardising of experimental conditions, setting up of parameters 
on the plate reader, and checking of results from assayed samples within the 
recommended range of the kit.  
2.6.6 Mouse/Rat Leptin ELISA 
Plasma leptin concentrations were measured using a commercially available kit 
(Peprotech, Inc., NJ, USA). It contained key components required for the 
quantitative measurement of natural and/or recombinant murine (m) leptin in a 
sandwich ELISA format. This involved the use of an antibody raised against mLeptin 
to capture the protein, and a biotinylated antigen-affinity purified anti-mLeptin 
antibody to detect it. An ABTS [2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic 
acid] liquid substrate was used to monitor concentration of product measured as a 
colour change. The sensitivity range of the kit was 20-1250 pg/ml, and the cross 
reactivity was 100% with rat, and 2% with human, leptin. The samples were assayed 
undiluted at a volume of 50µl. At 1ng/ml the intra- and inter-assay coefficient of 
variation were 3.5% and 4.2% respectively (Peprotech, Inc., NJ, USA).  
2.6.7 Rat Insulin ELISA 
Plasma concentrations of insulin were measured using a commercially available kit 
(Mercodia, Uppsala, Sweden). Initially, an ELISA of standard sensitivity was used, 
but it was unable to detect insulin in the samples; therefore, an ultrasensitive rat 
insulin ELISA was used instead. During incubation, insulin in the sample reacted 
with peroxidase-conjugated anti-insulin antibodies and anti-insulin antibodies bound 
to the plate. This kit was used in conjunction with control samples of rat insulin also 
supplied by the company [Diabetes Antigen Control (Low, Medium, and High)], as 
well as a TMB (3,3’,5,5’-tetramethylbenzidine) liquid substrate to monitor 
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concentration of product measured as a colour change. The sensitivity range of the 
kit was 0.020-450 µg/L and the cross-reactivity was 100% with rat, 75% with mouse, 
and <0.05% with human insulin. The samples were assayed undiluted at a volume of 
25µl. At 0.2ug/L the intra- and inter-assay coefficient of variation were 2.6% and 
3.5% respectively (Mercodia, Uppsala, Sweden).  
2.6.8 Rat Adiponectin ELISA 
Plasma adiponectin concentrations were measured using a commercially available kit 
(ALPCO, NH, USA). Adiponectin is often referred to by molecular subtype (low, 
medium and high molecular weights), and this kit involved the use of specific, high-
affinity antibodies to measure total adiponectin in the sample. It was selected because 
measurements of total adiponectin are of greater diagnostic value than any one of the 
subtypes alone (Blüher et al., 2007). It has been demonstrated that total serum 
adiponectin is significantly decreased in insulin-resistant and type 2 diabetic, 
compared to insulin-sensitive subjects, and that this cannot be replicated when 
measuring subtypes alone (Lara-Castro et al., 2006). Furthermore, studies have 
shown correlations between total serum adiponectin and insulin sensitivity and the 
ability of total serum adiponectin concentration to predict insulin resistance and 
impaired glucose tolerance (Blüher et al., 2007). TMB liquid substrate was used to 
monitor concentration of product measured as a colour change. The sensitivity range 
of the kit was 0.25 - 10 ng/ml and the cross reactivity was 0% with mouse, rat, rabbit, 
goat, sheep, pig, horse and bovine samples of adiponectin. Prior to use, samples were 
diluted to 1:2,500 at a volume of 5µl. At 4µg/ml the intra- and inter-assay coefficient 
of variation were 4.5% and 5.0% respectively (ALPCO, NH, USA). 
2.6.9 Rat BDNF ELISA 
Plasma concentrations of BDNF were measured using a commercially available kit 
(Boster Biological Technology Ltd., Wuhan, China). TMB liquid substrate was used 
to monitor concentration of product measured as a colour change. The sensitivity 
range of the kit was 30-2000 pg/ml, and there was no detectable cross reactivity with 
any other cytokines. Prior to use, samples were diluted to 1:10 at a volume of 25µl. 
At 160pg/ml the intra- and inter-assay coefficient of variation were 5.6% and 4.2% 
respectively (Boster Biological Technology Ltd., Wuhan, China). 
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2.6.10 Rat/Mouse Corticosterone ELISA 
Plasma concentrations of corticosterone were measured using a commercially 
available kit (Demeditec Diagnostics, GmbH, Germany). This ELISA was based on 
competitive binding principles; thus, an unknown amount of corticosterone in the 
sample, and a known amount of corticosterone conjugated to horseradish peroxidase, 
competed for binding sites of corticosterone antiserum coating the plate wells. This 
kit was used in conjunction with control samples of rat corticosterone also supplied 
by the company (Rat Control Set DEV99RC). TMB and hydrogen peroxidase liquid 
substrate were used to monitor concentration of product measured as a colour 
change. The sensitivity range of the kit was 3.6-245.5 ng/ml, and the cross reactivity 
was <0.02% with other steroids, including aldosterone, cortisol, deoxycorticosterone, 
estriol, estradiol, progesterone, testosterone and pregnolone. The samples were 
assayed undiluted at a volume of 25µl. At 180ng/ml the intra- and inter-assay 
coefficient of variation were 5.3% and 4.8% respectively (Demeditec Diagnostics, 
GmbH, Germany). 
An illustration of how samples were typically arrayed for analysis in the 
current studies can be seen in Figure 2.11. 
CHAPTER 2 
 
104 
 
 
Figure 2.11. Example ELISA plate design. All plasma samples across the exposure period were counterbalanced according to dietary group. The standard 
curve was always on the left of the plate to prevent contamination of the samples with standard and control solutions during wash steps. Abbreviations: 
PUFA = polyunsaturated fatty acid; SFA = saturated fatty acid.     
CHAPTER 2 
 
105 
 
2.7 Enzymatic Assays 
The enzymatic assay is a useful method for the quantitative determination of the 
concentration of a particular biological compound within a solution, often plasma or 
serum. It exploits the fact that the compound of interest will be converted, dependent 
on the presence of a certain enzyme or enzymes, into another compound through a 
series of reactions. This commonly produces a chromophore, such that the 
concentration of the compound of interest is directly related to the depth of colour in 
the solution and is thereby quantifiable at a particular wavelength using a 
spectrophotometer.  Such assays are of obvious diagnostic value, and many have 
been conveniently developed to provide all required components of the enzymatic 
pathway in a single kit. This speeds up routine laboratory analyses significantly 
(Glick & Pasternak, 2003). The plasma samples assayed in this way were obtained as 
described above [Location 2.2]. 
2.7.1 Principle of the Triglyceride Assay 
The commercial assay for the determination of triglyceride (TG) concentrations in 
plasma (Sigma-Aldrich Co., Ltd., Dorset, U.K.) involved a series of reactions, as 
follows: 
TGs are enzymatically hydrolysed by lipoprotein lipase (LPL) to free fatty acids 
(FFAs) and glycerol: 
TGs + H2O   Glycerol + FFAs  
The glycerol is phosphorylated by ATP with glycerol kinase (GK) to produce 
glycerol-1-phosphate and ADP: 
Glycerol + ATP         glycerol-1-phosphate + ADP 
Glycerol-1-phosphate is oxidised to dihydroxyacetone phosphate (DAP) by glycerol 
phosphate oxidase (GPO) producing hydrogen peroxidise (H2O2): 
Glycerol-1-phosphate + O2    DAP + H2O2 
In a colour reaction catalysed by peroxidase (POD), the H2O2 reacts with 4-
aminoantipyrine (4-AAP) and sodium N-ethyl-N-(3-sulfopropyl) m-anisidine (ESPA) 
LPL 
GK 
GPO 
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to produce a red coloured quinoneimine dye that shows an absorbance maximum at 
540 nm.  
The increase in absorbance at 540 nm is directly proportional to the triglyceride 
concentration of the sample:  
H2O2 + 4-AAP + ESPA           Quinoneimine dye + H2O 
 
2.7.2 Protocol for Determination of TG Concentration in Plasma 
Only a single reagent was required for this test, and its active ingredient 
included ATP, 4-AAP, ESPA, POD, GK, GPO and LPL. One ml of the reagent was 
added to plastic cuvettes containing plasma samples (25µ l volume) and distilled 
water, in the case of the blank. The final concentrations of the above ingredients 
were 2.5 mM, 0.8 mM, 1 mM, 5.4 units per ml (U/ml), 0.56 U/ml, 6 U/ml and 31 
U/ml, respectively. Samples were compared to an aqueous solution of glycerol 
standard (0.025 mg/ml; Sigma-Aldrich Co., Ltd., Poole, Dorset, U.K.) mixed with 
reagent. The solutions were mixed and after a reaction time of 15 min at room 
temperature, absorbances were read at 520 nm, referencing against the blank. These 
values were then applied to the following formula: 
[TG, mg/ml] = absorbance of sample   x concentration of standard  
             absorbance of calibrator       
where 
concentration of standard = 0.26 mg/ml (equivalent triolein concentration).  
 
  
POD 
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2.8 RNA Extraction from White Adipose Tissue   
2.8.1 TRI-Reagent Method   
Extraction of ribonucleic acid (RNA) from epididymal, perirenal and inguinal white 
adipose tissue (WAT) depots was carried out using the TRI-reagent® method (Sigma 
Aldrich, Dorset, UK). In a chemical fume hood, forceps and homogenizer blade 
attachments were pre-treated with RNase AWAY™ (Molecular BioProd Inc, CA, 
USA) and rinsed with UV-irradiated distilled water several times prior to use, to 
avoid contamination. Between the processing of tissue samples from each dietary 
group, the homogenizer was again rinsed twice in UV-irradiated distilled water. 
Approximate 100-mg blocks of tissue were cut from the frozen sample, using a 
sterile scalpel blade and forceps, and placed into a 4-ml collection tube. One ml of 
TRI-Reagent® was added to the tube and the tissue homogenized using an electric 
homogenizer (Polytron Ultra-Turrax T25). The homogenate was then transferred into 
a 2-ml micro centrifuge tube and centrifuged at 12,000 rpm for 10 min at 4˚C. The 
clear supernatant layer was then transferred into a fresh 2-ml tube. After leaving the 
tissue to stand at room temperature for 5 min, 200 µl of chloroform (Fisher 
Scientific, Leicestershire, UK) were added. Each tube was then vortexed for 15 sec 
and allowed to stand for 10 min at room temperature. This was followed by 
centrifugation at 12,000 rpm for 15 min at 4˚C, separating the solution into three 
layers, a lower red phenol layer (protein), a white interphase layer (DNA) and a 
colourless upper layer (total RNA). The upper layer containing the RNA was 
transferred into a fresh 2-ml tube. To reduce contamination of the sample with DNA, 
50 µl of isopropanol (Sigma-Aldrich, Dorset, UK) was added and the sample 
vortexed and allowed to stand for 10 min at room temperature before further 
centrifugation at 12,000 rpm for 10 min at 4˚C. The supernatant was then transferred 
into a 1.5-ml tube and 450 µl isopropanol added to precipitate the total RNA. This 
was followed by vortexing, incubation of the sample for 10 min at room temperature 
and centrifugation at 12,000 rpm for a further 10 min at 4˚C. On completion of this 
step, the supernatant was discarded, and 100 µl of a 75% solution of molecular grade 
ethanol (VWR International Ltd, Devon, UK) in ultra-pure water (0.1 µm filtered, 
DNase and RNase free) was added to the RNA pellet. This was followed by 
vortexing and centrifugation at 12,000 rpm for 5 min at 4˚C. The supernatant was 
again removed and the RNA pellet allowed to air dry for 5 min at room temperature. 
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The RNA pellet was then dissolved by adding 10 µl of ultra-pure water and briefly 
vortexed. Between extractions, equipment was cleaned of tissue, rinsed, 
decontaminated by soaking in 1% Virkon (Antec International, Suffolk, UK) for two 
hours and finally rinsed.  RNA samples were stored at -80°C until use. 
2.8.1.1 RNA Quantification  
Total RNA was diluted 1:70 by adding 1 µl to 69 µl of distilled water. The diluted 
sample was placed in a plastic cuvette, inserted into a spectrophotometer 
(BioPhotometer, Eppendorf UK Limited, Stevenage, UK) and light absorbance 
measured at 260 nm (A260) and 280 nm (A280). Distilled water was used as a blank. 
Maximal light absorbance by nucleic acids occurs at A260, whilst proteins absorb 
light maximally at A280 (Glasel, 1995). The extinction coefficient of RNA at A260 
is approximately 40. The concentration of RNA in each sample was determined 
automatically by the Beer-Lambert law (Beer, 1852):  
[RNA] µg/µl = A260 x 40 x DF, 
where 
Dilution Factor (DF) = 70 
The concentration of protein in each sample was determined: 
[Protein] µg/µl = A280 x 40 x DF, 
where 
DF = 70 
The ratio between the values obtained at A260 and A280 indicated the purity 
of the RNA in the sample. A ratio of 1.8-2.0 suggested high purity. If samples were 
of low purity, then RNA extraction was repeated.   
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2.8.2 Real-Time Polymerase Chain Reaction (qPCR) – Taqman System  
2.8.2.1 Real-Time Polymerase Chain Reaction  
Real-time PCR (qPCR) is a commonly used technique that allows the relative 
quantification of the amount of cDNA template in a sample. It monitors the amount 
of PCR product formed during each cycle via detection of a fluorescent signal 
(Logan et al., 2009). The signal emitted increases in proportion to the amount 
produced. This is particularly evident during the exponential phase of the reaction 
(Glick & Pasternak, 2003). There are a number of different detection methods 
available for qPCR; these include TaqMan Probe Systems, SYBR Green I, Molecular 
Beacons and Hybridisation Probes (Tamarin, 1999). The in-house method of choice 
for qPCR detection was the TaqMan Probe System.  
2.8.2.2 Taqman® System  
This system involved the use of forward and reverse primers and a TaqMan probe 
(Applied Biosystems, Cheshire, UK) to amplify the gene of interest. The TaqMan 
probe is an oligonucleotide with a fluorescent (reporter) dye (FAM-6-
carboxyfluorescein) on the 5’ base, and a quenching dye (TAMRA-6-
carboxytetrametheyrhodamine) on the 3’ base (Lawyer et al., 1993). Energy is 
transferred from the reporter dye to the quenching dye by a process known as 
fluorescence resonance energy transfer (FRET). FRET is undetectable by the PCR 
machine, yet when the Taq polymerase copies a template onto which the probe is 
bound, its 5’ exonuclease activity cleaves the probe separating the reporter and 
quenching dyes, ending the FRET (Giulietti et al., 2001). The reporter dye is then 
able to emit fluorescence at a wavelength of 518 nm for detection of FAM, which the 
PCR machine can detect (see Figure 2.12). The amount of fluorescence increases in 
each cycle proportionally to the DNA amplification (Logan et al., 2009; see Figure 
2.13). This accumulation of product is detected by monitoring the increase in 
fluorescence of the reporter dye plotted after normalisation to a reference dye, in this 
instance ROX (carboxy-X-rhodamine). The reference dye is used to correct for 
differences in reaction volumes between wells (Sails, 2009). 
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Figure 2.12. TaqMan detection method for qPCR. The TaqMan assay uses a probe 
oligonucleotide with a reporter fluorophore at the 5’ end (R), and a quencher dye at the 3’ 
end (Q). As the product is amplified, the 5’-to-3’ exonuclease activity cleaves the end of the 
probe, allowing fluorescence emission from the reporter dye to occur. This emission is then 
monitored by the PCR machine. Source: www.appliedbiosystems.com.   
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Figure 2.13. Example plot demonstrating the amplification of fluorescent product 
produced at each cycle of PCR. The amount of fluorescence increases in each cycle 
proportionally to the DNA amplification. The accumulation of product is then detected by 
monitoring the increase in fluorescence of the reporter dye plotted after normalisation to a 
reference dye. Source: www.bio-rad.com.  
 
2.8.2.3 Preparation for Real-Time PCR  
A master mix was prepared for each gene of interest, comprised of forward and 
reverse primers (see Table 2.5), Taqman probe and GoldStar enzyme (qPCR Core 
Kit RT-QP73-05; Eurogentec Ltd., Hampshire, UK), and according to the following 
protocol (per well): 1.25 µl 10x reaction buffer, 1.25 µl (2.5 mM) 50 mM magnesium 
chloride, 0.5 µl (100 mM) 5 mM dNTP, 0.038µl Sense primer, 0.038 µl anti-sense 
primer, 0.063 µl Taqman probe, 0.0625 µl (0.025 U/µl) of 5 U/µl Hot Goldstar 
enzyme and 8.29 µl Ultra-pure water, for a total reaction mixture of 11.5 µl per well.  
The mix was aliquoted into a 96-well plate, and one µl of template cDNA 
sample was then added to each well for a total reaction volume of 12.5 µl. Non-
template controls were included for all primers and probes. The plate was then sealed 
and centrifuged at 1000 rpm, for 15 sec (IEC Centra-7R Centrifuge, Damon, Global 
Medical Instrumentation Inc., Minnesota, USA).  
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Table 2.5. Details of specific primers used for real-time qPCR analysis.  
Primer Product 
(bp) 
Conc. 
(nM) 
Sequence (5’-3’) 
Β-actin s 101 300 GACAGGATGCAGAAGGAGATTACTG 
Β-actin as 300 GAGCCACCAATCCACACAGA 
B-actin P 225 CACCATGAAGATCAAGATCATTGCTCCTCCT 
Leptin s 100 900 AACCCTCATCAAGACCATTGTCA 
Leptin as 900 CCCGGGAATGAAGTCCAAA 
Leptin P 225 TGACATTTCACACACGCAGTCGGTATCC 
Adiponectin s 64 900 CCCCTGGCAGGAAAGGA 
Adiponectin as 900 CCTACGCTGAATGCTGAGTGAT 
Adiponectin P 225 AGCCCGGAGAAGCCGCTTACATG 
 
The primers used for qPCR were β-actin, leptin and adiponectin (Eurogentec Ltd., 
Hampshire, UK). Abbreviations: as = antisense primer; P = probe; s = sense primer. 
 
When quantifying the level of expression of a particular gene of interest, it is 
compared with that of a gene expressed at a concentration which is known to be 
stable; this is known as a ‘housekeeping’ gene. The selection of an appropriate 
housekeeping gene is critical, as it is used to assess the relative degrees of expression 
of the genes of interest. Common examples of housekeeping genes include β-actin, 
glyceraldehyde-3-phosphate (GAPDH), 18S rRNA and RNA polymerase IIa 
(RNAPolIIa). Studies examining gene expression in WAT have successfully used β-
actin as the housekeeping gene (Gorzelniak et al., 2001; Eisele et al., 2005; Zhang et 
al., 2005), and this, therefore, was the gene of choice for the assays described here. A 
second housekeeping gene, RNAPolIIa was also tested. However, expression of this 
gene was variable within the tissue samples and therefore, its use as a housekeeping 
gene was abandoned.   
2.8.3.4 Real-Time PCR Set-up  
Reactions were performed using a real-time PCR machine (Mx3000P, Agilent 
Technologies, CA, USA). The plate was inserted into the heat block and 
amplifications were performed as follows:  
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1. 50˚C for 2 min (activation of Hot Goldstar enzyme)  
2. 95°C for 10 min (denaturation)  
3. 35-40 cycles (dependent on the level of expression of gene)  
i. 95˚C for 15 sec (denaturation)  
ii. 60˚C for 60 sec (combined primer annealing and extension)  
 
2.8.2.5 Analysis of qPCR Data  
Once amplifications were complete, data were collected and analysed by software 
(MxPro-Mx3000P software, Agilent Technologies, Berkshire, UK), which also 
displayed amplification plots on a log scale. The threshold was adjusted to reduce 
background noise from the plot. Results were exported as Microsoft Excel files and 
gene expression analysed by relative quantification, by the 2-∆∆CT method (Livak 
& Schmittgen, 2001). Samples were normalised to values for the housekeeping gene, 
β-actin, and results expressed as fold changes of threshold cycle (CT) values relative 
to the controls which in this instance was the SFA-fed group:   
∆CT = CT(PUFA) – CT(β-actin)  
∆∆CT = Mean ∆CT(PUFA) – Mean ∆CT(SFA)  
Fold Change = 2-∆∆CT 
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PART B: Neurogenic Methods 
2.9 Neurogenic markers 
Mapping cell fate was originally carried out to understand the origin of tissues in an 
adult organism by establishing the association between individual cells at one stage 
and their progeny at later stages of development (Gimlich & Jochen, 1985). The 
process of neurogenesis has three stages; the initial growth of a cell, known as 
proliferation, the migration of the cell to specific regions within the brain, and 
finally, differentiation into a mature neuron. As discussed in Chapter 1, this has been 
studied extensively in the hippocampus (Eriksson et al., 1998; Balu & Lucki, 2009; 
Figure 2.14). 
The original studies which investigated cell proliferation in situ, and 
determined the origin, migration and fate of neuronal cells in the central nervous 
system, all involved the use of autoradiography with tritiated ([3H]) thymidine 
(Sidman et al., 1959; Angevine, 1965; Schlessinger et al., 1975; Crespo et al., 1986). 
This method was also used to provide the first evidence that neurogenesis occurs 
within the SVZ and DG of the adult rodent brain (Altman & Das, 1965; Altman, 
1969). The use of this radiolabeled substrate was reported to induce cell-cycle arrest, 
apoptosis and DNA damage within the cell (Hu et al., 2002) and therefore, the 
development of new strategies to study cell proliferation and neurogenesis resulted in 
the replacement of [3H]thymidine with the thymidine analogue, 5-bromo-2-
deoxyuridine (BrdU) (Nowakowski & Hayes, 2000; Taupin, 2007). 
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Figure 2.14. Neurogenesis in the hippocampal system. Top panel: a coronal section of rodent brain showing the sites of neurogenesis in the dentate gyrus 
(DG) of the hippocampus. Cells proliferate in the subgranular layer (SGL) located at the interface between the hilus and the granular layer (GL), where they 
migrate and differentiate into mature neurons. Bottom panel:  the sequence of cell types involved in neuronal development, along with specific markers 
allowing cell identification (Kempermann et al., 2004). Source: Abrous et al., 2005. Physiol Rev. 85(2):523-69. 
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2.9.1 Bromodeoxyuridine 
Exogenous administration of BrdU is currently the most commonly used means of 
labelling the maximum number of proliferating cells in the brain. Although cell cycle 
proteins, such as Ki-67 and proliferating cell nuclear antigen (PCNA), can be 
immunostained in post-mortem brain sections, without the need for prior invasive 
technique, this provides only a “snapshot” of dividing cells at the point of animal 
sacrifice, and cannot indicate cell fate (Kee et al., 2002; Gage et al., 2008). 
[Immunostaining, or Immunohistochemistry, is discussed in Section 2.10] 
BrdU is a halopyrimidine, a thymidine analog that intercalates into the DNA 
of dividing cells during the synthesis (S) phase of the cell cycle (Figure 2.15). It is 
used as a tracer for birth dating and monitoring of cell proliferation and 
subsequently, neurogenesis (Nowakowski et al., 1989). BrdU is administered in vivo 
to an animal and the incorporated compound can then be detected ex vivo after 
termination by immunohistochemistry, using an antibody directed against single-
stranded DNA containing BrdU (Gratzner, 1982). The process of neurogenesis is 
then confirmed using additional immunohistochemical markers of the type of cell or 
stage of development (Fig. 2.14).  
 
Figure 2.15. Cell cycle diagram and structural illustration of 5-bromo-2-deoxyuridine 
(BrdU) which incorporates into the cell cycle during the synthesis phase. BrdU is a 
thymidine analog that incorporates into DNA of dividing cells during the S-phase of the cell 
cycle, and is used for birth dating and monitoring cell proliferation. This can be revealed by 
immunohistochemistry using a monoclonal antibody directed against single-stranded DNA 
containing BrdU. BrdU immunohistochemistry is currently the most used technique for 
studying adult neurogenesis. Abbreviations: G1 = first growth phase; G2 = second growth 
phase; M = mitotic phase; S = synthesis phase. Sources: www.abcam.com  and Taupin, 
2007. Brain Res Rev 53:198- 214.  
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Neural stem cells have the capability of either self renewing or becoming 
glial cells (astrocytes or oligodendrocytes) or neurons (Abrous et al., 2005; Figure 
2.16). Because of this potential, in instances where BrdU or other 
immunohistochemical markers are used to label cell proliferation, the techniques do 
not necessarily indicate neurogenesis. To confirm this process, markers of cell-type 
and stages of development must also be used (Fig. 2.14); for example, antibodies for 
the proteins doublecortin (DCX) and NeuN can both be used for immature and 
mature neurons, respectively. Furthermore, these immunohistochemical markers are 
successfully used to indicate cell proliferation in all tissues, not just neurons; 
therefore, they can be used to monitor processes such as myogenesis or adipogenesis 
(Kubis et al., 2007).    
 
 
Figure 2.16. Neural stem cell development. Stem cells have the potential to self-renew or 
develop into early progenitor cells which then become neurons, oligodendrocytes or 
astrocytes. Source: www.prometheism.net; Abrous et al., 2005. Physiol Rev. 85(2):523-69. 
 
2.9.2 Ki-67 & PCNA 
Additional immunohistochemical markers which are used to detect cell proliferation 
include PCNA and Ki-67. PCNA is expressed during the S-phase of the cell cycle 
(Kurki et al., 1986), as well as during DNA repair, and is also present in some non-
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proliferating neurons (Ino & Chiba, 2000). This means that if PCNA is used as a 
marker of cell proliferation, the result may not be a true reflection of cell 
proliferation alone. In comparison, Ki-67 is expressed in all phases of the cell cycle, 
except the resting phase (Endl & Gerdes, 2000; Kee et al., 2002; Zacchetti et al., 
2003) It has a short half-life and  therefore, is not detectable during DNA repair 
(Scholzen & Gerdes, 2000; Zacchetti et al., 2003). Hence, it is a more viable option 
for the labelling of proliferating cells. The quantification of Ki67-immunopositive 
cells has been shown to reflect proliferation in a manner consistent with BrdU 
labelling in the adult hippocampus, supporting the use of this marker for studying 
adult neurogenesis. Estimation of the extent of cell proliferation by quantification of 
Ki-67-positive cells in immunostained tissue is more accurate than that of BrdU- and 
PCNA-positive cells. As explained, this is because Ki-67 is expressed during most 
phases of the cell cycle, whereas BrdU and PCNA are markers of S-phase cells only. 
This, therefore, allows better estimation of proliferative activity alone (Kee et al., 
2002; Eadie et al., 2005).  
2.9.3 Technical Limitations of BrdU 
Although BrdU labelling is currently the most utilised method for studying adult 
neurogenesis, there are known limitations to this technique. For instance, BrdU is a 
toxic substance, the integration of which alters DNA stability, increasing the risk of 
mutations, DNA strand breaks, and lengthening of the cell cycle (Saffhill & Ockey, 
1985; Morris, 1991, 1992). Although no apparent toxic effect has been reported 
when studying adult neurogenesis specifically, it is likely that even low doses of 
BrdU may have a toxic effect on newly generated cells in the adult brain (Sekerkova 
et al., 2004), which may result in artificially low estimations of proliferation and 
increased measures of apoptosis (Gould & Gross, 2002).  
DNA repair is a normally occurring process in the life of a cell and is carried 
out by cellular enzymes which secure genomic stability (Memo, 1999). Because 
DNA repair involves DNA synthesis and because BrdU is not a marker of cell 
proliferation per se, but DNA synthesis, there is a concern that BrdU 
immunohistochemistry may not only detect dividing cells in the brain, but also cells 
undergoing DNA repair (Taupin, 2007).   
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BrdU immunohistochemistry (IHC) has several limitations with respect to the 
study of cell proliferation and adult neurogenesis. This method involves the use of 
antibodies raised against DNA containing BrdU. In order for the antibody to gain 
access to the BrdU within the DNA, a denaturation process must be carried out (see 
Section 2.10.5). Common procedures involve the use of HCl acid treatments to 
hydrolyse the tissue (Moran et al., 1985; del Rio & Soriano, 1989; Taupin, 2007). 
These sorts of harsh treatments affect tissue structure and antigenicity recognition in 
multiple antibody labelling studies, ultimately limiting identification of newly 
forming cells. Denaturation procedures further prevent the use of fluorescent 
counterstains, such as 4’,6-diamidine-2’-phenylindole (DAPI; detailed below in 
Section 2.10.6) and propidium iodide (PI), both of which bind to double-stranded 
DNA and aid in the observation of cell nuclei (Chazotte, 2011).   
Furthermore, the extent and intensity of BrdU immunostaining is largely 
dependent on the particular techniques used for detection and may not realistically 
reflect the amount of DNA replication (Nowakowski & Hayes, 2000). Therefore, 
data must be carefully interpreted and sequential immunostaining in adjacent tissue 
sections should be carried out with other markers of neurogenesis. Appropriate 
controls must also be used to ensure that incorporation of BrdU truly reflects the 
generation of new neurons in the adult brain (Taupin, 2007). Examples of these are 
outlined in Section 2.10.3.1.      
2.9.4 Alternative Methods 
Recently, the thymidine analogue, 5-ethynyl-2′-deoxyuridine (EdU), has also been 
investigated for detecting DNA synthesis (Cappella et al., 2008; Chehrehasa et al., 
2009; Zeng et al., 2010). EdU is incorporated into the DNA of a cell during the 
replication stage of the cell cycle and is detected through a copper-catalysed reaction 
between the ethynyl group and fluorescent azide (Click-iTTM EdU Cell Proliferation 
Assay Kit; Invitrogen, Paisley, UK; Chehrehasa et al., 2009). Because of the small 
size of the fluorescent azide, it can diffuse into the double-stranded DNA, 
eliminating the need for DNA denaturation and protecting the integrity and 
antigenicity of the sample. This new technique has been evaluated against the 
traditional BrdU method and has demonstrated comparable results. In some 
instances, EdU has proven to be more sensitive than BrdU. For example, in studies 
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where mice were intentionally stressed by physical restraint, counts for EdU positive 
immunoreactivity were drastically reduced below that of BrdU counts, suggesting, 
that as stress is known to reduce cell proliferation within the brain, this marker was 
more sensitive. While this new compound is currently under scrutiny, it has been 
suggested that the combined staining of both markers might provide a valuable 
double-labelling approach (Zeng et al., 2010).  
As this method is currently under development and extremely expensive to 
carry out, as well as for the reasons discussed above, a combination of approaches 
involving the use of BrdU and other ex vivo immunohistochemical markers was 
considered appropriate for the current project.    
2.9.5 Modes of Administration of BrdU 
BrdU must be administered in vivo to allow for incorporation into the DNA of cells. 
The compound is purchased as a powder, which is then dissolved in solution and 
administered either peripherally via intraperitoneal (i.p.) injections or orally, through 
the drinking water (Taupin, 2007), or centrally via intracerebroventricular (i.c.v.) 
infusion (Kokoeva et al., 2005; Table 2.6). Most studies have involved repeated 
injection of BrdU i.p., at a recommended dosage and frequency (Table 2.7), to ensure 
a degree of uptake that will label the most dividing cells. This is a popular method 
because it avoids surgical intervention (Gould et al., 2001; Kornack & Rakic, 
2001a). However, as BrdU in human plasma is metabolised rapidly by 
dehalogenation, with a half life of approximately 10 minutes (Kriss et al., 1963), and 
as it has to enter the circulation and cross the blood-brain-barrier (BBB), the 
concentration that reaches the brain, at least at certain sites, is often minimal in 
comparison to the initial administered dose (Kokoeva et al., 2007; Cifuentes et al., 
2011).  
Table 2.6. Routes of delivery, common concentration ranges and frequencies of delivery 
for BrdU administration.  
Route of Delivery Concentration Frequency 
i.p. injection 50-100 mg/kg  2-4 per day 
i.c.v. infusion 1 µg/µl constant 
drinking water 1 mg/ml constant 
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Researchers have assessed the suitability of central BrdU delivery to better 
capture the proliferative potency of brain regions distant from the principal 
neurogenic sites, such as the hypothalamus and substantia nigra. They have found the 
number of labelled newborn cells to be much higher after i.c.v. infusion of BrdU than 
after i.p. delivery (Zhao et al., 2003; Kokoeva et al., 2007; Cifuentes et al., 2011). 
Extended BrdU exposure methods, such as i.c.v. infusion and incorporation into 
drinking water are often required when studying adult brain sites with a generally 
low mitogenic activity (Zhao et al., 2003; Kokoeva et al., 2005, 2007; Bennett et al., 
2009; Cifuentes et al., 2011). However, oral delivery may be preferred over i.c.v. 
infusion, as the invasive nature of the latter may induce stress, which is known to 
affect the rate of neurogenesis (Gould et al., 1998). Despite the comparative ease of 
this method, and therefore, its compatibility with other study interventions which 
may run concurrently, it appears to have been used only occasionally (Zhao et al., 
2003; Bennett et al., 2009).  It may be that researchers prefer to be able to control the 
amount of BrdU absorbed from drinking water (Zhao et al., 2003): Animals in a 
given study will drink variable amounts, thereby receiving variable ‘doses’ of BrdU. 
In addition, it is uncertain how much intact BrdU crosses the gut lining, also 
potentially affecting the ‘dose’ which crosses the BBB. On the other hand this loss 
may be offset by the frequency of constant administration through drinking, 
compared to the intermittent delivery with i.p. administration. These issues are only 
speculative at present, as it appears that they have not been put to the test in any 
published papers in the field to date. In pilot studies undertaken during my MRes, I 
had directly compared all three routes of BrdU delivery in rat and found 
administration through the drinking water to be superior to i.p. injection and 
comparable with direct i.c.v. infusion, with respect to the extent of BrdU uptake in 
the hypothalamus, as indicated by the number of BrdU-immunolabelled cells. 
Therefore, this was the method of choice for the current project. The technicalities 
surrounding the stimulation and observation of cell proliferation in the adult rat 
hypothalamus using this method ultimately required study in their own right and are 
detailed in Chapters 6 and 7.  
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2.10 Immunohistochemistry  
Immunohistochemistry (IHC) is a technique commonly used to investigate the 
localisation and distribution of a specific antigen, such as a protein, within a cell or 
tissue. In comparison, immunocytochemistry (ICC) is performed on samples of intact 
cells that have had their surrounding extracellular matrix removed, such as cells in 
culture, aspirates and blood smears (Polak & Norden, 2005). Accurate preparation of 
the sample for IHC is important for maintaining the original morphology of the 
tissue. This involves careful collection of the tissue, fixation and sectioning. Fixation 
is commonly carried out using a paraformaldehyde-based solution, and then the 
sample is sliced into sections using a microtome or cryostat. These sections can then 
be mounted onto slides or processed ‘free-floating’. Sometimes the tissue sample 
may require additional processes to allow antibodies access to the antigen of interest. 
These steps may include antigen retrieval methods, such as acid denaturation 
(Gratzner, 1982; Moran et al., 1985), described below with reference to BrdU-
immunostaining (Section 2.10.5).        
 IHC employs antibodies which bind to the specific antigen in the tissue. 
Observation of this interaction can be achieved in several ways. For example, within 
the studies documented here, the antibodies had been tagged with a fluorophore and 
detected with an epi-fluorescent microscope. IHC is a popular technique in the field 
of neurobiology, as it enables examination of protein expression within specific 
structures of the brain, which are non-uniform, preventing the loss of information 
which occurs with techniques requiring tissue homogenisation. Its main disadvantage 
is that, unlike other techniques, such as Western blotting, where staining is 
commonly checked against a molecular-weight ladder, it is not possible to show that 
the staining observed corresponds to the protein of interest (Polak & Norden, 2005). 
For this reason, antibodies are thoroughly validated upon development using Western 
blotting; if the antibody is specific for the selected target, a band at the predetermined 
molecular weight for the target antigen will appear (Major et al., 2006; Bordeaux et 
al., 2010). An alternative, but less commonly used, validation method involves the 
use of blocking peptides which have the same sequence used to create the antibody 
and are incubated with the antibody in excess. The antibody, with and without the 
blocking peptide, is then used to stain tissue samples which are known to express the 
target of interest. If the antibody is specific, the addition of the peptide will result in 
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no observed staining in the tissue (Skliris et al., 2009). Although this method shows 
that the antibody is specific, it does not prove selectivity, as non-specific binding will 
also be inhibited by pre-adsorption with the peptide (Michel et al., 2009). Therefore, 
the antibody in question should always be validated in-house with appropriate 
controls. These are defined below in Section 2.10.3.   
2.10.1 Indirect Immunofluorescence  
There are two methods involving the use of immunofluorescence, direct and indirect. 
Direct immunofluorescence involves the use of a primary antibody tagged with 
fluorophore. Although it involves fewer steps and is, therefore, less time-consuming 
than indirect immunofluorescence, it is not commonly used because the number of 
fluorescent molecules that can be bound to the primary antibody is limited and as a 
result the method is less sensitive and therefore, gives less signal amplification 
(Polak & Norden, 2005; see Figure 2.17).  
Indirect immunofluorescence involves the use of two antibodies, an unlabeled 
primary antibody, raised in a host species, against the antigen of interest, and which 
specifically binds to the target antigen; and a secondary antibody, which carries a 
fluorophore, recognises the primary antibody, binds to it, and fluoresces. In this 
instance, multiple secondary antibodies can bind to a single primary antibody; 
therefore, providing greater signal amplification by increasing the number of 
fluorophore molecules per antigen (Polak & Norden, 2005; see Figure 2.17). 
Localisation of antigens in studies documented here was determined by indirect 
immunofluorescence. 
CHAPTER 2 
 
124 
 
 
Figure 2.17. Direct and indirect methods of immunofluorescent staining. Direct method: 
Primary antibody with fluorescent tag binds directly to antigen of interest. Indirect method: 
Primary antibody binds to antigen of interest, secondary antibody with fluorescent tag binds 
to primary antibody. Abbreviations: A = target antigen; B = other antigen present on cell. 
Source: adapted from www.badrilla.com, using principles described in Polak & Norden, 
2005. Introduction to Immunocytochemistry. 3rd Edition. BIOS. 
 
2.10.2 Antibody Types 
There are two different types of antibodies that can be used for indirect 
immunofluorescence, monoclonal and polyclonal. Monoclonal antibodies are 
specific to a single epitope (the part of the antibody which is recognised by 
antibodies in the immune system) and are therefore more specific (Polak & Norden, 
2005). Monoclonal antibodies are produced in mice challenged with the specific 
antigen, and activated B-lymphocytes from the spleen, the source of the antibodies, 
are fused with cultured myeloma cells from mice of the same strain which are unable 
to produce the antibody. The fusion results in hybrid cells which continue to grow 
and divide in culture and also produce antibodies. One hybrid cell produces only one 
type of antibody. The cultured hybrid myeloma cells are gradually cloned by testing 
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the culture medium for secreted antibodies at each stage of culture. This leads to the 
development of a cell line derived from a single cell which produces a single 
antibody (monoclonal) (Figure 2.18; Ritter, 1986; Ritter & Ladyman, 1995). 
Monoclonal antibodies raised against the cell proliferation markers BrdU and PCNA 
were used in this project (Table 2.8; Chapters 6 & 7). 
 
Figure 2.18. Production of monoclonal antibodies. Spleen cells from a mouse challenged 
with antigen are fused with myeloma cells, producing hybridomas. These are cultured in 
HAT medium (containing hypoxanthine, aminopterin, and thymidine), and monoclonal 
antibodies are harvested. Source: www.proteopedia.org based on principles described in 
Ritter & Ladyman, 1995 Monoclonal Antibodies, Production, Engineering and Clinical 
Application. Cambridge University Press, Cambridge.   
 
In contrast, polyclonal antibodies are isolated from the host serum (Polak & 
Norden, 2005). Injection of the host animal with the antigen of interest induces an 
immune response specific to that antigen. This produces IgG immunoglobulins 
(Johnstone & Thorpe, 1996), which are then removed by purification of the host 
animal’s serum (Figure 2.19). 
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Figure 2.19. Production of polyclonal antibodies. The host species is selected based on quantity of antibody needed. Antigen is injected into the body of the 
animal, stimulating an immune response. Polyclonal antibodies from different B cells are produced and removed from the serum. Source: www.wikibooks.org 
based on principles described in Elsadig & Ali, 2012. Polyclonal Antibody Production. LAP LAMBERT Academic Publishing.  
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For detection purposes, antibodies are categorised as primary and secondary. 
Primary antibodies are raised against the antigen of interest, while secondary 
antibodies are raised against the immunoglobulins of the species used to raise the 
primary antibody. As mentioned previously, it is the secondary antibody that is 
directly bound to the fluorophore, which acts as a reporter molecule, allowing for 
detection of an antigen (Polak & Norden, 2005). 
2.10.3 Controls for Immunohistochemistry  
Sometimes antibodies bind to tissue sites that do not contain the specific antigen of 
interest; this is because the antiserum contains a mixture of antibodies including 
some from the host animals’ serum. Their detection produces ‘background’ staining. 
Background staining is an issue, as it may mask staining of the antigen of interest 
preventing quantification. Background staining can also be caused by cross-reactivity 
between antibodies raised in varying species. Because of the similarities of 
immunoglobulin molecules from different species, it is possible that the secondary-
layer anti-immunoglobulin will react with the primary-immunoglobulin of the animal 
in which the antigen is to be immunostained, for example anti-mouse 
immunoglobulin with rat immunoglobulin (Polak & Noorden, 2005). Most 
manufacturers test commercially available antibodies for cross-reactivity during 
development using ELISAs. Product data sheets will then specify any known cross-
reactivity and the species which the antibody has been tested against.       
There are two main types of controls, positive and negative, which aid in the 
confirmation of background staining and accuracy of results found.  
2.10.3.1 Positive Controls 
Positive control samples known to contain the antigens in question can be obtained, 
often by harvesting appropriate tissue samples at the time of perfuse-fixation. For 
example, in the studies outlined here, spleen samples were removed during dissection 
and sections processed and stained alongside brain sections. Spleen was selected as a 
control tissue for the staining of proliferating cells, as it rapidly regenerates when 
injured, but also has a high turnover of cells in general (Levy et al., 1976). The pia 
mater was also used, as an internal brain control, albeit outside the BBB. It is the 
innermost layer of the meninges, the membrane which surrounds the brain and is 
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lined by epithelial cells, a cell-type which self-regenerates (Decimo et al., 2012). 
This rapid cell turnover is ideal for demonstrating uptake of BrdU. Without the use 
of such controls, a negative result on the test material cannot be confirmed as either 
real or artefact; because there is no guarantee that the reagents are in good working 
condition and have been applied in the correct order and at the correct dilutions. If 
the positive control is satisfactory, it is a reasonable assumption that the correct 
method has been carried out on the test material as well (Heyderman, 1972; Polak & 
Noorden, 2005). 
2.10.3.2 Negative Controls 
Negative controls are preparations wherein application of the primary antibody 
solution is omitted. In all other respects, the treatment is exactly the same as for the 
test preparation. There should be no staining visible at the end of the reaction. If 
there is, it must be assumed that it is non-specific, and attempts to prevent it can be 
made. There are two commonly used solutions to this problem. The first is to dilute 
the antibody as much as possible prior to use, and the second is to block any potential 
binding sites with a highly concentrated protein solution. Either of these steps should 
lessen the effect of background staining mentioned previously. Non-specific binding 
sites can normally be blocked with normal serum or an ‘inert’ protein such as bovine 
serum albumin (BSA) or casein, at a concentration of 2% solution in buffer (Polak & 
Norden, 2005). However, these steps can generally be prevented by suitable wash 
steps, as these non-specific bonds are weaker than the specific ones (Buffa et al., 
1979). Thus, in the studies documented here, working antibody solutions were made 
from stock solutions containing 0.1% BSA and removed from sections by washing in 
10 mM PBS multiple times between incubations (see Section 2.10.4, below). 
2.10.3.3 Absorption Controls 
To demonstrate that an antibody is binding specifically to the antigen of interest, it 
can be pre-incubated with the same peptide (immunogen) used to immunise the 
animals that produced the antibody. This should deactivate the antibody, and the 
tissue should show little or no staining. This is often referred to as an absorption 
control or specificity control, and the peptide is often referred to as the blocking 
peptide (see Figure 2.20). The pre-absorbed antibody can then be incubated with 
tissue in place of the primary antibody alone. The staining pattern produced by the 
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primary antibody can be compared to that produced by the pre-absorbed antibody 
(Polak & Norden, 2005).  
 
Figure 2.20. Absorption Control. As in a competitive assay, the immunogen peptide 
competes with the protein of interest in the tissue sample for antibody binding sites. Source: 
www.neuromics.com. 
 
Absorption controls work best when the immunogens are peptides. However, 
if antibodies have been raised against a whole protein, then addition of the mixture of 
antibody and protein may result in even greater non-specific staining. Therefore, it is 
important to note that an absorption control using whole protein may not always 
confirm the specificity of an antibody for the protein of interest in the tissue. An 
absorption control is essentially a competitive assay, as the peptide competes with 
the protein of interest for antibody binding sites in the tissue sample (Figure 2.20). 
Therefore, absorption with excess peptide is preferable, to favour the antibody 
binding with the peptide while inhibiting binding with the protein of interest.  
Both primary and secondary antibodies used in these studies had been well-
characterised previously by the manufacturers, ourselves and others (as revealed by 
consultation with the literature) and were known to stain their target proteins without 
the need for additional specificity tests.  
2.10.4 Immunohistochemistry and Image Analysis  
For the studies detailed in this thesis, rats were perfuse-fixed (see Section 2.5) and 
brains were removed, placed in a brain blocker (Kopf®, David Kopf Instruments, 
CA, USA) and the hypothalamus blocked at the anterior-posterior coordinates of 
8.16 and 3.36 mm (Paxinos & Watson, 2004), using the plane of the interaural line as 
reference. They were then post-fixed in the same fixative used for perfusion (4% 
paraformaldehyde, with 0.2% picric acid in 100 mM PB) for three hours and 
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transferred to cryoprotectant (30% sucrose in 100 mM PB) overnight at 4°C. 
Cryoprotectant was then refreshed, and brains stored until use.  
Fixed hypothalamic blocks and positive control tissues were prepared as 
described above (Section 2.5). They were serially sectioned at a thickness of 50 µm, 
using a freezing microtome (Leica 2000R). Sections were collected free-floating into 
well-plates containing 10mM PBS. Any spare sections were stored at -20°C in 
cryoprotectant (50% v/v 10mM PBS; 30% w/v Sucrose; 1% w/v 
Polyvinylpyrrolidone; 30% v/v Ethyleneglycol). Sections were washed 3 x 10 
minutes in 10 mM PBS between each of the following steps:  
Sections were first incubated in primary antibody solution overnight (15-20 
hrs) at 4°C. This was followed by a 1-hour room temperature incubation in 
secondary antibody solution in the dark. Both incubations were carried out under 
constant agitation on an agitator (200 Double Rocker, VWR International Ltd., 
Leicestershire, UK). Details of primary and secondary antibodies can be seen in 
Table 2.7. Optimal working concentrations had been determined in earlier tests on 
spare tissue through by applying serial dilutions prepared with 10mM PBS 
containing 0.3% Triton-X, a detergent to aid penetration of the antibody into the 
tissue. 
Table 2.7. Details of primary and secondary antibodies.  
Antigen Host Dilution Manufacturer Secondary Dilution 
BrdU Mouse  1:50 Roche Mouse Dylight 594 1:500 
Ki-67 Rabbit  1:100 Vector Labs Rabbit Dylight 594 1:500 
PCNA Mouse 1:100 Santa Cruz Mouse Dylight 594 1:500 
A4.74 Human 1:10 DSHB Mouse Dylight 594 1:500 
A4.840 Human 1:10 DSHB Mouse Dylight 594 1:500 
 
Antibodies were used in studies described in Chapters 4, 6 and 7, as markers of cell 
proliferation (BrdU, Ki-67 and PCNA) and muscle fibre-type (A4.74 and A4.840).   
Secondary antibodies were manufactured by Jackson ImmunoResearch Laboratories 
(Stratech, Suffolk, UK). Dylight 594 is a red fluorophore-conjugate. Abbreviations: A4.74 
= fast fibre type, A4.840 = slow fibre type, BrdU = bromodeoxyuridine, PCNA = 
proliferating cell nuclear antigen.  
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2.10.5 DNA Denaturation 
Protocols to detect BrdU by IHC have been devised using monoclonal antibodies 
directed against single-stranded DNA containing BrdU (Gratzner, 1982). This 
requires the denaturation of DNA, the standard procedures for which involve partial 
hydrolysis of the tissue with HCl acid (Gratzner, 1982; Moran et al., 1985). Prior to 
immunolabelling with anti-BrdU antibodies, brain and spleen sections were 
incubated in 1M HCl for 30 minutes at 37°C (Chapters 6 & 7), and muscle sections 
were incubated in 1 M HCl for 15 minutes at room temperature (Chapter 4). The acid 
was then neutralised by rinsing the sections three times in 10 mM PBS with constant 
agitation. Methods described by Wojtowicz & Kee (2006) were adapted and 
optimised to  suit the tissue-types processed here; these modifications included 
increased duration of wash steps, reduced temperature for denaturation and reduced 
time for acid exposure for the thinner muscle sections (10- vs. 50-µm-thick).  
2.10.6 DAPI 
DAPI (4',6-diamidino-2-phenylindole; Sigma-Aldrich Co., Ltd., Dorset, U.K.), a 
fluorescent molecule that binds strongly to DNA, was applied to muscle sections (1% 
solution) described in Chapter 4 to act as a counterstain for BrdU. DAPI is excited by 
ultraviolet light (Du et al., 1998), and the blue emission is convenient for use as a 
counterstain in a single sample (Haugland, 1992).    
2.10.7 Microscopy 
After a final wash, sections were mounted onto chrome-alum-coated glass slides and 
allowed to air dry overnight before application of Vectashield® mounting medium 
(Vector Laboratories, Inc.) and coverslips. 
Immunostaining was examined under an epi-fluorescent microscope (Zeiss 
Axio Imager. M1), and images captured by digital microphotography (Hamamatsu 
ORCA I-ER digital camera, Hamamatsu Photonics, Welwyn Garden City, Herts) and 
image analysis program (AxioVision, Zeiss Imaging Systems). The photographic 
panels in Chapters 6 and 7 were created using Microsoft PowerPoint 2007.  
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2.11 Statistical Analyses 
Data collection, summary calculations, descriptive statistics, meal pattern 
calculations and syntax derivation were carried out using Microsoft Excel 2007. 
Grubb’s Test was then used to detect outliers in the raw data. This test calculated the 
ratio Z as the difference between the outlier and the mean, divided by the standard 
deviation: 
Z = mean-value 
 SD 
Calculated Z values were then compared to a table of critical values (see 
Table 2.8) dependent on the total number of data points in a group (n). When the 
value of Z was higher than those tabulated the value of p was < 0.05 and the data 
point was excluded as an outlier. 
Table 2.8. Critical values for Z.  
N Critical Z   N Critical Z 
3 1.15   27 2.86 
4 1.48   28 2.88 
5 1.71   29 2.89 
6 1.89   30 2.91 
7 2.02   31 2.92 
8 2.13   32 2.94 
9 2.21   33 2.95 
10 2.29   34 2.97 
11 2.34   35 2.98 
12 2.41   36 2.99 
13 2.46   37 3.00 
14 2.51   38 3.01 
15 2.55   39 3.03 
16 2.59   40 3.04 
17 2.62   50 3.13 
18 2.65   60 3.20 
19 2.68   70 3.26 
20 2.71   80 3.31 
21 2.73   90 3.35 
22 2.76   100 3.38 
23 2.78   110 3.42 
24 2.80   120 3.44 
25 2.82   130 3.47 
26 2.84   140 3.49 
 
Z is calculated using the Grubb’s equation. The critical value of Z is then found in the table 
above, where N (n) is the number of values in the group. If Z is higher than the tabulated 
value, the p value is less than 0.05. Source: Barnett & Lewis, 1994. Outliers in Statistical 
Data. Wiley Series in Probability & Statistics. Wiley Publishing, Chichester, UK.  
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To determine position and dispersion (spread) of data, descriptive statistics 
(mean ± SEM) were first applied. All data within this thesis are presented as mean ± 
SEM unless otherwise stated.  
Statistical analysis was carried out using software SPSS v19. It tests for 
equality of variance within groups (an assumption of parametric tests) and 
automatically carries out non-parametric tests (such as the Mann-Whitney U test), 
where this assumption fails. However, for the data presented in this thesis, it was 
unnecessary to use any non-parametric tests. Similarly, the data was automatically 
tested for normality.  
Effects of diet treatment on several parameters including cumulative energy 
intake, cumulative body weight gain, percent change from baseline of plasma 
concentrations were determined by one-way ANOVA followed by post hoc 
Bonferroni correction (Chapters 3 and 5). Differences were considered significant at 
critical p < 0.0166, as is suitable for three comparisons (i.e. between control, high-
SFA and high-PUFA diets). Additionally, area under the curve analysis, using the 
trapezoidal rule, was also carried out for satiety ratio.  
Several measures were taken repeatedly over time from the same individual 
rats. These were food intake, body weight, plasma hormone and lipid concentrations 
and meal pattern parameters. Application of two-way ANOVA with repeated 
measures with post-hoc Bonferroni correction was applied to account for factors of 
time, diet and individual variation within animals. Results were considered 
significant at p < 0.05. A repeated measure is a term used when the same entities take 
part in all conditions of an experiment (Dytham et al., 2003). For example here rats 
eat diets over several time points whereby certain measures are taken at each time 
point from each rat. In this type of experiment it is important to control for individual 
differences in tolerance to the diet: some rats can eat a lot of food without gaining 
weight and others will eat a small amount and gain weight. To control for these 
individual differences we can test the same rats in all conditions of the experiment so 
we test each rat after they have consumed the diet for one week, two weeks, or three 
weeks etc. Following each week’s consumption several parameters (e.g. body 
weight, plasma hormones) are assessed from each rat monitoring the progression of 
the effects of the diet over time. Parametric tests based on the normal distribution 
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assume that data points are independent. This is not the case in a repeated measures 
design because data for different conditions have come from the same entities. This 
means that data from different experimental conditions will be related; because of 
this we have to make an additional assumption to those of the standard ANOVA. 
This assumption is known as the assumption of sphericity and assumes that the 
relationships between pairs of experimental conditions is similar (i.e. the level of 
dependence between pairs of groups is roughly equal). This process calculates the 
differences between results in all combinations of the treatment over time and then 
calculates the variance of these differences. Sphericity is met when these variances 
are roughly equal as is the case for all data presented here (Dytham et al., 2003). If 
data do not meet this assumption then the degrees of freedom for the effect are 
reduced making the assessment more conservative. SPSS applies these adjustments 
automatically. In the case of a 2-way ANOVA with repeated measures; two 
independent variables are manipulated (diet type and time) and the same rats have 
been used across time to eat the three diet types. Therefore this analysis type is 
appropriate when you have two-repeated measures independent variables: each rat 
does both of the conditions in the experiment and provides results for each 
permutation of the two variables. 
The effects of diet treatment on adipokine gene expression in white adipose 
tissue depots (Chapter 3) and muscle fibre-type ratios (Chapter 4) were determined 
by Student’s 2-tailed t-test. Results were considered significant at p < 0.05. 
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2.12 Gantt Chart 
As mentioned previously, work detailed in the following data chapters overlapped in 
places. A Gantt chart detailing this can be seen in Figure 2.21.  
 
 
 
 
  
 
 
Figure 2.21. Gantt chart of chronological ordering for studies detailed in Chapter 3-7. 
Horizontal arrows indicate where protocols were applied, or tissues were analysed, between 
studies. 
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Characterisation of Chronic High-PUFA Feeding in Rat 
3.1 Introduction  
Obesity is a risk factor for several metabolic disorders which impact on quality of 
life for an increasing number of people worldwide. Its phenotypic hallmark is 
elevated body weight, due to an abnormal level of adiposity (Schwartz & Brunzell, 
1997; Seidell & Flegal, 1997). The development of obesity depends on the 
expression of a number of genes, largely determined by interaction with 
environmental factors. The nutrients we consume are among the most influential of 
these factors, and include fatty acids (FAs).  
3.1.1 Effects of Dietary Fatty Acids on Adiposity 
A diet high in fat will encourage weight gain, but the nature of this gain depends not 
only on the amount, but also the types of FAs consumed (Fernández-Quintela et al., 
2007). This appears to dictate not only the FA composition of the fat tissue, but also 
where fat is deposited in the body, which is of therapeutic interest because 
subcutaneous fat deposition is considered to be healthier than intra-abdominal (Field 
et al., 2008). Evidence from marine mammals, which consume a fish-based diet, 
suggests that polyunsaturated FAs (PUFAs) in fish oils accrue selectively in the 
subcutaneous depot (Brunborg et al., 2006). Studies in rat have shown that 
consumption of  diets consisting of  elevated levels of fish oils containing the 
omega-3 PUFAs, EPA and DHA, protects against body fat gain (Belzung et al., 
1993; Hainault et al., 1993; Hill et al., 1993; Baillie et al., 1999). This is important 
in terms of disease prevention, as, for example, the incidence of glucose intolerance, 
which precedes obesity-induced (type 2) diabetes in humans, is affected by both the 
amount and distribution of body fat (Kissebah et al., 1982).  
FAs exert their effects on adipose tissue at the level of the fat cell 
(adipocyte). They regulate gene transcription within the adipocyte to control the 
degree of body fat accumulation (Fernández-Quintela et al., 2007): although findings 
in humans are inconsistent, rodent models have generally shown that “good” fats 
(PUFAs) can attenuate the accumulation of adipose tissue resulting from 
consumption of  “bad” fats (saturated FAs, SFAs) (Buckley & Howe, 2009). They 
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do this by inhibiting expression of lipogenic genes and stimulating transcription of 
those involved in lipid oxidation (Fernández-Quintela et al., 2007).  
3.1.2 Adiposity Signals 
Three key appetite-related hormones act to regulate body weight over the long-term, 
in part through control of body fat stores. Leptin, encoded by the ob gene, is one of a 
classic set of hormones (adipokines) secreted by the adipocyte, which inhibits 
appetite and regulates lipid metabolism to promote weight loss (Schwartz & Seeley, 
1997). Another adipokine, adiponectin, helps to manage weight, blood sugar and 
cholesterol levels by acting in a feedback system to reduce appetite and prevent 
accumulation of excess blood sugar and fats (Hu et al., 1996; Yang et al., 2001; 
Chan et al., 2005). In addition, the pancreatic hormone insulin increases uptake of 
lipids and glucose from the circulation into peripheral tissue, primarily adipose tissue 
and skeletal muscle, respectively (Ferrannini et al., 2004; Fukuchi et al. 2004). 
Glucose is then used as an energy source and stops the body burning fat. Thus, 
insulin is an adipogenic hormone, such that high circulating levels are associated 
with fat deposition and weight gain (Pasquali & Vicemati, 2000; Catalano et al., 
2005). All three of these hormones can also influence brain sensitivity to satiety 
signals, such as gut hormones, as well as to nutrients per se; i.e. glucose and FAs 
(Woods & Lutz, 2006). However, the differential responses of these hormones in 
humans to individual dietary FAs remains unclear, as relatively few data from well-
controlled studies are available. The few studies which have been conducted using 
the human population have been short-term, with small samples sizes, making it 
difficult to draw any valid conclusions (Buckley & Howe, 2009). On the other hand, 
experimental rodent models of obesity have successfully provided the means to 
study these relationships in controlled ways that, mainly for ethical and compliance 
reasons, are difficult in humans. However, studies to date vary considerably in a 
number of parameters, including species, duration and dietary fat content and type. 
Dysregulated metabolism of these three key hormones results from excess 
SFA consumption and is characteristic of obesity resistance (Gray et al., 1993; 
Pasquali & Vicemati, 2000; Catalano et al., 2005). Thus, measurement of their gene 
expression and circulating concentrations,  while controlling for the sources of 
variation listed above, would make a fundamental contribution to the establishment 
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of valid animal models of FA feeding, and therefore, to our understanding of the 
potential mechanism by which dietary FA types differentially affect body weight 
metabolism. 
3.1.3 Meal Patterns 
Obesity is associated not only with numerous morphometric and metabolic 
abnormalities, such as those described above, but also behavioural ones. These 
include altered feeding behaviour, expressed as altered meal patterns (MPs) 
(Farshchi et al., 2005). MPs can be described according to several measures, 
including length and frequency of meals, rate of feeding, total energy consumption, 
and satiety, the feeling of fullness experienced after a meal, which aids in the 
regulation of appetite and determines intermeal interval (IMI). These measures vary 
according to alterations in diet composition, including SFA content. For example, it 
has been shown that individuals consume greater amounts of energy from high-fat 
diets (HFDs) than from diets high in carbohydrates (Blundell et al., 1994). Where 
this refers to high-SFA content specifically, as opposed to other FA types, this effect 
is known as passive overconsumption (Blundell & Burley, 1990) and is due to the 
high-energy density of high-fat foods (Blundell & Macdiarmid, 1997). There are a 
number of mechanisms behind this, one of which involves direct stimulation of 
appetite (Blundell & Burley, 1994). This has been demonstrated, for instance, by 
gavage feeding of oily SFAs in rats, which stimulates food intake and has been 
linked to the pleasant taste of the oil (Tordoff & Reed, 1991). Palatability overrides 
the acutely satiating effects of ingested fat (Lawton et al., 2000; Strubbs et al., 
2001), which result from the ability of fat-sensing in the gut to suppress ongoing 
feeding (Drewnowski, 1995). This is evidently a mechanism which eventually fails 
with chronic SFA consumption (Lawton et al., 2000; Strubbs et al., 2001), 
explaining, at least in part, why SFAs exert a weaker effect on satiety than protein 
and carbohydrate (Blundell et al., 1993; Blundell & Macdiarmid, 1997; Fernandez-
Quintela et al., 2007). Thus, in both humans and rodent models, obesity is associated 
with chronic consumption of diets high in SFAs and abnormal MPs, characterised by 
the intake of fewer, but larger, meals (Hariri & Thibault, 2011). In contrast, PUFAs, 
known to attenuate weight gain, have been revealed through human MP analysis to 
be more satiating than SFAs. However, this has been examined only under 
conditions where PUFAs have been consumed as a supplement, and only in the short 
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term (Lawton et al., 2000). In general, the metabolic effects of long-term 
consumption of PUFAs incorporated into foodstuffs need to be clarified, under 
controlled conditions employing isoenergetic, purified, and low-fat control diets. In 
particular, the MP signature of chronic PUFA intake has yet to be determined in 
either humans or animal models.  
3.1.4 Beneficiaries 
The successful treatment of obesity has been limited by the difficulty in developing 
acceptably safe and effective drug therapies (Field et al., 2008). Natural 
interventions (nutraceuticals), such as the PUFAs found in fish oils, may be an 
alternative approach which encourages compliance in human patients. If their 
associated health claims could be substantiated by proven molecular and 
physiological changes favouring healthy body composition and enhanced satiety, the 
food industry would be encouraged to further develop methods for incorporation into 
widely consumed foodstuffs.  
3.1.5 Research Question 
Does chronic consumption of a diet highly enriched in PUFAs improve energy 
homeostasis in rat? 
3.1.6 Predictions 
If so, then significant differences would be observed between morphometric, 
metabolic and behavioural indices of energy metabolism in rats fed high-PUFA diets 
long-term, compared to those fed high-SFA or low-fat, control diets. 
3.1.7 Aims 
To test these predictions by assessing diet-induced differences in 
1. body weight and composition associated with  
2. corresponding alterations in energy intake and meal patterns and  
3. circulating concentrations of appetite-related factors. 
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3.1.8 Expected Outcomes 
PUFA-fed rats would display 
1. attenuated weight gain,  
2. improved fat-to-lean ratio, 
3. reduced energy intake,  
4. changes in meal patterns indicating enhanced satiety, and 
5. reduced circulating concentrations of triglycerides, leptin and insulin, and 
increased concentrations of adiponectin. 
It was important to bear in mind that these expectations would have to be 
balanced against the potential effects of the increased energy content of the chosen 
high-PUFA diet compared to that of the low-fat, control diet, which might occur 
independently of, and possibly override, the effects of the specific PUFAs present in 
the diet (Hill et al., 1993). 
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3.2 Materials and Methods  
3.2.1 Animals and Dietary Treatment 
Age-matched adult male Wistar rats (~250 g) were stratified by body weight and 
randomly assigned to one of two groups (n=8/group, except where otherwise 
indicated; see meal pattern data acquisition below). For eight weeks, they were fed 
isoenergetic diets, enriched with either SFAs or PUFAs. Both diets provided 40% of 
energy from fat, mainly from lard and fish oil, respectively. These acted as controls 
for one another by eliminating the potentially confounding factor of differing energy 
intake. A third group of adult male Wistar rats (~250 g; also n=8), fed standard (low-
fat) chow (providing 10% of energy from fat, from soybean oil) was run separately 
several months later, when its need was realised and funds became available. It acted 
as a control for obesity induction, demonstrating normal weight gain and food 
intake. All diets were manufactured by Research Diets, Inc.™ (NJ, USA). Body 
weight was measured weekly and food and water intake daily. Details of general 
husbandry and maintenance can be found in Chapter 2, Section 2.1.6. A summary of 
the diet compositions can be seen in Table 3.1. Full nutritional breakdowns are given 
in Appendix I & II.  
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Table 3.1. Nutritional composition of low-fat (control) and isoenergetic high-fat diets. 
 Diet Type 
Macronutrient content Control SFA-enriched PUFA-enriched 
Total energy content (kcal/gm) 3.85 4.58 4.58 
% energy from carbohydrates 70 40 40 
% energy from protein 20 20 20 
% energy from fat 10 40 40 
% energy from fat as SFAs 23 36 27 
% energy from fat as PUFAs 48 19 52 
% energy from MUFAs 29 45 21 
% energy from fat as EPA & DHA 
(omega-3) 
0 0 25 
% energy from sucrose 10 10 10 
 
The high-PUFA diet and its high-fat control, enriched in SFAs, contained equal amounts of energy 
overall (isoenergetic) and contributed equal amounts of energy from fat. The fat content in both diets 
was a mixture of PUFAs and SFAs. Only the high-PUFA diet contained omega-3 fatty acids. 
Abbreviations:  DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; PUFA, polyunsaturated 
fatty acid; SFA, saturated fatty acid.  
 
3.2.2 BrdU Administration 
Rats received the cell proliferation tracer, bromodeoxyuridine (BrdU) dissolved in 
their drinking water (1 mg/ml) for the last seven days of the study, at which time a 
single play tube was introduced to the cage as an enrichment tool. The results of this 
part of the study are presented and discussed in Chapter 7. 
3.2.3 Meal Pattern Data Acquisition and Analysis 
Meal pattern information was gathered from rats (n=4/group) every two weeks over 
three-day periods for the duration of the study. Group size was limited by available 
cage numbers and logistical constraints of the study. Rats were removed from home 
cages and placed in specialised cages equipped with automated food intake 
monitoring systems, where they were given access to diets and water ad libitum. 
Raw data acquired in diurnal and nocturnal phases were analysed and are displayed 
according to the following previously published parameters: total energy intake (kJ), 
number and duration (min) of feeding episodes (hereafter referred to as ‘meals’), rate 
of feeding (g/min), intermeal interval (IMI; min) and satiety ratio (IMI/average 
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energy content of the previous meal consumed; min/kJ) (Farley et al., 2003; Cattone 
et al., 2007; Hariri & Thibault, 2011). Details of the cage and software analysis 
system can be found in Chapter 2, Section 2.4.3. 
3.2.4 Blood Chemistry 
After an overnight fast, and under brief gaseous anaesthesia, blood samples (200µl) 
were collected from the tail vein at baseline and fortnightly thereafter and plasma 
separated by centrifugation. Blood glucose concentrations were measured 
immediately by glucose-oxidase strips and a hand-held glucose meter. Plasma 
concentrations of triglycerides (TGs) were measured by diagnostic (enzymatic, 
colorimetric) kit and concentrations of leptin, adiponectin and insulin by ELISA, 
according to manufacturers’ protocols, except where adapted to in-house 
specifications. Details of suppliers and manufacturers’ protocols can be found in 
Chapter 2, section 2.6).  
3.2.5 Termination & Body Composition Analysis 
Rats were perfuse-fixed and brains removed for histological analysis of BrdU uptake 
and other cell proliferation markers, as described in Chapter 2 (Section 2.9), where 
details of anaesthetic protocols can also be found (Section 2.2.1). Results of these 
analyses are presented and discussed in Chapter 7. The descending aorta was 
clamped to prevent fixation of peripheral tissues required fresh. White adipose tissue 
(WAT) pads, interscapular brown adipose tissue (BAT), gastrocnemius and soleus 
muscle and liver were  dissected free, weighed, snap-frozen in liquid nitrogen, and 
stored at -80°C for further analysis.  Tissue weights were expressed as a percentage 
of final body weight.  
3.2.6 Real-Time PCR 
WAT samples from PUFA- and SFA-fed rats were homogenised and RNA extracted 
using the TRIReagent® method. RNA was then reverse-transcribed on a thermal 
cycler with reverse transcriptase enzyme to create cDNA. All PCR reactions were 
performed using a real-time PCR machine and data collected and analysed 
automatically by the integral software at the end of each run. Gene expression was 
determined by relative quantification with the 2-∆∆CT method (Livak & 
Schmittgen, 2001). Extraction and reactions were carried out according to 
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manufacturers’ protocols. Details of reaction stages, equipment and suppliers can be 
found in Chapter 2, location 2.8. The low-fat control group was run separately and 
adipose samples collected and stored for future analysis. 
3.2.7 Statistical Analysis 
Data are expressed as mean ± SEM. All tissue masses are presented as a relative 
percentage of final body weight. Differences between diet groups in three-way 
comparisons were determined using one-way ANOVA with post-hoc Bonferroni 
correction and considered significant at critical p<0.0166 for 3 comparisons. 
Differences between diet groups over a time course were determined using 2-way 
ANOVA with repeated measures and post-hoc Bonferroni correction and considered 
significant at p<0.05. In all instances comparisons demonstrated roughly equal 
variation and therefore the sphericity criteria were met and consequently variation 
data is not presented here.  Differences in two-way comparisons were determined by 
Student’s 2-tailed t-test, and considered significant at p<0.05. Statistical analysis 
was carried out using software SPSS v19. Between-group comparisons of satiety 
time course data were made after first quantifying by calculation of area under the 
curve (AUC; StatsDirect software), using the trapezoidal rule. Justification for use of 
all statistical analyses can be found in Chapter 2 section 2.11. 
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3.3 Results  
3.3.1 Energy Intake & Body Weight 
PUFA- and SFA-fed rats consumed comparable amounts of energy overall (p>0.05), 
which were greater than that consumed by controls (+27±2.1% for SFA-fed and 
+29±0.8% for PUFA-fed, p<0.01; Figs. 3.1A & B). Daily energy intake remained 
constant in control animals throughout the study, whereas that in both high-fat-fed 
groups reduced progressively, after a transient initial increase in the first week of 
feeding (Fig. 3.1A). This would appear to account for their greater cumulative 
intake, as there were no differences in absolute body weight or weight gain 
compared to controls (Figs. 3.2A & B). Indeed, weekly body weight gain was 
reduced comparably in all diet groups as the study progressed (Fig. 3.2C). Together, 
these outcomes were reflected in equally reduced food efficiency in both high-fat-fed 
groups (-28±1.2% and –24±1.7% vs. controls in SFA and PUFA groups, 
respectively; both p<0.01; Fig. 3.2D) 
   
Figure 3.1. Energy intake evolution (A) and cumulative energy intake (B) in control, SFA- 
and PUFA-fed rats consuming diets for eight weeks. Reduced intake at two-week intervals 
(A) reflects imposed overnight fasts prior to blood sampling. Overall energy intake was 
increased equally in the high-fat-fed groups. Values are expressed as mean ± SEM 
(n=8/group); **p<0.01 compared to controls (1-way ANOVA).  
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Figure 3.2. Absolute body weight evolution (A), cumulative weight gain (B), weight gain evolution (C) and food efficiency (D) in control, SFA- and PUFA-
fed rats consuming diets for eight weeks. Diet had no effect on body weight, but food efficiency was reduced equally in the high-fat-fed groups. Values 
are expressed as mean ± SEM (n=8/group); **p<0.01 compared to controls (1-way ANOVA).  Food efficiency = ∆body weight (g)/Σfood intake (MJ). 
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3.3.2 Terminal Tissue Mass and Body Composition 
Despite the lack of effect on body weight, adiposity was increased in both high-fat-
fed groups. Comparable increases in WAT accrual were observed between the two 
groups in the perirenal depot (+60±1.9% for SFA-fed and +50±2.5% for PUFA-fed 
rats vs. controls; both p<0.01; Fig. 3.3A) and inguinal depots (+59±3.1% for SFA-
fed and +68±2.9% for PUFA-fed vs. controls; both p<0.01; Fig. 3.3A). The 
epididymal depot was increased in SFA-fed animals only (+46±4.1% vs. controls; 
p<0.01; Fig. 3.3A). BAT mass was unchanged, as were skeletal muscle masses (Figs. 
3.3B, D). Body composition was altered accordingly by both types of high-fat 
feeding, which increased the ratio of fat-to-lean tissue (+91% and +70%, SFA and 
PUFA vs. controls, respectively; Fig. 3.3E). Liver mass was increased in PUFA-fed 
rats compared to both controls and SFA-fed rats (+33% and +16%, respectively; both 
p<0.01; Fig. 3.3C) and paler in colour, suggesting an increase in fat deposition. 
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Figure 3.3. Tissue mass relative to final body weight in control, SFA- and PUFA-fed rats after consumption of diets for eight weeks: WAT (A), BAT (B), 
liver (C) and skeletal muscle (D). Body composition (E) was calculated as the ratio of summed WAT depot to muscle masses. Both types of high-fat feeding 
led to accumulation of WAT in all depots, reflected in altered body composition, and increased liver mass. Values are displayed as mean ± SEM 
(n=8/group); **p<0.01 compared to controls; †p<0.01 compared to SFA (1-way ANOVA). 
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3.3.3 Circulating Factors 
3.3.3.1 Leptin - Plasma Concentrations and Gene Expression 
Analysis by two-way ANOVA with repeated measures demonstrated a significant 
difference in circulating leptin concentrations between diet groups (F (2, 21) = 32.33, 
p<0.0001), over time (F (4, 84) = 27.04, p<0.0001) and a significant interaction 
between diet and time (F (8, 84) = 3.968, p=0.0005). Consistent with increased 
adiposity, both high-fat-fed groups had become comparably hyperleptinaemic by two 
weeks of consumption, demonstrating an increase from baseline in circulating 
concentrations of leptin of 160±8.9% in SFA-fed rats and 157±5.2% in PUFA-fed 
rats. This was sustained throughout the remainder of the study, such that at 
termination, both high-fat-fed groups showed a 63±2.4% increase above control 
concentrations (both p<0.05; Fig. 3.4). 
 
 
Figure 3.4. Plasma leptin concentrations in control, SFA- and PUFA-fed rats consuming 
diets for eight weeks. High-fat-fed groups were equally hyperleptinaemic by the second 
week of consumption. Values are expressed as mean ± SEM (n=8/group); *p<0.05 
compared to controls (2-way ANOVA with repeated measures). 
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In contrast to equal circulating levels of leptin, gene expression was reduced 
in PUFA- compared to SFA-fed rats in all adipose depots examined. Although this 
difference was significant in the epididymal and inguinal depots (Fig. 3.5), all mean 
values were less than one relative fold change and therefore, not considered to reflect 
a biologically significant difference (Glick & Pasternak, 2003; Logan et al., 2009).   
 
Figure 3.5. Terminal WAT leptin gene expression in SFA- and PUFA-fed rats consuming 
diets for eight weeks. Differential effects on leptin expression were observed in all fat 
depots. However, although only those reductions by high-PUFA feeding in the epididymal 
and inguinal depots were statistically significant, they were not considered biologically 
meaningful (see text). All values are expressed as mean ± SEM (n=8/group); *p<0.05 
compared to SFA-fed controls (Student’s 2-tailed t-test).  In this instance SFA-fed rats act as 
a control for PUFA-fed rats. 
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3.3.3.2 Adiponectin - Plasma Concentrations and Gene Expression 
Analysis by two-way ANOVA with repeated measures demonstrated no differences 
in circulating adiponectin concentrations between diet groups (F (2, 21) = 1.811, 
p=0.1881), over time (F (4, 84) = 1.772, p=0.1420) or any interaction between diet 
and time (F (8, 84) = 0.7459, p=0.6509). Circulating plasma adiponectin 
concentrations were similar for all dietary groups at all time points for the duration of 
the study (all p>0.05). By the end of the study there was a slight increase in 
concentrations from baseline for all three dietary groups (+26±2.1% for controls, 
+19±4.7% for SFA-fed rats and +27±1.8% for PUFA-fed rats; see Fig. 3.6).  
 
Figure 3.6. Plasma adiponectin concentrations in control, SFA- and PUFA-fed rats 
consuming diets for eight weeks. High-fat feeding had no effect. Values are expressed as 
mean ± SEM (n=8/group); all p>0.05 (2-way ANOVA with repeated measures). 
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Consistent with the comparable circulating levels of adiponectin, gene 
expression was also similar in epididymal, perirenal and inguinal adipose depots of 
PUFA-fed animals compared to those of SFA-fed animals (all p>0.05; Fig. 3.7).  
 
Figure 3.7. Terminal WAT adiponectin gene expression in SFA- and PUFA-fed rats 
consuming diets for eight weeks. High-fat feeding did not differentially affect expression. 
All values are expressed as mean ± SEM (n=8/group); all p>0.05 (Student’s 2-tailed t-test).  
In this instance SFA-fed rats act as a control for PUFA-fed rats. 
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3.3.3.3 Whole-Blood Glucose Concentrations 
Analysis by two-way ANOVA with repeated measures demonstrated no differences 
in whole-blood glucose concentrations between diet groups (F (2, 21) = 3.587, 
p=0.0921), over time (F (4, 84) = 2.287, p=0.0667) or any interaction between diet 
and time (F (8, 84) = 3.423, p=0.0911). There were no differences in whole-blood 
glucose concentrations between diet groups over the course of the study (all p>0.05 
vs. controls). In addition, within-group concentrations at termination had changed 
very little from baseline: +6±0.4%, -16±1.1% and -14±1.4% in control, SFA- and 
PUFA-fed groups, respectively (Fig. 3.8). 
 
Figure 3.8. Fasting whole-blood glucose concentrations in control, SFA- and PUFA-fed rats 
consuming diets for eight weeks. High-fat feeding had no effect. Values are expressed as 
mean ± SEM (n=8/group); all p>0.01 (2-way ANOVA with repeated measures). 
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3.3.3.4 Plasma Insulin Concentrations 
Analysis by two-way ANOVA with repeated measures demonstrated a significant 
difference in circulating insulin concentrations between diet groups (F (2, 21) = 
66.50, p<0.0001), over time (F (4, 84) = 318.1, p<0.0001) and a significant 
interaction between diet and time (F (8, 84) = 17.56, p<0.0001). All groups became 
progressively hyperinsulinaemic, with terminal plasma insulin concentrations having 
increased from baseline by 260±8.5% in controls, 520±6.2% in SFA-fed animals and 
432±7.4% in PUFA-fed animals. Concentrations were significantly raised above 
those of controls by four weeks’ exposure to the high-fat diets (+118±8.4% in SFA-
fed and +91±6.7% in PUFA-fed rats vs. controls) and remained so until termination 
at week eight (both p<0.05; Fig. 3.9). 
Figure 3.9. Plasma insulin concentrations in control, SFA- and PUFA-fed rats consuming 
diets for eight weeks. All groups became progressively hyperinsulinaemic. Both high-fat 
diets induced equivalent hyperinsulinaemia, exceeding that of controls by six weeks of 
consumption. Values are expressed as mean ± SEM (n=8/group); *p<0.05 compared to 
controls (2-way ANOVA with repeated measures). 
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3.3.3.5 Plasma Triglyceride Concentrations  
Analysis by two-way ANOVA with repeated measures demonstrated a significant 
difference in circulating triglyceride concentrations between diet groups (F (2, 21) = 
17.56, p<0.0001) and over time (F (4, 84) = 7.462, p<0.0001), but no interaction 
between diet and time (F (8, 84) = 1.933, p<0.0655). Despite the strong association 
between high SFA intake and increased circulating triglycerides (e.g. Ghibaudi, et al. 
2002), concentrations remained consistent throughout. In contrast, PUFA-fed 
animals exhibited significantly reduced concentrations in comparison to both control 
rats, and unlike other circulating factors examined, to SFA-fed animals as well         
(-44±0.8% and –51±1.2%, respectively, at termination; both p<0.05; Fig. 3.10). The 
reduction in triglycerides for PUFA-fed rats was apparent by two weeks of 
consumption and was sustained throughout the study (-44±3.9% from baseline).  
 
Figure 3.10. Plasma triglyceride concentrations in control, SFA- and PUFA-fed rats 
consuming diets for eight weeks. High-PUFA-feeding reduced circulating triglyceride 
concentrations throughout dietary exposure. Values are expressed as mean ± SEM 
(n=8/group); *p<0.05 compared to controls; †p<0.05 compared to SFA (2-way ANOVA 
with repeated measures). 
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3.3.4 Meal Patterns 
High-fat feeding appeared to have no effect on diurnal or nocturnal energy intake 
when analysed separately over the duration of the study (Fig. 3.11A), in contrast to 
the increase observed in cumulative 24-hour intake (Fig. 3.1B). As expected in a 
nocturnal species, diurnal intake was consistently less than nocturnal intake               
(-78±2.1% for SFA-fed rats and -79±1.6% for PUFA-fed rats, p<0.05; Fig. 3.11A), 
reflected in greater intermeal interval (IMI; Figs. 3.12A, B). As the study progressed, 
nocturnal energy intake and number of meals gradually decreased. (Figs. 3.11A, B). 
Similarly, there were no differences between diet groups in meal duration or feeding 
rate (Figs. 3.11C, D), though there was an increase in rate over time from baseline 
for all groups (nocturnal, +41±0.9% for SFA-fed rats and +40±1.2% for PUFA-fed 
rats; diurnal, +93±2.1% for SFA-fed rats and +93±1.9% for PUFA-fed rats). 
In addition, although high-fat feeding had no overall effect on IMI in either 
phase (AUC; all p>0.01; Figs. 3.12A, B), it induced an acute (non-significant) 
increase in diurnal IMI in the early part of the study, between weeks 1 and 3, which 
did not persist. Diurnal IMI in control animals also increased and then approached 
baseline toward the end of the study, but gradually (Fig. 3.12A). IMI changes over 
time in both phases were mirrored by changes in satiety (Figs. 3.12C, D). The 
enhancement in diurnal IMI and satiety observed between weeks 1 and 3 corresponds 
to the decline in energy intake observed over the same period (Fig. 3.1A). Again 
reflecting the natural activity patterns of rodents, and consistent with reduced diurnal 
energy intake and number of meals (Figs. 3.11A, B), IMI and satiety were greater in 
the diurnal than the nocturnal phase, irrespective of diet (e.g. PUFA-fed satiety ratio 
AUC; +98±0.6%; p<0.01). Satiety was markedly enhanced, by more than two-fold, 
throughout the diurnal phase in PUFA-fed, compared to control and SFA-fed, 
animals (AUC; +217±4.8% vs. controls, p<0.01; Fig. 3.12E).  
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Figure 3.11. Diurnal and nocturnal energy intake (A), number of meals (B), meal duration (C) and feeding rate (D) in control, SFA- and PUFA-fed rats 
consuming diets for eight weeks. Diet had no effect on these meal pattern parameters. Values are expressed as mean ± SEM (n=4/group); all p>0.05 (2-
way ANOVA with repeated measures). 
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Figure 3.12. Diurnal and nocturnal intermeal interval (A, B) and satiety ratio (C, D) in 
control, SFA- and PUFA-fed rats consuming diets for eight weeks. Summary measure of 
satiety over time is expressed as area under the curve (AUC; E, F). High-PUFA feeding 
enhanced diurnal satiety. Values are expressed as mean ± SEM (n=4/group); **p<0.01 
compared to controls; †p<0.01 compared to SFA (1-way ANOVA). 
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3.3.5 Circadian Rhythmicity  
The patterns of feeding rhythmicity stimulated by each diet across the study period 
are displayed in Fig. 3.13. They clearly support the summary data indicating a 
gradual reduction in energy intake and number of meals in all diet groups over the 
course of the study (Figs. 3.13A-D vs. Figs. 3.11A, B), and in addition, reveal subtle 
alterations over the study weeks in distribution of meals, particularly across the 
nocturnal phase. These shifts can be more fully appreciated by examining ranges of 
values associated with related parameters of feeding activity (Table 3.2) and become 
particularly clear when qualitatively comparing activity between the first (week 1) 
and final weeks (week 7) of analysis (Fig. 3.13A vs. D).   
The most noteworthy changes were the disappearance after week 1 of the 
large meal taken by control animals just prior to the onset of the nocturnal phase 
(‘lights off’; Fig. 3.13A vs. B-D). Diurnal intake did not persist in any group, but fell 
below the level of detection, as defined by automated cage software criteria, sooner 
in high-fat-fed animals than controls (after week 1 vs. week 3; Figs. 3.13A vs. B). 
Secondly, all groups began to consume meals within a more restricted nocturnal 
window after week 1 (Fig. 3.13A), which became most pronounced at week 5 in the 
high-fat-fed groups (Fig. 3.13C), before expanding slightly again in the final week 7. 
In contrast, this clustering became most pronounced later in controls, at week 7 (Fig. 
3.13D). This narrower window of activity occurred in the middle hours of the night, 
with the disappearance of meals initially observed in week 1 from the periods just 
after ‘lights off’ and just before ‘lights on’ the next day. Aside from the widest range 
of meal sizes being consumed by the high-SFA-fed group (Table 3.2), there did not 
appear to be any marked differences in feeding rhythmicity between the two high-fat 
groups.
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Table 3.2. Ranges of values associated with the circadian rhythmicity of feeding.  
Diurnal Week 1 Week3 Week 5 Week 7 
Range Control SFA PUFA Control SFA PUFA Control SFA PUFA Control SFA PUFA 
Consumption 
window 
15.30-17.30 
(4 hours) 
14.30-15.00 
(0.5 hours) 
17.00-17.30 
(0.5 hours) 
18.30-19.30 
(1 hour) - - - - - - - - 
Number of 
meals 
2 1 1 2 0 0 0 0 0 0 0 0 
Energy 
intake/range 
of meal (kJ) 
11-49kJ 
(38kJ) 6kJ 5kJ 
6-19kJ 
(12.5kJ) 0 0 0 0 0 0 0 0 
Nocturnal Week 1 Week 3 Week 5 Week 7 
Range Control SFA PUFA Control SFA PUFA Control SFA PUFA Control SFA PUFA 
Consumption 
window 
20.30-05.30 
(9 hours) 
20.00-07.00 
(11 hours) 
20.30-06.00 
(9.5 hours) 
20.00-06.30 
(9 hours) 
20.30-07.30 
(11 hours) 
21.00-07.00 
(10 hours) 
20.00-05.00 
(10 hours) 
23.30-06.00 
(6.5 hours) 
22.30-06.00 
(7.5 hours) 
22.30-05.00 
(7.5 hours) 
21.30-05.30 
(9 hours) 
21.00-06.00 
(9 hours) 
Number of 
meals 
9 11 12 11 13 15 9 10 11 10 8 9 
Energy 
intake/range 
of meal (kJ) 
20-50kJ 
(30kJ) 
19-54kJ 
(35kJ) 
15-54kJ 
(39kJ) 
18-36kJ 
(18kJ) 
23-43kJ 
(20kJ) 
12-42kJ 
(30kJ) 
20-36kJ 
(16kJ) 
20-38kJ 
(18kJ) 
5-41kJ 
(36kJ) 
15-31kJ 
(16kJ) 
17-26kJ 
(9kJ) 
11-34kJ 
(23kJ) 
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Figure 3.13. Circadian rhythmicity of feeding activity at one (A), three (B), five (C) and 
seven (D) weeks of consumption in control, SFA- and PUFA-fed rats. Data are presented as 
means of 30-minute intervals over 72 hours. Values are expressed as mean ± SEM 
(n=4/group). Grey shading represents the nocturnal phase.  
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3.4 Discussion  
To briefly summarise, there were few effects of diet on parameters of energy 
metabolism in this study. However, independently of an otherwise apparently obese 
phenotype, lipid metabolism and feeding behaviour were improved by high-PUFA 
intake. 
While this study was underway, the ongoing overlap of food intake data collected 
from both high-fat fed groups was revealed. At first this was considered fortuitous, as 
it would have meant that any differences observed would be attributable solely to fat 
composition. However, the overlap observed later, on most other outcomes, raised 
the question of how much the two diets actually differed in composition. Closer 
examination revealed the presence of SFAs in the PUFA-enriched diet, and vice 
versa (Table 3.1), which could have offset or overridden the other’s effects. Almost a 
third of the energy source from fat in the PUFA-enriched diet (~30%) was derived 
from SFAs present in the menhaden fish oil which also acted as the main PUFA 
source. Furthermore, almost a fifth of the energy source from fat in the SFA-enriched 
diet (~20%) was derived from PUFAs present in the lard, which also acted as the 
main SFA source (Appendices I and II). Therefore, it was clear that diets containing 
purer sources of SFAs and PUFAs would be required for future modelling of their 
individual effects. Findings are discussed in light of this realisation, and often in the 
general context of high-fat effects, irrespective of type. 
3.4.1 Energy Intake, Body Weight & Adiposity  
The equivalent, albeit transient, hyperphagia seen in both the PUFA- and SFA-fed 
groups compared to controls, unsurprisingly resulted in equivalent body weight gain. 
This suggests that provision of 40% of energy content as fat is sufficient to disturb 
appetite regulation, but that the type of fat has no effect. This is supported by some 
previous studies, where composition of dietary FAs has been shown to have little 
effect on body weight in rodents (Awad et al., 1990; Hill et al., 1992; Hill et al., 
1993). In others, when dietary fats have been shown to differentially affect body 
weight, this has been overridden by total fat intake (Buettner et al., 2006). 
Furthermore, diets containing approximately 40% energy as fat have been shown to 
induce obesity without stimulating hyperphagia, through elevated food efficiency 
(Oscai et al., 1984). Although in the current study, food efficiency was similar in 
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both PUFA- and SFA-fed groups and reduced below that of low-fat-fed controls, 
when one considers the transience of the observed hyperphagia and the increased 
adiposity in both high-fat-fed groups, it could be argued that obesity had been 
effectively induced in the absence of hyperphagia. In addition, the amount of energy 
consumed decreased as the study progressed. This is typically observed in studies of 
this kind, and is most likely due to habituation, or adaptation, to the diet (e.g. Wood 
& Reid, 1975; Gajda et al., 2007). Rodents consuming a diet low in fat will begin to 
eat less when switched to a high-fat diet, as they tend to regulate their energy intake, 
rather than grams of food consumed (Ricci & Ulman, 2008).  
Surprisingly, the PUFA- and SFA-fed rats gained no more overall body 
weight than the control group, despite consuming more energy overall. The increased 
cumulative intake measure takes into account the transient increase within the first 
few weeks of dietary exposure, which may not have lasted long enough to 
permanently affect body weight. It is perplexing; however, that increased adiposity in 
these two groups did not lead to increased weight gain. It is possible that although 
there was fat accrual in the depots examined, there may have been fat loss in other 
depots not examined here, which offset this; i.e. an overall redistribution of body fat 
(Santosa & Jensen, 2008). Scanning the animals with Dual-energy X-ray 
absorptiometry (DEXA) can be used to measure total body composition and fat 
content with a high degree of accuracy. Whole-body composition measures, for 
example, by bioimpedance scanning, may also have provided a more accurate 
assessment of overall adiposity, and in light of this, was carried out in the following 
study (Chapter 5).  
The lack of clear separation between control and experimental animals on this 
outcome (as well as others discussed below) was likely due to the presence of 
sucrose in the control diet (10% wt/wt). Studies have shown that feeding Wistar rats 
a diet containing elevated quantities of sucrose (63% wt/wt) causes a significant 
increase in body weight, specifically through increased epididymal fat pad mass 
(Soria et al., 2001). Foods high in sugars (refined carbohydrates) stimulate weight 
gain by a number of means: stimulation of appetite through enhanced palatability; to 
an extent, passive overconsumption through their higher energy density; and ready 
conversion to triglyceride, storage in adipose tissue and growth in fat cell size 
(Tsujita et al., 1995; Berger & Barnard, 1999; Dam & Seidel, 2007). Therefore, it is 
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clear that a more appropriate control diet, which did not contain sucrose, would be 
required for future modelling studies. 
Composition of dietary FAs has been shown to affect distribution of adipose 
tissue differentially (Hill et al., 1992; Hill et al., 1993). SFAs will increase whereas 
PUFAs will decrease WAT mass (Belzung et al., 1993; Hainault et al., 1993; Hill et 
al., 1993; Baillie et al., 1999). Consistent with this, SFA-fed rats in the current study 
showed increased fat mass. So did the PUFA-fed group, probably due to the presence 
of SFAs in this diet. As there was no effect of diet on muscle mass, the increase in 
body composition ratio in high-fat diet groups reflected this increase in adiposity 
alone. This alteration in body composition by high-fat diets has been shown 
previously in rodent models fed diets providing one half or more of energy from 
SFAs (Hegarty et al., 2002; Dourmashkin et al., 2005). In contrast, there was no 
effect of diet on BAT mass. BAT hypertrophy has been shown previously in rodents 
fed high-fat and cafeteria-style diets and has been associated with increased 
thermogenesis (diet-induced thermogenesis). It has been suggested that the additional 
energy intake is partially dissipated by BAT in an attempt to counteract obesity 
(Rothwell & Stock, 1979). However, this is subject to ongoing debate, as others have 
found that BAT is atrophied in diet-induced obesity (Muralidhara & Desautels, 
1994). In addition, whether individual macronutrients or calories per se are 
responsible for this effect is the subject of ongoing research. In male Wistar rats fed 
diets ranging in fat content (17-93%), expression of genes involved in the regulation 
of thermogenesis increased accordingly, but only the diet with the highest content 
also increased BAT mass (through increased adipocyte size) (Betz et al., 2012). It 
appears, therefore, that in the diets used here, provision of only 40% of energy as fat 
was insufficient to induce changes in BAT mass.      
PUFA-fed rats also had enlarged livers which were paler in colour, 
suggesting an increase in fat deposition; this is consistent with the literature, as 
although PUFAs are incorporated into all cell membrane phospholipids, they are 
readily integrated into liver phospholipids, increasing the overall mass of the organ 
(Hill et al., 1993; Rapoport et al., 2010). PUFAs suppress hepatic lipogenesis and 
triglyceride synthesis, while inducing peroxisomal fatty acid oxidation (Clarke & 
Jump., 1994; Rambjor et al., 1996; Ren et al., 1996; Akinori et al., 2012). These 
effects on lipid metabolism are due to changes in gene expression leading to 
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induction or suppression of genes encoding key metabolic enzymes (Ntambi, 1992; 
Jump et al., 1993; 1994). While the molecular mediators for PUFA regulation of 
these genes have not been defined, studies on the regulation of peroxisomal enzymes 
suggest that fatty acids activate a nuclear receptor to control gene transcription 
(Kliewer et al., 1994; Braissant et al., 1996; Schoonjans et al., 1996).  
3.4.2 Plasma Leptin Concentrations & Adipose Leptin Gene Expression  
The hyperleptinaemia displayed in both high-fat-fed groups is consistent with their 
equivalent fat masses, as leptin is expressed in proportion to the amount of body fat 
(Schwartz & Seeley, 1997). This relationship has been observed previously in rats 
fed SFA- and PUFA-enriched diets containing 40% of energy from fat (Reseland et 
al., 2001). In contrast, others have shown that the consumption of PUFA-enriched 
diets elevates plasma concentrations of leptin above those in rats consuming high-
SFA diets (Cha and Jones, 1998). However, discrepancies between this study and the 
one described here could be due to differences in diet composition, where energy 
from fat was half that of the current study and the PUFA source was mixed. Feeding 
patterns also differed as did the rat strain (Sprague-Dawley). Alternatively, these 
effects of PUFAs in the current study may have been overridden by those of SFAs 
present in the high-PUFA diet. Elevated concentrations of leptin in the blood should 
lead to a satiated state and maintenance of a normal body weight. However, both 
high-fat-fed groups gained in adiposity. This combined with the sustained elevation 
of leptin concentrations suggest that leptin resistance had been induced. This has 
been observed previously in rat in response to both types of high-fat diet (Lin et al., 
2000; Oh-I et al., 2005).    
The equivalent plasma leptin concentrations observed in the high-fat-fed 
groups were not reflected in equivalent gene expression. The PUFA-fed group 
showed reduced leptin gene expression in all adipose depots, significantly so in the 
epididymal and inguinal depots. This at first seems paradoxical, given the 
confounding presence of SFAs in the PUFA diet. However, it has been observed 
previously, again in the work of Reseland et al. (2001), who also found that dietary 
PUFAs providing 40% of energy decreased leptin gene expression in rat epididymal 
adipose tissue. Nevertheless, observed changes were below one relative fold change 
and therefore unlikely to be of biological relevance (Glick & Pasternak, 2003; Logan 
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et al., 2009). Measurements taken at the gene level and protein level rarely correlate; 
this is because of differences in post-transcriptional modifications and regulations. 
The impact of these mechanisms on the propagation of co-expression from gene to 
protein levels has not yet been systematically investigated. The dynamics introduce a 
time delay, since the corresponding molecular processes are not instantaneous 
(Anderson & Seilhamer, 1997; Tian et al. 2004; Cox et al., 2005; de Sousa Abreu et 
al., 2009; Wang et al., 2010). Studies have shown that leptin gene expression varies 
across different adipose depots, but whether this contributed markedly to observed 
differences in plasma leptin concentrations was uncertain (Rayner & Trayhurn, 
1996). Others have also suggested that there is no link between leptin gene 
expression and circulating plasma concentrations (Ranganathan et al., 1998).  
3.4.3 Plasma Adiponectin Concentrations & Adipose Adiponectin Gene 
Expression  
Plasma adiponectin concentrations remained unchanged in both high-fat diet groups 
for the duration of the study. This is inconsistent with the observed increase in body 
weight and the increased fat mass also seen in these rats, as adiponectin is secreted 
from adipose tissue in concentrations inversely proportional to adiposity (Hu et al., 
1996). These very similar circulating concentrations in the high-fat groups were 
consistent with their statistically equal fat pad masses and gene expression in the 
WAT depots examined. This is in contrast to previous research in which partial 
replacement of SFAs with marine (omega-3) PUFAs in a high-fat diet increased 
adiponectin gene expression in the epididymal and perirenal fat pads of mice. A diet 
containing PUFAs is thought to increase both circulating adiponectin concentrations 
and adipose tissue gene expression due to a reduction in adiposity (Flachs et al., 
2006).  
3.4.4 Whole-Blood Glucose & Plasma Insulin Concentrations 
Fasting whole-blood glucose concentrations did not alter in response to either high-
fat dietary intervention. Although diets high in SFAs can increase blood glucose 
concentrations, a mechanism has not been proposed (Briaud et al., 2002), and in 
contrast, other studies modelling diet-induced obesity in rat have shown consistent 
normoglycaemia (e.g. Pickavance et al., 1999; 2001; 2005). Also supporting the 
current results, it has been shown that PUFA supplementation does not affect glucose 
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concentrations (Rapoport et al., 2010). Over the course of the study, plasma insulin 
concentrations continued to rise above baseline in all three diet groups, and 
significantly above control concentrations in both high-fat-fed groups, suggesting the 
development of insulin resistance (Ravussin et al., 2002). These results are consistent 
with the observed increase in body weight over time, as insulin is adipogenic. Stable, 
baseline glucose concentrations and the observed hyperinsulinaemia together suggest 
the rats were in a state of impaired glucose tolerance, which can prevail for many 
years in humans before the onset of frank diabetes (Ferrannini et al., 2004). β-cell 
failure, leading to hyperglycaemia and overt diabetes are rarely, if ever, observed in 
DIO models (Levin et al., 1997; Pickavance et al., 2001; Rossmeisl et al., 2003; 
Collins et al., 2004; Chatzigeorgiou et al., 2009; Peyot et al., 2010). The differences 
observed here in circulating concentrations of insulin between rats fed the high-fat 
and control diets could, in part, be due to the increased adiposity of the high-fat-fed 
groups. Human studies have shown that consumption of diets high in fat cause 
weight gain, specifically through increased fat storage in and around abdominal 
organs (Isganaitis & Lustig, 2005). This is mirrored by the increased epididymal and 
perirenal fat pad masses observed in the rats in the current study. It is well-
established that abdominal obesity is associated with insulin resistance (Gray et al., 
1993; Pasquali & Vicemati, 2000; Catalano et al., 2005) and that dietary fatty acids 
per se are implicated in its cause. Indeed, insulin resistance has been observed in 
high-fat-fed rats after just three weeks’ consumption (Kraegen et al., 1991) and 
before a measurable increase in adiposity (Storlein et al., 1991). Thus, consumption 
of SFAs, such as those found in lard, seems to be an effective way of producing 
insulin resistance in animal models (Storlien et al., 1991). However, this can also be 
achieved by feeding rodents diets high in sucrose (Gajda et al., 2007) and probably 
explains the progressive rise in circulating insulin in the control group. This 
undesired effect would be avoided in future, again, by designing a diet formulation 
without sucrose. Indeed, the sucrose in the high-PUFA diet may have exacerbated 
the insulin resistance induced by the SFAs also present in it. This is suggested by 
previous work in which menhaden fish oil could not prevent insulin resistance in 
sucrose-fed rats (Podolin et al., 1998).  
Although fish oil PUFAs are known to lower insulin concentrations in rat 
(Storlien et al., 1987; Storlein et al., 1991) and are thought to explain the low rates of 
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insulin resistance, diabetes, and obesity that occur in individuals living 
predominantly on a fish-based diet (Ebbesson et al., 1999), their lack of effect here is 
likely due, once again to being superseded by SFAs present in the diet. 
3.4.5 Plasma Triglyceride Concentrations   
Although the PUFA- and SFA-fed rats were phenotypically almost identical, PUFA-
feeding markedly reduced plasma TG concentrations below normal following only 
two weeks of consumption, an effect which was sustained throughout the study. This 
is a robust property of PUFAs and one of the known benefits of their consumption 
(Buckley & Howe 2009), particularly in the treatment of cardiovascular disease 
associated with hypertriglyceridaemia (Reseland et al., 2001).  
TGs act as transporters of dietary fat in the circulatory system. Lipoprotein 
lipase (LPL), found in vascular endothelium, is responsible for hydrolysing 
circulating TGs into glycerol and FAs. It is these free FAs and circulating TG that 
enable a dynamic equilibrium to exist between fat oxidation and fat storage in 
animals when consuming a normal diet (Scharrer, 1999). However, when a diet high 
in SFAs is consumed, changes in hypothalamic-pituitary-adrenal activity result in 
elevated glucocorticoid concentrations, which can lead to hypertriglyceridaemia 
through a reduction in LPL concentrations (Ghibaudi, et al. 2002). In contrast, when 
a diet high in fish oil is consumed, very-low-density lipoproteins, which enable fat 
and cholesterol to be transported within the bloodstream, can be decreased, which 
ultimately results in a reduction in plasma triglycerides (Lin et al., 2005). The 
mechanisms behind this are thought to involve decreased hepatic triglyceride 
synthesis and more rapid oxidation of PUFAs than SFAs (Lin et al., 2005).  
Despite increased energy intake and adiposity in the SFA-fed group, 
triglyceride concentrations did not increase as expected. This may be due to the 
observed increase in insulin concentrations, as increased insulin secretion will 
promote storage of triglycerides in adipocytes, reducing circulating concentrations 
(Nishino et al., 2007). Indeed, the partial reduction in TG levels in the SFA-fed 
group may be explained by the presence of PUFAs in that diet. Thus, in both high-
fat-fed groups, dietary PUFAs and high levels of insulin may have acted in 
combination to prevent hypertriglyceridaemia. 
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3.4.6 Meal Patterns & Circadian Rhythmicity 
The high-fat diets did not disrupt the temporal sequence of feeding (diurnal-nocturnal 
partitioning). With all diets, diurnal meals were consistently smaller and less frequent 
than nocturnal ones, which was to be expected, as rats are well-known for their 
nocturnal feeding activity (Strubbe & Woods, 2004). Although nocturnal feeding 
frequency decreased over the course of the study, in that rats took progressively 
fewer meals, the rate of feeding at each meal increased, while meal duration 
remained unchanged. This suggests that, as if to compensate for feeding less often, 
rats increased the amount they ate at each visit to the hopper, rather than increasing 
the amount of time spent eating, but not enough to prevent an overall reduction in 
food intake. The constancy of meal lengths also corresponds to unchanging glucose 
concentrations across the study in all groups, as blood glucose levels correlate with 
hunger, determining the start and termination of meals (Strubbe & Woods, 2004). 
Studies of rat models of both diet-induced and monogenic forms of obesity mirror 
findings in humans that obesity correlates directly with meal size, but inversely with 
meal frequency (Hariri & Thibault, 2010; Hinney et al., 2010). Specifically, 
consumption of high-fat diets over a five-month period have been shown to lead to 
hyperphagia in male outbred rats through an increase in meal size, not number 
(Farley et al., 2003). Although this pattern was shown in the high-fat-fed groups in 
the current study, its manifestation in the control group as well suggest that, at least 
in terms of influencing feeding behaviour, the diet compositions were not sufficiently 
different, such that, at the given concentrations, sucrose and fatty acids have similar 
effects. It is also possible that in only two months, group differences had not had 
time to develop. 
Although the high-fat diets appeared to have little measurable impact on most 
aspects of feeding activity, importantly, they were distinguished by their effects on 
satiety. This is to be expected, as FAs are known to be metabolised differently 
depending on their degree of saturation, which differentially affects satiety in 
humans (Blundell et al., 1993; Blundell & Macdiarmid, 1997; Fernandez-Quintela et 
al., 2007). The enhancement of high-PUFA feeding in daytime satiety over the 
course of the study substantiates findings on PUFA-induced satiety in humans 
(Lawton et al., 2000); for example, when consumed for three months, omega-3 FAs 
will suppress appetite in humans, and the mechanism of this action is thought to 
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occur through the associated elevation of satiety signal levels (Scharrer, 1999). 
However, the novelty of the current result means that there are no previous findings 
to explain the significance of enhanced satiety occurring during the day, rather than 
the night. The circadian effects of high-SFA diets have been examined, on the other 
hand, but findings are inconsistent. In some studies, high-SFA diets have been shown 
to increase food intake in rodents during the diurnal phase (Kohsaka et al., 2007; 
Kaneko et al., 2009), but to be less effective in producing satiety at the end of a 
feeding cycle (Geliebter, 1979; Walls et al., 1992). This is thought to affect 
metabolism, leading to obesity (Arble et al., 2009). Thus, it is unclear how the 
PUFA-induced satiety can coexist with the observed increase in adiposity, without 
being balanced, for example, by a reduced satiety at night. This is, in fact, what was 
observed (Figs. 3.12B, D & F), but again, only slightly below that of SFA-fed 
animals, possibly due, once again, to the SFA content in the PUFA diet. In other 
studies, rodents consuming diets very high in SFAs (67% energy from fat) consume 
fewer meals in the day than controls, consistent with increased IMI and satiety ratio 
(Hariri & Thibault, 2010). This, too, was observed here, but only subtly. What is 
perhaps most striking overall when considering the three diets together is that, 
although the shapes of the IMI and satiety ratio curves (Figs. 3.12A-D), and 
therefore, the progress of change in satiety differs, they all converge at the end of the 
study, supporting, once again, the idea of adaptation to the high-fat diets.  
The rat consumes 90% of its energy intake in several discrete meals 
throughout the nocturnal phase (Armstrong, 1980; LeMagnen, 1981), with peaks 
occurring towards the beginning and end of this period (Siegal, 1961). This pattern 
alters in rats fed diets very high in fat (86% of energy provided as lard), as meals 
tend to shift towards the latter part of the dark phase (Tempel et al., 1985). Food 
ingested throughout the first half of the nocturnal phase may be utilised to fulfil any 
immediate energy requirements, as well as for lipogenesis, whereas feeding at the 
end of the nocturnal phase may be more anticipatory of the diurnal phase to follow, 
and therefore, serves to build energy reserves. Indeed, the rats’ stomach contains 
large amounts of undigested food at the end of the nocturnal phase (Armstrong et al., 
1978). Therefore, a high energy meal may be consumed at the end of the nocturnal 
phase in preparation for the 12-hour diurnal period when little feeding activity occurs 
(Tempel et al., 1989). This shift was not observed here, but this could be due to the 
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more moderate fat content. Moreover, the characteristic peaks described above, 
towards ‘lights on’ and ‘lights off’, were not obvious in the control group either, 
again casting doubt on the validity of the control diet and suggesting that normal 
feeding periodicity may not actually have been observed in this study. Finally, the 
temporary clustering of meals in the middle hours of the night in the high-fat-fed 
groups’ mid-way through the study may have been instrumental in stimulating 
accumulation of fat mass. Early nocturnal meal skipping has recently been shown to 
alter the peripheral clock and increase lipogenesis in mice (Yoshida et al., 2012).  
 
3.5 Conclusion 
Overall, there were few effects of diet on parameters of energy metabolism in this 
study, likely due to similar diet compositions. However, independently of an 
otherwise apparently obese phenotype, lipid metabolism and feeding behaviour were 
improved by high-PUFA intake. This suggests that providing 52% of fat source from 
fish oil, with almost half derived from omega-3 FAs (Table 3.1), is sufficient to 
improve energy metabolism, at least to a limited extent, overriding the effects of 
potentially damaging SFAs present in the same diet. The confounding impact of 
SFAs on other parameters indicates that current dietary advice regarding increasing 
consumption of oily fish (Ruxton, 2004) should be balanced against greater 
awareness of the mixed composition of some fish oils and the detrimental effects it 
may have on health. The extent of these effects could be clarified by identifying the 
FA composition of the fat pads in the PUFA-fed group, for example, by fatty acid 
methyl ester (FAME) analysis. If mainly composed of PUFAs, this would have very 
different implications for the health of the model (Buckley & Howe, 2010). Also, a 
diet providing 40% of energy from fat is extreme and unlikely to be accepted long-
term by humans, even if proven entirely healthful. Therefore, future studies would 
have to involve the use of purer sources of FA types, to help distinguish effects more 
clearly, as well as an expanded range of FA concentrations. The first of these criteria 
was to be addressed by the next dietary study in the project (Chapter 5). 
Aside from the overlap in diet compositions and the moderately high sucrose 
content in the control diet, the lack of statistical differences between groups on 
several parameters could have been due to the fact that the rats were an outbred 
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strain. Such strains have inherent genetic variation (Koolhass, 2010) resulting from 
random DNA mutations. Laboratory rodent colonies are highly susceptible to genetic 
drift, as DNA variation often remains hidden at the molecular level and may be 
perpetuated by breeder selection processes. The result is a minefield of genetic 
variation which can confound research interpretation and results (Charles River, 
Margate, UK); the model in question is gradually altered, such that the response to a 
particular diet, for example, becomes less predictable (L.C. Pickavance, personal 
communication). However, given that common human obesity is believed to occur 
on a polygenic background, it was this very variation which could be argued to make 
outbred strains better representatives of human obesity than isogenic strains. It is also 
possible, with respect to the analysis of meal patterns in this study, that these 
experiments were underpowered (n=4/group), as behavioural studies, including those 
examining feeding, are known for high levels of variation, and the sample size is 
usually high (e.g. n=12/group; Farley et al., 2003). Therefore, although logistically 
and financially challenging, future studies on the determination of meal pattern 
signatures, with a limited set of automated cages, should be designed to 
accommodate larger sample sizes wherever possible. 
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Effects of Chronic Intake of Dietary Fatty Acids on Skeletal Muscle 
Fibre Composition 
 
4.1 Introduction 
4.1.1 Effects of Obesity and Dietary SFAs on Muscle 
As reviewed in the General Introduction (Chapter 1, Section 1.2), the detrimental 
effects on health due to long-term consumption of saturated fatty acids (SFAs) are 
well-established, and include the development of obesity and associated conditions 
(Blundel et al., 1993; Blundell & Macdiarmid, 1997). Particularly in view of the fact 
that there is no pharmaceutical intervention for obesity which has proven both safe 
and effective in the long-term, many experts still maintain that lifestyle interventions, 
including increased exercise, are as effective, if not more so (Fujioka et al., 2000). 
Energy expenditure, through sustained exercise, depends on the aerobic capacity of 
muscle, and can help reverse some of these detrimental effects (Ripple & Hess, 1998; 
Strømme & Høstmark, 2000).  
Most muscles consist of a mixture of different fibre-types, depending on the 
function of the whole muscle, which are categorized as Type I or Type II. Type I 
fibres are suited to endurance activities and are slow to fatigue because they use 
oxidative metabolism to generate ATP. Type II fibres are efficient for short bursts of 
speed and power, as they are quicker to fatigue and use both oxidative metabolism 
and anaerobic metabolism. Muscles which enable aerobic exercise are “fat-burning” 
and fatigue-resistant, and so are richer in the slow-twitch, lipid-oxidative fibre-type 
(Type I) than the fast-twitch, glycolytic type (Type II) (Peter et al., 1972). There is 
evidence from both animal and human studies that obesity is associated with altered 
fibre-type proportions. In comparison to their lean counterparts, genetically obese 
(ob/ob) mice show fewer fast-twitch (Type II), in relation to slow-twitch (Type I) 
fibres, in both soleus and extensor digitorum longus (EDL) muscles (Warmington et 
al., 2000). Consistent with this slower-type profile, these muscles also show an 
increased fatigue resistance. Although this may at first seem counterintuitive, it could 
be that these features reflect a response to the inactivity associated with the obesity. 
Indeed, these muscles show reduced mass, resulting from lack of use (atrophy) and a 
reduced ability to hypertrophy (Warmington et al., 2000).  
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The effects of diet-induced obesity on the relationship between muscle form 
and function appear to vary. Rodent studies have shown that SFAs impair the ability 
of muscle to oxidize lipid (Sparks et al., 2005) by impairing mitochondrial capacity 
for fat oxidation (Holloszy, 2009), and that they can do so after only very short 
periods of consumption (e.g. 3-15 days) (Sparks et al., 2005). In general, this 
alteration in muscle function also appears to arise from changes in morphology. For 
example, mice with obesity induced by high-fat feeding (60% energy from fat for 8 
weeks) ultimately showed reduced oxidative capacity in muscle, despite early 
adaptation to diet reflected in increased numbers of Type I fibres and fewer Type II 
fibres. This occurred in gastrocnemius, but not tibialis muscle, and was thought to be 
insufficient to influence contractile properties (Shortreed et al., 2009). Human 
subjects sensitive to an obesity-inducing diet, as defined by resistance to weight loss, 
have also been shown to develop an increase in Type I fibres, thought to be an 
adaptive response to obesity (Gerrits et al., 2010). Other human studies have shown 
the opposite, a reduction in Type I fibres associated with obesity-related variables, 
such as increased body fat percentage and waist-to-hip ratio (Karjalainen et al., 
2006). Conversely, increased muscle mass in transgenic mice, due to relative 
abundance of Type II fibres, is associated with regression of obesity induced by a 
high-fat, high-sucrose diet (Izumiya et al., 2008). Findings in rat appear somewhat 
contradictory, however. Although muscle expression of genes encoding fat oxidative 
enzymes was shown to increase in obesity-prone Wistar rats fed a high-fat diet (40% 
energy from fat for 5 weeks), it was not accompanied by a change in fibre 
composition in gastrocnemius, soleus or EDL muscles (Zou et al., 2003). In contrast, 
this gene expression was unaltered in the soleus muscle of Sprague-Dawley rats fed 
for the same length of time on a diet providing almost twice as much energy from fat 
(78%; McAinch et al., 2003). Further confounding is the discovery that Wistar rats 
resistant to obesity, induced in susceptible counterparts by 4 weeks’ consumption of 
diet providing 60% of energy from fat, showed an increased proportion of Type I 
fibres in gastrocnemius muscle; and this was thought to be linked to the increased 
fatty acid oxidation capacity which favours resistance to body fat accumulation 
(Abou Mrad et al., 1992). 
Thus, although fibre-type profiles in diet-induced obesity are variable, it is 
probably safe to say that, in general, SFA consumption stimulates a change in fibre-
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type profile which is both time-dependent and muscle-specific, but where anatomy 
and function do not always relate. The differences in both dietary SFA concentration 
and duration of exposure across studies may also account for their discrepancies. It 
could be cautiously proposed that an initial, adaptive response to the presence of 
SFAs occurs to prevent obesity, one which stimulates fat oxidation and involves a 
transition to a slow fibre-type profile. However, with sustained exposure to SFAs, 
this response does not persist. If studies are conducted outside this early window, 
when obesity is established, it could explain observations of fast fibre-type profile 
and reduced capacity for sustained physical activity, and in turn, the increased 
likelihood of further weight gain.  
4.1.2 Effects of Dietary PUFAs on Muscle 
In contrast to the effects of SFAs, polyunsaturated fatty acids (PUFAs) in the diet 
may be beneficial to muscle function. Indeed, the shift toward overall improvement 
in metabolic function, which is induced by PUFAs, is partly achieved by 
upregulation of gene expression favouring fatty acid oxidation, including that within 
muscle tissue itself (Izumiya et al., 2008; Shortreed et al., 2009), and downregulation 
of expression which favours adipogenesis (Bordoni et al., 2006). PUFAs also 
influence membrane-dependent activities, including those required for muscle 
function, through their incorporation into membrane phospholipids (Benatti et al., 
2004). In humans and birds, PUFA consumption has been shown to protect muscle 
function, stimulating energy metabolism and increasing the capacity for sustained 
exercise by improving fatigue-resistance (Maillet & Weber, 2006; Demmig-Adams 
& Carter, 2007). Therefore, there is indirect evidence that PUFAs increase the 
capacity of muscle for sustained exercise, but anatomical underpinning is required.  
Although some direct effects of dietary SFA composition on proportions of fibre-
types have been examined, as discussed above, those of PUFAs are currently 
unknown.  
In humans, it is thought that dietary PUFAs, consumed as fish oil 
supplements, act within skeletal muscle to reduce whole-body oxygen demand 
during extended periods of exercise (Peoples et al., 2008).  Exercise capacity of 
patients suffering chronic obstructive pulmonary disease (COPD) has also been 
shown to increase after consuming a PUFA-enriched diet, due to increased oxidative 
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capacity in muscle (Broekhuizen et al., 2005). In rats, the omega-6 and omega-3 FA 
profile of the diet determines phospholipid composition of muscle (Ayre & Hulbert, 
1996), but how this may be reflected in fibre composition has not yet been examined. 
In general, however, these findings point to the replacement of dietary SFAs with 
PUFAs as a rational therapeutic approach to improving the metabolic profile and 
function of muscle (Demmig-Adams & Carter, 2007; Gillies, 2007). Increasing the 
capacity for fatigue-resistant muscle and therefore, allowing for sustained, extended, 
periods of exercise would aid obese individuals in targeting weight loss through 
increased physical activity.  
Another question is what might cause the transition between predominating 
fibre-types, and this is partly addressed in Chapter 7. Muscle development results 
from the complex interaction of diet, genes, and exercise (Demmig-Adams & Carter, 
2007), and its mechanism provides the rationale for FA-induced remodelling. 
Although different levels and types of exercise drive differential expression of 
muscle fibre-types (Howald et al., 1985), the impact of diet is still not fully 
understood. Gene deletion and over-expression studies have shown that peroxisome 
proliferator-activated receptors (PPARs) regulate the synthesis of muscle fibres and 
induce changes in fibre composition (Ahmetov et al., 2006; Schuler et al., 2006). It 
has also been shown that dietary FAs act as PPAR ligands to regulate the expression 
of a variety of genes involved in nutrient metabolism (Kersten, 2002; Fernández-
Quintela et al., 2007). Therefore, we might reasonably suppose that dietary FAs exert 
their effects on the synthesis and development of muscle via PPARs. This has been 
suggested in transgenic mice, where enhanced PPARγ activity has been shown to 
protect against the effects of high-fat feeding, including insulin resistance, and to 
increase the proportion of Type I fibres in muscle (Amin et al., 2010). The 
supposition is contradicted, however, by the fact that very high-fat feeding (78% 
energy from fat) has no effect on PPARα or PPARγ protein expression in slow 
(soleus) or fast (EDL) muscles (McAinch et al., 2003). Thus, more work is required 
to confirm the distinguishing effects of dietary FA composition on relationships 
between muscle form and function.  
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4.1.3 Research Question 
Do dietary fatty acid composition determine the fibre-type population of skeletal 
muscle? If so, do PUFAs induce a shift towards fatigue-resistant fibre-types? 
4.1.4 Aims & Expected Outcomes 
To address these questions by   
1. demonstrating that consumption of diets equally enriched in SFAs and 
PUFAs would induce different ratios of fast- to slow-twitch fibres in skeletal 
muscle of rat; and furthermore, that 
2. high-PUFA consumption would result in a greater proportion of slow-twitch 
fibres. 
Although the answer to this research question is valuable in its own right, there is an 
additional, implied purpose to this study, which is to explore further the effects of 
chronic PUFA consumption documented in Chapter 3: 
4.1.5 Background 
Dietary fatty acids differentially affect adipose tissue on several parameters 
[distribution, fatty acid composition, accrual (fat accumulation and adipocyte size)], 
as well as whole-body composition (fat-to-lean ratio) (Hill et al., 1992, 1993; Gajda 
et al., 2007; Barasi, 2008; Buckley & Howe, 2009).  
4.1.6 Research Question 
Thus, it is interesting to determine if this remodelling capacity of PUFAs extends to 
the functional microanatomy of other peripheral tissues, such as skeletal muscle. 
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4.2 Materials and Methods  
4.2.1 Animals and Dietary Treatment 
The analyses presented here were carried out on the same animals used in the study 
described in Chapter 3 (Section 3.2). Two groups of adult male Wistar rats (~ 250 g) 
were fed isoenergetic diets enriched with either SFAs or PUFAs for eight weeks. 
Both diets provided 40% of energy from fat, mainly from lard and fish oil, 
respectively (n=8/group). Details of general husbandry and maintenance can be 
found in Chapter 2, Section 2.1.6 and diet composition in Chapter 3 (Table 3.1). Due 
to financial and logistical constraints of the project, the low-fat control group 
(n=8/group) was run separately and muscle samples collected and stored for future 
analysis. 
4.2.2 Tissue Collection and Processing 
Gastrocnemius and soleus muscles were dissected fresh from rat cadaver hind limbs, 
as representative examples of anaerobic/glycolytic and aerobic/lipid-utilizing types, 
respectively, such that any alteration of fibre composition would be clearly 
observable. Histological processing was carried out according to protocols optimised 
in-house with Dr. I.S. Young (Institute of Integrative Biology, University of 
Liverpool). After immersion-fixation for three hours in 4% buffered 
paraformaldehyde, muscles were cryoprotected in 10% buffered sucrose. The belly 
of each muscle was blocked, mounted on a specimen holder in OCT compound 
(Fisher Scientific, Surrey, UK) and frozen at -20oC within a cryostat (Leica CM1900, 
Leica Microsystems, GmbH, Germany). Transverse 10-µm sections (perpendicular 
to the long axis of the muscle) were collected 60 µm apart, thaw-mounted onto 
chrome-alum and gelatin-coated slides, air-dried and washed 3 x 10 minutes in 10 
mM PBS.  
4.2.3 Immunohistochemistry, Image Analysis and Quantification 
To allow distinction between fast and slow fibre-types, sections were incubated for 
two hours at room temperature with monoclonal antibodies raised against adult 
human myosin isoforms (A4.74 and A4.840, markers of fast and slow fibres, 
respectively; Developmental Studies Hybridoma Bank, Iowa, USA). These 
antibodies show cross-reactivity with rat myosin and were applied at a dilution of 
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1:10. After washing, all sections then underwent a one-hour incubation, at room 
temperature in the dark, with Dylight 594-conjugated donkey anti-mouse IgG (1:500; 
Jackson ImmunoResearch Laboratories). After a final wash, all sections were air-
dried and coverslips applied over VectaShield® anti-fade mounting medium (Vector 
Laboratories Inc., Burlingame, USA). General details of antibody dilution, 
incubation and wash steps are outlined in Chapter 2 Section 2.10.4. 
Immunofluorescent staining was examined under epi-fluorescence microscopy (Zeiss 
Axio Imager. M1). Images were captured by digital microphotography (Hamamatsu 
ORCA I-ER, Hamamatsu Photonics, Welwyn Garden City, Herts) and image 
analysis software (AxioVision, Carl Zeiss MicroImaging, GmbH, Germany).  
Systematic counting was used to estimate fibre-type numbers in whole muscle cross 
sections taken from gastrocnemius and soleus muscles in rats fed high-SFA or high-
PUFA diets for 8 weeks. All transverse muscle fibre profiles within each section 
were counted and categorised as stained or unstained respectively. Using image 
analysis software (Image J, National Institutes of Health, USA), counts were 
performed twice, on images photographed at 20x magnification, by two 
experimenters blind to the dietary treatment, muscle type or myosin isoform which 
had been stained (Abramoff et al., 2004). 
4.2.4 Statistics 
Counts of fibre profiles with specific staining were expressed as a proportion of the 
total number of profiles (stained + unstained). Data are expressed as mean ± SEM. 
Differences in proportions of fibre-types between the two high-fat diet groups were 
determined using Student’s 2-tailed t-test and were considered significant at p<0.05. 
Gastrocnemius and soleus muscles are known to consist of significantly different 
proportions of fibre-types (Peter et al., 1972), and so it was not necessary to 
statistically compare results in response to this factor (muscle-type).   
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4.3 Results 
Analysis of myosin immunohistochemistry (Figs. 4.1 & 4.2) revealed that, 
irrespective of diet, gastrocnemius and soleus muscles predictably showed inverse 
fibre compositions: more fast than slow fibres were present in the gastrocnemius 
muscle (mean across diets: 69±2.2% fast vs. 31±1.1% slow, p<0.05; Fig. 4.3). The 
opposite was true of the soleus muscle, and was more pronounced (12±0.8% fast vs. 
88±2.8% slow, p<0.05; Fig. 4.3). No significant differences were found between diet 
effects in either muscle (both p>0.05).  Mean fibre counts are presented in Table 4.1.   
 
 
Figure 4.1. Representative photomicrographs of fast and slow fibres-types in transverse 
sections of gastrocnemius muscle from rats fed high-SFA (A, B) or high-PUFA diets (C, D) 
for 8 weeks (n=8/group). Stained fibres are indicated by red fluorescent angular profiles. 
Fibre-types were identified as fast (A, C) or slow (B, D), depending on the myosin isoform 
stained. In this instance SFA-fed rats act as a control for PUFA-fed rats.  
 
A 
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Figure 4.2. Representative photomicrographs of fast and slow fibre-types in transverse 
sections of soleus muscle from rats fed high-SFA (A, B) or high-PUFA  diets (C, D) for 8 
weeks (n=8/group). Stained fibres are indicated by red fluorescent angular profiles. Fibre-
types were identified as fast (A, C) or slow (B, D), depending on the myosin isoform stained. 
In this instance SFA-fed rats act as a control for PUFA-fed rats. 
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Table 4.1. Total fibre-type counts in whole muscle cross sections taken from gastrocnemius 
and soleus muscles in rats fed high-SFA or high-PUFA diets for 8 weeks. All transverse 
muscle fibre profiles within each section were counted and categorised as stained or 
unstained respectively. Values are expressed as mean ± SEM (n=8/group): p>0.05 between 
diet groups. In this instance SFA-fed rats act as a control for PUFA-fed rats.  
 Diet Type 
Muscle/Fibre Type SFA PUFA 
G –Fast 42±4.8 47±6.2 
G – Slow 29±6.5 30±3.7 
G – Total 71±8.1 77±6.5 
S – Fast 16±1.8 16.94± 
S – Slow 66±5.5 70.19± 
S - Total 82±7.8 86±5.4 
Abbreviations: G = gastrocnemius, S = soleus.  
 
  
Figure 4.3. Fibre-type composition of gastrocnemius and soleus muscle in all rats fed high-
SFA or high-PUFA diets for 8 weeks. Proportions were determined by quantification of total 
fibres immunostained for fast and slow myosin isoforms in all muscle cross sections 
collected (Figs. 4.1 and 4.2). Values are expressed as mean ± SEM (n=8/group): p>0.05 
between diet groups. In this instance SFA-fed rats act as a control for PUFA-fed rats. 
Abbreviations: G = gastrocnemius, S = soleus.  
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4.4 Discussion 
Results in Chapter 3 show that neither high-fat diet affected the mass of 
gastrocnemius nor soleus muscles compared to that of low-fat-fed control animals 
(Fig. 3.3D). This is consistent with the lack of effect of diet on the total number of 
fibres present in each muscle. The failure of the high-SFA diet to influence muscle 
mass contradicts findings in humans and animals, in which obesity has been 
associated with changes in the capacity of muscles to hypertrophy, although these 
findings themselves are contradictory. In ob/ob mice, atrophy and reduced ability to 
hypertrophy (Warmington et al., 2000) is in contrast to the increased hypertrophy 
observed in human subjects sensitive to an obesity-inducing diet (Gerrits et al., 
2010). However, these discrepancies could be due to the properties of different 
muscles examined in the two studies (i.e. if they were not homologues), and/or to the 
differing etiologies of genetic and diet-induced obesity.  
 Neither were there different fibre-type proportions associated with the 
different high-fat diets, and therefore, no observed shift from fast- to slow- fibre-
types induced by the high-PUFA diet. This is consistent with the overlap in several 
other outcomes presented in Chapter 3, including concentrations of circulating 
adipokines and insulin. Leptin replacement in ob/ob mice has been shown to shift the 
soleus muscle toward a fast fibre-type (Type II) profile (Warmington et al., 2000). 
Therefore, the leptin resistance observed in the two high-fat-fed groups in the current 
study (Fig. 3.4) may provide some explanation for the lack of effect, although the 
anticipated effect of PUFAs was the opposite to this (a shift toward a slow fibre-
type). Furthermore, in transgenic mice, enhanced PPARγ activity induces increases 
in both Type I fibre-type proportion and local secretion of adiponectin, which 
enhances muscle insulin sensitivity, suggesting there may be a relationship between 
all three features (Amin et al., 2010). Again, the similar adiponectin levels and 
insulin resistance observed in the high-fat-fed groups in the current study (Figs. 3.6 
& 3.9) are, therefore, consistent with similar fibre-type proportions.  
 As skeletal muscle composition is thought to result from the complex 
interaction of diet, genes, and exercise (Demmig-Adams & Carter, 2007), and as 
different levels and types of exercise drive differential expression of muscle fibre-
types (Howald et al., 1985), it could be proposed that exercise was the missing 
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stimulus for change in fibre-type proportions in the current study. Rats were 
sedentary and were not given opportunities to exercise, for example, by being 
provided with exercise wheels. However, this idea is challenged by a number of 
previous studies in which humans and rodents displayed altered muscle composition 
or oxidative gene expression in association with genetic or high-fat diet-induced 
obesity, despite the absence of exercise (Warmington et al., 2000; McAinch et al., 
2003; Gerrits et al., 2010).  
It is also tempting to think that diet exposure may not have been long enough 
to induce change in muscle composition. This possibility is suggested by one other 
study, in which Wistar rats fed a high-fat diet providing the same amount of energy 
from fat as that of the current study (40%), but over a shorter period (5 weeks vs. 8 
weeks here), showed no change in fibre composition in a range of skeletal muscles, 
including those examined here (gastrocnemius and soleus; Zou et al., 2003). On the 
other hand, a number of other studies involving high-fat feeding for the same or 
shorter periods, and in which muscle composition or oxidative gene expression was 
altered, would dispute this (Abou Mrad et al., 1992; McAinch et al., 2003; Shortreed 
et al., 2009). These latter studies, however, also involved the use of diets providing 
higher concentrations of energy from fat than those used here (60-78% vs. 40%), 
suggesting that this feature of the diet may be the critical one for altering fibre-type 
proportion. As discussed in Chapter 3, it would also seem entirely likely that the two 
high-fat diets used here failed to induce distinct fibre-type proportions because of 
their impure compositions.  
Therefore, it has yet to be determined whether dietary PUFAs can remodel 
skeletal muscle by altering the ratio of fast-to-slow fibre-types, or if their beneficial 
effects on muscle function occur by another mechanism entirely (Broekhuizen et al., 
2005).  
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Characterisation of a Refined PUFA-Feeding Model 
5.1 Introduction 
5.1.1 Rationale  
The study described in Chapter 3 had aimed to develop a valid rat model of chronic 
high-PUFA consumption. Adult male Wistar rats fed a diet providing 40% of energy 
from PUFAs for two months were compared to controls fed an isoenergetic diet 
enriched with SFAs on a range of morphometric, metabolic and behavioural 
parameters. Compared to a low-fat-fed control group, they differed on only two 
measures, satiety and circulating concentrations of triglycerides. The otherwise 
extensive overlap between the outcomes of both types of dietary intervention was 
attributed to the presence of each FA type in the opposing diet. Furthermore, the 
incomplete separation between both high-fat diet and the control group on some 
parameters was attributed to the presence of sucrose in the control diet.  
Thus, the original experimental aim had not been fully met, and it was 
considered that the model required refinement through re-design of diets. This 
entailed identification of PUFA and SFA sources with the least possible 
contamination by the other FA type. Thus, the study was designed to re-address the 
original aim, but while also taking account of financial constraints on the project 
which had arisen by this time, as well as limited availability of the chosen PUFA 
source. This meant that the diet exposure period, though not acute (as in only a few 
days long), was shorter than the previous one (3 vs. 8 weeks), and that concentrations 
of only a limited range of circulating factors could be examined. Those selected 
included triglycerides (TGs), to enable confirmation of the metabolic efficacy of the 
new high-PUFA diet, and brain-derived neurotrophic factor (BDNF), in an attempt to 
integrate findings with concurrent exploration of the diet’s effects on cell 
proliferation in the brain. 
5.1.2 Short-Term Exposure to PUFAs and Selection of Omega-3 Fatty Acid 
The beneficial effects of PUFA consumption observed in the previous dietary study 
(Chapter 3; i.e. reduced plasma TGs and increased satiety) have been documented in 
humans (Buckley & Howe, 2009) and therefore, support the partial validity of that 
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model. These changes had occurred within the first two weeks of consumption. 
Short-term exposure to diets high in SFAs increases weight gain, but critically, 
impairs learning and cognition even prior to obesity onset (Kanoski & Davidson, 
2011). In contrast, similar short periods of PUFA consumption show positive 
metabolic effects, such as attenuation of weight gain and decreased adiposity and 
circulating concentrations of TGs (Cunnane et al., 1986; Belzung et al., 1993; 
Hainault et al., 1993; Baillie et al., 1999; Ruzickova et al., 2004), and these health 
benefits have been attributed in particular to omega-3 FAs (Buckley & Howe, 2009). 
Therefore, a high-omega-3 source commercially purified from fish oil was 
considered an optimal replacement for the mixed-content fish oil used in the previous 
study (Chapter 3); docosahexaenoic acid (DHA) was selected because of its positive 
effects on health, both peripherally and centrally. For instance, it improves lipid 
metabolism, is required for normal nervous system (CNS) development, and its 
dietary supplementation is associated with improved cognitive health (Ruzickova et 
al., 2004; Buckley & Howe, 2009; Gomez-Pinilla, 2011; Poudyal et al., 2011).  
5.1.3 Obesity and BDNF 
BDNF is a neurotrophin with diverse functions, ranging from development of the 
nervous system to the control of appetite (Chao et al., 2006; Ooi et al., 2012). 
Evidence from both human and rodent studies suggests that alterations in BDNF 
signaling, in appetite related regions of the brain, may be responsible for the 
increased food intake associated with obesity (Tapia-Arancibia et al. 2004; Levin 
2007; Cordeira & Rios, 2011; Noble et al. 2011). BDNF and its receptor, TrkB, are 
currently under study to fully determine their functions, as they represent a potential 
target for the development of anti-obesity therapies (Hashimoto et al., 2005; Ooi et 
al., 2012). The dual role of BDNF is important in both the peripheral and central 
nervous systems, as it is key to aiding in proliferation, differentiation and survival of 
neurons, processes increasingly being found to underpin its requirement for 
sustaining behavioural processes, such as feeding (Cordeira & Rios, 2011; Noble et 
al. 2011). This latter role is investigated further in the study described in Chapter 7. 
In the CNS, BDNF is expressed at its highest concentrations in neurons of the 
hypothalamus, specifically, within regions related to feeding, such as the 
ventromedial hypothalamic (VMH) and paraventricular nuclei (PVN; Wu et al., 
2004a; Wu et al., 2004b; Webster et al., 2006; Godar et al., 2011). It is known to 
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regulate food intake and energy expenditure through its actions in these two nuclei 
(Wu et al., 2004a; Wu et al., 2004b; Vaynman & Gomez-Pinilla, 2006; Godar et al., 
2011; Noble et al., 2011; Rosas-Vargas et al., 2011).   
Indeed, leptin, insulin, glucagon-like peptide-1 (GLP-1) and other appetite 
regulators exert their effects through BDNF (Vaynman & Gomez-Pinilla, 2006; 
Rosas-Vargas et al., 2011). The concentration of BDNF in the blood parallels that in 
the brain, where most circulating BDNF is produced (Forsgen et al., 2011). Mutation 
in the BDNF gene leads to disturbed meal patterns and obesity (Fox & Byerly, 2004; 
Akkerman et al., 2011), and reduced serum concentrations of BDNF are observed in 
obese people (El-Gharbawy et al., 2006). BDNF is essential for body weight control, 
as suggested by low concentrations of circulating plasma BDNF in individuals with 
type 2 diabetes and obesity (Krabbe et al., 2007) and the inverse relationship 
observed between BDNF concentrations and body mass index (BMI) in adults and 
children (Lommatzsch et al., 2005). Furthermore, the deletion of the BDNF gene is 
associated with childhood obesity, decreased satiety and hyperphagia (Han et al., 
2008; Burns et al., 2010). However, individuals suffering from type 2 diabetes can 
display decreased concentrations of plasma BDNF in the absence of obesity, 
suggesting that the regulating mechanisms of BDNF behind insulin resistance and 
obesity are different (Pedersen et al., 2009).  
5.1.4 Food Intake Regulation and BDNF 
As reviewed in the General Introduction (Chapter 1, Section 1.1), food intake 
regulation is fundamentally involved in the maintenance of a stable body weight and 
energy homeostasis. This involves hormonal signaling in a range of brain regions, 
and BDNF is one of the key molecules currently being actively researched in this 
regard. Chronic i.c.v infusion of BDNF attenuates weight gain in rats by suppressing 
appetite (Lapchack et al., 1992; Pelleymounter et al., 1995; Gomez-Pinilla et al., 
2008), and this is thought to occur within the classic ‘satiety centre’, the VMH (Xu et 
al., 2003). Repeated injections of BDNF administered directly to the VMH reduce 
body weight and insulin concentrations and reverse hyperleptinemia by decreasing 
feeding and increasing energy expenditure, physical activity and fat oxidation in DIO 
rodents (Godar et al., 2011). These actions may be mediated by leptin, as central 
administration of leptin stimulates expression of the BDNF gene and its associated 
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protein in the VMH (Komori et al., 2006). However, the mechanisms behind this 
have yet to be fully determined. It is possible that the leptin interaction directly 
influences a signal transduction cascade which induces BDNF in the VMH (Rosas-
Vargas et al., 2011). BDNF is also responsive to diet composition. A diet high in 
SFAs has been shown to decrease its gene expression and circulating plasma 
concentrations (Stranahan et al., 2008), whereas, conversely, the intake of omega-3 
PUFAs has been shown to increase them (Wu et al., 2004b; Vaynman & Gomez-
Pinilla, 2006; Bousquet et al. 2009). Thus, in the current study, it was considered 
useful to determine whether the new high-PUFA feeding model could be defined by 
relationships between peripheral BDNF concentrations, indices of body weight, and 
meal patterns.  
5.1.5 Research Question 
Does chronic consumption of a diet highly enriched in omega-3 fatty acids 
improve energy homeostasis in rat? 
5.1.6 Predictions 
If so, then significant differences would be observed between morphometric, 
metabolic and behavioural indices of energy metabolism in rats fed diets highly 
enriched in omega-3 and saturated fatty acids derived from relatively pure sources 
and as compared to low-fat-fed controls. 
5.1.7 Aims 
To test these predictions by assessing diet-induced differences in  
1. body weight and composition associated with  
2. corresponding alterations in energy intake and meal patterns and  
3. circulating concentrations of appetite-related factors. 
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5.1.8 Expected Outcomes 
Rats fed the diet high in omega-3 fatty acids would display  
1. attenuated weight gain  
2. improved fat-to-lean ratio 
3. reduced energy intake  
4. changes in meal patterns, indicating enhanced satiety, and  
5. reduced circulating concentrations of triglycerides and increased 
concentrations of BDNF. (Leptin, insulin and adiponectin could not be 
measured, so qualitative comparison with Chapter 3 would not be possible.)  
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5.2 Materials & Methods   
5.2.1 Animals and Treatment 
Age-matched adult male Wistar rats (~250 g) were stratified by body weight and 
randomly assigned to one of three groups (n=6/group). Two groups were fed 
isoenergetic diets for three weeks. These were enriched with either SFAs or PUFAs. 
Both diets provided 40% of energy from fat, mainly from coconut oil and a 
commercially purified source of the omega-3 fatty acid, docosahexaenoic acid 
(DHA; Incromega™ Marine Lipid Concentrate E1070, Croda Europe Ltd., Leek, 
Staffs, UK), respectively. These acted as controls for one another by eliminating the 
potentially confounding factor of differing energy intake. A third group, fed standard 
(low-fat) chow (providing 10% of energy from fat, from soybean oil) acted as a 
control for obesity induction, demonstrating normal weight gain and food intake. In 
addition to the changes in duration of exposure (due to time and financial constraints 
on the project) and in fatty acid sources and concentrations from those used in the 
original PUFA-fed characterisation study (Chapter 3), sucrose was also eliminated to 
avoid development of insulin resistance in control animals (see Table 5.1 for a 
summary of diet compositions and Appendix III & IV for full nutritional 
breakdowns).  
As for the original study, group size was determined by Mead’s resource 
equation (Chapter 2, Section 2.1.4). The larger, original group size (n=8) arose from 
initial requirements for only two treatment groups (high-SFA- and high-PUFA-fed). 
[In factorial design, sample size reduces as treatment groups increase (Festing et al., 
2004).] The third, control group was run separately several months later, when its 
need was realised and funds became available. All diets were manufactured by 
Research Diets, Inc. (NJ, USA). Body weight was measured weekly and food and 
water intake daily. Details of general husbandry and maintenance, as well a 
bioimpedance technique can be found in Chapter 2, Sections 2.1.6 and 2.5.2, 
respectively.   
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Table 5.1. Nutritional composition of low-fat (control) and isoenergetic high-fat diets.  
 Diet Type 
Macronutrient content Control SFA-enriched PUFA-enriched 
Total energy content (kcal/gm) 3.85 4.58 4.58 
% energy from carbohydrates 70 40 40 
% energy from protein 20 20 20 
% energy from fat 10 40 40 
% energy from fat as SFAs 30 95 1 
% energy from fat as PUFAs 36 3 98 
% energy from fat as MUFAs 34 2 1 
% energy from EPA & DHA (omega-3) 8 <0.05 78 
% energy from sucrose 0 0 0 
 
The high-PUFA diet and its high-fat control, enriched in SFAs, contained equal amounts of energy 
overall (isoenergetic) and contributed equal amounts of energy from fat. In contrast to those described 
in Chapter 3, fat sources were almost exclusively from PUFAs (specifically, omega-3 fatty acids) or 
SFAs in the respective diets. Note also that manufacture of specialised diets requires incorporation of 
a selection of carbohydrates, including sucrose (see Table 3.1, Chapter 3; Dr. L. Leiter, Research 
Diets, Inc., personal communication). However, due to the confounding influence of sucrose on 
insulin resistance and associated parameters, it was removed completely from the diets used here. 
Abbreviations:  DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; PUFA, polyunsaturated 
fatty acid; SFA, saturated fatty acid.  
 
5.2.2 Cell Proliferation Markers 
Rats in the original characterisation study (Chapter 3) had received the cell 
proliferation tracer, BrdU, in their drinking water for the last week of dietary 
exposure. By the time the study described here was planned, the limitations of BrdU 
use were becoming clear. Thus, these animals did not receive BrdU, but were 
examined for other histological markers of cell proliferation instead (Chapter 7). As a 
potential stimulus for this process, a play tube was placed in each cage for the 
duration of the study for all groups.  
5.2.3 Meal Pattern Data Acquisition and Analysis 
Meal pattern information was gathered over a 24-hour period at the end of the study. 
Rats were removed from home cages and placed in specialised cages equipped with 
automated food intake monitoring systems, where they were given access to diets 
and water ad libitum. Raw data acquired in diurnal and nocturnal phases were 
analysed and are displayed according to previously published parameters: total 
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energy intake (kJ), number and duration (min) of meals, rate of feeding (g/min), inter 
meal interval (IMI; min) and satiety ratio (IMI/average energy content of the 
previous meal consumed; min/kJ; Cattone et al., 2007; Farley et al., 2003; Hariri & 
Thibault, 2011).  Details of the cage and software analysis system can be found in 
Chapter 2, Section 2.4.3. 
5.2.4 Blood Chemistry 
After an overnight fast, and under brief gaseous anaesthesia, blood samples were 
collected from the tail vein at baseline and weekly thereafter and plasma separated by 
centrifugation. Blood glucose concentrations were measured immediately by 
glucose-oxidase strips and a hand-held glucose meter. Plasma concentrations of 
triglycerides (TGs) were measured by (enzymatic, colorimetric) diagnostic kit and 
concentrations of BDNF by ELISA, according to manufacturers’ protocols. Details 
of suppliers and manufacturers’ protocols can be found in Chapter 2, location 2.6.2. 
Plasma concentrations of leptin, adiponectin and insulin, measured in the original 
characterisation study (Chapter 3) were not measured here, due to financial 
constraints.  
5.2.5 Body Composition Analysis & Termination 
Under deep anaesthesia, final whole-body composition was assessed by 
bioimpedance (EM-SCAN/TOBEC® SA-3114 Small Animal Body Composition 
Analysis System, Royem Scientific, Luton, UK). Rats were then perfuse-fixed and 
brains removed for histological analyses described in Chapter 7. The descending 
aorta was clamped to prevent fixation of peripheral tissues required fresh for this 
study. White adipose tissue (WAT) pads, interscapular brown adipose tissue (BAT), 
gastrocnemius and soleus muscle and liver were dissected free, weighed, snap-frozen 
in liquid nitrogen, and stored at -80°C for further analysis. Tissue weights were 
expressed as a percentage of final body weight.  
5.2.6 Statistical Analysis 
Data are expressed as mean ± SEM. All tissue masses are presented as a relative 
percentage of final body weight. Differences between diet groups in three-way 
comparisons were determined using one-way ANOVA with post-hoc Bonferroni 
correction and considered significant at critical p<0.0166 for 3 comparisons. 
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Differences between diet groups over a time course were determined using 2-way 
ANOVA with repeated measures and post-hoc Bonferroni correction and considered 
significant at p<0.05. In all instances comparisons demonstrated roughly equal 
variation and therefore the sphericity criteria were met and consequently variation 
data is not presented here.  Statistical analysis was carried out using software SPSS 
v19. Justification for use of all statistical analyses can be found in Chapter 2 section 
2.11. 
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5.3 Results  
5.3.1 Energy Intake & Body Weight 
PUFA (omega-3)- and SFA-fed rats consumed comparable amounts of energy over 
the course of the study (p>0.05), which were greater than that consumed by controls 
(+13±1.1% in SFA-fed animals, +12±1.8% in PUFA-fed animals, both p<0.01; Figs. 
5.1A & B). This, and other significant effects presented here, are similar to those 
described in Chapter 3, but after less than half the duration of dietary exposure (3 vs. 
8 weeks). Increased energy intake in the SFA-fed group did not induce weight gain 
(Figs. 5.2A-C). Despite an equivalent energy intake, body weight was attenuated in 
the PUFA-fed rats upon termination (-9±0.9% and –11±1.3% vs. control and SFA-
fed, respectively; p<0.05; Fig. 5.2A). Body weight gain was also attenuated in 
PUFA-fed animals (-31±2.8% and –38±4.3% vs. control and SFA-fed, respectively; 
both p<0.01; Figs. 5.2B & C). Energy efficiency was predictably reduced in this 
group (-28±4.5% vs. control, p<0.01; Fig. 5.2D).   
   
Figure 5.1. Energy intake evolution (A) and cumulative energy intake (B) in control, SFA- 
and PUFA (omega-3)-fed rats consuming diets for three weeks. Reduced intake at weekly 
intervals (A) reflects imposed overnight fasts prior to blood sampling. Overall energy 
intake was increased equally in high-fat-fed groups. Values are expressed as mean ± SEM 
(n=6/group): **p<0.01 compared to controls (1-way ANOVA). 
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Figure 5.2. Absolute body weight evolution (A), cumulative weight gain (B), weight gain evolution (C) and food efficiency (D) in control, SFA- and PUFA 
(omega-3)-fed rats consuming diets for three weeks. High-omega-3 feeding attenuated weight gain, reflected in reduced food efficiency. Values are 
expressed as mean ± SEM (n=6/group): *p<0.05 compared to controls (2-way ANOVA with repeated measures); **p<0.01 compared to controls; † compared 
to SFA (1-way ANOVA). Food efficiency = ∆body weight (g)/Σfood intake (MJ). 
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5.3.2 Terminal Tissue Mass and Body Composition 
High-SFA feeding had no effect on adiposity, despite the associated increase in 
energy intake, but consistent with unchanged body weight gain. Attenuated weight 
gain in PUFA (omega-3)-fed rats was reflected in smaller fat pad masses across all 
WAT depots examined, significantly so in the epididymal and perirenal depots          
(-37±4.5% and -35±2.8%, and –26±3.7% and -28±4.1%, respectively, vs. control and 
SFA-fed; p<0.01; Fig. 5.3A), and in dramatic contrast to induction of adiposity in 
this group in Chapter 3. Despite the suggestion, by these combined results, of raised 
energy expenditure in the PUFA-fed group, BAT mass was unaffected (Fig. 5.3B). 
Muscle mass was unaffected by diet (Fig. 5.3D); thus, reduced adiposity by high-
PUFA feeding was reflected in improved body composition (fat-to-lean ratio;            
-36±3.8% vs. control and -32±2.6% vs. SFA-fed; both p<0.01; Fig. 5.3E). There was 
no effect of diet on liver mass (Fig. 5.3C).
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Figure 5.3. Tissue masses relative to final body weight in control, SFA- and PUFA (omega-3)-fed rats after consumption of diets for three weeks: WAT (A), 
BAT (B), liver (C) and muscle (D). Body composition (E) was calculated as the ratio of summed WAT depot to muscle masses. High-omega-3 feeding 
reduced adiposity, reflected in enhanced body composition. Values are displayed as mean ± SEM (n=6/group): **p<0.01 compared to controls; †p<0.01 
compared to SFA (1-way ANOVA).
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5.3.3 Bioimpedance Analysis 
Terminal bioimpedance analysis (Table 5.2) showed that assessment of whole-body 
composition was in general agreement with that determined by surrogate measures 
(select tissue masses; Figs. 5.3A-E). None of the measures were affected by high-
SFA feeding, but high-PUFA (omega-3) feeding reduced total fat and lean mass 
compared to control and SFA-fed groups (both p<0.01). The reduction in overall lean 
mass, in addition to fat mass, suggests a reduction in whole-body weight, consistent 
with findings (Figs. 5.2A-C), and may explain why the relative total fat mass (%) 
was unchanged by high-PUFA feeding. The discrepancies with surrogate findings 
may result from the fact that the discrete tissues selected did not reflect whole-body 
change; i.e. other fat depots and skeletal muscles which were not examined may have 
responded to the diets differently. 
 
Table 5.2. Diet effects on whole-body composition.  
 Control SFA PUFA (omega-3) 
Lean body mass (g) 198±6.3 203±5.9 184±3.4**† 
Total body fat (g) 241±6.4 243±4.7 219±3.1**† 
Total body fat (%) 55±0.5 54±0.3 53±0.8 
Fat-free mass (g) 69±2.6 72±2.3 66.8±1.5 
 
Terminal bioimpedance scores show that three weeks of high-omega-3 feeding reduce 
overall mass. Values are displayed as mean ± SEM (n=6/group): **p<0.01 compared to 
controls; †p<0.01 compared to SFA (1-way ANOVA). 
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5.3.4 Circulating Factors  
5.3.4.1 Whole-Blood Glucose Concentrations 
Analysis by two-way ANOVA with repeated measures demonstrated no differences 
in whole-blood glucose concentrations between diet groups (F (2, 15) = 0.2085, 
p=0.8141), over time (F (3, 45) = 2.076, p=0.1168) or any interaction between diet 
and time (F (6, 45) = 0.7208, p=0.6349). Similar to findings presented in Chapter 3, 
there were no differences in whole-blood glucose concentrations between diet groups 
over the course of the study (all p>0.05), and within-group, terminal concentrations 
had changed very little from baseline: -2±0.1%, +20±2.2% and +16±2.8% in control, 
SFA- and PUFA-fed groups, respectively (Fig. 5.4).  
 
Figure 5.4. Fasting whole-blood glucose concentrations in control, SFA- and PUFA (omega-
3)-fed rats consuming diets for three weeks. These were unaffected by high-fat feeding. 
Values are expressed as mean ± SEM (n=6/group): all p>0.05 (2-way ANOVA with repeated 
measures).  
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5.3.4.2 Plasma BDNF Concentrations 
Analysis by two-way ANOVA with repeated measures demonstrated no differences 
in circulating BDNF concentrations between diet groups (F (2, 15) = 1.232, 
p=0.3196), over time (F (3, 45) = 1.842, p=0.1530) or any interaction between diet 
and time (F (6, 45) = 0.5037, p=0.8022). There were no differences in circulating 
BDNF concentrations between diet groups over the course of the study (all p>0.05). 
All three dietary groups show an increase in circulating concentrations by the end of 
the study with respect to baseline (+189±18.9%, +76±11.2% and +42±5.4% in 
PUFA (omega-3), control and SFA-fed animals, respectively; Fig. 5.5).  
 
Figure 5.5. Plasma BDNF concentrations in control, SFA- and PUFA (omega-3)-fed rats 
consuming diets for three weeks. These were not significantly affected by high-fat 
feeding. Values are expressed as mean ± SEM (n=6/group): all p>0.05 (2-way ANOVA with 
repeated measures). 
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5.3.4.3 Plasma Triglyceride Concentrations  
Analysis by two-way ANOVA with repeated measures demonstrated a significant 
difference in circulating triglyceride concentrations between diet groups (F (2, 15) = 
5.271, p=0.0185) and over time (F (3, 45) = 5.853, p=0.0018), but no interaction 
between diet and time (F (6, 45) = 1.667, p<0.1513). Similar to results in Chapter 3, 
though the expected relationship between high SFA consumption and an increase in 
circulating TG concentrations was again not observed, a dramatic and progressive 
fall was observed in the PUFA (omega-3)-fed animals (-60±5.4% from baseline;       
-65±6.8% and -68±4.7% vs. control and SFA-fed respectively; both p<0.05) (Fig. 
5.6), a reduction 16±1.8% greater than that seen in Chapter 3 (as confirmed by AUC 
analysis).  
 
Figure 5.6. Plasma triglyceride concentrations in control, SFA- and PUFA (omega-3)-fed 
rats consuming diets for three weeks. High-omega-3 feeding progressively reduced 
triglyceride concentrations from week 1. Values are expressed as mean ± SEM 
(n=6/group); *p<0.05 compared to controls; †p<0.05 PUFA compared to SFA (2-way 
ANOVA with repeated measures). 
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5.3.5 Meal Patterns 
Similar to results presented in Chapter 3, diet appeared to have no significant effect 
on diurnal or nocturnal energy intake, when analysed separately after three weeks of 
consumption (all p>0.01; Fig. 5.7A). The overall lack of effect conflicts with the 
increase in cumulative 24-hour intake observed here in both SFA- and PUFA 
(omega-3)-fed groups (Fig. 5.1B), but could reflect the fact that other meal pattern 
changes offset one another; i.e. increased diurnal, but decreased nocturnal, meal 
duration induced by SFA feeding (+26±1.6% and -21±2.9% vs. controls, 
respectively; both p<0.01; Figs. 5.7C) and nocturnal reduction in number of meals, 
but also feeding rate, induced by PUFA feeding (-33±2.4% and -23±1.8% vs. 
controls, respectively; both p<0.01; Figs. 5.7B&D).  
Increased diurnal meal duration in SFA-fed animals was reflected in 
decreased intermeal interval (IMI) and satiety during the day (-34±3.8% and              
-48±2.7% vs. controls, respectively; Figs. 5.8A, C). Though reduced nocturnal meal 
duration in this group might predict extended IMI and enhanced satiety at night, 
nocturnal satiety measures were unchanged, possibly because the slight (albeit non-
significant) increase in meal numbers was compensated by the slight reduction in 
feeding rate at night (Figs. 5.8B, D). Similarly, although PUFA-fed animals took 
fewer meals at night (Fig. 5.7B), they also slowed their rate of feeding (Fig. 5.7D), 
consistent with unchanged satiety overall (Figs. 5.8B, D). 
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Figure 5.7. Final 24-hour diurnal and nocturnal energy intake (A), number of meals (B), meal duration (C) and feeding rate (D) in control and high-SFA- and 
-PUFA (omega-3)-fed rats consuming diets for three weeks. High-omega-3 feeding altered nocturnal meal patterns by reducing the number of meals 
taken and rate of feeding. In contrast, high-SFA feeding altered meal duration during both phases. Values are expressed as mean ± SEM (n=4/group): 
**p<0.01 compared to controls; †p<0.01 compared to SFA (1-way ANOVA).
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Figure 5.8. Final 24-hour diurnal and nocturnal intermeal interval (A, B), and satiety ratio (C, D) in control, SFA- and PUFA (omega-3-fed)-fed rats 
consuming diets for three weeks. High-SFA feeding reduced daytime satiety, but high-PUFA feeding had no effect during either phase. Values are 
expressed as mean ± SEM (n=4/group); **p<0.01 compared to controls (1-way ANOVA). 
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5.3.6 Circadian Rhythmicity  
Feeding rhythmicity data gathered over the final 24 hours of this three-week study 
show clearly that in both SFA- and PUFA (omega-3)-fed groups, energy intake per 
meal generally exceeded that of controls (Fig. 5.9). This is consistent with summary 
measures of energy intake (Fig. 5.1B & 5.7A). All groups consumed the majority of 
their meals at night, as expected in a nocturnal species, and these were more 
intermittent in the experimental groups than the controls (Table 5.3). Furthermore, 
these meals appeared to be taken in small clusters of two or three in PUFA-fed 
animals, whereas those of the other two groups were more evenly spread across the 
phase. Both control and SFA-fed animals consumed two meals just prior to ‘lights 
off’, the second meal being larger than the first in both cases, but markedly so in the 
case of the SFA-fed group. In contrast, the extent of diurnal feeding in the PUFA-fed 
group was the consumption of a single meal around midday. Nocturnal meals began 
at ‘lights off’, whereas feeding activity was absent from this period in the SFA-fed 
group. Finally, comparison of these patterns to those presented for week 3 in Chapter 
3 show a marked reduction here, by almost half, in the number meals taken at night 
in both SFA- and PUFA-fed animals, with less consistent meal sizes (i.e. a greater 
range in energy intake per meal) in the latter compared to their PUFA-fed 
counterparts in Chapter 3. 
Table 5.3. Ranges of values associated with the circadian rhythmicity of feeding.  
Diurnal Week 3 
Range Control SFA PUFA 
Consumption 
window 
18.30-20.00 
(1.5 hours) 
19.00-20.00 
(1 hour) 
12.30-13.00 
(0.5 hours) 
Number of 
meals 
2 2 1 
Energy 
intake/range 
of meal (kJ) 
4-14kJ 
(10kJ) 
6-43kJ 
(37kJ) 3kJ 
Nocturnal Week 3 
Range Control SFA PUFA 
Consumption 
window 
21.00-06.30 
(9.5 hours) 
22.00-07.30 
(9.5 hours) 
20.00-07.30 
(11.5 hours) 
Number of 
meals 
12 8 10 
Energy 
intake/range 
of meal (kJ) 
2-30kJ 
(28kJ) 
8-51kJ 
(43kJ) 
11-60kJ 
(49kJ) 
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Figure 5.9. Circadian rhythmicity of feeding activity after three weeks of control, SFA- and 
PUFA (omega-3) diet consumption. Data are presented as means of 30-minute intervals over 
the final 24 hours of feeding. Values are expressed as mean ± SEM (n=4/group). Grey 
shading represents the nocturnal phase.  
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5.4 Discussion  
5.4.1 Morphological and Metabolic Phenotype 
Overall, the refined high-PUFA (omega-3) feeding model appeared to be a valid one, 
when compared to published findings in humans and animals. Over the course of 
only three weeks, PUFA-fed rats displayed significant improvements in key 
measures of body weight homeostasis, in comparison to both high-SFA- and low-fat-
fed control groups. However, the lack of separation between these two groups on 
most parameters calls into question the suitability of coconut oil as the SFA source in 
a high-fat control diet, at least under shorter-term exposure conditions.  
Although this study cannot be directly compared with the original study 
(Chapter 3), their apparent similarities and differences are worth mentioning. Here, 
in contrast to the original high-PUFA-fed group, high-omega-3 feeding attenuated 
body weight gain by reducing adiposity. This was in spite of increased energy intake, 
comparable with that consumed by the high-SFA-fed animals. This suggests that the 
omega-3 FAs enhanced energy expenditure, which is a known outcome of their 
consumption (Buckley & Howe, 2009). Though not reflected in a change in BAT 
mass, it may have been revealed in molecular and histological measures of increased 
thermogenesis; for instance, mice fed a diet enriched in omega-3 FAs for four weeks 
have shown increased BAT thermogenic activity, as measured by increased GDP 
binding, BAT hyperplasia and mitochondrial content (Oudart et al., 1997).  
Alternatively, increased expenditure may have been detectable by calorimetry 
or measures of increased locomotor activity (Kemp, 1999). As in the original study 
(Chapter 3), diet had no effect on skeletal muscle mass, such that the surrogate body 
composition ratio was, in fact, a measure of adiposity. Reduced adipose mass in the 
omega-3-fed group was reflected in reduced food efficiency, suggesting that omega-
3 FAs were being utilized to satisfy immediate energy demands, rather than going 
into storage (Buckley & Howe, 2009; Puglisi et al., 2011), which, again, could have 
been supported by observation of increased physical activity. Indeed, PUFAs are 
oxidised more rapidly, decreasing available time for deposition (DeLany et al., 2000; 
Bell & O’Keefe, 2011). This occurs as PUFAs influence the up-regulation and 
expression of genes involved in FA oxidation in organs such as the liver and 
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intestine, and the down-regulation of genes in adipose tissue that promote lipogenesis 
(Buckley & Howe, 2009). 
Bioimpedance analysis expanded on these findings to reveal that attenuation 
of weight gain was due to a combined whole-body reduction in fat and lean mass 
(see Results, Section 5.3.3), such that relative fat mass was unchanged by high-
omega-3 feeding. Whether this represents an attenuation of overall growth would 
require a longer duration study. As lean mass is now considered to be an important 
peripheral driver of energy metabolism (Blundell et al., 2012), its overall reduction 
could represent a detrimental effect of such a high concentration of an omega-3 FA 
in the diet, compromising normal function. Although findings are inconsistent, in 
general, omega-3 FAs appear to stimulate nutrient delivery to skeletal muscles and 
alter gene expression involved in metabolism to increase lean mass (Demmig-Adams 
& Carter, 2007). Once again, the short duration of the current study could explain 
this discrepancy. 
Studies have shown that composition of dietary FAs affects whole-body 
distribution of adipose tissue differentially (Hill et al., 1992; 1993). This is consistent 
with the differential effects of the omega-3 diet on the three fat depots examined. 
Considered together with the corresponding results in Chapter 3, these results are 
consistent with previous findings that increased WAT mass is observed in rats fed 
diets high in SFAs, compared to those fed diets high in omega-3 PUFAs (Parrish et 
al., 1990; Hill et al., 1992; Belzung et al., 1993; Hainault et al., 1993; Hill et al., 
1993; Flachs et al., 2006; Okere et al., 2006; Fernandez-Quintela et al., 2007). 
Numerous studies have shown that incorporating omega-3 PUFAs, including DHA, 
into high-fat diets reduces body fat accumulation in rodents (Cunnane et al., 1986; 
Belzung et al., 1993; Hainault et al., 1993; Baillie et al., 1999; Ruzickova et al., 
2004). This appears to occur after both long- and short-term exposure. Reduced body 
weight has been observed in mice fed diets supplemented with 10% cod liver oil for 
several months, in the absence of any change in energy intake (Cunnane et al., 1986). 
However, a similar effect has been observed in rats fed for only 16 days on a diet 
high in fat (50% of energy provided as fat), where 15% of the fat was sourced from 
fish oil. They showed 30% reductions in subcutaneous and visceral fat mass, despite 
food intake and body weight similar to that of a low-fat-fed control group (10% of 
energy provided as fat) (Hainault et al., 1993).  
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This protective effect of PUFAs against fat accumulation is now well-
recognised and is thought to be concentration-dependent. Of rats fed diets containing 
high (40.6% of energy), medium (18.6% of energy) and low (0.7% of energy) 
omega-3 FA content for one month, those receiving the highest concentration 
displayed the greatest reduction in epididymal and retroperitoneal fat accumulation. 
This was explained by the lowering of circulating TGs, which was also 
concentration-dependent (Belzung et al. 1993). Although increasing the omega-3 FA 
concentration to 78% from 25% in the original study did not result in any greater 
reduction in TG levels here (both reaching a minimum of 0.04 mg/ml), it appears that 
this latter reduction may have been continuing on a downward trajectory (Fig. 5.7), 
rather than cycling around a plateau (Fig. 3.10). The mechanisms behind reduction of 
circulating TG levels by PUFAs are explained in Chapter 3 (Section 3.4.5).  
Furthermore, the observed reduction in visceral fat, of which peritoneal and 
epididymal are constituent, is thought to be mediated primarily by DHA, as opposed 
to EPA. This has been demonstrated in mice fed high-fat diets containing mixtures of 
the two omega-3 FAs for five weeks. It was found that DHA, rather than EPA, 
attenuated the accumulation of epididymal fat, but neither had an effect on the 
accumulation of subcutaneous fat, suggesting that DHA, rather than EPA, was 
primarily responsible for promoting the anti-obesity effect (Ruzickova et al., 2004). 
This is consistent with the unchanged inguinal (subcutaneous) mass seen here, and 
highlights the importance of considering relative concentrations of the two omega-3 
FAs when making dietary recommendations. 
Finally, PUFA consumption has previously been associated with augmented 
liver size, and specifically, DHA is readily incorporated into liver phospholipids, 
increasing the overall mass of the organ (Hill et al., 1993; Rapoport et al., 2010). 
However, there was no effect of diet on liver mass in the current study, suggesting 
that three weeks of consumption was not a sufficient length of time for this effect to 
manifest. This is further supported by the findings in Chapter 3 that eight weeks of 
consumption was sufficient to increase liver mass in the PUFA-fed group, above that 
of both the control and SFA-fed group.  
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5.4.2 Plasma BDNF Concentrations 
There was no effect of diet on circulating concentrations of BDNF. Had dietary 
exposure been extended, then rats fed the PUFA diet may have demonstrated an 
increase in BDNF concentrations, as an elevation in BDNF secretion in rats has been 
observed after one and ten months’ PUFA consumption (Wu et al., 2004b; Bousquet 
et al. 2009). A reduction in BDNF levels in the high-SFA-fed group may also have 
become apparent as SFA consumption has been shown to reduce concentrations in 
rats fed for two and eight months (Molteni et al., 2002; Stranahan et al., 2008). Thus, 
an extended dietary exposure may be required to demonstrate the relationships 
between plasma BDNF concentrations and body weight described in the Introduction 
(Section 5.1.3) before an affect of FA type can be determined.  
5.4.3 Meal Patterns & Circadian Rhythmicity 
Consistent with original findings in Chapter 3, the high-fat diets here did not disrupt 
the overall temporal sequence of feeding (diurnal-nocturnal partitioning). With all 
diets, diurnal meals were again consistently smaller and less frequent than nocturnal 
ones, as expected for the active phase of the rat (Strubbe & Woods, 2004). Also 
similar was the failure of energy intake, as determined by meal pattern analysis, to 
fully reflect the cumulative, crudely measured increase in intake observed over the 
course of the study (Figs. 5.1A&B). Increases were, in fact, observed during both the 
light and dark phases, in both studies, but were minor and non-significant. This could 
be due to the fact that the automated cages represented a new environment, for which 
rats required a longer acclimatization period than 24 hours in order for normal 
responses to the diets to fully emerge. However, statistical comparison of energy 
intake between days 1 and 3 of the 72-hour meal analysis period in the original study 
did not reveal any differences in any group (data not shown), suggesting that 
acclimatization might have to be extended beyond three days. 
Meal duration was unchanged by diet in the original study, but here was 
disrupted in the high-SFA-fed group. Longer meals taken in the day were offset by 
shorter meals at night. Statistically unchanged glucose concentrations in this group 
suggest that the usual relationship between glucose and meal-to-meal control of 
feeding behaviour is lost on this diet. However, the slight, non-significant rise in 
CHAPTER 5 
217 
 
glucose levels in this group at the end of the study, suggesting increased hunger 
(Bray, 2000), does correlate with the reduced diurnal satiety observed in this group.  
Meal pattern signature in high-omega-3-fed animals was defined by changes 
on different parameters (decreased number of meals and feeding rate), and only at 
night, but which would also offset one another. These suggest enhanced nocturnal 
satiety, in this group, which was, in fact, observed, though not to a significant extent. 
Had a significant difference been drawn out, for instance, by a longer duration of 
exposure to the diet, it would have contrasted with the PUFA-induced satiety 
occurring in the opposite phase (daytime) in the original study, and suggested a 
differential effect on temporal sequence by individual omega-3 FAs and/or their 
concentrations; i.e. in the current study, omega-3 FAs provided three times the 
energy from fat as those in Chapter 3, as well as being comprised of a higher 
DHA:EPA ratio (126:17 vs. 19:22; see Appendices II and IV).  
Despite a general absence of obese phenotype in the SFA-fed group on 
morphometric and metabolic parameters (unchanged adiposity and TG levels), the 
characteristic feeding pattern associated with obesity, of fewer and larger meals, was 
observed during the nocturnal phase (Fig. 5.9 and Table 5.3). This appears to conflict 
with the subtle increase in number of meals shown in the summary analysis (Fig. 
5.7B) because the circadian rhythmicity graphs show average meal numbers in a 30 
minute interval, a disadvantage of the binning technique. However, this was also 
apparent in the omega-3-fed group, which had shown marked improvements on these 
same phenotypic measures. Thus, the influence of FAs on energy homeostasis may 
not be expressed at all levels of feeding behaviour. Rhythmicity of feeding in 
response to individual FAs may vary according to their type. Although here it 
appears to be independent of FA type, in other studies, it does not (Hariri & Thibault, 
2010). As these findings are being reported in relation to a pure omega-3 source for 
the first time, more studies are needed to determine if this independence is, indeed, 
typical of this family of FAs. On the other hand, three features of nocturnal 
periodicity appeared to differ between the SFA- and omega-3-fed groups. These 
were energy intake per meal, which showed the greater variability in the latter group, 
the pairing of lower- with higher- energy meals, also in the latter group, and the 
timing of the first nocturnal meals immediately after ‘lights off’ (the very start of the 
dark phase) in this group, compared with its possible counterpart just before ‘lights 
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off’ in the SFA-fed group (the very end of the light phase). This suggests fulfillment 
of immediate energy and lipogenesis requirements (Armstrong et al., 1978) at times 
which are slightly offset in the two groups, possibly indicating effects of the different 
FAs on the central clock (Mendoza et al., 2008).  
5.5 Conclusion 
In general, it appears that the refined PUFA model designed here was an 
improvement on that in the original study. Even in the short-term, substantial 
positive effects on adiposity and lipid metabolism were observed, and the stimulation 
of energy expenditure suggested, in response to a high intake of the omega-3 FA, 
DHA. Whether its benefits are expressed behaviourally may require further work 
over longer periods of dietary exposure. This would also answer the question 
regarding whether or not the benefits observed are sustained. That this model showed 
changes equally in relation to the low-fat-fed control group and an isocaloric control 
group, indicates that the changes seen were attributable to the omega-3 FAs, not to 
differences in dietary energy content. As the changes were towards a lean, rather than 
obese phenotype, and moreover, below normal, it could be argued that the 
isoenergetic control was unnecessary. This is perhaps just as well, given the issue of 
suitability of coconut oil as an SFA source for obesity induction. The interesting 
question then becomes whether the high-DHA diet would prevent or reverse the 
detrimental effects of an effective high-SFA diet, perhaps the original, lard-based 
one, or perhaps one containing coconut oil, but allowed to be consumed for longer 
(Buchner et al., 2008; Lee et al., 2008). 
Thus, it could now be concluded with greater confidence that chronic 
consumption of a PUFA-enriched diet would improve energy metabolism. However, 
this would require confirmation over more prolonged feeding periods and inclusion 
of additional measures, such as adipokine and insulin levels in the blood.  This model 
could then be used to investigate changes in the hypothalamus, including cell 
proliferation, which underpin these responses. Initial tests in this area are presented 
and discussed in Chapter 7.   
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Stimulation and Observation of Hypothalamic Cell Proliferation  
6.1 Introduction  
6.1.1 Hypothalamic Neurogenesis  
Until recently, neurogenesis was thought to occur only in the embryo, but it is now 
also known to occur in the adult mammalian brain. The regions which show it 
include the subventricular zone (SVZ), dentate gyrus (DG) of the hippocampus 
(Jessberger & Gage, 2008; Miguad et al., 2010) and most recently, the hypothalamus 
(Kokoeva et al., 2007; Migaud et al., 2010; Yuan & Arias-Carrion, 2011) and 
circumventricular organs (Bennett et al., 2009). A variety of influences stimulate 
neurogenesis, ranging from the metabolic (e.g. diet, exercise) (Lindqvist et al., 2006; 
Rafalski & Brunet, 2011) to the environmental (e.g. scent communication, 
enrichment of surroundings) (Kempermann et al., 1997; Mak et al., 2007).  
The role of hypothalamic nuclei in regulating appetite and body weight is 
well-established. These nuclei include the appetite centre of the brain, the lateral 
hypothalamic area (LHA), and the satiety centre, the ventromedial hypothalamus 
(VMH). The arcuate (ARC) and paraventricular nuclei (PVN) also play critical roles 
in regulating appetite (Schwartz et al., 2000; Marx, 2003). The third ventricular 
cavity (3V), which is located between these feeding related nuclei in the 
hypothalamus, has an ependymal lining  comprised of a single layer of cells, some of 
which extend long processes into the hypothalamic parenchyma. These are known as 
tanycytes (Flament-Durand & Brion, 1985) and are morphologically similar to 
embryonic radial glia cells, which, in turn, have been regarded as similar to stem 
cells in the developing and adult central nervous system (Tamamaki et al., 2001; 
Antony et al., 2004; Mathew, 2008; Lee et al., 2012). These discoveries have 
prompted research which has confirmed that there are stem cells in the ependymal 
lining of the adult 3V which may originate from tanycytes, and that then migrate to 
the hypothalamic parenchyma, to become functional neurons in the adult rat (Xu et 
al., 2005; Mathew, 2008). These findings have substantiated the hypothalamus as a 
neurogenic niche.  
Mice with diet-induced obesity (DIO) show reduced hypothalamic cell 
proliferation (Kokoeva et al., 2005), but whether this is due primarily to elevated 
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concentrations of saturated fatty acids (SFAs) in the diet is unknown. These animals 
also show sustained weight loss when hypothalamic neurogenesis is stimulated by 
central administration of ciliary neurotrophic factor (CNTF). The fate of these 
proliferating cells, tracked by co-administration of bromodeoxyuridine (BrdU), is 
such that they differentiate into neurons and integrate into appetite-related 
hypothalamic nuclei, expressing the feeding-related neuropeptides, neuropeptide Y 
(NPY) and agouti-related peptide (AgRP). Indeed, inhibition of cell proliferation by 
administration of the mitotic inhibitor, Ara-C, reverses these effects. Thus, new 
neurons in the mouse hypothalamus become functionally mature and may play a role 
in body weight regulation (Kokoeva et al., 2005). 
6.1.2 Observing Hypothalamic Neurogenesis in vivo  
BrdU has been used in numerous studies of in vivo cell proliferation and 
neurogenesis (Abrous et al., 2005; Taupin et al., 2007). The administration of BrdU 
in adult rats has revealed high levels of mitotic activity in the 3V, including amongst 
tanycytes in the ependymal lining. It has allowed the fate of new neurons to be 
tracked, such that it is now known that they are integrated into the hypothalamic 
neural system by the formation of synapses and generation of neuropeptides (Xu et 
al., 2005). BrdU is traditionally delivered peripherally, by injection into the 
peritoneum (intraperitoneally, i.p.). Because i.p.-injected BrdU has to enter the 
circulation and cross the blood-brain barrier (BBB) before reaching its central 
targets, its concentrations may be  insufficient, at least at certain sites, to be 
detectably incorporated into the DNA of dividing cells (Kokoeva et al., 2007; 
Cifuentes et al., 2011). Studies have assessed the suitability of central BrdU delivery 
to better capture the proliferative potency of the adult hypothalamus, a brain region 
distant from the principal neurogenic sites (Koekova et al. 2007; Cifuentes et al., 
2011). It was found that the number of newborn cells detected in the hypothalamus 
was much higher after intracerebroventricular (i.c.v.) infusions of BrdU than after 
i.p. injections. Extended BrdU exposure methods, such as i.c.v. infusion (Kokoeva et 
al., 2007; Cifuentes et al., 2011) and incorporation into drinking water (Zhao et al., 
2003; Bennett et al., 2009), are often required when studying adult brain sites with a 
generally low mitogenic activity.  
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Both of these infusion methods were tested in studies carried out prior to 
those discussed here (Yon & Pickavance, unpublished observations). The drinking 
water method was found to be at least as effective as invasive approaches, despite 
potential issues surrounding transport and integrity of the tracer. As alluded to above, 
it is unknown whether BrdU is degraded in the gut, and whether its crossing of the 
gut lining or BBB are compromised, affecting the final concentration which reaches 
the brain tissue. These issues may be offset to an extent, however, by the increased 
frequency of administration which would effectively occur with this mode of 
delivery. In contrast, i.p. administration is usually carried out twice a day. This 
approach is also more compatible with other experimental manipulations, as it 
prevents the need for animal handling or surgical intervention, thereby minimising 
stress to the animal.  
6.1.3 Stimulation of Neurogenesis by Environmental Enrichment 
The functional significance of neurogenesis is still debated, but its occurrence in the 
hippocampus is associated with improved memory and spatial learning in laboratory 
rodents, in response to complex environmental enrichment. This usually includes 
multiple simultaneous interventions: toys, food treats and shared housing 
(Kempermann et al., 1997, 2002; Mak et al., 2007). These confounding factors mean 
the adoption of such an approach presents difficulties for scientists restricted to 
single-housing paradigms requiring a tidy cage environment (e.g. diet intervention 
studies). These factors also make it complicated to determine the independent 
contribution of each enrichment tool to the resulting neurogenesis.  
Under typical laboratory conditions, neurogenesis is minimal even in the 
hippocampus, a known region of rapidly dividing cells, and a stimulus appears to be 
required (Kempermann et al., 1997). This has been substantiated in-house, in studies 
carried out previously in singly housed male Wistar rats; in which baseline levels of 
proliferation were observed to be minimal (Yon & Pickavance, unpublished 
observations). In contrast, the endogenous cell cycle protein Ki-67 commonly used 
as a marker of cell proliferation is abundantly expressed in nuclei of the hippocampi 
of squirrels living wild, but it could be argued that these animals were actively using 
this structure to access memory of food caches (Amrein et al., 2004). The likelihood 
of this is further supported by findings that the induction of long-term potentiation 
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(signal transmission between two neurons that results from stimulating them 
synchronously) in the rat DG enhances proliferation of neural progenitor cells (Chun 
et al., 2006). Long-term potentiation is one of the major mechanisms that underpin 
learning and memory (Bliss & Collingridge, 1993; Cooke & Bliss, 2006). In-house 
preliminary investigations showed no significant change in Ki-67 expression in the 
brains of rats with DIO, compared to chow-fed controls, suggesting that a novel diet 
alone might not be a sufficient neurogenic stimulus (Yon & Pickavance, unpublished 
observations). In feeding studies, the laboratory rodent’s cage environment is 
typically impoverished and neurogenesis must be induced by stimulating tasks, or 
trophic or pharmaceutical intervention (Kokoeva et al., 2005).  
As feeding studies require individual housing and an uncluttered 
environment, a non-invasive method, such as a simple enrichment, by which to 
stimulate neurogenesis is preferable. Furthermore, if levels of neurogenesis could be 
raised by the presence of such a simple enrichment in the cage environment, would 
this intervention necessarily synergise with the dietary stimulus to raise neurogenic 
levels above this new ‘baseline’?  
6.1.4 Pilot Study Findings 
In order to address some of the questions raised, a pilot study (n=1/group) was 
conducted to investigate whether a non-invasive approach might achieve the same 
results as trophic intervention. The addition of a simple play tube to the home cage of 
each laboratory rodent, to act as an environmental enrichment factor, was of 
particular interest. This was because dietary intervention studies often require sparse 
cage environments and single-housing paradigms that make it difficult to provide 
sufficient enrichment without introducing variability that can confound results. This 
study showed, for the first time, that a PVC play tube placed in the cages of singly 
housed rats succeeds in dramatically stimulating neurogenesis, not only in the 
hippocampus, but also in the hypothalamus. These findings required further 
confirmation and were expanded upon in the study detailed here.  
Evidence of a neurobiological basis for welfare improvements in laboratory 
rodents, exposed to simple environmental enrichment, is lacking and would 
encourage more widespread take-up of enrichment approaches by scientists. 
Complex enrichment, which stimulates neurogenesis in group-housed mice 
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(Kempermann et al., 1997), is not possible where single-housing and uncluttered 
cage environments are required (e.g. feeding studies). The findings of such a study 
would also take a step toward mimicking more natural conditions in these otherwise 
environmentally compromised studies, thereby leading to more realistic and easily 
interpretable results in animal modelling studies. 
6.1.5 Relevant Circulating Factors  
Exposure to non-threatening environments is now also thought to lead to increased 
neurogenesis (Olson et al., 2006), whereas animals exposed to stressful situations 
show a rapid decrease in cell proliferation (Warner-Schmidt & Duman, 2006). 
Corticosterone (CORT) is a steroid hormone produced in the adrenal glands and 
involved in the control of stress. Recent studies have suggested that environmental 
enrichment can lessen negative physiological responses to stressful situations (Belz 
et al., 2003; Fox et al., 2006) and therefore, reduce circulating concentrations of 
CORT (Belz et al., 2003). Social isolation is also considered a stressor for rodents, as 
they are commonly group-housed, and therefore, this may also affect levels of cell 
proliferation in the brain (Wu & Wang, 2010). In order to investigate these effects, 
plasma concentrations of circulating CORT were measured.   
Brain-derived neurotrophic factor (BDNF) is a neurotrophin which promotes 
neuronal differentiation, survival during early development, adult neurogenesis, and 
neural plasticity (Chao et al., 2006; Noble et al., 2011; Ooi et al., 2012). BDNF is 
expressed and present in high circulating concentrations in the hippocampus and 
cerebral cortex of the brain. BDNF and its receptor, TrkB, are also extensively 
expressed in neurons of the hypothalamus (Wu et al., 2004a; Wu et al., 2004b; 
Webster et al., 2006; Godar et al., 2011; Noble et al., 2011). The involvement of 
BDNF in neural plasticity and neurogenesis within the hippocampus is known to 
influence learning and memory, but less is known about how it influences 
hypothalamic neurogenesis (Noble et al., 2011). In order to investigate whether 
circulating concentrations of BDNF would correlate with cell proliferation, to act as 
an easy-to-measure surrogate marker for future studies, concentrations of circulating 
BDNF were measured here.  
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6.1.6 Research Question  
Is a simple physical enrichment tool sufficient to stimulate central cell 
proliferation in singly housed rats?  
6.1.7 Pilot Study 
6.1.7.1 Aims 
To address this question by assessing the quantity of proliferating cells observed in 
central neurogenic niches of rats housed with a single play tube each, compared to 
those without play tubes. 
6.1.7.2 Expected Outcomes  
In rats exposed to play tubes, enhanced cell proliferation would be observed in the 
hypothalamus and hippocampus.  
6.1.8 Full Study  
6.1.8.1 Aims 
1. To statistically confirm the above findings,  and  
2. To test whether any observed reduction in cell proliferation over time was 
due to habituation to the enrichment tool.  
6.1.8.2 Expected Outcomes  
In rats exposed to play tubes, 
1. enhanced cell proliferation in the hypothalamus and hippocampus was a 
reproducible finding, and 
2. proliferation levels which had fallen as a result of habituation would be 
restored by introduction of a new tube (stimulus renewal). 
A technical issue with this project aim was raised early on: concurrent attempts to 
optimise the method uncovered difficulties in dual-labelling of BrdU and neuronal 
markers; thus, within the time constraints of the project, only cell proliferation was 
examined (not neurogenesis per se). 
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6.2 Materials & Methods  
6.2.1 Animals and Treatment 
Age-matched adult male Wistar rats (~250 g) were used in both pilot and full studies. 
In the pilot study, a PVC play tube was introduced to the cage of an experimental rat, 
but not to that of its control (‘+tube’ vs. ‘-tube’; n=1/group), for 7 days, while BrdU 
(Sigma, Dorset, UK) was administered in the drinking water (1 mg/ml). Rats were 
perfuse-fixed under deep anaesthesia and brains dissected free for histological 
processing.   
In the full study, rats were stratified by body weight and randomly assigned 
to six groups (n=6/group) (Fig. 6.1). Tube exposure periods of 7, 21 and 28 days 
were selected to examine the time course of effects of simple physical enrichment on 
cell proliferation and neurogenesis in the proliferative regions observed in the pilot 
study (3V/hypothalamus and DG). Exposure periods would also enable observation 
of both proliferating cells (7 days), young (21 days) and mature neurons (28 days). 
Acute (7-day) exposure was included to determine if pilot findings (increased 
proliferation in response to enrichment; Fig. 6.2) could be replicated and if so, 
increased sample size would allow for statistical analysis. This could then be 
compared to the effects of chronic (21-day) exposure, where it was predicted that 
proliferation might be reduced, as a result of habituation to the tube. A link between 
reduced neurogenesis and habituation to neurogenic stimuli has been shown 
previously (Veyrac et al., 2009), and was therefore suspected as a possible reason for 
conflicting results in animals examined concurrently with pilot animals, in which 
proliferation was minimal after exposure to tubes for 8 weeks (diet study described in 
Chapter 7). Therefore, the introduction of a fresh tube (renewal of stimulus) at 21 
days, for an additional 7 days, was included as an experimental group (Group 6; see 
Fig 6.1) to investigate whether the new stimulus restored neurogenic levels. 
Olfactory stimuli from rodent con-specifics are well-known to influence 
neurogenesis (Mak et al., 2007; Veyrac et al., 2009). Therefore, tubes were first 
cleaned to eliminate any previous animal scent, which could confound results by 
acting as an additional form of enrichment and therefore, stimulus to neurogenesis.  
Body weight was measured weekly, and food and water intake daily, to 
monitor any changes in health as a result of BrdU consumption. Rats were perfuse-
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fixed and brains removed, as for the pilot study. Spleens were also removed to 
provide positive control tissue for BrdU uptake. Details of general husbandry and 
maintenance and termination and tissue harvesting protocols are further detailed in 
Chapter 2, Sections 2.1.6 and 2.5. 
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Figure 6.1. Study design and expected outcomes for effects of simple physical enrichment on cell proliferation. Blood sampling was kept to a minimum 
(terminal sample only), to avoid unnecessary stress effects on neurogenesis. Plasma concentrations of corticosterone (CORT) were measured as an indirect 
index of stress. It was predicted that the stress of prolonged social isolation of single-housing in the 21-day groups might elevate CORT concentrations, 
compared to 7-day isolation. At study end, animals were perfuse-fixed and it was planned that brains would be examined between groups for changes in 
immunohistochemical evidence of cell proliferation (BrdU+) and new neurons (DCX+). Terminal plasma concentrations of BDNF were also determined, as a 
potential surrogate marker of neurogenesis. 
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6.2.2 Blood Chemistry 
Repeated blood sampling was avoided, as stress is known to inhibit neurogenesis 
(Fox et al., 2006; Warner-Schmidt & Duman, 2006). After an overnight fast, and 
under brief gaseous anaesthesia, blood samples were collected from the tail vein and 
plasma separated by centrifugation. As an indirect measure of stress, possibly arising 
from prolonged social isolation (Stranahan et al., 2006), plasma concentrations of 
corticosterone (CORT), also known to be associated with alterations in neurogenesis 
(Olson et al., 2006), were determined. BDNF concentrations were also measured to 
determine whether they might correlate with neurogenic levels (Chao et al., 2006; 
Noble et al., 2011; Ooi et al., 2012). Both were measured by ELISA, according to 
manufacturers’ protocols, as detailed in Chapter 2, location 2.6.   
6.2.3 Histology 
For both studies, after a three-hour post-fixation and overnight immersion in 
cryoprotectant at 4°C, hypothalamic blocks isolated from brain were sectioned at a 
thickness of 50 µm on a freezing microtome and processed free-floating. Spleen 
tissue, a positive peripheral control for cell proliferation, was processed identically 
throughout and at the same time. Brain sections were collected throughout the 
3V/hypothalamic region and the hippocampus, within which the DG acted as a 
positive internal control for cell proliferation. Prior to immunolabelling, sections 
underwent an acid pre-treatment to denature the DNA. They were incubated in 1M 
HCl for 30 minutes at 37°C to allow antibody access to BrdU incorporated into 
DNA. The acid was then neutralised by rinsing the sections three times in 10 mM 
PBS with constant agitation (adapted from Wojtowicz & Kee, 2006).  
Investigations of cell proliferation were carried out using an antibody raised 
against BrdU. Though proliferation was extensive in the pilot study, it was scant in 
the full study (Figs. 6.2 & 6.3).  To confirm whether this was due to failure of BrdU 
uptake, antibodies raised against endogenous markers of cell proliferation (Ki-67 and 
PCNA) were applied to adjacent sections. Primary antibody incubations were carried 
out with mouse anti-BrdU (1:50; Roche), rabbit anti-Ki-67 (1:100; Vector Labs) or 
mouse anti-PCNA (1:100; Santa Cruz) at 4°C overnight. This was followed by one-
hour incubations with red fluorophore-conjugated secondary antibodies raised in 
appropriate host species [DyLight 594 (1:500); Jackson ImmunoResearch 
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Laboratories] at room temperature in the dark. Sections were washed in 10 mM PBS 
between each step and finally mounted onto chrome-alum-coated glass slides. After 
air drying overnight, anti-fade reagent (Vector Laboratories, Burlingame, USA) and 
coverslips were applied. Full details of antibodies and staining procedures are given 
in Chapter 2, Section 2.10.4. 
6.2.4 Image Analysis  
Immunostaining was examined under an epi-fluorescent microscope (Zeiss Axio 
Imager. M1), and images captured by digital microphotography (Hamamatsu ORCA 
I-ER digital camera, Hamamatsu Photonics, Welwyn Garden City, Herts) and image 
analysis program (AxioVision, Zeiss Imaging Systems). Photographic panels were 
created using Microsoft PowerPoint 2007.  
6.2.5 Statistical Analysis 
Data are expressed as mean ± SEM. Differences between groups over a time course 
were determined using 2-way ANOVA with repeated measures and post-hoc 
Bonferroni correction and considered significant at p<0.05. In all instances 
comparisons demonstrated roughly equal variation and therefore the sphericity 
criteria were met and consequently variation data is not presented here. Statistical 
analysis was carried out using software SPSS v19. Justification for use of all 
statistical analyses can be found in Chapter 2 section 2.11. 
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6.3 Results  
6.3.1 Pilot Study 
Seven days of simple environmental enrichment with a single PVC play tube (+ 
tube) dramatically increased cell proliferation in the lateral wall lining of the third 
ventricle, as well as in the adjoining medial hypothalamic parenchyma (Figs. 
6.2A&B; 9±2 vs. 82±6 cells per field of view). Proliferation was also markedly 
increased in the dentate gyrus of the hippocampus (Figs. 6.2C&D; 3±3 vs. 68±9 cells 
per field of view). As this is an inherently proliferative region, it was investigated as 
a positive internal control. Extensive BrdU immunoreactivity here indicated, 
therefore, that BrdU uptake into the brain had been successful and staining 
conditions optimal, validating expression in the hypothalamic region. 
 
Figure. 6.2. Pilot study. Representative photomicrographs of cell proliferation in response 
to 7-day cage enrichment with a play tube (‘+tube’). Control rats did not receive a tube       
(‘-tube’; n=1/group). Proliferating cells show BrdU-positive immunoreactivity in cell nuclei 
(red fluorescent profiles; examples indicated by arrows). Extensive proliferation was 
stimulated by tube presence in the lateral wall 3V lining, medial hypothalamus (A, B) and 
dentate gyrus of the hippocampus (positive control; C, D). Abbreviations: 3V = third 
ventricle, DG = dentate gyrus, MH = medial hypothalamus. 
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6.3.2 Full Study  
In contrast to findings in the pilot study, the addition of a play tube to rat cages for 7, 
21 or 28 days did not stimulate cell proliferation in hypothalamic or hippocampal 
regions (Figs. 6.3A-D). Positive BrdU immunoreactivity was observed in the roof of 
the third ventricle, but this was very sparse, occurring to a similar minimal extent in 
all exposure groups, irrespective of tube presence (Fig. 6.4A, D). It was also 
observed in nuclei of epithelial cells comprising the pia mater, lining the outside 
surface of brain sections. This confirmed that BrdU had been administered in 
sufficient concentration that a high-turnover tissue in very close proximity to the 
brain had taken up the tracer, and that anti-BrdU immunolabelling had been 
successful. However, it did not prove that BrdU had crossed the BBB, and therefore, 
confirmation was sought that the lack of specific staining reflected a real absence of 
proliferation. Thus, immunoreactivity against the endogenous proliferation markers, 
Ki-67 and PCNA, was examined, but also found to be equally scant in all groups 
(Figs. 6.4B, C, E & F). Spleen tissue, the cells of which are also quickly self-
replicating, was examined as an additional positive control. Specific staining with all 
antibodies in this tissue indicated the success of peripheral BrdU uptake and the 
adequacy of the immunohistochemical technique as a whole.  
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Figure. 6.3. Full study. Representative photomicrographs of time course of cell proliferation 
in response to cage enrichment with a play tube (‘+tube’), in regions matching those 
observed in the pilot study. Control rats did not receive a tube (‘-tube’; n=6/group). As all 
periods of tube exposure (7, 21 and 28 days) produced similar results, only photos of 7-day 
findings are presented. Proliferating cells show BrdU-positive immunoreactivity in cell 
nuclei (red fluorescent profiles; examples indicated by arrows). In contrast to pilot study 
findings, tube presence failed to stimulate proliferation in the lateral wall 3V lining and 
medial hypothalamus (A, B) or dentate gyrus of the hippocampus (positive control; C, D). 
BrdU uptake was confirmed, however, in the pia mater [(E, F); positive control]. 
Abbreviations: 3V = third ventricle, DG = dentate gyrus, MH = medial hypothalamus. 
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Figure. 6.4. Full study.  Representative photomicrographs of cell proliferation survey in response to cage enrichment with a play tube (‘+tube’).  Control rats 
did not receive a tube (‘-tube’; n=6/group). As all periods of tube exposure (7, 21 and 28 days) produced similar results, only photos of 7-day findings are 
presented. Proliferating cells show BrdU- (A, D), Ki-67- (B, E) and PCNA-positive immunoreactivity (C, F) in cell nuclei (examples indicated by arrows). 
Although sparse proliferation observed as BrdU-positive cells was confirmed by endogenous markers Ki-67 and PCNA, none indicated that tube 
presence had a stimulatory effect. BrdU uptake and proliferation in general were confirmed, however, in spleen (G, H, I; peripheral positive control tissue).  
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Analysis by two-way ANOVA with repeated measures demonstrated no 
differences in circulating CORT concentrations between groups (F (1, 10) = 0.4400, 
p=0.5221), over time (F (2, 20) = 2.556, p=0.1027) or any interaction between 
enrichment and time (F (2, 20) = 1.801, p=0.1909). Therefore, the presence of the 
play tube had no effect on circulating CORT concentrations at any of the exposure 
times examined (p>0.05; Fig. 6.5).  
 
 
Figure 6.5. Time course of plasma corticosterone concentrations in rats with or without cage 
enrichment in the form of a play tube (+tube). There was no effect of tube exposure at 7, 
21 or 28 days. Values are expressed as mean ± SEM; n=6/group; all p>0.05 compared to 
controls (-tube) (2-Way ANOVA with repeated measures). 
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Analysis by two-way ANOVA with repeated measures demonstrated no 
differences in circulating BDNF concentrations between groups (F (1, 10) = 0.05642, 
p=0.8170) or any interaction between enrichment and time (F (2, 20) = 0.4287, 
p=0.6572), but it did detect a difference over time (F (2, 20) = 4.649, p=0.0220). 
Therefore, the presence of the play tube had no effect on circulating BDNF 
concentrations but BDNF concentrations in both groups increased over time 
irrespective of enrichment (p>0.05; Fig. 6.6).  
 
Figure 6.6. Time course plasma BDNF concentrations in rats with or without cage 
enrichment in the form of a play tube (+tube).  There was no effect of tube exposure at 7, 
21 or 28 days. Values are expressed as mean ± SEM; n=6/group; all p>0.05 compared to 
controls (-tube) (2-Way ANOVA with repeated measures). 
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6.4 Discussion 
6.4.1 Pilot Study 
The pilot study described here demonstrated that simple environmental enrichment in 
the form of a play tube can stimulate cell proliferation within regions of the medial 
hypothalamus and lining of the third ventricle, regions of slow cell turnover, as well 
as in the dentate gyrus of the hippocampus, a prolific site, in singly housed rats. 
Assuming that adult neurogenesis is beneficial, this novel result provides the first 
evidence that improvements to laboratory rodent welfare are reflected at the cellular 
level. Nonetheless, this result was somewhat surprising, as the literature suggests that 
to stimulate cell proliferation in the rodent hypothalamus or hippocampus, a trophic 
or pharmaceutical intervention may be required (Yoshimizu & Chaki, 2004; 
Kokoeva et al., 2005). In addition, the findings were treated with caution, as only a 
single experimental and control animal had been tested. In order to corroborate the 
findings of the pilot study, a full study with appropriate statistical power was 
conducted.  
6.4.2 Full Study 
In contrast to findings in the pilot study, the addition of a play tube to rat cages for 7, 
21 and 28 days had no effect on cell proliferation in the medial hypothalamus, lining 
of the third ventricle or dentate gyrus. Positive immunoreactivity in control tissues 
confirmed that BrdU had been successfully taken up, and that immunohistochemical 
techniques had worked. Therefore, the general absence of BrdU-positive cells in 
regions of interest demonstrated that the play tube was an insufficient stimulus to cell 
proliferation here and therefore, that the findings of the pilot study were not 
reproducible. As such, the additional investigations planned to test for any observed 
reduction in cell proliferation over time could not be answered. In hindsight, it would 
have been useful to have collected spleen and pia mater from animals in the pilot 
study to determine the levels of proliferation that could have been expected under 
successfully stimulated conditions; i.e. it could be that although there was more 
proliferation here in positive control tissues than in regions of interest, the extent of 
staining did not reflect ‘normal’ levels resulting from optimal BrdU uptake. 
However, given the striking results in the pilot study, this precaution had not been 
thought necessary. The inability to reproduce the findings of the pilot study may be 
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due to the rats being of an outbred strain, with inherent genetic variation, as 
discussed in Chapter 3, Section 3.5 (Koolhass, 2010).  
Seemingly paradoxically, some studies have shown that there is reduced cell 
proliferation in the brains of mice exposed to more complex enrichment. In the work 
of Veyrac et al. (2009), this involved the use of odours in a tea ball suspended from 
the cage lid and replaced every 24 hours. This reduction was likely due to 
habituation. This evidence supports the likelihood that the play tube alone was 
insufficient in enriching the cage environment in such a way that influenced central 
proliferation. A variety of additional items, including tubes, wheels and materials 
(paper and cardboard) would need to be added to do so (Kempermann et al., 1997; 
van Praag et al., 2000; Madroñal et al., 2010), even before considering habituation. 
Environmental enrichment is commonly defined as a mixture of complex inanimate 
and social stimulation (Rosenzweig et al., 1978), including housing in groups, large 
and complex cage systems, and a variety of objects. All of this combined is thought 
to increase hippocampal neurogenesis (Kempermann et al., 1997; Nilsson et al., 
1999; van Praag et al., 2000; Kempermann et al., 2002; Olson et al., 2006) relative to 
standard housing conditions. The addition of a running wheel to the cage has been 
associated with increased numbers of neurons within the DG of adult rats (van Praag 
et al., 1999a; van Praag et al, 1999b; Farmer et al., 2004). Studies have shown that 
social isolation will delay the positive effects on adult neurogenesis caused by the 
addition of a running wheel. In one particular study, enhancement of neurogenesis 
eventually occurred in  individually housed runners, but only after a considerably 
longer time period than for group-housed animals (48 days instead of 12) (Stranahan 
et al., 2006). A ‘control’ group of rats given extensive environmental enrichment 
could have been used in the current study to establish a sense of scale when looking 
at the effect of environmental enrichment on cell proliferation. 
6.4.3 Circulating CORT Concentrations   
Circulating concentrations of CORT were examined as a simple marker of 
anxiety/stress (De Souza & Loon, 1982). Had reductions in proliferation been 
observed at any point or in any group, this would have suggested an association 
between the two phenomena, as indeed, stress is known to inhibit neurogenesis (Fox 
et al., 2006; Warner-Schmidt & Duman, 2006). Irrespective of the presence of 
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enrichment all animals groups at all time points with and without a play tube showed 
similar concentrations of circulating CORT.   
Recent studies have suggested that environmental enrichment can lessen 
negative physiological responses to stressful situations (Belz et al., 2003; Fox et al., 
2006). Studies have shown that rats housed with environmental enrichment in the 
form of rubber toys and nest materials have lower plasma CORT concentrations than 
those housed without (Belz et al., 2003). Stress responses are mediated by the 
hypothalamic-pituitary-adrenal (HPA) axis, and enrichment is thought to decrease 
activity of the HPA and therefore, to decrease CORT concentrations (Warner-
Schmidt & Duman, 2006). Exposure to non-threatening environments is now also 
thought to lead to increased cell proliferation in the hippocampus (Olson et al., 
2006), whereas animals exposed to stressful situations show a rapid decrease in cell 
proliferation (Warner-Schmidt & Duman, 2006). However, as CORT concentrations 
were unchanged here in rats with play tubes, it may be that this intervention is not 
sufficient to reduce stress, or that all the animals, including controls, were already 
experiencing minimal stress possibly as a result of single housing. Although this 
result is supported by some findings in the literature, it directly opposes that of 
others, and the current consensus is that results are inconclusive (Smith & Corrow, 
2005). This is mainly due to the extreme variability in enrichment methods that are 
carried out in different research groups (Sztainberg & Chen, 2010). Several groups 
have provided animals with wheels to encourage exercise, which in turn, has reduced 
baseline CORT concentrations (Olsson & Dahlborn, 2002), as well as hippocampal 
neurogenesis (Kobilo, et al., 2011). This further supports the idea that the play tube 
alone was insufficient enrichment. Rats kept in enriched environments can have 
higher resting plasma CORT concentrations at the first instance of handling, 
followed by their rapid extinction upon exposure to repeated handling (Moneck et 
al., 2004). Although there was minimal handling involved in this study (e.g. for 
maintenance only), it is possible that this, and the daily interaction when weighing 
food and water for health assessment, was enough to induce this extinction response, 
as stress responses have been shown to recover rapidly after brief handling periods, 
causing a reduction in sensitivity to parameters such as CORT concentrations 
(Konkle et al., 2010). One study suggested that if rats were kept in a stress-free 
environment, the presence of environmental enrichment would have no link with 
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physiological status, such as those reflected in CORT concentrations (Morley-
Fletcher et al., 2003). The lack of effect observed here suggests that environmental 
enrichment may only be important in recovery from acute stressful stimuli 
(Benaroya-Milshtein, et al., 2004; Moncek, et al., 2004). An additional point for 
consideration is the use of the Wistar rat strain in this particular study. A review of 
existing literature reveals that there have been few behavioural investigations into the 
effects of environmental enrichment on stress responses. The few that have been 
carried out have favoured the use of Sprague-Dawley and Long Evans rats over the 
Wistar, and have produced inconsistent results at best (Konkle et al., 2010). Wistars 
may have been avoided in these studies because they are known to be an inherently 
anxious strain (Simpson & Kelly, 2011); a characteristic which could explain 
generally inhibited cell proliferation, although the normal CORT levels observed 
would dispute this. Some studies have shown no differences in CORT concentrations 
for Long-Evans and Lister Hooded rat strains housed in standard and 
environmentally enriched conditions after exposure to stress (Francis et al., 2002; 
Schrijver et al., 2002; Morley-Fletcher et al., 2003), whereas others have shown 
inconsistent results under conditions of enrichment; i.e. reductions in Sprague–
Dawley rats (Belz et al., 2003), and increases in Wistar rats (Moncek et al., 2004). 
These differences are likely due to strain-specific responsivity to stress. This 
specificity has been discovered when examining effects of enrichment on weight 
gain (where weight loss indicates stress): group-housed and isolated control Wistar 
rats showed no differences in weight gain (von Frijtag et al., 2000), whereas physical 
and social enrichment reduced weight gain in Sprague-Dawley rats (Pena et al., 
2006). This suggests that Wistar rats show less sensitivity to stress, but contradicts 
the findings above (Simpson & Kelly, 2011). Perhaps stress responses are dependent 
on the interaction of strain with the specific stress stimulus. Overall, therefore, in 
order to assess the effects of enrichment thoroughly, future studies could be designed 
to examine other indices of stress apart from circulating CORT concentrations, and 
in several rat strains; e.g. behavioural (anxiety) tests, such as the open field or 
elevated plus maze test (Kulesskaya et al., 2011).  
6.4.4 Circulating BDNF Concentrations  
Environmental enrichment increases the expression of several different neurotrophic 
factors that have been implicated in cell proliferation and neuronal differentiation 
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and survival, including BDNF and the corresponding receptor, TrkB (Pham et al., 
1999; Young et al., 1999; Ickes et al., 2000; Gobbo and O’Mara, 2004). Here 
however, there was an early gradual rise in circulating concentrations of BDNF 
independent of tube presence. This leads to the speculation that, as BDNF is involved 
in the process of learning and memory formation (Dragunow, 1996; Yamada et al., 
2002), rodents showed an increase in these initial weeks due to exploration of their 
new cage environment (after transport and acclimatization) or to any other factor that 
both groups may have experienced that had not been controlled for, such as reduced 
cage size and social contact (after group housing during acclimatization), or any 
unidentified changes to experimental conditions. 
Some research has shown that the addition of environmental enrichment, such 
as a running wheel, to the cage increases expression of BDNF in the brain (Neeper & 
Gomez-Pinilla, 1996), but that plasma concentrations are often unaffected (Vedovelli 
et al., 2011), as seen here. Studies which investigated the effects of environmental 
enrichment on BDNF expression in the hippocampus and serum of rats exposed to 10 
weeks of standard or enriched conditions (increased opportunity for physical 
exercise) revealed  that animals maintained in the enriched condition showed no 
alterations in central or peripheral BDNF concentrations (Vedovelli et al., 2011). 
Like environmental enrichment, exercise can also increase concentrations of BDNF 
(Adlard et al., 2004; Farmer et al., 2004; Vaynman et al., 2004a), as shown by the 
introduction of a running wheel (Neeper & Gomez-Pinilla, 1996) or enforced swim 
test (Badowska-Szalewska et al., 2010). The level of BDNF expression is directly 
related to the amount of exercise carried out (Adlard et al., 2004). This suggests that 
environmental enrichment which increases exercise (e.g. a running wheel) will 
promote concentrations of BDNF above those associated with other forms of 
enrichment.    
6.4.5 Corticosterone & Brain-Derived Neurotrophic Factor 
Physiological and pharmacological increases in plasma CORT concentrations have 
been shown to reduce BDNF expression and thereby, increase hippocampal neuronal 
loss following brain injury. Stress, or the direct administration of CORT, has been 
shown to decrease BDNF gene expression and circulating concentrations in the rat 
hippocampus (Smith et al., 1995). On the other hand, the removal of circulating 
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CORT by adrenalectomy increases the levels of BDNF mRNA in rat hippocampus 
(Chao et al., 1998), which is then reversed upon direct administration of CORT 
(Schaaf et al., 1998). Therefore, these two measures are inversely related, but the 
mechanism behind this is, as yet, unexplained. This relationship was suggested here: 
as CORT concentrations decreased between days 7 and 21, BDNF concentrations 
increased. The chronic forced swim test (FST) combines factors such as the novelty 
effect of water and the physiological stressors of exercise and swimming. For rats, 
this represents a stressful situation that they may not frequently encounter in their 
natural environment. Studies have shown a decreased density of BDNF- and TrkB-
immunoreactive neurons in the hippocampus of juvenile rats, which is linked with 
increased CORT concentrations (Badowska-Szalewska et al., 2010). This study also 
investigated the effects of the FST on both juvenile and aged rats; however, there 
were no changes in the density of BDNF- or TrkB-expressing neurons in aged rats, 
suggesting that juvenile rats are more sensitive to stress than aged rats. The rats used 
in the study presented here were young adults (8 weeks old), having reached sexual 
maturity (Koolhaas, 2010), and therefore, may have grown beyond any such window 
of sensitivity.  
6.5 Conclusion 
This study aimed to address whether simple physical enrichment would stimulate cell 
proliferation in the hypothalamus of singly housed rats. The pilot study suggested 
that the presence of a play tube may be sufficient to stimulate cell proliferation in the 
hypothalamus and hippocampus; however, these results were non-reproducible in the 
full study. As a result, it was impossible to determine any effects of habituation.  
There are several possible explanations for the lack of effect on cell 
proliferation and related circulating factors, but insufficient enrichment seems to be 
the most likely candidate. However, as the influences on neurogenesis are many, re-
testing the original hypothesis would require the careful design of a multifactorial 
study to control for each of these factors individually.   
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Effects of High-PUFA Feeding on Hypothalamic Cell Proliferation 
and Myogenesis  
7.1 Introduction  
7.1.1 Background  
The current obesity epidemic can be largely attributed to excessive consumption of 
foods high in sugar (refined carbohydrates) and saturated fatty acids (SFAs), 
resulting in a range of cardiovascular and metabolic disorders (Kanoski & Davidson, 
2011), as well as decreased neurogenesis in the brain (McNay et al., 2012). These 
can be attenuated, if not reversed, upon consumption of polyunsaturated fatty acids 
(PUFAs; Poudyal et al., 2011). Obesity is now increasingly being linked to depressed 
mood, impaired cognition and neurodegenerative diseases, such as Alzheimer’s 
(Barnes & Yaffe, 2011). Conversely, dietary interventions with omega-3 FAs have 
been shown to counteract or prevent these conditions (Bourre, 2005; Hashimoto & 
Hossain, 2011). The use of animal models has shed some light on possible 
underlying mechanisms to explain these associations (Gomez-Pinilla, 2011). Adult 
neurogenesis has been proposed as an “interface” between energy metabolism and 
cognition (Vaynman & Gomez-Pinilla, 2006), but it is only recently that researchers 
have begun to identify the factors which may mediate this relationship; for example, 
changes in circulating concentrations of appetite-regulators, such as the adipokine 
leptin (Park et al., 2011) and the neurotrophin, brain-derived neurotrophic factor 
(BDNF) (Bousquet et al., 2009). In addition, to date, these relationships have been 
only examined in response to high-SFA consumption. Currently, there is no direct 
evidence that known neuroprotective effects of PUFAs are mediated through changes 
in energy metabolism.  
7.1.2 Effects of High-Fat Diet on Neurogenesis  
7.1.2.1 Saturated Fatty Acids 
Studies have shown that rats fed a diet high in SFAs for only nine days displayed 
reduced memory ability in the radial arm maze paradigm (Murray et al., 2009), and 
after only 72 hours, made significantly more memory errors when learning about 
spatial cues (Kanoski and Davidson, 2010). Both studies reported that memory 
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deficits occurred prior to the development of greater body weight gain (Murray et al., 
2009; Kanoski and Davidson, 2010). This finding suggests that the short-term 
detrimental cognitive effects of consuming a diet high in SFAs can occur in the 
absence of differences in body weight. The results seen in these studies were 
underpinned by impaired hippocampal-dependent learning and memory via 
decreased cell proliferation in the same area (Kanoski and Davidson, 2011) and 
impaired blood-brain barrier (BBB) function (Davidson et al., 2012). High-fat diet 
fed rats showed reduced expression of several proteins that are essential to BBB 
integrity and displayed elevated concentrations of a dye which is normally prevented  
from crossing the BBB in the hippocampus (Wolburg & Lippoldt, 2002). It was 
suggested that the consumption of a diet high in SFAs contributed to hippocampal 
inflammation, as a consequence of BBB permeability, via increased concentrations 
of peripheral proinflammatory cytokines, thus, making the hippocampus more 
accessible to these inflammatory agents (Fung et al., 2012), as well as interfering 
with leptin transport across the BBB (Hsuchou et al., 2010). The inability of leptin to 
cross the BBB under these conditions has been linked with reduced hippocampal 
memory and learning function (Farr et al., 2006). This impairment has been 
attributed to insufficient concentrations of leptin for the facilitation of long-term 
potentiation, a process which is known to enhance cell proliferation in the 
hippocampus (Chun et al., 2006). 
Some studies have shown that rats fed a diet high in SFAs exhibit reduced 
cell proliferation and neurogenesis within the hippocampus (Lindqvist et al., 2006; 
Hwang et al., 2008; Park et al., 2010; McNay et al., 2012). In the majority of these 
studies, body weight data were not collected. However, even in the one study where 
rats displayed increased adipose accumulation in response to the high-fat diet,  this 
was not significant and did not result in overall body weight gain; therefore, the 
reduction in neurogenesis was independent of adiposity and was related to dietary fat 
per se (Lindqvist et al., 2006). Research has also shown that mice with diet-induced 
obesity (DIO) display reduced hypothalamic neurogenesis, but that central 
administration of ciliary neurotrophic factor (CNTF) induces cell proliferation in 
feeding centres, and subsequently weight loss (Kokoeva et al., 2005). Furthermore, 
some of these newborn cells within the hypothalamus express neuronal markers and 
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demonstrate functional phenotypes relevant to energy homeostasis (Kokoeva et al., 
2005; McNay et al., 2012).  
7.1.2.2 Polyunsaturated Fatty Acids 
In contrast, it is known that animals fed a diet high in PUFAs, specifically, the 
omega-3 FA, docosahexaenoic acid (DHA), demonstrate an increase in cell 
proliferation and adult neurogenesis within the dentate gyrus of the hippocampus 
(Kawakita et al., 2006; Beltz et al., 2007; Ma et al., 2008; Dyall et al., 2010). 
However, the mechanisms behind this are still not fully understood. In adult rats, 
learning and cognitive behaviour are linked to brain DHA status, which, in turn, is 
related to the concentrations of the dietary omega-3 FAs consumed (Moriguchi et al., 
2000). Furthermore, the administration of DHA is commonly thought to enhance 
learning in both young and aged rats (Gamoh et al., 1999, 2001), and protects against 
the decline of learning and memory ability in rodent models of Alzheimer’s disease 
(Hashimoto et al., 2002; 2005; Lim et al., 2005). It has also been shown to protect 
neurons from the effects of oxidative stress (Hossain et al., 1998, 1999; Hashimoto et 
al., 2002, 2005), although the mechanisms behind these beneficial effects have yet to 
be determined. As neurogenesis has been shown to play a critical role in learning and 
memory processes (Schinder and Gage, 2004; Becker, 2005), some studies have 
suggested that the beneficial effects of DHA on learning could, in part, be due to its 
ability to increase neurogenesis in the brain (Katakura et al., 2009).  
Recent evidence has suggested that a link between omega-3 FAs and the 
BDNF/TrkB signalling pathway may explain the neuroprotective effects of omega-3 
consumption in rodent models in neurodegenerative conditions (Logan, 2003; Wu et 
al., 2004; Rao et al., 2007; Levant et al., 2008). These protective mechanisms may 
include the modulation of signal transduction pathways and the reduction of 
inflammatory cytokines (Stoll et al., 1999; Balanzá-Martínez et al., 2011). The 
consumption of diets high in SFAs is known to decrease BDNF expression in the 
brain and circulating plasma concentrations (Stranahan et al., 2008); conversely, the 
consumption of PUFAs is thought to increase them (Wu et al., 2004; Bousquet et al. 
2009). Furthermore, altered meal patterns such as dietary restriction can stimulate 
neuronal plasticity, including neurogenesis, through the stimulation of BDNF 
(Mattson et al., 2003). 
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Therefore, to date, there has been direct evidence for enhanced hippocampal 
neurogenesis due to PUFA consumption, but only indirect evidence for enhanced 
neurogenesis in the hypothalamus. Possible links between the BDNF in the 
regulation of feeding behaviour, and the role of PUFAs in enhancing neurogenesis 
suggest that this neurotrophin could act as an easily measurable circulating marker of 
this relationship. 
7.1.2.3 Additional Dietary Factors Affecting Neurogenesis 
A comparative reduction in energy intake has many health benefits and has been 
shown to offer protection against neuronal loss via increased adult neurogenesis 
(Levenson & Rich, 2007). It is known that neurogenesis decreases with age; 
therefore, as PUFAs have been shown to enhance learning during old age (Willis et 
al., 2009); it may be as a result of increased neurogenesis. Previous work has been 
carried out comparing different types of dietary supplementation, including high-
carbohydrate vs. high-fat (Chavez et al. 1998), high-fat vs. high-sugar (Archer et al., 
2004) and omega-3 diets (Huang et al., 2004) and studies of neurogenesis (Lindqvist 
et al., 2006; Hwang et al., 2008; Park et al., 2010; McNay et al., 2012) in several 
rodent models. However, there is still a need for clarification of the particular 
neuronal populations affected by dietary changes, and the processes involved.  
7.1.3 Environmental Enrichment and Neurogenesis 
As described previously, in Chapter 6 (Section 6.3.1), the effect of adding a single 
play tube to each laboratory rat’s cage was piloted and shown to increase cell 
proliferation above baseline levels. However, this result was irreproducible, a fact 
which did not become apparent until dietary studies, detailed in Chapters 3 and 4, 
were underway and the concurrent expanded enrichment study had been completed 
(Chapter 6, Section 6.3.2). Therefore, this simple intervention had been applied 
before gaining a full appreciation of the likely outcomes and associated limitations. 
The rationale behind the intervention is detailed in Chapter 6 (Section 6.1.3 and 
6.1.4). In brief, given the baseline sparsity of cell proliferation in unstimulated 
(singly housed, sedentary) Wistar rats previously observed in-house, and supported 
indirectly by the learning and cognition literature (Kempermann et al., 1997), it was 
thought that stimulating proliferation to a  quantifiable level  would provide the 
cellular density range necessary to allow for  comparison of different dietary 
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interventions; for example, it was anticipated that the high-SFA diet would inhibit 
proliferation, but this change would be undetectable from an already minimal level. 
This consideration was particularly important with respect to the hypothalamus, 
known for its low rate of cell turnover (Koekova et al. 2007; Cifuentes et al., 2011).   
7.1.4 Research Question 
Do dietary PUFAs stimulate hypothalamic neurogenesis? 
7.1.4.1 Aims & Expected Outcomes 
To address this question,   
1. the quantity of proliferating cells in the hypothalami of PUFA-fed and control 
rats would be assessed and shown to be increased in the former, and  
2. to correlate with altered circulating concentrations of BDNF. 
7.1.5 Effects of High-Fat Diet on Myogenesis  
In addition to dietary factors, exercise is known to improve cognition, learning and 
memory, and to alleviate depression, possibly through enhancement of neurogenesis 
in the brain (Hollman et al., 2007; Carek et al., 2011). Intriguingly, there appears to 
be bidirectional communication between skeletal muscle and neurogenic brain 
regions, although the identity of these communicating biological factors and 
underlying mechanisms largely remains to be elucidated (Lista & Sorrentino, 2010). 
Pharmacological activation of skeletal muscle is suggested to mediate cognitive 
effects (Kobilo et al., 2011), and so it is reasonable to think that nutraceutical 
activation could do the same. Dietary PUFAs also stimulate neurogenesis and 
improve mental health, but how they interact with exercise and skeletal muscle along 
these parameters also remains to be fully addressed (van Praag, 2009). 
The detrimental effects on health of long-term consumption of SFAs are well-
established, and as detailed above, include the reduction of cell proliferation within 
the brain. However, they also impair the ability of individuals to carry out types of 
endurance exercise, which aid in combating obesity by altering muscle fibre types 
(Ripple & Hess, 1998; Strømme & Høstmark, 2000). As detailed in Chapter 4, 
muscles consist of a mixture of different fibre-types (fast and slow), depending on 
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the function of the whole muscle. However, consuming a diet high in SFAs impairs 
the ability of muscles to oxidize lipid (Sparks et al., 2005), increasing the tendency to 
build fast fibres rather than slow fibres, and thereby reducing the capacity for 
sustained physical activity, and in turn, increasing the chance of weight gain and 
likelihood of obesity. 
In contrast, PUFAs have been shown to protect muscle function, stimulating 
energy metabolism and increasing the capacity for sustained exercise by improving 
fatigue resistance (Maillet & Weber, 2006; Demmig-Adams & Carter, 2007) through 
the reduction of whole-body oxygen demand during extended periods of exercise 
(Peoples et al., 2008). As the consumption of SFAs has been shown to have a 
detrimental effect on muscle composition and brain neurogenesis, it is a logical step 
to suggest that they may also affect the process of new muscular tissue growth, 
which is known as myogenesis (Carlson, 1973).  
Myogenesis in the adult results from the proliferation of satellite cells, which 
lie just under the muscle external lamina (Collins et al., 2005; Zammit et al., 2006). 
The population is a mixture of stem and precursor cells, and it is the latter which are 
activated under conditions of muscle regeneration after trauma (Bodine-Fowler, 
1994; Ten Broek et al., 2010), or of hypertrophy in response to loading, for example, 
during exercise (Kadi et al., 2005; Cassano et al., 2009; Smith & Merry, 2012). The 
extent of muscle repair depends on the viability and extent of the satellite pool, 
dependent on the presence of certain growth factors in the myogenic niche (Bodine-
Fowler, 1994). Proliferation has been shown to be inhibited by ageing (Stoll et al., 
2011) and high-fat diet feeding (Kokoeva et al., 2005). For example, it has been 
shown that postnatal exposure to a diet high in SFAs results in excessive 
intramuscular fat accumulation, in Sprague-Dawley rats at 12 weeks of age (Yang et 
al., 2012). This accumulation is associated with a decrease in muscle glycogen and 
impairment of myogenesis, suggesting that the potential for inappropriate muscle 
growth contributes to the predisposition for developing a metabolic syndrome-like 
phenotype during adulthood (Yang et al., 2012). Mice which develop insulin 
resistance from chronic high-fat feeding have also shown impairment of satellite cell 
proliferation (Hu et al., 2010); although in this case, this was independent of raised 
circulating free fatty acids, which indicates that the mechanism for this change is 
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uncertain. The effect of PUFAs on myogenesis, and whether they can restore 
proliferation and regeneration, has yet to be investigated.  
Markers of DNA synthesis, including the endogenous marker of cell proliferation 
Proliferating Cell Nuclear Antigen (PCNA) and BrdU, have been used successfully 
to show proliferation in muscle (Sha et al., 1997; Peterson et al., 2008; Jump et al., 
2009; Rathbone et al., 2009). It was thought that examination of BrdU uptake in 
muscles sampled from diet-fed animals in the current study (Chapter 3) might 
provide support for any observed alterations in fibre composition or overall numbers; 
although proliferation would not indicate fate (fibre-type), unless tracked along a 
time course, it would still indicate developmental activity. BrdU-immunoreactive 
satellite cells in muscle would also provide an additional indicator, after spleen, of 
the extent of peripheral uptake, thereby acting as a technical control. 
7.1.6 Research Question 
Do dietary fatty acids differentially influence the extent of myogenesis in skeletal 
muscle? 
7.1.6.1 Hypothesis 
Changes in skeletal muscle fibre-type populations induced by dietary fatty acids are 
underpinned by changes in levels of myogenesis. 
7.1.6.2 Aim  
To test this hypothesis by determining whether high-SFA and –PUFA feeding result 
in different quantities of proliferating cells in skeletal muscle of rat. 
7.1.6.3 Expected Outcomes 
Skeletal muscle of PUFA-fed rats would display higher numbers of proliferating 
cells than that of SFA-fed rats.  
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7.2 Materials & Methods  
Details of animal husbandry, maintenance, treatments and tissue processing are 
described in detail in Chapters 2-6; however, a brief summary is included below. 
Steps leading to the generation of tissue for analysis of cell proliferation in dietary 
studies (Chapters 3 and 5) are also summarised below in Fig. 7.1. 
7.2.1 Animals and Treatment – Chapters 3&4 
Adult male Wistar rats (~250 g) were stratified by body weight and randomly 
assigned to one of three groups (n=8/group). For eight weeks, they were fed 
isoenergetic diets, enriched with either SFAs or PUFAs (40% of energy from fat, 
mainly from lard and fish oil, respectively) or a standard (low-fat) chow (10% of 
energy from fat, from soybean oil). A summary of the diet compositions can be seen 
in Table 3.1. Rats received the cell proliferation tracer, bromodeoxyuridine (BrdU) 
dissolved in their drinking water (1 mg/ml) for the last seven days of the study, at 
which time a single play tube was introduced to the cage as an enrichment tool. Rats 
were perfuse-fixed and brains, gastrocnemius and soleus muscle removed for 
histological analysis of BrdU uptake and other cell proliferation markers, as 
described in Chapter 2 (Section 2.9). The brain regions examined include the third 
ventricular lining of the hypothalamus, medial hypothalamus and the dentate gyrus 
of the hippocampus. Full details of the immunohistochemical procedure can be seen 
in Chapter 2 sections 2.10.4-7 and Table 2.7. 
7.2.2 Animals and Treatment – Chapter 5 
Adult male Wistar rats (~250 g) were stratified by body weight and randomly 
assigned to one of three groups (n=6/group). Two groups were fed isoenergetic diets 
for three weeks, enriched with either SFAs or PUFAs (40% of energy from fat, 
mainly from coconut oil and a commercially purified source of the omega-3 fatty 
acid, docosahexaenoic acid (DHA; Incromega™ Marine Lipid Concentrate E1070, 
Croda Europe Ltd., Leek, Staffs, UK), respectively) or a standard (low-fat) chow 
(10% of energy from fat, from soybean oil). A summary of the diet compositions can 
be seen in Table 5.1. Rats in the original characterisation study (Chapter 3) had 
received the cell proliferation tracer, BrdU, in their drinking water for the last week 
of dietary exposure. By the time the study described here was planned, the 
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limitations of BrdU use were becoming clear. Thus, these animals did not receive 
BrdU, but were examined for other histological markers of cell proliferation instead. 
As a potential stimulus for this process, a play tube was placed in each cage for the 
duration of the study for all groups. Rats were perfuse-fixed and brains removed for 
histological analyses. The brain regions examined include the third ventricular lining 
of the hypothalamus, medial hypothalamus and the dentate gyrus of the 
hippocampus. Full details of the immunohistochemical procedure can be seen in 
Chapter 2 sections 2.10.4-7 and Table 2.7. 
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Chapter 3  Chapter 6 Chapter 5 
Chapter 4 
Diet 
8-weeks 
BrdU & Tube 
Perfusion 
Brain Muscle 
BrdU 
Ki67 
BrdU/DAPI 
BrdU &Tube 
1-4-weeks 
Perfusion 
Brain Spleen 
BrdU 
Ki67 
PCNA 
Diet 
3-weeks & Tube 
Perfusion 
Brain Spleen 
Ki67 
PCNA 
Figure 7.1.  A summary of steps leading to the generation of tissue for analysis of cell proliferation in dietary studies (Chapters 3 and 5).  
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7.3 Results  
7.3.1 Effects of High-SFA & High-PUFA Diets on Cell Proliferation 
Cell proliferation was largely absent from hypothalamic and hippocampal regions in 
all diet groups administered BrdU (Figs. 7.2A-F). Positive BrdU immunoreactivity 
was observed in the roof of the third ventricle (Figs. 7.3A-C) and in the lateral 
ventricular wall (Figs. 7.3D-F), but this was sparse and occurred to a similar minimal 
extent in all groups; i.e. irrespective of diet.  Similarly, proliferation was extremely 
scant in gastrocnemius and soleus muscle taken from the same animals, also 
irrespective of diet (Figs. 7.4A-D). More extensive staining was observed in the pia 
mater (Figs. 7.2G-I), however, verifying BrdU administration and staining technique. 
However, this did not prove that BrdU had crossed the BBB, and therefore, 
confirmation was sought that the lack of specific staining reflected a real absence of 
proliferation. Thus, immunoreactivity against the endogenous proliferation marker, 
Ki-67, was examined, but also found to be equally scant in all groups (Figs. 7.3B, C, 
E & F).  
7.3.2 Effects of High-SFA & High-Omega-3 Diets on Cell Proliferation 
Similarly, cell proliferation, as indicated by Ki-67 and PCNA immunoreactivity, was 
largely absent from hypothalamic and hippocampal regions in all diet groups (Figs. 
7.5A-F & 7.6A-F). Positive staining in pia mater (Figs. 7.5G-I & 7.6G-I) and spleen 
(Figs. 7.7C, F) in both cases suggested that scarcity of new cells in regions of interest 
was real, and not the result of failed technique.
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Figure. 7.2. Chapter 3. Representative photomicrographs of cell proliferation in response to high-fat feeding. Rats were fed control, high-SFA or high-PUFA 
diets for eight weeks (n=8/group). Proliferating cells show BrdU-positive immunoreactivity in cell nuclei (examples indicated by arrows). Proliferation was 
absent in all groups in the third ventricular (3V) lining and medial hypothalamus (MH; to the left of the 3V; A-C) and in the dentate gyrus (DG) of the 
hippocampus (positive control; D-F). However, BrdU uptake was confirmed in the pia mater (positive control; G-I)  
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Figure. 7.3. Chapter 3. Representative photomicrographs of cell proliferation survey in response to high-fat feeding. Rats were fed control, high-SFA or 
high-PUFA diets for eight weeks (n=8/group). Proliferating cells show BrdU- (A-C) and Ki-67-positive immunoreactivity (D-F) in cell nuclei (examples 
indicated by arrows). Although sparse proliferation observed as BrdU-positive cells in the roofs of the third and lateral ventricles was confirmed by 
the endogenous marker Ki-67, neither indicated a differential effect of diet. Antibody function and staining conditions were confirmed in the pia mater 
(positive control; G, H). Abbreviations: 3V = third ventricle; LV = lateral ventricle.
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Figure 7.4. Chapter 4. Representative photomicrographs of cell proliferation in muscle in 
response to high-fat feeding. Rats were fed high-SFA or high-PUFA diets for eight weeks 
(n=8/group). In this instance SFA-fed rats act as a control for PUFA-fed rats.  BrdU-
immunoreactive cell nuclei are shown in transverse sections of gastrocnemius (A, B) and 
soleus muscle (C, D; red fluorescence indicated by arrows). There was no differentiating 
effect of diet on proliferation in either muscle type. Sections were counterstained with 
DAPI (blue fluorescent nuclei). 
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Figure. 7.5. Chapter 5. Representative photomicrographs of cell proliferation in response to high-fat feeding. Rats were fed control, high-SFA or high-PUFA 
(omega-3) diets for three weeks (n=6/group). Proliferating cells show Ki-67-positive immunoreactivity in cell nuclei (examples indicated by arrows).  
Proliferation was absent in all groups in the third ventricular (3V) lining and medial hypothalamus (MH; to the left of the 3V; A-C), dentate gyrus (DG) of 
the hippocampus (positive control; D-F). Antibody function and staining conditions were confirmed in the pia mater (positive control; G-I). BrdU had not 
been administered to rats due to lack of confidence in the technique.  
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Figure. 7.6. Chapter 5. Representative photomicrographs of cell proliferation in response to high-fat feeding. Rats were fed control, high-SFA or high-PUFA 
(omega-3) diets for three weeks (n=6/group). Proliferating cells show PCNA-positive immunoreactivity in cell nuclei (examples indicated by arrows). 
Proliferation was absent in all groups in the third ventricular (3V) lining and medial hypothalamus (MH; to the left of the 3V; A-C), dentate gyrus (DG) of 
the hippocampus (positive control; D-F). Antibody function and staining conditions were confirmed in the pia mater (positive control; G-I). BrdU had not 
been administered to rats due to lack of confidence in the technique.  
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Figure 7.7. Chapter 5. Representative photomicrographs of cell proliferation survey in response to high-fat feeding. Rats were fed control, high-SFA or 
high-PUFA (omega-3) diets for three weeks (n=6/group). Proliferating cells show Ki-67- (A, C, E) and PCNA-positive immunoreactivity (B, D, F) in cell 
nuclei (examples indicated by arrows). Although sparse proliferation was observed in all groups as PCNA-positive cells in the roof of the 3V, this 
distribution was not mirrored by Ki-67, observed only in the wall of the LV. Neither endogenous marker indicated a differential effect of diet. BrdU 
had not been administered to rats due to a lack of confidence in the technique. Antibody function and staining conditions were confirmed in the spleen 
(positive control; G, H). Variation in staining distribution reflects the structure of the spleen; i.e. the central region showing fewer stained nuclei is white pulp 
(as opposed to the surrounding red pulp). Abbreviations: 3V = third ventricle; LV = lateral ventricle.
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7.4 Discussion 
7.4.1 Effects of Diet Composition on Central Cell Proliferation  
All diet groups, high-SFA-, high-PUFA- and low-fat-fed controls, described in 
Chapter 3, showed similarly absent or minimal levels of cell proliferation in the 
established neurogenic niches of the hippocampal DG and SVZ of the lateral 
ventricle, as well as the third ventricular lining and parenchyma of the hypothalamus. 
BrdU immunoreactivity in the pia mater (positive control tissue) suggested that this 
minimal staining was real, rather than an artefact of suboptimal BrdU administration. 
However, without being able to compare to the proliferation level in the pia mater of 
rats in the successful pilot enrichment study (Chapter 6), it is impossible to be 
certain.  
On the one hand, the lack of effect by the high-SFA diet may appear to be in 
contrast to repeated findings that consumption of such diets inhibits cell proliferation 
and neurogenesis in the rodent DG and hypothalamus (Kokoeva et al., 2005; 
Lindqvist et al., 2006; Park et al., 2010; McNay et al., 2012), but on the other, a 
near-absence of proliferation in the control animals as well prevents a meaningful 
comparison. However, it may be that the effects of SFAs on neurogenesis are not 
entirely predictable. Examination of dietary intervention in neurodegenerative 
disease has provided some insight into the effects of high-fat diet on neurogenesis. 
For example, the ketogenic diet, which is used to treat epilepsy, and which is very 
high in SFAs (80% of energy from fat), also fails to alter the number of BrdU-
immunoreactive cells in the DG of Wistar rats from that in low-fat-fed controls (5% 
of energy from fat) after a month of feeding (Strandberg et al., 2008). The general 
sparsity of new cells in the current study was similar to that reported in the full 
(repeat) enrichment study described in Chapter 6, confirming that the play tube was 
an insufficient stimulus to cell proliferation. Hence, the baseline level of proliferation 
remained too low to allow for any quantifiable reduction that may have been induced 
by the high-SFA diet.   
It was hypothesized that the high-PUFA diet would enhance hypothalamic 
neurogenesis. This is supported indirectly by extensive literature (Kawakita et al., 
2006; Beltz et al., 2007; Ma et al., 2008; Valente et al., 2009; Dyall et al., 2010; 
Fernández-Fernández et al., 2012). However, the lack of effect could be explained by 
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the fact that the PUFAs were either not at a sufficient concentration to stimulate 
proliferation above this baseline, or that any stimulatory effect they may have had 
was overridden by the inhibitory effect of the SFAs also present in the diet (Chapter 
3, Section 3.4). SFAs inhibit neurogenesis via mechanisms involving 
neuroinflammation. Rodent models of obesity induced by high-SFA diet feeding are 
characterised by inflammation both in peripheral tissues and areas of the 
hypothalamus involved in energy homeostasis (Monje et al., 2003; Molina-Holgado 
& Molina-Holgado, 2010; Cota & Marsicano, 2011; Thaler et al., 2012). Unlike 
inflammation in peripheral tissues, however, which develops as a consequence of 
obesity (Posey et al., 2009), hypothalamic inflammatory signaling is evident in rats 
within three days of high-SFA diet consumption, before the development of weight 
gain, and markers of neuron injury and inflammation are evident in the arcuate 
nucleus within one week (Thaler et al., 2012). Although these responses temporarily 
subside, suggesting that neuroprotective mechanisms may initially limit the damage, 
with continued high-SFA diet feeding, inflammation returns permanently and 
impairs neurogenesis (Monje et al., 2003; Molina-Holgado & Molina-Holgado, 
2010; Cota & Marsicano, 2011; Thaler et al., 2012). Although PUFAs are 
neuroprotective and anti-inflammatory (Dyall, 2010; Hashimoto & Hossain, 2011), 
they may not have been at a sufficient concentration in the high-PUFA diet to 
prevent or repair damage caused by the SFAs also present. This suggests that 
PUFAs, rather than directly stimulating neurogenesis, would act to protect normal 
levels of proliferation.  
Again, however, other research indirectly suggests that the current findings 
may not be surprising. Rats fed for three months on diets as high in fat as those used 
here (40% of energy from fat) displayed equal impairments in various learning 
paradigms, regardless of the fat source [lard (SFAs) or soybean oil (PUFAs)] 
(Winocur & Greenwood, 1993; 2005). The effect was concentration-dependent in 
rats fed high-SFA diets (20% vs. 40%), but specific to the highest level of PUFAs 
(Winocur & Greenwood, 2005). Based on the association between hippocampal 
neurogenesis and cognition, learning and memory (Amrein & Lipp, 2009; Noble et 
al., 2011), these findings indirectly support those here. The mechanisms behind these 
impairments were not investigated by the authors, although they did consider the 
involvement of diet-induced insulin resistance in reducing glucose uptake by the 
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brain. This is thought to contribute to the cognitive decline seen both with ageing and 
type 2 diabetes (Gage et al., 1984; Cunnane et al., 2011; McNay & Recknagel, 
2011). Conversely, Winocur and Greenwood (2005) showed that i.p. glucose 
treatment improved memory function in the high-fat-fed rats used in the various 
learning paradigms by enabling glucose metabolism in the hippocampus. Therefore, 
it is reasonable to suggest that the reversal of glucose intolerance may in turn reverse 
the inhibition of neurogenesis by dietary fats. This idea is further supported by 
evidence that memory dysfunction in aged animals, a process linked to a decline in 
cell proliferation, correlated with an impairment in glucose metabolism (Gage et al., 
1984). Furthermore, genes involved in the breakdown of glucose (Glucose-6-
phosphate dehydrogenase) are upregulated during differentiation of Neural Stem 
Cells (NSC) (Gurok et al., 2004; Rafalski & Brunet, 2011). Glucose-6-phosphate 
dehydrogenase is an important factor for cell growth. Studies have shown that the 
inhibition of this enzymes activity prevents the incorporation of [3H]thymidine 
incorporation into cells, but, over expression stimulated cell growth, as measured by 
an increase in [3H]thymidine incorporation (Tian et al., 1998). The likely insulin 
resistance observed in all three groups in the current study, reflected in their 
hyperinsulinaemia (Chapter 3, Fig. 3.9), may have impaired central glucose uptake, 
thereby impairing cell proliferation and accounting for the low levels seen here. 
7.4.2 Effects of High-Fat Diets on Myogenesis  
The sparse cell proliferation observed in skeletal muscles from both high-SFA- and 
high-PUFA-fed rats is consistent with that observed centrally, although the possible 
issue of whether this is an artefact of the administration method still remains 
(Chapter 2, Section 2.9.5). If the findings are real, however, the equivalent satellite 
cell proliferation in the two high-fat-fed groups supports their similarities in muscle 
mass (Chapter 3, Fig. 3.3D), muscle fibre proportions and numbers of fibres overall 
(Chapter 4, Section 4.3 and Fig. 4.3). The lack of satellite cell activation indicates 
that no significant muscle regeneration or hypertrophy had been taking place. This 
makes sense, as new muscle cell growth is most common following injury (Zammit 
et al. 2006; Kuang et al., 2008; Cassano et al. 2010), but here there had been no 
trauma here; nor had there been significant hypertrophy due to loading (the sedentary 
cage environment precludes  exercise). This raises the question of whether diet alone 
is an intervention capable of stimulating muscle regeneration. Indeed, originally it 
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was thought that once a muscle had formed, the body was no longer capable of 
producing any new muscle fibres, should damage occur. However, it is now known 
that the fibre-type ratio of soleus muscle can be altered to one of increased Type I 
oxidative fibres, and can undergo regeneration, in rats fed the dietary supplement, 
acetyl-L-carnitine (Cassano et al., 2010). Although the mechanisms behind these 
types of changes have yet to be determined (Howald et al. 1985; Bodine-Fowler, 
1994; Zammit et al. 2006; Kuang et al., 2008; Cassano et al. 2010), satellite cells are 
thought to be involved in this process of alteration in muscle composition (Zammit et 
al. 2006; Kuang et al., 2008; Cassano et al. 2010). In addition to the proliferative 
action of amino acids, the published findings reviewed in Chapter 4 and above, in 
Section 7.1.5, indicate that dietary FAs are also able to alter muscle composition and 
that SFAs inhibit proliferation in muscle, as they do in brain (Hu et al., 2010; Yang 
et al., 2012). Whether PUFAs counteract this inhibition and/or stimulate proliferation 
in muscle, as they have been shown to do in brain (Kawakita et al., 2006; Beltz et al., 
2007; Ma et al., 2008; Dyall et al., 2010), still remains to be seen. Again, it is 
reasonable to suggest that the presence of SFAs in the high-PUFA diet used in the 
current study would have overridden any proliferative effect they may have had 
(Chapter 3, Section 3.4). Finally, had immunohistochemical staining been carried out 
for markers of satellite cells, such as Pax7, MyoD and lysenin, positive 
immunoreactivity may have indicated the stage in myogenesis at which the satellite 
cells were (Nagata et al., 2006; Zammitt et al., 2006), possibly indicating that the 
muscle was undergoing change that had not yet manifested itself as a change in fibre-
type per se.  
7.4.3 Effects of Diet High in Omega-3 FAs on Central Cell Proliferation 
Intervention with a purified dietary source of PUFAs also failed to stimulate 
substantial cell proliferation, either in the hypothalamus or hippocampus. This is in 
contrast to a number of previous findings showing enhanced neurogenesis in  
animals fed  diets enriched with DHA, the omega-3 FA used here (Kawakita et al., 
2006; Beltz et al., 2007; Ma et al., 2008; Dyall et al., 2010). Aside from the possible 
reasons discussed above and in Chapter 6 (Section 6.4), including issues of 
enrichment and rat strain, this lack of effect is consistent with similar circulating 
BDNF concentrations across all the diet groups for the duration of the study. 
However, there is a tantalising hint, from the acute, albeit non-significant, increase in 
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BDNF concentration at three weeks of high-omega-3  exposure, that  had the study 
run for longer, BDNF levels may have become sufficient to stimulate proliferation. 
Omega-3 FA consumption has been shown to stimulate secretion of BDNF after one 
and ten months (Wu et al., 2004; Bousquet et al., 2009), both time periods longer 
than the one studied here. As an increase in BDNF concentrations is known to 
indirectly stimulate neurogenesis by increasing synaptic transmission and long-term 
potentiation (Gomez-Pinilla, 2011), this may then have led to an increase in observed 
cell proliferation also.  
Although the link between dietary DHA supplementation and hippocampal 
neurogenesis has been proven in vivo (Kawakita et al., 2006), it is possible that it had 
the opposite effect here, on cell proliferation per se. There are two possible reasons 
for this. First of all, DHA has been shown to stimulate neurogenesis by controlling 
the transcription factors responsible for regulating the cell cycle (Ohnuma et al., 
2001; Cremisi et al., 2003). Specifically, it inhibits cell proliferation but promotes 
neuronal differentiation by promoting cell cycle exit and suppressing cell death 
(Kageyama et al., 2005; Kawakita et al., 2006; Kageyama et al., 2008). In addition, 
DHA’s effects are concentration-dependent, whereby high concentrations reduce 
survival by inducing apoptosis leading to neuronal death (Kim et al., 2000; Katakura 
et al., 2009). This suggests that the concentration of DHA used in the current study 
may have been so high as to have the opposite effect to that desired, inhibiting, rather 
than stimulating, cell proliferation, and accounting for the low levels of proliferation 
observed. Although this effect had been discovered in vitro, in cultured neural stem 
cells, and therefore, cannot be directly translated to the in vivo state, a similar 
principle may apply. The equivalent concentrations of diet-incorporated DHA and 
their in vivo effects will have to be determined. Humans taking supplements can 
safely consume 120 mg per day of DHA for general health purposes, but this can be 
increased to 1.4 g per day to control specific medical conditions, such as high 
cholesterol and blood pressure, by the lowering of circulating triglycerides (Zargar & 
Ito, 2011). The concentration of DHA within the diet used here was quite high: 
Weight per weight, rats consumed, on average, 26 grams of food per day, 20% of 
which was fat. Of this, 96% was provided by omega-3 FAs, and in turn, 82% of this 
by DHA; therefore, approximately 4 grams of DHA were consumed per day. This 
dose is almost three times greater than that recommended for therapeutic purposes to 
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the human population, and effectively even greater, when the small body size of the 
rat is considered. However, whether this is an issue depends on whether DHA is 
metabolised in the same way in rats and humans. 
7.5 Conclusion 
The studies described here aimed to investigate whether PUFA consumption would 
stimulate hypothalamic neurogenesis and alter myogenesis in skeletal muscle. It is 
possible that neither effect was seen because the diet composition was not conducive 
to cell proliferation, due to the presence of inhibitory SFAs (Chapter 3). However, 
similar minimal levels of proliferation in response to a purified PUFA source 
(Chapter 5), as well as to control diets, suggest that other influences on neurogenesis 
in the current model must be disentangled and identified before the effects of dietary 
FA intervention can be determined.  
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General Discussion and Future Perspectives 
8.1 Summary  
Feeding the male Wistar rat for chronic (3-8-week) periods with isoenergetic diets 
highly enriched with saturated and polyunsaturated fatty acids (SFAs and PUFAs) 
provided valuable insight into the differential effects of these FA classes on body 
weight regulation. The primary aim of this project had been to create a rational 
model of chronic PUFA consumption for future application in studies of 
nutraceutical treatment of obesity. On the whole, this was achieved, and the design 
requirement for comparison with an equally high-SFA-fed model expanded our 
current knowledge of the character of diet-induced obesity. Although the 
mechanisms by which PUFAs exert long-term body weight control remain to be fully 
elucidated, the experiments described in this thesis have revealed that they do so, at 
least in part, through improved feeding behaviour and body composition.  
The secondary aim of the project had been to develop methods for 
stimulating and visualising neurogenesis in the hypothalamus of rat, in ways 
compatible with dietary manipulation, given the growing body of evidence for this 
region as a nutrient-responsive neurogenic niche. It was hoped that if this could also 
be carried out successfully, the conditions would be set for the future combining of 
the two sets of interventions, dietary and neurogenic, to determine whether 
stimulation of neurogenesis is one of the means by which PUFAs regulate body 
weight. This proved more problematic, such that this second aim could not be 
addressed. However, the technical difficulties incurred did generate the research 
questions which must be answered next to progress toward this aim. The following 
discussion explores what might be done to address these remaining gaps in the 
knowledge and continue to advance the field.  
8.2 Salient Findings and Future Work 
8.2.1 Dietary Studies  
Previous work on human body weight metabolism had examined only the effects of 
short-term consumption of PUFA supplements (Lawton et al., 2000; Buckley & 
Howe, 2009). Attempts to model in rodents long-term consumption of PUFAs 
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incorporated into chow have been difficult to interpret because of a general lack of 
isoenergetic controls (Ricci & Ulman, 2008). The studies described here were 
designed to address these shortcomings.  
Rather than simply repeat previous work, studies were expanded to examine 
in closer detail the circadian rhythmicity of PUFA feeding, and for the first time have 
revealed that the satiety with which it has previously been associated (Scharrer, 
1999; Lawton et al., 2000) occurs during the day (Chapter 3). Importantly, however, 
this exciting effect is transient, showing acute enhancement after three weeks of 
consumption, but gradually disappearing after that. Surprisingly, this enhancement 
was observed with a PUFA sourced from menhaden fish oil, which also contains 
SFAs, but not with a purified PUFA, the omega-3 FA, DHA (Chapter 5). Satiating 
effects of DHA (Ogawa et al., 2008; Parra et al., 2008) may occur in a different 
window entirely. Alternatively, the SFAs in the high-fish oil diet may have still been 
exerting satiating effects at this early stage. Fat-sensing in the gut suppresses ongoing 
feeding acutely, a mechanism which is eventually lost with chronic SFA feeding, as 
obesity develops (Buettner et al., 2006). Although the same general pattern was 
observed in the high-SFA-fed group, it may have fallen short of significance because 
the higher SFA content of the diet disabled the mechanism sooner. This could be 
tested by examining concurrent alterations in circadian rhythm and weekly 
expression of satiety peptides in the gut, such as cholecystokinin (CCK), peptide YY 
(PYY) and glucagon-like peptide-1 (GLP-1). In diet-induced obesity (DIO), these are 
reduced, and levels of FA receptors, GPR40 and GPR120 are altered (Duca et al., 
2012). PUFAs, on the other hand, are found to be more satiating than SFAs when 
infused into the upper small intestine in human subjects (French et al. 2000) and 
when incorporated into food items (Lawton et al. 2000). These findings may relate to 
the chemical responses evoked following ingestion of these FAs. CCK has been 
shown to be released in larger quantities following the consumption of foods 
containing PUFAs, compared with other types of FAs (Beardshall et al. 1989).  
The clear improvements in adiposity and lipid metabolism observed with the 
high-DHA diet encourage the view that this is a valid model of high-PUFA 
consumption, demonstrating changes to energy metabolism expected from both the 
human and animal literature (Ruzickova et al., 2004; Buckley & Howe, 2009). 
However, it requires further development to corroborate these findings. For example, 
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measurement of circulating adipokine and insulin concentrations is now needed to 
help clarify the apparently opposing relationships between energy intake and 
adiposity which suggest enhanced energy expenditure. It is expected that the reduced 
adiposity would be reflected in increased adiponectin levels but reduced insulin and 
leptin levels, although the increased energy intake contradicts this. Ideally, enhanced 
energy expenditure would be confirmed through calorimetry testing, for example, 
and at the molecular level, through demonstration of increased expression of UCP1 
in BAT and UCP3 in skeletal muscle (McClave & Snider, 1992; Tsuboyama-
Kasaoka & Ezaki, 2001; Mailloux et al., 2012). Indeed, omega-3 FAs are known to 
alter gene expression involved in increasing lean muscle tissue, fat oxidation and 
energy expenditure in muscle and decreasing fat deposition in this tissue, but more 
long-term trials are needed to determine mechanisms of action (Bordoni et al., 2006; 
Demmig-Adams & Carter, 2007; Izumiya et al., 2008; Shortreed et al., 2009). 
Histological examination of the muscle from this study (Chapter 5) would hopefully 
confirm reduced ectopic fat deposition in a long-term design, and would address the 
aim of Chapter 4, possibly showing a Type I fibre-type profile.  
That there were few phenotypic differences between the SFA- and low-fat-
fed control groups in Chapter 5 deserves further comment. This suggested that 
coconut oil, though a purer source of SFAs than lard, was not an appropriate choice 
for inducing obesity (99% vs. 35% SFA content w/w; see Appendices II & IV, where 
lard contains comparable quantities of SFAs and MUFAs). It has, in fact, been 
observed previously that lard is the more effective of the two in this respect (Buettner 
et al., 2006). Closer study of the nutrient breakdown of the diets used here confirms 
this: coconut oil is comprised of small-medium-chain FAs [lauric (C12) and myristic 
acids (C14); see Appendix IV], which are more readily oxidised than the longer-
chain FAs found in lard [Chapter 3; palmitic (C16), stearic (C18) and oleic acids 
(C18); see Appendix II], and are, therefore, less likely to be stored in adipose tissue 
(Papamandjaris et al., 1998; Buettner et al., 2006). Nonetheless, diets utilising 
coconut oil have been shown to induce obesity following three or more months of 
feeding, but these diets commonly contain 58-60% of energy as fat (more than the 
40% used here; Buchner et al., 2008; Lee et al., 2008). The influence of these FAs 
(type and concentration) would have to be tested in isolation and across a time course 
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to determine which might act as the optimal isocaloric control for the PUFA-fed 
group.  
Ideally, an extended time course of diet exposure, including periodic body 
composition analysis and meal pattern analysis would build on this foundation to 
more fully characterise the model. This is important, as the transitory nature of 
enhanced satiety with fish oil could have important implications for human dietary 
recommendations, as well as the cost implications of purifying omega-3 FAs for 
incorporation into human foodstuffs.  
Further validation of the model should also entail reversal studies, which 
would confirm the role of PUFAs in improving phenotype; i.e. it would be expected 
that reduced body weight, adiposity and TG levels would be normalised upon 
withdrawal of the diet and replacement with the control diet. By using a reversal 
paradigm, strength is added to the notion that observed changes are indeed due to the 
dietary intervention.  
Finally, a thorough characterization of the model would require investigation 
of central mechanisms (other than neurogenesis, discussed below). For example, 
dopaminergic activity could be measured in the LHA and VMH, where it regulates 
meal size and meal number (IMI), respectively (Meguid et al., 1996; Fetissov et al., 
2002), to see if it would correlate with alterations in feeding periodicity in response 
to the different FAs and their concentrations. Indeed, high-SFA, though not high-
PUFA, diets have been shown to activate expected regions of the hypothalamus in 
mouse (LHA and PVN), but the populations to which these activated neurons belong 
have not been identified (Wang et al., 1999). Early gene activation in brain tissue 
harvested from animals studied here was similarly examined by c-Fos 
immunohistochemistry, but was found to be minimal in all diet groups (data not 
shown). The reasons for this are unknown at present, but may be related to diet being 
too subtle a stimulus in the chosen model, as discussed with respect to neurogenesis.  
8.2.2 Cell Proliferation Studies 
Pilot work (Chapter 6) carried out concurrently with the first high-PUFA study 
(Chapter 3) showed that hypothalamic cell proliferation could be stimulated 
dramatically in response to simple environmental enrichment in the form of a plastic 
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play tube introduced to the cage. This non-edible toy supported feeding study 
requirements, where individual consumption is measured, and so stimulation by 
social enrichment, for example, from cage companions (Kempermann et al., 1997, 
2002; Mak et al., 2007), is not an option. However, these findings could not be 
reproduced; reinforcing the knowledge that neurogenesis is subject to many 
influences, including age, species, strain and stress (Kempermann et al., 1997; 
Lindqvist et al., 2006; Mak et al., 2007; Rafalski & Brunet, 2011), the degrees of 
influence of which would have to be determined in a series of systematically 
controlled studies. Failure to stimulate cell proliferation above control levels in 
DHA-fed animals (Chapter 7) suggested further that change in dietary FA 
composition is not a powerful enough intervention to stimulate neurogenesis, when 
used alone in Wistar rat.  
Levels of cell proliferation in control animals (low-fat-fed) were absent-to-
minimal (irrespective of niche), and so were those in normally active neurogenic 
niches, such as the DG of the hippocampus and the SGZ of the lateral ventricle 
(irrespective of diet group), not only when examined with the tracer, BrdU, but also 
with cell cycle markers, Ki-67 and PCNA. Taken together, these indicate that the 
focus of attention in future studies can be diverted from issues surrounding tracer 
administration method, and must fall on creating a model in which barriers to 
proliferation are eliminated, such that the neuroprotective actions of PUFAs can be 
enabled. These barriers include impoverished environment, older age, strain 
(anxious/stressed temperament), and central inflammation. The first two of these 
have already been discussed (Chapters 6 & 7), but the last two will be expanded 
upon here. 
It seems reasonable to think that a rat strain with a low-anxiety temperament, 
such as the hooded Long-Evans (LE), which is also more responsive in learning 
paradigms than albino rats (Harker & Wishaw, 2002; Simpson & Kelly, 2011), might 
prove to have a naturally high level of neurogenesis. This appears to be the case with 
juvenile LE rats, which show a similar baseline level of hippocampal cell 
proliferation and survival of immature neurons to that seen in juvenile wild rats, and 
which is increased above that of Sprague-Dawley rats. However, this difference 
disappears in adulthood, as wild and LE levels fall into the normal range for other 
captive-bred strains (Epp et al., 2009). However, the very fact that a baseline range 
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could be measured at all in alternative captive strains suggests that, for whatever 
reason, the Wistar used here is an inappropriate choice for studies of neurogenesis.  
As this contradicts a number of other studies in which Wistars have been used 
successfully (e.g. Urbach et al., 2008; Soumier et al., 2009; Zhuang et al., 2012), it 
points to issues of genetic drift (Kacew & Festing, 1996), discussed in Chapter 3, and 
as yet unidentified inhibiting factors specific to husbandry conditions applied in this 
project. 
A synthesis of the current obesity and neurodegenerative literature reveals a 
number of key facts (Yon et al., in submission). These are that   
(1) raised circulating concentrations of TGs and pro-inflammatory cytokines, 
such as TNF-α and IL-6, compromise the integrity of the blood-brain barrier 
(BBB), blocking access to the brain by neuroprotective factors, such as leptin 
and insulin. Together with central inflammation, they are the likely cause of 
impaired central neurogenesis induced by high-SFA feeding (Lindqvist et al., 
2006; Stranahan et al., 2008; Thaler et al., 2012). PUFAs are likely to restore 
neurogenesis through their well-established suppression of TGs and 
inflammatory cytokines, as well as known improvements to BBB function 
(Sinn & Howe, 2008; Kuo et al., 2010; Shearer et al., 2012). 
(2) PUFAs are thought to stimulate hippocampal neurogenesis through 
mechanisms involving a number of receptors, including the FA receptor, 
GPR40, glutamate receptors and retinoic acid receptors (RARs) (de Urquiza 
et al., 2000; Katakura et al., 2009; Oh & Lagakos, 2011), and to alleviate 
SFA-induced hypothalamic inflammation via activation of GPR120 (Cintra et 
al., 2012). 
(3) SFA-induced impairment of neurogenesis is associated with reduced gene 
expression and protein levels of BDNF in the hippocampus (Obrietan et al., 
2002; Park et al., 2010). As PUFAs enhance synthesis, secretion and 
intracellular signalling of BDNF, they may restore neurogenesis by these 
means (Wu et al., 2004; Balanzá-Martínez et al., 2011).   
These points raise questions as to whether the Wistar rat has inherently low 
levels of neurogenesis due to strain-specific defects which disable the action of 
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PUFAs; i.e. a susceptibility to inflammation, a weakened BBB, or innately low levels 
of key receptors and BDNF. Although information on RARs, RXRs and GPRs is 
lacking in this area, and it appears that there are no strain-specific differences in 
levels of glutamate receptors or BDNF expression, it does appear that there is a strain 
dependence in rodent susceptibility to some inflammatory conditions, and glutamate 
modulation of activation of other receptor-types (Lariviere et al., 2006; Mori et al., 
2010; Mustafi et al., 2012). Although Wistar rats have not been examined in any of 
these comparisons, the potential for a strain difference is suggested. BDNF gene 
expression in spinal cord has also been shown to correlate with rat strain differences 
in neuropathic pain and in hippocampus, with prenatal stress (Herradon et al., 2007; 
Neeley et al., 2011). Interestingly, the correlation between hippocampal BDNF 
mRNA expression and general and locomotor activity also differs according to 
mouse strain (Nesher et al., 2012). This highlights again the important role of 
exercise as an intermediary between BDNF and neurogenesis (Wu et al., 2008), and 
suggests that lack of exercise in the current model could be partly responsible for the 
low neurogenic levels and unchanging BDNF concentrations observed in control 
animals.  
In addition to the extrinsic factors mentioned above, any future model would 
also have to be tested for the presence of intrinsic factors (local signals and cellular 
machinery) required for maintenance of the neurogenic niche (Massirer et al., 2011). 
For example, studies similar to those of Katakura et al. (2009) would have to be 
carried out on cultured hypothalamic cells to see whether the same bHLH 
transcription factors are at play in response to omega-3 FAs. Indeed, in vitro studies 
would allow for the study of individual neurogenic influences in isolation, which is 
perhaps a good starting point in an area as complex as the impact of diet on 
neurogenesis. Adult-derived rat hypothalamic cell lines are now commercially 
available from the researchers who originally showed that leptin and GLP-1 
stimulate neurogenesis in these cells and in the latter case, that this is mediated by 
CNTF (Belsham et al., 2004, 2009; Dalvi et al., 2011; Cellutions package insert). 
Substances such as BrdU, individual FAs of different classes and concentrations, and 
trophic factors could be added to the culture medium and effects on proliferation 
observed using immunohistochemical techniques. 
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Although, as mentioned above, stimulation, rather than identification, of 
proliferating cells has been the key issue here, once a model of optimal neurogenic 
capacity were created, it might be possible to develop a transgenic rat using similar 
reporter line technology to that used by Encinas and Enikolopov (2008). They 
created nestin-CFPnuc mice, in which (hippocampal) neural progenitor cells express 
fluorescent proteins. On the genetic background of a rat strain with inherently 
increased neurogenic capacity, this would at least eliminate issues of BrdU 
administration. As argued above, this would not necessarily address the issue of 
inherently reduced mitotic capability of hypothalamic cells; i.e. it would not 
necessarily follow that because high levels of neurogenesis occur in the 
hippocampus, they would also occur in the hypothalamus. This might still require an 
extrinsic stimulus, such as i.c.v. infusion of a trophic factor; e.g. BDNF, CNTF, EGF 
or IGF-1 (Yoshimizu & Chaki, 2004; Kokoeva et al., 2005; Lee & Son, 2009; Noble 
et al., 2011).   
8.3 Conclusion 
In conclusion, application of appropriate controls for dietary energy content and 
composition show that benefits to body weight metabolism of long-term 
consumption of diets highly enriched with PUFAs, and in particular, omega-3 fatty 
acids can be successfully modelled in rat. However, further work is required to 
determine the precise timeline of their emergence and underlying mechanisms.  
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